read0138449/published_papers/54144617 Kazuki Maeda Sota Koyama Kei Kawada Toshinobu Hayashi Toshihiko Yoshioka Tomoaki Ishida Hitoshi Fukuda I O Horikawa Fuka Aizawa Takahiro Niimura Kenta Yagi Mitsuhiro Goda Yuki Izawa-Ishizawa Shinji Abe Keisuke Ishizawa Fosnetupitant Versus Fosaprepitant for Delayed Vomiting Upon Irinotecan-Oxaliplatin Combination Chemotherapy for Pancreatic/Colorectal Cancer. BACKGROUND/AIM: Real-world comparative data on neurokinin-1 receptor antagonists are needed among patients receiving FOLFOXIRI or FOLFIRINOX. We aimed to evaluate the antiemetic effectiveness of fosnetupitant versus that of fosaprepitant in patients treated with FOLFOXIRI/FOLFIRINOX regimens for pancreatic/colorectal cancer. PATIENTS AND METHODS: This single-center retrospective study included patients treated from April 2018 to September 2024. Patients were matched 1:1 between treatment groups via propensity scores based on age, sex, alcohol history, prior treatment, and regimen dose, as appropriate. Antiemetic effectiveness was assessed as no vomiting/no nausea during days 1-7; safety outcomes were also evaluated. Inverse probability of treatment weighting (IPTW) was conducted to validate the robustness of the results. Between-group comparisons were performed using Fisher's exact tests for categorical variables and Mann-Whitney U-tests for continuous variables. RESULTS: After matching, 43 patient pairs in the pancreatic cancer cohort and 28 pairs in the colorectal cancer cohort were analyzed; the groups had generally comparable baseline characteristics. In the pancreatic cancer cohort, fosnetupitant was associated with higher no-vomiting rates during the long-delayed phase (100% vs. 81%, p=0.006) and overall period (95% vs. 74%, p=0.014) than fosaprepitant. No significant differences in effectiveness were observed in the colorectal cancer cohort. Injection site reactions were significantly less frequent with fosnetupitant in the colorectal cancer cohort (4% vs. 29%, p=0.025). These findings remained consistent in the IPTW sensitivity analysis. CONCLUSION: The effectiveness of fosnetupitant may vary according to cancer type, suggesting the need to tailor antiemetic strategies for patients receiving irinotecan-oxaliplatin combination chemotherapy. Anticancer research 46 6 3191 3203 20260600 10.21873/anticanres.18190 42203343 read0138449/published_papers/54058074 Mizuho Asada Fuka Aizawa Takahisa Mikami Mitsuhiro Goda Yuhei Sonoda Takahiro Niimura Yoshito Zamami Masayuki Chuma Yoshihiro Uesawa Keisuke Ishizawa Bile acids as candidate therapies for multiple sclerosis: inverse signal analysis using the FDA adverse event reporting system and preclinical validation. BACKGROUND: Alterations in bile acid metabolism have been observed in individuals with multiple sclerosis (MS), yet the therapeutic implications of bile acid supplementation remain uncertain. METHODS: We conducted a two-stage study integrating pharmacovigilance analysis with preclinical validation to evaluate bile acid derivatives as candidate therapies for MS. A disproportionality analysis of the FDA Adverse Event Reporting System (FAERS; Q4/2003-Q2/2025) was performed to identify inverse associations between MS and bile acid preparations. The effects of ursodeoxycholic acid (UDCA) and obeticholic acid (6-ECDCA) were evaluated in a therapeutic experimental autoimmune encephalomyelitis (EAE) model, with treatment initiated after disease onset. RESULTS: Among 13,734,539 FAERS reports, 75,659 involved MS. Inverse associations were identified for UDCA (odds ratio [OR]: 0.197, 95% confidence interval [CI]: 0.117-0.333) and 6-ECDCA (OR: 0.128, 95% CI: 0.041-0.396). In the EAE model, UDCA was associated with lower clinical scores at the peak (day 18) and late phases (days 26-28), whereas 6-ECDCA showed only a non-significant trend toward improvement at day 28. CONCLUSION: This two-stage investigation highlights the potential utility of pharmacovigilance-guided approaches for identifying therapeutic candidates. Bile acid derivatives, particularly UDCA, are biologically plausible candidates meriting further investigation in the context of MS. Multiple sclerosis and related disorders 109 107113 107113 20260500 10.1016/j.msard.2026.107113 41832842 read0138449/published_papers/54165253 薗田 悠平 相澤 風花 西橋 彩香 谷田 奨太 八木 健太 新村 貴博 堀川 伊和 合田 光寛 川田 敬 石澤 有紀 石澤 啓介 胆汁酸製剤による多発性硬化症抑制効果の検討 徳島医学会 四国医学雑誌 2758-3279 81 5-6 246 247 20260400 read0138449/published_papers/54165247 酒巻 左奈子 合田 光寛 堀川 伊和 新村 貴博 相澤 風花 八木 健太 川田 敬 石澤 有紀 石澤 啓介 MATEを含む膜輸送体複合体の相互作用解析 徳島医学会 四国医学雑誌 2758-3279 81 5-6 252 252 20260400 read0138449/published_papers/54069660 Satoko Namba Mitsuhiro Goda Yurika Kuniki Keisuke Ishizawa Midori Iida Jun-ichi Takeshita Yoshihiro Yamanishi Mechanism-based prediction of drug synergy via network controllability analysis of therapeutic pathways in intractable diseases Elsevier BV iScience 2589-0042 29 4 115339 115339 20260400 10.1016/j.isci.2026.115339 read0138449/published_papers/54054240 Shiho Ueta Takahiro Niimura Mitsuhiro Goda Tomoaki Ishida Naohiro Iwata Tatsuaki Takeda Kei Kawada Koji Miyata Fuka Aizawa Kenta Yagi Hirofumi Hamano Masayuki Chuma Yuki Izawa-Ishizawa Yoshito Zamami Keisuke Ishizawa Muscle Atrophy-Related Adverse Events of Antidiabetic Drug Classes: A Pharmacovigilance Analysis Using VigiBase Data. BACKGROUND: Diabetes mellitus-a chronic metabolic disorder associated with an increased risk of muscle atrophy-can significantly impact patients' quality of life and overall health outcomes. While antidiabetic medications are crucial for managing blood glucose levels, some have been linked to muscle-related adverse events, potentially exacerbating the already elevated risk of muscle deterioration in diabetic patients. However, a comprehensive analysis of muscle atrophy-related adverse events across different classes of antidiabetic drugs has been lacking. Therefore, this study investigates the profile of muscle atrophy-related adverse events across major antidiabetic drug classes using the World Health Organization's (WHO's) Individual Case Safety Reports database. METHODS: A pharmacovigilance analysis was conducted using data from VigiBase, the WHO's global reporting database, from 1968 to September 2025. The study examined adverse event signals related to muscle atrophy, sarcopenia, muscular weakness and motor function decline for nine classes of antidiabetic medications. Reporting odds ratios (RORs) were calculated to assess signal detection, and co-occurrence patterns of adverse events were analysed. RESULTS: Among 41 551 306 adverse event reports, 2 095 847 were related to antidiabetic medications. Safety signals for muscle atrophy were detected with sulfonylureas (ROR: 1.2, 95% CI: 1.01-1.43, p = 0.042), GLP-1 analogues (ROR: 1.2, 95% CI: 1.02-1.41, p = 0.031) and SGLT2 inhibitors (ROR: 1.5, 95% CI: 1.19-1.78, p < 0.001). SGLT2 inhibitors also showed a signal for sarcopenia (ROR: 6.2, 95% CI: 3.71-10.3, p < 0.001). Biguanides demonstrated signals for muscular weakness (ROR: 1.6, 95% CI: 1.54-1.71, p < 0.001) and motor function decline (ROR: 1.7, 95% CI: 1.41-2.13, p < 0.001). Thiazolidinediones, glinides, DPP-4 inhibitors and alpha-glucosidase inhibitors showed no safety signals for the examined adverse events. Additionally, co-occurrence analysis revealed frequent associations between muscle atrophy and nausea/vomiting, falls and decreased appetite across different drug classes. CONCLUSIONS: These findings indicate notable differences in the profiles of muscle atrophy-related adverse events among major classes of antidiabetic drugs, suggesting that drug selection may influence the risk of muscle function decline in patients. Clinicians should consider these safety profiles when prescribing antidiabetic therapies; however, causal relationships cannot be inferred solely from pharmacovigilance data. Further studies are warranted to establish causality between antidiabetic drug use and muscle-related adverse events and to elucidate the underlying mechanisms. Journal of cachexia, sarcopenia and muscle 17 2 e70251 null 20260400 10.1002/jcsm.70251 41980862 read0138449/published_papers/52874824 Fuka Aizawa Kenta Yagi Tsukasa Higashionna Hirofumi Hamano Shimon Takahashi Yoshito Zamami Kazuaki Shinomiya Takahiro Niimura Mitsuhiro Goda Kei Kawada Keisuke Ishizawa Prescription Support Practice for Pharmacy Students: Pre-Post Educational Intervention Study. BACKGROUND: In the field of team-based care, pharmacists are vital for optimizing medication therapy. However, many medical professionals lack the opportunity to learn how to propose prescription changes with precision. OBJECTIVE: This study aimed to address this knowledge gap by developing and assessing a new educational program for pharmacy students focused on prescription support and interprofessional collaboration. METHODS: We recruited 191 fifth-year pharmaceutical students during the 2022-2024 academic years. The program featured a 7-day intensive curriculum that included learning how to assist with prescriptions, analyzing clinical data, and engaging in role-playing exercises. A web-based questionnaire and a paper test were used to evaluate students' awareness and knowledge both before and after the program. Statistical analyses were performed to verify the significance of changes; we utilized the Wilcoxon signed-rank test for the ordinal data derived from the specific behavioral objectives and 2-tailed paired t tests for the interval data from the knowledge tests. The magnitude of change was quantified using r for Wilcoxon tests and Cohen dz for 2-tailed t tests, with 95% CI calculated to ensure the stability and reliability of the observed results. RESULTS: Analysis of the primary outcome specific behavioral objectives revealed statistically significant effects across all items (Wilcoxon signed-rank test; P<.001). Effect sizes (r=0.505-0.835) ranged from moderate to large, with particularly large effects observed in identifying contents issue (r=0.835, 95% CI 0.126-0.330; P<.001). Knowledge test scores showed significant improvement in the following 3 subjects: pharmacology (r=-0.504, 95% CI -0.215 to 0.127; P<.001), organic chemistry (r=0.254, 95% CI -0.148 to -0.193; P=.004), and communication (r=0.221, 95% CI -0.151 to -0.190; P=.01). No significant changes were observed in pathology or pharmacokinetics. CONCLUSIONS: This program provides strong evidence that practical, hands-on learning with hospital pharmacists helps improve pharmacy students' professional skills and optimize pharmaceutical therapies in interprofessional care. By teaching pharmacists to effectively propose prescription changes, the program equips them to become integral members of interprofessional care, ultimately leading to optimized pharmaceutical care for patients. JMIR medical education 12 e79545 null 20260302 10.2196/79545 41773683 read0138449/published_papers/52813544 Yuki Kono Takahiro Niimura Yumiko Hosaka Koji Yahara Aki Hirabayashi Toshiki Kajihara Mitsuhiro Goda Koji Miyata Kei Kawada Fuka Aizawa Kenta Yagi Yuki Izumi Yuki Izawa-Ishizawa Keisuke Ishizawa Impact of antimicrobial stewardship interventions in pediatric populations on antimicrobial resistance: analysis of national claim and antimicrobial resistance surveillance data in Japan. BACKGROUND: Excessive antibiotic use contributes to the emergence of antimicrobial resistance (AMR). The Japanese government implemented an antimicrobial stewardship incentive program for the pediatric population in 2018. However, its effect on prescription patterns and the AMR rates remains unclear. OBJECTIVES: To investigate the impact of the implementation of the antimicrobial stewardship incentive program on AMR rates through changes in antimicrobial prescribing patterns. METHODS: We retrospectively analyzed prescription patterns using data from a nationwide claims database and extracted pediatric patient data from healthcare facilities with ≥20 beds from January 2014 to July 2021. The antibiotic prescription amounts were calculated per 1,000 patient-days. The AMR rates of urinary E. coli were analyzed using data from the comprehensive national AMR surveillance database. Changes were evaluated using interrupted time-series analysis. RESULTS: After the intervention, antibiotic prescription patterns in 8,292 healthcare facilities of both broad- and narrow-spectrum antimicrobials, but not of first-generation cephalosporin, showed a decreasing trend. Prescriptions of fluoroquinolone and broad-spectrum penicillin prescriptions changed from increasing to decreasing trends, whereas those of third-generation cephalosporins continued to decline. The AMR patterns of urinary E. coli to both broad- and narrow-spectrum antibiotics showed decreasing trends in over 800 healthcare facilities. CONCLUSIONS: After the introduction of the antimicrobial stewardship incentive program, prescriptions for broad-spectrum antibiotics and a part of narrow-spectrum antibiotics declined and the AMR rates of urinary E. coli to both broad- and narrow-spectrum antibiotics decreased. These findings suggest the effectiveness of policy-driven interventions for containing AMR in the pediatric population. The Journal of hospital infection null null 20260112 10.1016/j.jhin.2025.12.010 41534744 read0138449/published_papers/54165218 Kazuki Maeda Kei Kawada Toshinobu Hayashi Sota Koyama Tomoaki Ishida Toshihiko Yoshioka Hitoshi Fukuda Io Horikawa Fuka Aizawa Takahiro Niimura Kenta Yagi Mitsuhiro Goda Yuki Izawa-Ishizawa Keisuke Ishizawa Comparative Efficacy of Fosnetupitant and Fosaprepitant for Delayed Vomiting in Patients Receiving Irinotecan-Oxaliplatin Combination Chemotherapy: A Retrospective Propensity Score-Matched Study. PURPOSE: Appropriate prevention of chemotherapy-induced nausea and vomiting (CINV) is essential for improving patients' quality of life; however, no studies have compared neurokinin-1 receptor antagonists in regimens combining oxaliplatin and irinotecan. We aimed to compare the antiemetic efficacy of fosnetupitant and fosaprepitant in patients receiving FOLFIRINOX or FOLFOXIRI regimens. PATIENTS AND METHODS: We reviewed records of patients receiving FOLFIRINOX or FOLFOXIRI between April 1, 2018 and September 30, 2024 at Tokushima University Hospital. Eligible patients completed the first chemotherapy cycle, received standard triple antiemetic prophylaxis, and had complete nursing-recorded CINV follow-up data for days 1-7. Patients were matched 1:1 using propensity scores for age, sex, alcohol consumption history, prior treatment, regimen, and chemotherapy doses. The primary objective was to compare the incidence of vomiting during the long-delayed phase (days 6-7) between the fosnetupitant and fosaprepitant groups. The no-vomiting and no-nausea rates were compared using Fisher's exact test, and the time to first vomiting using the Log rank test. RESULTS: After matching, data from 68 balanced patient pairs were analyzed. The fosnetupitant group had higher no-vomiting rates in the long-delayed phase (100% vs. 91.2%, p=0.028) and overall period (95.6% vs. 83.8%, p=0.045), compared with the fosaprepitant group. No significant intergroup difference was observed in the overall no-nausea rate (26.5% vs. 32.3%, p=0.573). With fosnetupitant, the time to first vomiting was longer (3/68 vs. 11/68, hazard ratio: 0.20, p=0.045), injection site reactions were fewer (0.0% vs. 19.1%, p<0.001), and constipation and hiccup incidences were fewer (p>0.05). CONCLUSION: Despite the retrospective design, possible calendar-time confounding, and limited number of events, our results suggest that fosnetupitant offers better control of long-delayed and overall vomiting and a favorable safety profile, compared with fosaprepitant, in patients receiving FOLFIRINOX/FOLFOXIRI regimens. Cancer management and research 18 579955 579955 20260000 10.2147/CMAR.S579955 42273006 read0138449/published_papers/51571347 Kenshi Takechi Takehiro Kawashiri Keisuke Mine Soichiro Ushio Hirofumi Hamano Noriko Hida Kenji Momo Masanobu Uchiyama Mami Uchida Mamoru Tanaka Noriaki Hidaka Hideki Yasui Masahiro Ueda Ryohei Fujii Misaki Hashimoto Yasutaka Sakamoto Kana Uyama Takahiro Niimura Yuki Hanai Ayaka Tsuboya Keisuke Suzuki Naoya Kamiyama Hiromi Hagiwara Naoto Okada Yoshito Zamami Keisuke Ishizawa Effectiveness of Statins for Oxaliplatin-Induced Peripheral Neuropathy: A Multicenter Retrospective Observational Study. Chemotherapy-induced peripheral neuropathy, including oxaliplatin-induced peripheral neuropathy (OIPN), can have a negative impact on patient quality of life for months or even years after discontinuation of chemotherapy. Statins are commonly used for lowering cholesterol; however, evidence indicates that statins have multiple pleiotropic effects. Although statins are anticipated to exert neuroprotective actions against OIPN, no large-scale investigations have been conducted in real-world clinical settings. Our investigation aimed to determine if statins protected against OIPN. This multicentre retrospective study enrolled Japanese patients with cancer, including those with colorectal cancer (CRC), who received oxaliplatin-containing chemotherapy between April 2009 and December 2019. Propensity score matching between groups was performed to assess the relationship between the occurrence of OIPN and statin use. Among the examined 2657 patients receiving oxaliplatin, 24.7% had Grade ≥ 2 OIPN. There was no significant difference in the incidence of OIPN between the statin and non-statin groups, even after propensity score matching. However, among the matched patients with CRC (n = 510), statin use was associated with a significantly lower incidence of Grade ≥ 2 OIPN than no statin use (19.8% vs. 28.3%, respectively; p = 0.029). Our findings indicate that statins may protect against OIPN in patients with CRC. Clinical and translational science 18 10 e70318 null 20251000 10.1111/cts.70318 41021349 read0138449/published_papers/51571348 Yuhei Sonoda Fuka Aizawa Nanami Tomochika Kanaho Miyauchi Ayaka Nishibashi Shimon Takahashi Hidetaka Kosako Shota Tanida Kenta Yagi Takahiro Niimura Mitsuhiro Goda Kei Kawada Yuki Izawa-Ishizawa Keisuke Ishizawa Ursodeoxycholic acid alleviates multiple sclerosis via TGR5-dependent microglial regulation in mice. Multiple sclerosis (MS) causes demyelination of the central nervous system (CNS) because of excessive inflammation of peripheral tissues. The pathophysiological mechanisms remain unclear because of disease background variability; therefore, antibody drugs and disease-modifying agents are ineffective therapeutic options. Alterations in bile acid metabolism correlate with the progression of MS. However, the effects of bile acid supplementation on the amelioration of MS have not been fully elucidated. Thus, in this study, we aimed to investigate the effects of ursodeoxycholic acid (UDCA) on the CNS in a mouse model of MS. Repeated high-dose administration of UDCA significantly improved disease scores and alleviated tissue damage in the spinal cord. The number of Iba1-positive cells increased in the MS spinal cord, which decreased after UDCA treatment. The effect of UDCA ceased with the activation of the TGR5 inhibitor in mice with MS. Proteomic analysis of UDCA-treated activated MG6 cells revealed that the TGR5 inhibitor significantly decreased the expression of 40 proteins, including anti-neuroinflammatory proteins (A2M, AHSG, ALB, APOA1, APOH, and SPP2), and significantly increased the expression of six proteins (Atxn7l3b, Basp1, Plekha3, Ptma, and Rrp15). UDCA may potentially regulate MS progression by modulating microglial activity via TGR5 in the spinal cord. Overall, these findings suggest that UDCA has potential applications as a novel therapeutic agent for MS. European journal of pharmacology 1003 177941 177941 20250915 10.1016/j.ejphar.2025.177941 40653076 read0138449/published_papers/50914169 Yoshika Sakamoto Takahiro Niimura Mitsuhiro Goda Nanami Tomochika Wakana Murakawa Fuka Aizawa Kenta Yagi Hirofumi Hamano Yuki Izawa-Ishizawa Yoshito Zamami Keisuke Ishizawa Unravelling the cardioprotective effects of calcitriol in Sunitinib-induced toxicity: A comprehensive in silico and in vitro study. Sunitinib (SUN), a drug used to treat advanced renal cell carcinoma and other cancers, causes cardiotoxicity. This study aimed to identify a potential drug candidate to counteract SUN-induced cardiotoxicity. We analysed real-world data from adverse event report databases of existing clinically approved drugs to identify potential candidates. Through in silico analyses and in vitro experiments, the mechanisms of action were determined. The study identified calcitriol (CTL), an active form of vitamin D, as a promising candidate against SUN-induced cardiotoxicity. In H9c2 cells, SUN decreased cell viability significantly, whereas CTL mitigated this effect significantly. The SUN-treated group exhibited increased autophagy in H9c2 cells, which was reduced significantly in the CTL group. Bioinformatics analysis using Ingenuity Pathway Analysis revealed the mechanistic target of rapamycin (mTOR) as a common factor between autophagy and CTL. Notably, rapamycin, an mTOR inhibitor, nullified the effects of CTL on cell viability and autophagy. Furthermore, SUN treatment led to significant reductions in cardiomyocyte diameters and increases in their widths, changes that were inhibited by CTL. SUN also induced morphological changes in surviving H9c2 cells, causing them to adopt a rounded shape, whereas CTL improved their morphology to resemble the elongated shape of the control group. In conclusion, the findings of the present study suggest that CTL has the potential to prevent SUN-induced cardiomyocyte damage through autophagy, particularly via mTOR-mediated pathways. The findings indicate that CTL could serve as an effective prophylactic agent against SUN-induced cardiotoxicity, offering a promising avenue for further research and potential clinical applications. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 188 118137 118137 20250700 10.1016/j.biopha.2025.118137 40373630 read0138449/published_papers/50914168 Takahiro Niimura Mitsuhiro Goda Satoshi Nakano Toshiki Kajihara Koji Yahara Aki Hirabayashi Koji Miyata Marie Ikai Motoko Shinohara Yusuke Minato Masato Suzuki Keisuke Ishizawa Clinical outcomes of flomoxef versus cefmetazole in hospitalized patients with urinary tract infections: combined retrospective analyses of two real-world databases and in vitro data. BACKGROUND: Flomoxef and cefmetazole have been reported to be effective against broad-spectrum β-lactamase-producing bacteria and have gained attention as a potential alternative to carbapenems. This study aimed to compare the efficacy of these two drugs in treating urinary tract infection (UTI) by integrating in vitro data and two real-world databases. METHODS: The susceptibility rates of third-generation cephalosporin-resistant Escherichia coli and Klebsiella pneumoniae to flomoxef and cefmetazole were compared using comprehensive national antimicrobial resistance surveillance data. Combined antimicrobial activities against an extended-spectrum beta-lactamase (ESBL)-producing multidrug-resistant bacterial strain were tested by diagonal measurement of n-way drug interactions. The effectiveness of the two drugs in treating UTIs was compared using hospital stay duration data obtained from the Japan Medical Data Center (JMDC) Claims Database. RESULTS: Third-generation cephalosporin-resistant E. coli and K. pneumoniae, including ESBL-producing strains, were similarly susceptible to flomoxef and cefmetazole. In vitro assessment against an ESBL-producing multidrug-resistant strain revealed similar antimicrobial interaction patterns. JMDC Claims data analysis showed that the median hospital stay was 11 (95% confidence interval [CI]: 11-11) and 4 (95% CI: 3-5) days in the cefmetazole and flomoxef groups, respectively (log-rank test, P < 0.001). Moreover, the flomoxef group demonstrated a significantly lower frequency of adverse events such as C. difficile infection and renal failure. CONCLUSIONS: The effectiveness of flomoxef is comparable to that of cefmetazole in treating UTIs without major complications. Thus, flomoxef is a viable treatment option for UTIs in locales with a high prevalence of ESBL-producing strains. BMC medicine 23 1 396 396 20250701 10.1186/s12916-025-04130-x 40598449 read0138449/published_papers/54165276 新村 貴博 八木 健太 石澤 啓介 医療ビッグデータを用いたサルコペニア治療薬の開発 (公財)臨床薬理研究振興財団 臨床薬理の進歩 0914-4366 46 37 45 20250600 read0138449/published_papers/52813567 薗田 悠平 相澤 風花 西橋 彩香 八木 健太 新村 貴博 合田 光寛 川田 敬 石澤 有紀 石澤 啓介 胆汁酸製剤による多発性硬化症抑制効果の検討 徳島医学会 四国医学雑誌 2758-3279 81 1-2 83 83 20250600 read0138449/published_papers/49893038 Yumi Kawai Yasuko Kurata Hirofumi Hamano Takahiro Niimura Mitsuhiro Goda Yoshito Zamami Keisuke Ishizawa Hideki Nawa Incidence of Myocarditis Caused by Drugs Used for Ulcerative Colitis as Examined Using VigiBase, a Spontaneous Adverse Drug Reaction Reporting Database Pharmaceutical Society of Japan Biological and Pharmaceutical Bulletin 1347-5215 48 4 383 389 20250417 10.1248/bpb.b24-00766 read0138449/published_papers/49948700 Fuka Aizawa Kenta Yagi Maki Sato Takahiro Niimura Mitsuhiro Goda Yuki Izawa-Ishizawa Keisuke Ishizawa Influence of statin intervention on peripheral neuropathy in patients treated with anticancer drugs identified from the insurer database. BACKGROUND: Statins, hydroxymethylglutaryl-CoA reductase inhibitors, possess neuroprotective properties. Given the potential neuroprotective properties of statins and their prevalent use in clinical settings, we aimed to investigate their impact on chemotherapy-induced peripheral neuropathy (CIPN) in Japan by assessing both their safety and efficacy in this context. METHODS: We conducted a retrospective observational study using the Japan Medical Data Centre database, which includes data from 2005 to 2021. We included patients who underwent anticancer therapy and were categorized into non-statin (10,920) and statin (1,537) groups. These groups were matched using a propensity score, resulting in 2,548 non-statin and 1,274 statin users. The primary endpoints were the incidence of CIPN post-first prescription of each anticancer drug and overall survival. RESULTS: Treatment with statins did not increase the incidence of CIPN (non-statin 27.2% vs. statin 28.4%, P = 0.443). Nevertheless, the incidence of CIPN was significantly high among women (non-statin 28.0% vs. statin 33.2%, P = 0.025). Overall survival was not impacted by statin use (hazard ratio 0.98, 95%CI: 0.83-1.16, P = 0.8846). Among men treated with paclitaxel, we observed an improvement in overall survival (hazard ratio: 0.72; 95% CI: 0.56-0.92; P = 0.0110). CONCLUSIONS: The use of statins in patients with cancer was not associated with CIPN incidence. However, in men receiving paclitaxel treatment, statins may be linked to improved overall survival. Further studies are necessary to clarify the factors influencing prognosis and CIPN severity. Journal of pharmaceutical health care and sciences 11 1 27 27 20250407 10.1186/s40780-025-00428-3 40197323 read0138449/published_papers/49948705 Rie Ando-Matsuoka Kei Kawada Takahiro Niimura Hitoshi Fukuda Tomoaki Ishida Toshihiko Yoshioka Yu Kawanishi Tomohito Kadota Shinji Abe Fuka Aizawa Kenta Yagi Yuki Izawa-Ishizawa Mitsuhiro Goda Tetsuya Ueba Keisuke Ishizawa Risk factors for clazosentan-induced fluid retention in subarachnoid hemorrhage from the Japanese adverse event database. BACKGROUND: Clazosentan, a selective endothelin receptor antagonist, is used to prevent cerebral vasospasm. We investigated patient characteristics and concomitant medications associated with an increased risk of clazosentan-induced fluid retention, the risk factors of which remain unknown. METHODS: We retrospectively reviewed cases of clazosentan-induced adverse drug reactions from the Japanese Adverse Drug Event Report (JADER) database, published by the Pharmaceuticals and Medical Devices Agency. We investigated the time course of fluid retention onset following clazosentan administration before analyzing whether specific patient characteristics and concomitant medications were associated with an increased risk of clazosentan-induced fluid retention. RESULTS: Among 241 cases of clazosentan use identified, fluid retention occurred in 114 (47.3 %). The median time interval from clazosentan initiation to onset of fluid retention was 3 days, and 88.7 % of fluid retention cases were reported within 1 week of initiation. Patients with fluid retention were older than those without; patients >70 years old accounted for 63.16 % of the cohort with fluid retention vs 44.1 % of the cohort without fluid retention. Fluid retention occurred more frequently in patients with concomitant use of fasudil hydrochloride, a conventional vasospasm drug in Japan, than in those without. Multivariate logistic regression analysis revealed that older age (>70 years) and concomitant use of fasudil hydrochloride remained independent risk factors for fluid retention. CONCLUSIONS: Clazosentan-induced fluid retention occurred more frequently in older adult patients. Clazosentan combined with fasudil hydrochloride increased the incidence of fluid retention. These findings can guide pharmacological treatment of cerebral vasospasm in patients with subarachnoid hemorrhage. Journal of stroke and cerebrovascular diseases : the official journal of National Stroke Association 34 6 108296 108296 20250402 10.1016/j.jstrokecerebrovasdis.2025.108296 40179823 read0138449/published_papers/49222685 Ayu Minagi Hideki Nawa Mitsuhiro Goda Takahiro Niimura Koji Miyata Hirofumi Hamano Yoshito Zamami Keisuke Ishizawa Evaluation of Interstitial Lung Disease Complications Caused by Biologic Agents Using a Spontaneous Adverse Drug Reaction Reporting Database ABSTRACT Interstitial lung disease (ILD) is a clinically relevant adverse event associated with biologic agent use. However, the current incidence of ILD remains unclear as large‐scale risk assessments of biologic agents have not been conducted. The aim of this study was to clarify the association between biologic agent use and ILD development in clinical practice by detecting adverse event signals using a spontaneous adverse drug reaction database. The VigiBase database is used for spontaneous adverse event reporting. The analysis focused on nine biologics used to treat psoriasis, rheumatoid arthritis, and Crohn's disease. The safety of each biologic agent was evaluated using the information component signal detection method. There were 32,520,983 reports in VigiBase, of which 68,489 (0.21%) were for ILD. Signals were mainly detected for tumor necrosis factor‐α inhibitors when the information component for ILD caused by biologic agents was calculated. Comorbidity analysis in patients who developed ILD and analysis of the time from the start of treatment with each drug to ILD onset showed differences for each biologic agent. ILD is a serious adverse effect of biologic agents, and there are several cases in which a causal relationship with ILD development cannot be ruled out. The occurrence of interstitial ILD should be noted when using biologics, particularly TNF‐α inhibitors. Wiley Pharmacology Research &amp; Perspectives 2052-1707 13 2 null null 20250221 10.1002/prp2.70063 read0138449/published_papers/49258076 Yuki Kono Takahiro Niimura Mitsuhiro Goda Shiho Ueta Kei Kawada Koji Miyata Fuka Aizawa Kenta Yagi Yuki Izawa-Ishizawa Keisuke Ishizawa Cardiovascular Toxicity Profile of Macrolides Investigated Using VigiBase Data: A Pharmacovigilance Study. Macrolides are associated with cardiovascular toxicity risk. However, data on their cardiovascular toxicity profiles beyond QT prolongation are limited, and differences in the profiles among various macrolide antibiotics remain unclear. We investigated the cardiovascular toxicity profiles of different macrolides using VigiBase, a global database of individual case-safety reports. Disproportionality analysis was performed using VigiBase, the WHO Pharmacovigilance database, from 1968 to December 2023. Associations between five macrolides (erythromycin, clarithromycin, azithromycin, josamycin, and roxithromycin) and adverse events (20 cardiovascular toxicities and diarrhea as a positive control) were predicted using the reporting odds ratio. Reported outcomes were evaluated for suggested drug-adverse event associations. Among the 36,129,107 reports analyzed, azithromycin was the most commonly used macrolide, followed by erythromycin, clarithromycin, roxithromycin, and josamycin. Diarrhea was frequently reported among users. Azithromycin use was associated with hypertension, cardiac valve disorders, supraventricular tachyarrhythmias, ventricular tachyarrhythmias, torsade de pointes/QT prolongation, cardiac conduction disorders, heart failure, and hemorrhage-related laboratory abnormalities. Erythromycin and clarithromycin use were also associated with cardiac valve disorders, ventricular tachyarrhythmias, torsade de pointes/QT prolongation, and cardiac conduction disorders. The rates of caused/prolonged hospitalization in azithromycin-related hypertension, heart failure, and bleeding-related laboratory abnormality were 46%, 45%, and 50%, respectively. Each of the macrolide antimicrobials was associated with various cardiovascular toxicities, including Cardiac valve disorder, shock, and QT prolongation. Notably, azithromycin was associated with an increased frequency of reported hypertension and heart failure, distinguishing it from the other drugs. These results highlight the importance of considering the cardiovascular toxicity profile of individual macrolide antibiotics when prescribing them. Cardiovascular toxicology null null 20250219 10.1007/s12012-025-09970-w 39971867 read0138449/published_papers/52813574 新田 綾香 合田 光寛 新村 貴博 佐藤 真希 川田 敬 辻中 海斗 宮田 晃志 河野 祐輝 相澤 風花 石澤 啓介 石澤 有紀 八木 健太 中馬 真幸 股関節形成術の術後感染症における抗MRSA薬とリファンピシン併用の実臨床成績 診療報酬データベースを用いたレトロスペクティブ解析 徳島医学会 四国医学雑誌 2758-3279 80 5-6 257 258 20250200 read0138449/published_papers/49948822 新田 綾香 合田 光寛 新村 貴博 佐藤 真希 川田 敬 辻中 海斗 宮田 晃志 河野 祐輝 相澤 風花 石澤 啓介 石澤 有紀 八木 健太 中馬 真幸 股関節形成術の術後感染症における抗MRSA薬とリファンピシン併用の実臨床成績 診療報酬データベースを用いたレトロスペクティブ解析 徳島医学会 四国医学雑誌 2758-3279 80 5-6 257 258 20250200 read0138449/published_papers/49948815 坂口 暁 沖 良祐 佐藤 康敬 八木 健太 藤田 浩司 楊河 宏章 和泉 唯信 石澤 啓介 ALSを対象とした医師主導治験の被験者及びその家族を対象としたアンケート調査 (一社)日本内科学会 日本内科学会雑誌 1883-2083 114 193 193 20250200 read0138449/published_papers/52490385 Mitsuhiro Goda Takahiro Niimura Keisuke Ishizawa [Analysis of the therapeutic efficacy of bacterial infections through medical big data]. In recent years, many studies have been conducted on various diseases to evaluate clinical efficacy reflecting actual clinical conditions through comprehensive analysis using medical big data, which include various patient groups and factors in clinical practice. On the other hand, there are still very few research reports in the world related to the treatment of infectious diseases using medical big data. This is due to the fact that much medical big data lacks information on the causative organisms of infectious diseases and on determining the effectiveness of infectious disease treatment. In this paper, we introduce a research case study in which analysis on the effectiveness of infectious disease treatment was conducted using medical big data. In this study, we performed a retrospective analysis of two real databases with the aim of validating the usefulness of cefmetazole and flomoxef in urinary tract infections (UTI) in which broad-spectrum β-lactamase (ESBL)-producing bacteria are the primary initiating organisms. Third-generation cephalosporin-resistant E. coli and K. pneumoniae, including ESBL-producing strains, were similarly susceptible to flomoxef and cefmetazole. JMDC Claims data analysis showed that the median time of hospital stay duration was significantly shorter in the flomoxef group than in the cefmetazole group. Flomoxef exhibits effectiveness that is comparable to cefmetazole in treating UTI. When using currently available medical big data to conduct analyses related to infectious disease treatment, valuable analysis results may be obtained by understanding the characteristics of the database and collaborating with clinicians who are familiar with infectious disease treatment. Nihon yakurigaku zasshi. Folia pharmacologica Japonica 160 3 191 194 20250000 10.1254/fpj.24086 40307048 read0138449/published_papers/52400933 Masayuki Chuma Mitsuhiro Goda Hirofumi Hamano Takahiro Niimura Kenshi Takechi Kenta Yagi Yuki Izawa-Ishizawa Yoshito Zamami Keisuke Ishizawa Yoshikazu Tasaki [Promotion of the appropriate use of antimicrobial agents by utilizing medical big data]. The global surge in antimicrobial resistance (AMR) highlights the critical need for the development of innovative therapies and the appropriate use of antimicrobial agents. Our research focused on preventing, managing, and mitigating the adverse effects of treatments for infection with methicillin-resistant Staphylococcus aureus. In this review, we present our investigations utilizing medical big data. The first study aimed to elucidate the relationship between renal outcome and survival following the onset of vancomycin-associated nephrotoxicity (VAN). An initial analysis using the US Food and Drug Administration Adverse Events Reporting System (FAERS) database revealed elevated mortality rates among patients with VAN compared with those without VAN, forming the basis for further investigation. A subsequent, more rigorous, retrospective analysis using electronic medical records confirmed that poor survival outcomes were significantly associated with non-recovery from VAN, particularly when progression to acute kidney injury of stage ≥2 occurred. Therefore, preventing progression to severe VAN is critical for enhancing survival outcomes. The second study investigated the relationship between statin use and daptomycin-related musculoskeletal adverse events. By employing a mixed-method approach combining meta-analysis with disproportionality analysis of the FAERS data, a significant association between statin therapy and daptomycin-related rhabdomyolysis was identified. This highlights the importance of cautious statin and daptomycin use, with careful consideration of potential safety risks. Each medical big-data database possesses unique characteristics that require careful consideration during analysis. The accurate interpretation of medical big data, coupled with its integration with complementary methodologies, will produce more robust and reliable research outcomes across diverse fields. Nihon yakurigaku zasshi. Folia pharmacologica Japonica 160 3 178 183 20250000 10.1254/fpj.24081 40307046 read0138449/published_papers/52810754 高橋 志門 小川 敦 辻中 海斗 村上 千晶 石澤 啓介 鈴木 正論 振り返れば国試(第18回) てんかんの発作ゼロ,副作用ゼロにするには? (株)じほう 薬事 0016-5980 66 16 3161 3166 20241200 read0138449/published_papers/48126954 Fuka Aizawa Hirofumi Hamano Naoto Okada Kenta Yagi Mitsuhiro Goda Hideki Nawa Yuya Horinouchi Toshimi Nakamura Harumasa Hakuno Kazuaki Shinomiya Yoshito Zamami Masahiko Azuma Masashi Akaike Keisuke Ishizawa Assessing the effects of interprofessional education by hospital pharmacists on pharmaceutical students using a self-evaluation scale. BACKGROUND: Understanding the roles and competencies of professions outside of one's specialty is essential for providing efficient healthcare. However, it is difficult for medical professionals to understand the roles and competencies of other related professions while performing their duties. This study examined the impact of clinical practice-based interprofessional education (IPE) on pharmacy students, who are future medical professionals. METHODS: Sixty-eight pharmaceutical students undergoing clinical practice were divided into non-IPE or IPE groups, with the IPE group attending an educational program with medical students conducted by doctors, pharmacists, and teachers during the clinical practice period. The effect was evaluated through a group survey using self-administered questionnaires focusing on contributing to multidisciplinary team medicine based on the Readiness for Interprofessional Learning Scale. The survey included specific behavioral objectives (SBOs), the Readiness for Interpersonal Learning Scale (RIPLS), and Kikuchi's Scale of Social Skills (KiSS-18). RESULTS: Regardless of group, SBOs [non-IPE: 3.2, 95% CI (2.6-3.8), p < 0.001; IPE: 3.7, 95% CI (2.5-4.9), p < 0.001] and social skills [non-IPE: 4.0, 95% CI (2.5-6.1), p < 0.001; IPE: 6.7 95% CI (3.0-10.4), p < 0.001] showed improvement after the clinical practice. In RIPLS Factor 3, pharmacy students with IPE awareness scored significantly higher by 1.5 points [95% CI (0.2-2.8), p = 0.025] post-practice than those without IPE awareness. CONCLUSIONS: This study suggests that IPE for students during clinical practice could enhance their expertise in multidisciplinary medicine and facilitate the development of seamless team care in the future. TRIAL REGISTRATION: This study was retrospectively registered and conducted in compliance with the "Ethical Guidelines for Medical Research Involving Human Subjects" and was approved by The Ethics Committee of Tokushima University Hospital (approval number: 3544). Journal of pharmaceutical health care and sciences 10 1 61 61 20241001 10.1186/s40780-024-00382-6 39354644 read0138449/published_papers/47952727 Fuka Aizawa Haruna Kajimoto Ami Okabayashi Daishi Moriyama Kenta Yagi Shimon Takahashi Yuhei Sonoda Takahiro Shibata Mitsuhiro Goda Takahiro Niimura Yuki Izawa-Ishizawa Hirofumi Hamano Kei Kawada Yoshito Zamami Keisuke Ishizawa Statins ameliorate oxaliplatin- and paclitaxel-induced peripheral neuropathy via glutathione-S-transferase. Some therapeutic agents have been found to have effects beyond their primary indications. Peripheral neuropathy, a common side effect of chemotherapy, remains inadequately treated. Identifying additional properties of existing medications could thus uncover novel therapeutic avenues. Previous studies have identified an additional effect of simvastatin in reducing neuropathy; however, the mechanism underlying this effect remains unclear. We investigated the novel effects of statins on chemotherapy-induced peripheral neuropathy in mice. Mice treated with oxaliplatin or paclitaxel did not show exacerbation or improvement in cold sensations upon acetone testing with statin administration. However, concurrent oral statin treatment mitigated the nociceptive response to mechanical stimuli induced by each anti-tumor agent. Co-administration of a glutathione-S-transferase inhibitor, which modulates redox reactions, abolished the ameliorative effect of statins on mechanical nociceptive behavior. Additionally, the glutathione-S-transferase inhibitor did not affect normal sensory perception or impair the anti-tumor effect of chemotherapy agents. A search for GST-associated molecules and pathways using artificial intelligence revealed that GST regulates inflammatory cytokines as a regulatory or causative gene. Our findings suggest that statins have class effects that ameliorate cytotoxic anti-cancer drug-induced mechanical allodynia via GST pathway activation. Neurochemistry international 105863 105863 20240920 10.1016/j.neuint.2024.105863 39307458 read0138449/published_papers/47866977 Koji Miyata Yuki Izawa-Ishizawa Kaito Tsujinaka Honoka Nishi Syuto Itokazu Tatsumi Miyata Masateru Kondo Toshihiko Yoshioka Takahiro Niimura Fuka Aizawa Kenta Yagi Maki Sato Mizusa Hyodo Hirofumi Hamano Kei Kawada Masayuki Chuma Yoshito Zamami Koichi Tsuneyama Mitsuhiro Goda Keisuke Ishizawa Unveiling the association between fluoroquinolones and aortic diseases using real-world database analysis and pharmacological experiments. Fluoroquinolones, which are widely used antibiotics, have been linked to aortic disease, which prompted an FDA warning in 2018. Recent reports have challenged the perception that fluoroquinolones pose a significant risk for vascular diseases. This study aimed to investigate whether fluoroquinolones increase the risk of aortic diseases by focusing on the onset of aortic dissection. Levofloxacin (LVFX), a fluoroquinolone, was studied in vitro using cultured vascular cells and in vivo using a mouse model prone to aortic dissection. Risk of adverse drug events was analyzed using VigiBase, a global safety database, and a retrospective cohort analysis was conducted using the JMDC Claims database. LVFX resulted in endothelial cell injury and increased matrix metalloproteinases in vitro. However, in vivo studies showed no significant effect on elastin degradation or aortic dissection incidence. The effect of LVFX on endothelial injury was altered during the onset of dissection, exacerbating injury before onset but inhibiting it afterward. Safety database analysis showed no significant risk signals for aortic dissection associated with fluoroquinolones, which was supported by findings in the receipt database. Inconsistencies were observed in the in vitro and in vivo actions of fluoroquinolones and differences in their effects on aortic dissection and aneurysms. Despite cytotoxicity, the risk of aortic dissection was not significantly increased in clinical scenarios. Based on our findings, concerns regarding aortic diseases do not justify discontinuation of fluoroquinolone use. Further studies are needed to elucidate the conflicting actions of fluoroquinolones, taking into account background pathophysiology such as infection and inflammation. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 179 117418 117418 20240911 10.1016/j.biopha.2024.117418 39265233 read0138449/published_papers/47422443 Naoki Okamoto Kenta Yagi Sayaka Imawaka Mayu Takaoka Fuka Aizawa Takahiro Niimura Mitsuhiro Goda Koji Miyata Kei Kawada Yuki Izawa-Ishizawa Satoshi Sakaguchi Keisuke Ishizawa Asciminib, a novel allosteric inhibitor of BCR-ABL1, shows synergistic effects when used in combination with imatinib with or without drug resistance. In the treatment of chronic myeloid leukemia (CML), resistance to BCR-ABL inhibitors makes it difficult to continue treatment and is directly related to life expectancy. Therefore, asciminib was introduced to the market as a useful drug for overcoming drug resistance. While combining molecular targeted drugs is useful to avoid drug resistance, the new BCR-ABL inhibitor asciminib and conventional BCR-ABL inhibitors should be used as monotherapy in principle. Therefore, we investigated the synergistic effect and mechanism of the combination of asciminib and imatinib. We generated imatinib-resistant cells using the human CML cell line K562, examined the effects of imatinib and asciminib exposure on cell survival using the WST-8 assay, and comprehensively analyzed genetic variation related to drug resistance using RNA-seq and real-time PCR. A synergistic effect was observed when imatinib and asciminib were combined with or without imatinib resistance. Three genes, GRRP1, ESPN, and NOXA1, were extracted as the sites of action of asciminib. Asciminib in combination with BCR-ABL inhibitors may improve the therapeutic efficacy of conventional BCR-ABL inhibitors and prevent the development of resistance. Its dosage may be effective even at minimal doses that do not cause side effects. Further verification of this mechanism of action is needed. Additionally, cross-resistance between BCR-ABL inhibitors and asciminib may occur, which needs to be clarified through further validation as soon as possible. Pharmacology research & perspectives 12 4 e1214 null 20240800 10.1002/prp2.1214 39031848 read0138449/published_papers/47866984 Midori Iida Yurika Kuniki Kenta Yagi Mitsuhiro Goda Satoko Namba Jun-Ichi Takeshita Ryusuke Sawada Michio Iwata Yoshito Zamami Keisuke Ishizawa Yoshihiro Yamanishi A network-based trans-omics approach for predicting synergistic drug combinations. BACKGROUND: Combination therapy can offer greater efficacy on medical treatments. However, the discovery of synergistic drug combinations is challenging. We propose a novel computational method, SyndrumNET, to predict synergistic drug combinations by network propagation with trans-omics analyses. METHODS: The prediction is based on the topological relationship, network-based proximity, and transcriptional correlation between diseases and drugs. SyndrumNET was applied to analyzing six diseases including asthma, diabetes, hypertension, colorectal cancer, acute myeloid leukemia (AML), and chronic myeloid leukemia (CML). RESULTS: Here we show that SyndrumNET outperforms the previous methods in terms of high accuracy. We perform in vitro cell survival assays to validate our prediction for CML. Of the top 17 predicted drug pairs, 14 drug pairs successfully exhibits synergistic anticancer effects. Our mode-of-action analysis also reveals that the drug synergy of the top predicted combination of capsaicin and mitoxantrone is due to the complementary regulation of 12 pathways, including the Rap1 signaling pathway. CONCLUSIONS: The proposed method is expected to be useful for discovering synergistic drug combinations for various complex diseases. Communications medicine 4 1 154 154 20240729 10.1038/s43856-024-00571-2 39075184 read0138449/published_papers/49948832 糸数 柊人 宮田 辰巳 宮田 晃志 近藤 正輝 相澤 風花 新村 貴博 八木 健太 合田 光寛 石澤 啓介 石澤 有紀 川田 敬 杜仲葉エキスによる大動脈疾患発症抑制効果の検討 徳島医学会 四国医学雑誌 2758-3279 80 1-2 90 91 20240600 read0138449/published_papers/49948827 宮田 辰巳 糸数 柊人 福岡 媛乃 宮田 晃志 辻中 海斗 相澤 風花 新村 貴博 八木 健太 合田 光寛 石澤 啓介 石澤 有紀 川田 敬 レボフロキサシンの血管炎症への影響 徳島医学会 四国医学雑誌 2758-3279 80 1-2 91 91 20240600 read0138449/published_papers/48895672 糸数 柊人 宮田 辰巳 宮田 晃志 近藤 正輝 相澤 風花 新村 貴博 八木 健太 合田 光寛 石澤 啓介 石澤 有紀 川田 敬 杜仲葉エキスによる大動脈疾患発症抑制効果の検討 徳島医学会 四国医学雑誌 2758-3279 80 1-2 90 91 20240600 read0138449/published_papers/48895666 宮田 辰巳 糸数 柊人 福岡 媛乃 宮田 晃志 辻中 海斗 相澤 風花 新村 貴博 八木 健太 合田 光寛 石澤 啓介 石澤 有紀 川田 敬 レボフロキサシンの血管炎症への影響 徳島医学会 四国医学雑誌 2758-3279 80 1-2 91 91 20240600 read0138449/published_papers/49948847 新村 貴博 八木 健太 相澤 風花 石澤 有紀 濱野 裕章 合田 光寛 座間味 義人 石澤 啓介 薬剤師による探索的アプローチの実際∼CQからRQへの変換と試験の組み立て方∼ 医療データ解析を起点とした臨床研究の実践 (一社)日本臨床腫瘍薬学会 日本臨床腫瘍薬学会雑誌 2189-129X 36 70 70 20240500 read0138449/published_papers/49948841 相澤 風花 八木 健太 新村 貴博 石澤 啓介 臨床情報を活用したドラッグ・リポジショニング研究の最前線 臨床データから抗がん剤治療最適化を進める鍵を探す (公社)日本薬剤学会 日本薬剤学会年会講演要旨集 39 61 61 20240500 read0138449/published_papers/46678693 Yurie Oka Jun Matsumoto Tatsuaki Takeda Naohiro Iwata Takahiro Niimura Aya Fukuma Ozaki Kensuke Bekku Hirofumi Hamano Motoo Araki Keisuke Ishizawa Yoshito Zamami Noritaka Ariyoshi Adverse events of nivolumab plus ipilimumab versus nivolumab plus cabozantinib: a real-world pharmacovigilance study. BACKGROUND: No head-to-head clinical trials have compared the differences in adverse events (AEs) between nivolumab plus ipilimumab (NIVO-IPI) and nivolumab plus cabozantinib (NIVO-CABO) in the treatment of metastatic renal cell carcinoma (mRCC). AIM: We analysed the two largest real-world databases, the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS) and the World Health Organization's VigiBase, to elucidate the differences in AEs between NIVO-IPI and NIVO-CABO. METHOD: In total, 40,376 and 38,022 records were extracted from FAERS and VigiBase, and 193 AEs were analysed. The reporting odds ratios (ROR) with 95% confidence interval were calculated using a disproportionality analysis (NIVO-CABO/NIVO-IPI). RESULTS: The reported numbers of immune-related AEs, including myocarditis, colitis, and hepatitis, were significantly higher with NIVO-IPI (ROR = 0.18 for FAERS and 0.13 for VigiBase). Contrarily, the reported numbers of other AEs, including gastrointestinal disorders (ROR = 2.68 and 2.92) and skin and subcutaneous tissue disorders (ROR = 2.94 and 3.55), considered to be potentiated by the combination of NIVO and CABO, were higher with NIVO-CABO. CONCLUSION: Our findings contribute to the selection and clinical management of NIVO-IPI and NIVO-CABO, which minimizes the risk of AEs for individual patients with mRCC by considering distinctive differences in the AE profiles. International journal of clinical pharmacy null null 20240417 10.1007/s11096-024-01713-1 38632203 read0138449/published_papers/49948837 吉岡 俊彦 合田 光寛 神田 将哉 杉本 祐悟 石澤 有紀 八木 健太 相澤 風花 宮田 晃志 新村 貴博 櫻田 巧 桐野 靖 石澤 啓介 バルプロ酸ナトリウムのシスプラチン誘発腎障害予防薬としての可能性 徳島医学会 四国医学雑誌 2758-3279 79 5-6 275 276 20240300 read0138449/published_papers/49553250 濱野 裕章 座間味 義人 牛尾 聡一郎 新村 貴博 合田 光寛 石澤 有紀 石澤 啓介 抗がん剤心毒性の統合的な理解∼基礎から臨床まで∼ 大規模医療情報データベースを用いた薬剤性心毒性の予防法の開発 著者らの研究グループでは，薬剤性心毒性への対策を確立することを目標に，大規模な医療情報を活用した研究を行い，医療情報解析によって多数のリスク因子を特定し，それら因子を抑える薬剤について探索している．今回，これまでの研究成果を以下の項目に分けて紹介した．1)医療ビッグデータ解析によって抽出した免疫チェックポイント阻害薬(ICI)関連心筋炎のリスク因子(年齢，性別，薬物相互作用)．2)医療ビッグデータ解析およびオミクスデータベース解析によって抽出したドキソルビシン誘発心毒性における予防候補薬の評価． (公社)日本薬学会 薬学雑誌 1347-5231 144 3 257 264 20240300 read0138449/published_papers/46663512 吉岡 俊彦 合田 光寛 神田 将哉 杉本 祐悟 石澤 有紀 八木 健太 相澤 風花 宮田 晃志 新村 貴博 櫻田 巧 桐野 靖 石澤 啓介 バルプロ酸ナトリウムのシスプラチン誘発腎障害予防薬としての可能性 徳島医学会 四国医学雑誌 2758-3279 79 5-6 275 276 20240300 read0138449/published_papers/52810755 小川 敦 辻中 海斗 神田 将哉 石澤 啓介 鈴木 正論 振り返れば国試(第8回) 脳梗塞急性期の薬物療法のポイントは? (株)じほう 薬事 0016-5980 66 3 607 613 20240200 read0138449/published_papers/54165268 八木 健太 高岡 麻佑 佐川 真琳 相澤 風花 新村 貴博 合田 光寛 川田 敬 石澤 有紀 石澤 啓介 造血幹細胞移植前処置薬とシナジー効果を示す薬剤の探索とそのメカニズムの解明 (一社)日本臨床薬理学会 日本臨床薬理学会学術総会抄録集 2436-5580 45 np331 np332 20240000 read0138449/published_papers/54165263 新村 貴博 植田 詩穂 村川 和奏奈 阿部 菜摘 八木 健太 相澤 風花 合田 光寛 石澤 有紀 石澤 啓介 糖尿病治療薬に関連した筋萎縮に関する検討 (一社)日本臨床薬理学会 日本臨床薬理学会学術総会抄録集 2436-5580 45 np500 np500 20240000 read0138449/published_papers/54165258 相澤 風花 薗田 悠平 西橋 彩香 高橋 志門 八木 健太 新村 貴博 合田 光寛 川田 敬 石澤 有紀 石澤 啓介 胆汁酸製剤がもたらす多発性硬化症抑制作用とメカニズムの検討 (一社)日本臨床薬理学会 日本臨床薬理学会学術総会抄録集 2436-5580 45 np505 np506 20240000 read0138449/published_papers/54024901 合田 光寛 坂東 寛 小川 敦 川田 敬 新田 侑生 平井 啓太 中瀧 理仁 中馬 真幸 内藤 隆文 沼田 周助 田崎 嘉一 石澤 啓介 医療ビッグデータ解析を基盤としたラモトリギン誘発皮膚障害発症リスクに影響する薬剤の探索 (一社)日本臨床薬理学会 日本臨床薬理学会学術総会抄録集 2436-5580 45 np273 np274 20240000 read0138449/published_papers/49950127 中馬 真幸 合田 光寛 座間味 義人 濱野 裕章 武智 研志 石田 俊介 坂東 貴司 新村 貴博 近藤 正輝 石澤 有紀 田崎 嘉一 石澤 啓介 ステロイドはバンコマイシン関連腎障害を予防する ビッグデータ解析・基礎研究・臨床研究の統合による検討 (一社)日本臨床薬理学会 日本臨床薬理学会学術総会抄録集 2436-5580 44 2 2 20240100 read0138449/published_papers/49948852 植田 詩穂 新村 貴博 阿部 菜摘 村川 和奏奈 八木 健太 相澤 風花 合田 光寛 石澤 有紀 石澤 啓介 医療データベースを活用したサルコペニア治療薬の探索 (一社)日本臨床薬理学会 日本臨床薬理学会学術総会抄録集 2436-5580 44 2 2 20240100 read0138449/published_papers/46663518 植田 詩穂 新村 貴博 阿部 菜摘 村川 和奏奈 八木 健太 相澤 風花 合田 光寛 石澤 有紀 石澤 啓介 医療データベースを活用したサルコペニア治療薬の探索 (一社)日本臨床薬理学会 日本臨床薬理学会学術総会抄録集 2436-5580 44 2 2 20240100 read0138449/published_papers/46486444 Kei Kawada Tomoaki Ishida Shumpei Morisawa Kohei Jobu Youichirou Higashi Fuka Aizawa Kenta Yagi Yuki Izawa-Ishizawa Takahiro Niimura Shinji Abe Mitsuhiro Goda Mitsuhiko Miyamura Keisuke Ishizawa Atractylodes lancea (Thunb.) DC. [Asteraceae] rhizome-derived exosome-like nanoparticles suppress lipopolysaccharide-induced inflammation in murine microglial cells. BACKGROUND: Exosome-like nanoparticles (ELNs) mediate interspecies intercellular communications and modulate gene expression. HYPOTHESIS/PURPOSE: In this study, we isolated and purified ELNs from the dried rhizome of Atractylodes lancea (Thunb.) DC. [Asteraceae] (ALR-ELNs), a traditional natural medicine, and investigated their potential as neuroinflammatory therapeutic agents. METHODS: ALR-ELN samples were isolated and purified using differential centrifugation, and their physical features and microRNA contents were analyzed through transmission electron microscopy and RNA sequencing, respectively. BV-2 microglial murine cells and primary mouse microglial cells were cultured in vitro, and their ability to uptake ALR-ELNs was explored using fluorescence microscopy. The capacity of ALR-ELNs to modulate the anti-inflammatory responses of these cells to lipopolysaccharide (LPS) exposure was assessed through mRNA and protein expression analyses. RESULTS: Overall, BV-2 cells were found to internalize ALR-ELNs, which comprised three microRNAs (ath-miR166f, ath-miR162a-5p, and ath-miR162b-5p) that could have anti-inflammatory activity. Pretreatment of BV-2 cells with ALR-ELN prevented the pro-inflammatory effects of LPS stimulation by significantly reducing the levels of nitric oxide, interleukin-1β, interleukin-6, and tumor necrosis factor-α. Notably, the mRNA levels of Il1b, Il6, iNos, ccl2, and cxcl10 in BV-2 cells, which increased upon LPS exposure, were significantly reduced following ALR-ELN treatment. Moreover, the mRNA levels of heme oxygenase 1, Irf7, ccl12, and Irg1 also increased significantly following ALR-ELN treatment. In addition, pretreatment of primary mouse microglial cells with ALR-ELN prevented the pro-inflammatory effects of LPS stimulation by significantly reducing the levels of nitric oxide. CONCLUSION: Our findings indicate that ALR-ELNs exhibit anti-inflammatory effects on murine microglial cells. Further validation may prove ALR-ELNs as a promising neuroinflammatory therapeutic agent. Frontiers in pharmacology 15 1302055 1302055 20240000 10.3389/fphar.2024.1302055 38738173 read0138449/published_papers/46485662 中馬 真幸 合田 光寛 座間味 義人 濱野 裕章 武智 研志 石田 俊介 坂東 貴司 新村 貴博 近藤 正輝 石澤 有紀 田崎 嘉一 石澤 啓介 ステロイドはバンコマイシン関連腎障害を予防する ビッグデータ解析・基礎研究・臨床研究の統合による検討 (一社)日本臨床薬理学会 日本臨床薬理学会学術総会抄録集 2436-5580 44 2 2 20240100 read0138449/published_papers/46485642 Koji Miyata Yuki Izawa-Ishizawa Takahiro Niimura Hirofumi Hamano Fuka Aizawa Kenta Yagi Kei Kawada Yoshito Zamami Mitsuhiro Goda Keisuke Ishizawa The Association between PDE5 Inhibitors and Aneurysm/Arterial Dissection:A Pharmacovigilance Study Using WHO Safety Database. Aneurysm and arterial dissection have been reported as adverse drug events, associated with angiogenesis inhibitors and fluoroquinolones. Specifically, several cases of severe arterial disease following cGMP-specific phosphodiesterase type 5 (PDE5) inhibitors usage have recently been reported. It is necessary to ascertain the risks of serious adverse events caused by PDE5 inhibitors. We aimed to evaluate the association of aneurysm and artery dissection with PDE5 inhibitors using VigiBase, which is a World Health Organization database of spontaneously reported adverse events, for explorative hypothesis-generating analysis. We performed disproportionality analysis using a dataset from inception in 1967 to December 2022 and calculated reporting odds ratios (ROR) between PDE5 inhibitors and arterial diseases. We extracted 195,839 reports on PDE5 inhibitors with 254 reports of arterial disease as adverse events from VigiBase. Disproportionality analysis showed disproportional signals for PDE5 inhibitors (ROR, 2.30;95% confidence intervals, 2.04-2.61);disproportional signals were detected in analyses restricting the lesion site to the aorta or cerebral arteries. From stratified analysis, disproportional signals were noted in females, as well as males, generally recognized as a risk factor for artery diseases. This real-world data analysis suggests that PDE5 inhibitors may play a role in the development of lethal arterial disease. J. Med. Invest. 71 : 134-140, February, 2024. The journal of medical investigation : JMI 71 1.2 134 140 20240000 10.2152/jmi.71.134 38735709 read0138449/published_papers/44486794 Masaki Imanishi Takahisa Inoue Keijo Fukushima Ryosuke Yamashita Ryo Nakayama Masataka Nojima Kosuke Kondo Yoshiki Gomi Honoka Tsunematsu Kohei Goto Licht Miyamoto Masafumi Funamoto Masaya Denda Keisuke Ishizawa Akira Otaka Hiromichi Fujino Yasumasa Ikeda Koichiro Tsuchiya CA9 and PRELID2; hypoxia-responsive potential therapeutic targets for pancreatic ductal adenocarcinoma as per bioinformatics analyses. A strong hypoxic environment has been observed in pancreatic ductal adenocarcinoma (PDAC) cells, which contributes to drug resistance, tumor progression, and metastasis. Therefore, we performed bioinformatics analyses to investigate potential targets for the treatment of PDAC. To identify potential genes as effective PDAC treatment targets, we selected all genes whose expression level was related to worse overall survival (OS) in The Cancer Genome Atlas (TCGA) database and selected only the genes that matched with the genes upregulated due to hypoxia in pancreatic cancer cells in the dataset obtained from the Gene Expression Omnibus (GEO) database. Although the extracted 107 hypoxia-responsive genes included the genes that were slightly enriched in angiogenic factors, TCGA data analysis revealed that the expression level of endothelial cell (EC) markers did not affect OS. Finally, we selected CA9 and PRELID2 as potential targets for PDAC treatment and elucidated that a CA9 inhibitor, U-104, suppressed pancreatic cancer cell growth more effectively than 5-fluorouracil (5-FU) and PRELID2 siRNA treatment suppressed the cell growth stronger than CA9 siRNA treatment. Thus, we elucidated that specific inhibition of PRELID2 as well as CA9, extracted via exhaustive bioinformatic analyses of clinical datasets, could be a more effective strategy for PDAC treatment. Journal of pharmacological sciences 153 4 232 242 20231200 10.1016/j.jphs.2023.10.003 37973221 read0138449/published_papers/44357701 Takashi Bando Masayuki Chuma Hirofumi Hamano Takahiro Niimura Naoto Okada Masateru Kondo Yuki Izumi Shunsuke Ishida Toshihiko Yoshioka Mizuho Asada Yoshito Zamami Kenshi Takechi Mitsuhiro Goda Koji Miyata Kenta Yagi Yuki Izawa-Ishizaka Momoyo Azuma Hiroaki Yanagawa Yoshikazu Tasaki Keisuke Ishizawa Concomitant Use of Multiple Nephrotoxins including Renal Hypoperfusion Medications Causes Vancomycin-Associated Nephrotoxicity: Combined Retrospective Analyses of Two Real-World Databases. There is a growing concern about the relationship between vancomycin-associated nephrotoxicity (VAN) and concomitant use of nephrotoxins. We examined this relationship by combined retrospective analyses of two real-world databases. Initially, the FDA Adverse Event Reporting System (FAERS) was analyzed for the effects of concomitant use of one or more nephrotoxins on VAN and the types of combinations of nephrotoxins that exacerbate VAN. Next, electronic medical records (EMRs) of patients who received vancomycin (VCM) at Tokushima University Hospital between January 2006 and March 2019 were examined to confirm the FAERS analysis. An elevated reporting odds ratio (ROR) was observed with increases in the number of nephrotoxins administered (VCM + one nephrotoxin, adjusted ROR (95% confidence interval [CI]) 1.67 [1.51-1.85]; VCM + ≥2 nephrotoxins, adjusted ROR [95% CI] 1.54 [1.37-1.73]) in FAERS. EMRs analysis showed that the number of nephrotoxins was associated with higher incidences of VAN [odds ratio: 1.99; 95% CI: 1.42-2.78]. Overall, concomitant use of nephrotoxins was associated with an increased incidence of VAN, especially when at least one of those nephrotoxins was a renal hypoperfusion medication (furosemide, non-steroidal anti-inflammatory drugs, and vasopressors). The concomitant use of multiple nephrotoxins, especially including renal hypoperfusion medication, should be avoided to prevent VAN. Acta medica Okayama 77 6 595 605 20231200 10.18926/AMO/66151 38145933 read0138449/published_papers/44059726 Naoto Okada Hirofumi Hamano Kenta Yagi Takahiro Niimura Fuka Aizawa Mitsuhiro Goda Yoshito Zamami Takashi Kitahara Keisuke Ishizawa Effect of pre-treatment of EGFR-TKIs on immune checkpoint inhibitor-associated interstitial lung disease in lung cancer patients: Analysis using a Japanese claims database. BACKGROUND: Immune checkpoint inhibitors (ICI) and epidermal growth factor receptor-tyrosine kinase inhibitors (EGFR-TKI) are key drugs for the treatment of EGFR mutation-positive lung cancer. While previous studies reported that the concomitant use of these drugs increases the risk of interstitial lung disease (ILD), the impact of sequential treatment on ILD risk is unknown. This study aimed to analyze the impact of EGFR-TKI pre-treatment on the risk of developing ILD after subsequent ICI administration. MATERIALS AND METHODS: We conducted a retrospective study using a Japanese health insurance claims database. ILD-naive lung cancer patients who had first ICI administration during the screening period from July 2014 to February 2019 were selected. Patients who had ILD within 1 year of receiving the first ICI dose were included in the ILD group. Multivariate logistic regression analysis was conducted to evaluate the effect of pre-treatment with EGFR-TKI on the development of ICI-associated ILD. RESULTS: A total of 353 patients were included, of which 61 were included in the ILD group. The median time to onset of ILD after ICI administration was 3 months. Multivariate logistic regression analysis revealed that pre-treatment with EGFR-TKI was not associated with ICI-associated ILD (odds ratio: 0.26, 95% confidence interval: 0.033 - 2.01). CONCLUSION: Although further analyses are required to confirm our findings, this study indicated that pre-treatment with EGFR-TKI might not increase the ILD risk after ICI treatment. International journal of clinical pharmacology and therapeutics null null 20231116 10.5414/CP204491 37969096 read0138449/published_papers/43518416 Kaito Tsujinaka Yuki Izawa-Ishizawa Koji Miyata Toshihiko Yoshioka Kohei Oomine Honoka Nishi Masateru Kondo Syuto Itokazu Tatsumi Miyata Takahiro Niimura Maki Sato Fuka Aizawa Kenta Yagi Masayuki Chuma Yoshito Zamami Mitsuhiro Goda Keisuke Ishizawa Angiogenesis inhibitor-specific hypertension increases the risk of developing aortic dissection. Aortic dissection is an adverse event of angiogenesis inhibitors; however, the association between the drugs and aortic dissection is unclear. Therefore, we investigated if and how angiogenesis inhibitors increase the onset of aortic dissection using pharmacologically-induced aortic dissection-prone model (LAB) mice, cultured endothelial cells, and real-world databases, which is a novel integrated research approach. Disproportionality analysis was performed and calculated using the reporting odds ratio as a risk signal using a worldwide database of spontaneous adverse events to estimate the risk of adverse events. Angiogenesis inhibitors, but not other hypertension-inducing drugs, showed significant risk signals for aortic aneurysms and dissection. A retrospective cohort analysis using JMDC, a medical receipt database in Japan, showed that the history of atherosclerosis and dyslipidemia, but not hypertension, were significantly associated with the onset of aortic dissection during angiogenesis inhibitor medication administration. For in vivo studies, sunitinib (100 mg/kg/day) was administered to LAB mice. Sunitinib increased systolic blood pressure (182 mmHg vs. 288 mmHg with sunitinib; p<0.01) and the incidence of aortic dissection (40% vs. 59% with sunitinib; p = 0.34) in mice. In vivo and in vitro studies revealed that sunitinib increased endothelin-1 expression and induced endothelial cell damage evaluated by intracellular- and vascular cell adhesion molecule-1 expressions. The increased risk of developing aortic dissection with angiogenesis inhibitors is associated with the development of drug-specific hypertension via endothelial cell damage and endothelin-1 expression. Our findings are invaluable in establishing safer anticancer therapies and strategies to prevent the development of vascular toxicity in high-risk patients. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 167 115504 115504 20230916 10.1016/j.biopha.2023.115504 37722188 read0138449/published_papers/43479577 Toshihiko Yoshioka Mitsuhiro Goda Masaya Kanda Sayuri Itobayashi Yugo Sugimoto Yuki Izawa-Ishizawa Kenta Yagi Fuka Aizawa Koji Miyata Takahiro Niimura Hirofumi Hamano Takumi Sakurada Yoshito Zamami Keisuke Ishizawa Valproic acid treatment attenuates cisplatin-induced kidney injury by suppressing proximal tubular cell damage. Cisplatin treatment is effective against several types of carcinomas. However, it frequently leads to kidney injury, which warrants effective prevention methods. Sodium valproic acid is a prophylactic drug candidate with a high potential for clinical application against cisplatin-induced kidney injury. Therefore, in this study, we aimed to elucidate the mechanism underlying the prophylactic effect of valproic acid on cisplatin-induced kidney injury in a mouse model and HK2 and PODO cells with cisplatin-induced toxicity. In the mouse model of cisplatin-induced kidney injury, various renal function parameters and tubular damage scores were worsened by cisplatin, but they were significantly improved upon combination with valproic acid. No difference was observed in cisplatin accumulation between the cisplatin-treated and valproic acid-treated groups in whole blood and the kidneys. The mRNA expression levels of proximal tubular damage markers, apoptosis markers, and inflammatory cytokines significantly increased in the cisplatin group 72 h after cisplatin administration but significantly decreased upon combination with valproic acid. In HK2 cells, a human proximal tubular cell line, the cisplatin-induced decrease in cell viability was significantly suppressed by co-treatment with valproic acid. Valproic acid may inhibit cisplatin-induced kidney injury by suppressing apoptosis, inflammatory responses, and glomerular damage throughout the kidney by suppressing proximal tubular cell damage. However, prospective controlled trials need to evaluate these findings before their practical application. Clinical and translational science 16 11 2369 2381 20230912 10.1111/cts.13638 37700528 read0138449/published_papers/54025058 坂東 寛 合田 光寛 新田 侑生 中馬 真幸 小川 敦 櫻田 巧 桐野 靖 石澤 啓介 医療ビッグデータ解析を基盤としたラモトリギン誘発皮膚障害のリスク因子解析 (一社)日本精神薬学会 日本精神薬学会総会・学術集会プログラム・抄録集 7 81 81 20230900 read0138449/published_papers/52810756 辻中 海斗 小川 敦 神田 将哉 石澤 啓介 鈴木 正論 振り返れば国試(第3回) 適切な抗菌薬選択を行うための考え方は? (株)じほう 薬事 0016-5980 65 12 2490 2496 20230900 read0138449/published_papers/46932872 Takahiro Niimura Mitsuhiro Goda Koji Miyata Jun Matsumoto Toshihiko Yoshioka Hirofumi Hamano Fuka Aizawa Kenta Yagi Yuki Izawa-Ishizawa Yoshito Zamami Keisuke Ishizawa Evaluation of cardiovascular toxicity of the atezolizumab and bevacizumab combination <jats:p><jats:bold>Introduction:</jats:bold> The combination of atezolizumab, an immune checkpoint inhibitor (ICI), and bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, is the first choice for systemic therapy in hepatocellular carcinoma. Immune-related cardiovascular toxicity—myocarditis and pericarditis—are known to occur during ICI treatment. By contrast, VEGF inhibitors (VEGFIs) cause cardiovascular complications such as hypertension and heart failure. Thus, different cardiovascular toxicities have been recognized for ICIs and VEGFIs, but the impact of their combination remains unclear. Here, we aimed to investigate the cardiovascular toxicity profile of atezolizumab in combination with bevacizumab using the World Health Organization adverse event reporting database—VigiBase.</jats:p><jats:p><jats:bold>Methods:</jats:bold> We analyzed data included in VigiBase till December 2022. To evaluate the frequency of reports related to atezolizumab, bevacizumab, and their combinations for 21 adverse events, we calculated the reporting odds ratio and information component. Analyses of the fatality of various cardiovascular toxicities associated with the use of each drug were performed.</jats:p><jats:p><jats:bold>Results:</jats:bold> The database included 84,951, 10,595, and 2,092 reports of treatment with bevacizumab, atezolizumab, and their combination, respectively. The disproportionality signal of hypertension, arterial embolism and thrombosis, supraventricular tachyarrhythmias, heart failure, myocarditis, hemorrhage-related clinical events, venous embolism and thrombosis, cardiomyopathy, respiratory failure with combination regimen of atezolizumab and bevacizumab was detected. Signals of these adverse events were also detected treatment with either atezolizumab or bevacizumab alone. Venous embolism and thrombosis exhibited the highest fatality rate in the two drug combination (12.82%) relative to those of atezolizumab (6.19%) and bevacizumab (4.54%).</jats:p><jats:p><jats:bold>Discussion:</jats:bold> Cardiovascular toxicity, owing to the combination of atezolizumab and bevacizumab, was similar to that of each single agent, and no new safety concerns were observed. Caution should be exercised when combining the two drugs since the fatality rate of thromboembolism increases with combination treatment.</jats:p> Frontiers in Drug Safety and Regulation 2674-0869 null null 20230804 10.3389/fdsfr.2023.1213771 read0138449/published_papers/43209322 Naoto Okada Takahiro Niimura Atsuyuki Saisyo Yoshitaka Kawaguchi Keisuke Ishizawa Takashi Kitahara Pharmacovigilance Study on Eosinophilic Pneumonia Induced by Anti-MRSA Agents: Analysis Based on the FDA Adverse Event Reporting System. BACKGROUND: Eosinophilic pneumonia (EP) is a rare adverse event caused by several types of drugs, such as antibiotics; however, its characteristics remain poorly described. This study aimed to analyze the disproportionality between the occurrence of EP and anti-methicillin-resistant Staphylococcus aureus (anti-MRSA) agents and to characterize anti-MRSA agent-induced EP events using the Food and Drug Administration Adverse Event Reporting System (FAERS). METHOD: Disproportionality linking EP and anti-MRSA agents was analyzed through bayesian confidence propagation neural networks of information components and reporting odds ratio methodologies. The FAERS data set for the fourth quarter of 2012 to the fourth quarter of 2022 was used. We also analyzed the characteristics of EP induced by anti-MRSA agents. RESULTS: A total of 14 805 795 reports were obtained from FAERS. Disproportionality analysis revealed that the EP signal was detected only in cases with the administration of daptomycin (DAP). This disproportionality signal was consistently detected in the sensitivity analysis. When compared with other reports of DAP-related adverse events, the reports of DAP-related EP were characterized by male sex (odds ratio [OR], 1.94; 95% CI, 1.12-3.37), older age (>70 years; OR, 2.70; 95% CI, 1.68-4.33), and longer duration of treatment (>21 days; OR, 5.08; 95% CI, 3.21-8.05). CONCLUSIONS: This study revealed that among the anti-MRSA agents, disproportionality in the occurrence of EP was observed only with DAP. Our results suggest that sex, age, and treatment duration may affect the occurrence of DAP-induced EP. Clinicians should exercise caution regarding EP during DAP administration. Open forum infectious diseases 10 8 ofad414 null 20230800 10.1093/ofid/ofad414 37601729 read0138449/published_papers/43126381 Tsukasa Higashionna Keisaku Harada Akinari Maruo Takahiro Niimura Elizabeth Tan Quynh Thi Vu Takayoshi Kawabata Soichiro Ushio Hirofumi Hamano Makoto Kajizono Yoshito Zamami Keisuke Ishizawa Ko Harada Shiro Hinotsu Mitsunobu R Kano Hideharu Hagiya Toshihiro Koyama Trends in Head and Neck Cancer Mortality from 1999 to 2019 in Japan: An Observational Analysis. Globally, the numbers of head and neck cancer (HNC) cases and related deaths have recently increased. In Japan, few studies have examined crude or age-adjusted HNC mortality rates. Therefore, this study aimed to determine the trends in crude and age-adjusted mortality rates for HNC per million individuals in Japan from 1999 to 2019. Data on HNC-associated deaths were extracted from the national death certificate database using the International Classification of Diseases, Tenth Revision (n = 156,742). HNC mortality trends were analysed using joinpoint regression models to estimate annual percentage change (APC) and average APC (AAPC). Among men, no significant change was observed in the age-adjusted death rate trend from 1999 to 2014; however, a marked decrease was observed from 2014 to 2019. No changing point was observed in women. Age-adjusted mortality rates continuously decreased over the 21-year period, with an AAPC of -0.7% in men and -0.6% in women. In conclusion, the overall trend in age-adjusted rates of HNC-associated deaths decreased, particularly among men, in the past 5 years. These results will contribute to the formulation of medical policies to develop targeted screening and prevention programmes for HNC in Japan and determine the direction of treatment strategies. Cancers 15 15 null null 20230726 10.3390/cancers15153786 37568602 read0138449/published_papers/42924712 Mami Neishi Hirofumi Hamano Takahiro Niimura Masaya Denda Kenta Yagi Koji Miyata Tsung-Jen Lin Tsukasa Higashionna Mitsuhiro Goda Yoshito Zamami Keisuke Ishizawa Hideki Nawa Structural characterization of the optical isomers esomeprazole and omeprazole using the JADER and FAERS databases. BACKGROUND: It is unclear whether the s (-) form of esomeprazole (EPZ) has an improved safety profile when compared with its racemic form omeprazole (OPZ). We assessed the potential complications of these optical isomers when combined with cilostazol, clopidogrel, and prasugrel, which are frequently used concomitant medications. METHODS: Using two adverse event spontaneous reporting databases, Japanese Adverse Drug Event Report (JADER) and FDA Adverse Event Reporting System (FAERS), adverse event names for hemorrhage, venous/arterial embolization, and thrombus were obtained from the Medical Dictionary for Regulatory Activities. Reported odds ratios were calculated using a 2 × 2 contingency table, and a signal was considered present if the lower limit of the 95% confidence interval was >1. RESULTS: In combination with cilostazol, a hemorrhagic signal for OPZ in JADER and arterial emboli and thrombus signals for EPZ were detected in both databases. In combination with clopidogrel, OPZ showed arterial emboli and thrombus signals in JADER and venous/arterial emboli and thrombus signals in FAERS, while EPZ displayed arterial emboli and thrombus signals in FAERS. In contrast, when in combination with prasugrel, there were no adverse event signals in either database. CONCLUSION: This study has confirmed using big data, that EPZ, the optical isomer and racemic form of omeprazole, has the beneficial characteristics of being less sensitive to CYP, as was intended by its design. Toxicology and applied pharmacology 475 116632 116632 20230721 10.1016/j.taap.2023.116632 37482254 read0138449/published_papers/44097639 岡田 直人 東 桃代 石澤 啓介 北原 隆志 菌血症患者に対する薬剤師主導のprospective audit and feedbackがもたらす臨床効果 (公社)日本化学療法学会 日本化学療法学会雑誌 1884-5886 71 4 490 490 20230700 read0138449/published_papers/43003895 Satoru Mitsuboshi Hirofumi Hamano Takahiro Niimura Aya F Ozaki Pranav M Patel Tsung-Jen Lin Yuta Tanaka Ikuya Kimura Naohiro Iwata Shoya Shiromizu Masayuki Chuma Toshihiro Koyama Yoshihiro Yamanishi Yasunari Kanda Keisuke Ishizawa Yoshito Zamami Association between immune checkpoint inhibitor-induced myocarditis and concomitant use of thiazide diuretics. Although an association has been reported between diuretics and myocarditis, it is unclear whether the risk of immune checkpoint inhibitor (ICI)-induced myocarditis is affected by concomitant diuretics. Thus, the aim of this work was to evaluate the impact of concomitant diuretics on ICI-induced myocarditis. This cross-sectional study used disproportionality analysis and a pharmacovigilance database to assess the risk of myocarditis with various diuretics in patients receiving ICIs via the analysis of data entered into the VigiBase database through December 2022. Multiple logistic regression analysis was performed to identify risk factors for myocarditis in patients who received ICIs. A total of 90 611 patients who received ICIs, including 975 cases of myocarditis, were included as the eligible dataset. A disproportionality in myocarditis was observed for loop diuretic use (reporting odds ratio 1.47, 95% confidence interval [CI] 1.02-2.04, P = .03) and thiazide use (reporting odds ratio 1.76, 95% CI 1.20-2.50, P < .01) in patients who received ICIs. The results of the multiple logistic regression analysis showed that the use of thiazides (odds ratio 1.67, 95% CI 1.15-2.34, P < .01) was associated with an increased risk of myocarditis in patients who received ICIs. Our findings may help to predict the risk of myocarditis in patients receiving ICIs. International journal of cancer 153 8 1472 1476 20230612 10.1002/ijc.34616 37306521 read0138449/published_papers/46485672 西内 栞 合田 光寛 新村 貴博 生田 賢治 八木 健太 相澤 風花 濱野 裕章 座間味 義人 石澤 啓介 西内 栞 石澤 有紀 ドキソルビシン誘発心筋障害の予防薬探索 徳島医学会 四国医学雑誌 2758-3279 79 1-2 139 139 20230600 read0138449/published_papers/43479683 西内 栞 合田 光寛 新村 貴博 生田 賢治 八木 健太 相澤 風花 濱野 裕章 座間味 義人 石澤 啓介 西内 栞 石澤 有紀 ドキソルビシン誘発心筋障害の予防薬探索 徳島医学会 四国医学雑誌 2758-3279 79 1-2 139 139 20230600 read0138449/published_papers/43209355 泉 侑希 岡田 直人 辻中 海斗 阿部 あかね 合田 光寛 東 桃代 石澤 啓介 基質特異性拡張型β-ラクタマーゼ産生菌による菌血症治療におけるセフメタゾールへのde-escalationがもたらす臨床効果および医療経済効果 (一社)日本病院薬剤師会 日本病院薬剤師会雑誌 1341-8815 59 6 605 609 20230600 read0138449/published_papers/44097640 泉 侑希 岡田 直人 辻中 海斗 東 桃代 阿部 あかね 石澤 啓介 ESBL産生菌による菌血症に対してCMZへのde-escalationの有用性 日本感染症学会・日本化学療法学会 日本感染症学会総会・学術講演会・日本化学療法学会学術集会合同学会プログラム・抄録集 97·71 P 037 20230300 read0138449/published_papers/43209360 岡田 直人 東 桃代 石澤 啓介 北原 隆志 菌血症患者に対する薬剤師主導のprospective audit and feedbackがもたらす臨床効果 日本感染症学会・日本化学療法学会 日本感染症学会総会・学術講演会・日本化学療法学会学術集会合同学会プログラム・抄録集 97·71 O 116 20230300 read0138449/published_papers/43209358 泉 侑希 岡田 直人 辻中 海斗 東 桃代 阿部 あかね 石澤 啓介 ESBL産生菌による菌血症に対してCMZへのde-escalationの有用性 日本感染症学会・日本化学療法学会 日本感染症学会総会・学術講演会・日本化学療法学会学術集会合同学会プログラム・抄録集 97·71 P 037 20230300 read0138449/published_papers/41889252 Satoru Mitsuboshi Hirofumi Hamano Yurika Kuniki Takahiro Niimura Masayuki Chuma Soichiro Ushio Tsung-Jen Lin Jun Matsumoto Tatsuaki Takeda Makoto Kajizono Yoshito Zamami Keisuke Ishizawa Proton Pump Inhibitors and Rhabdomyolysis: Analysis of Two Different Cross-Sectional Databases. BACKGROUND: It is unclear whether use of a proton pump inhibitors (PPIs) increases the risk of rhabdomyolysis. OBJECTIVE: To clarify whether use of PPIs increases the risk of rhabdomyolysis. METHODS: This cross-sectional study analyzed data entered into the Medical Data Vision (MDV) database in Japan and into the U.S. Food and Drug Administration Adverse Event Reporting System (FAERS). The MDV data were analyzed to evaluate the association between use of PPIs and rhabdomyolysis. Then, the FAERS data were analyzed to evaluate whether the risk of rhabdomyolysis was increased further when a statin or fibrate was used concomitantly with a PPI. In both analyses, histamine-2 receptor antagonist was set as a comparator because it is used to treat gastric disease. In the MDV analysis, Fisher's exact test and multiple logistic regression analysis were performed. In the FAERS analysis, a disproportionality analysis using Fisher's exact test and multiple logistic regression analysis were performed. RESULTS: Multiple logistic regression analysis of both databases showed a significant association between use of PPIs and an increased risk of rhabdomyolysis (odds ratio [OR] = 1.74-1.95, P ≤ 0.01). However, use of a histamine-2 receptor antagonist was not significantly associated with increased risk of rhabdomyolysis. In the sub-analysis of the FAERS data, use of a PPI did not increase the risk of rhabdomyolysis in patients receiving a statin. CONCLUSION AND RELEVANCE: The data in 2 separate databases consistently suggest that PPIs may increase the risk of rhabdomyolysis. The evidence for this association should be assessed in further drug safety studies. The Annals of pharmacotherapy 57 11 10600280231156270 10600280231156270 20230227 10.1177/10600280231156270 36847276 read0138449/published_papers/41441929 Kenta Yagi Akinori Maruo Shunsuke Ishida Fuka Aizawa Soichiro Ushio Satoshi Sakaguchi Makoto Kajizono Takahiro Niimura Mitsuhiro Goda Hirofumi Hamano Yuki Izawa-Ishizawa Yoshito Zamami Keisuke Ishizawa Effects of vonoprazan and proton pump inhibitors on the efficacy of bevacizumab: a multicentre retrospective study. Gastric acid secretion inhibitors such as proton pump inhibitors (PPIs) and vonoprazan may change the duration of treatment with bevacizumab, a vascular endothelial growth factor (VEGF) inhibitor, for cancer. However, there are no data on this prolongation effect. Here, we aimed to determine whether the use of PPIs or vonoprazan in patients with cancer receiving bevacizumab affected the duration of bevacizumab treatment. This observational study was conducted at two national university hospitals in Japan and involved 222 patients using oral PPIs (N = 190) or vonoprazan (N = 32) at the start of bevacizumab treatment between January 2015 and December 2018. Patients who received only one course of bevacizumab were excluded. The primary endpoint was the duration of bevacizumab treatment. The duration of bevacizumab treatment varied significantly between the PPI and vonoprazan groups. For cancer types other than colorectal cancer (breast, lung, brain, and ovarian cancers), the median duration of treatment was 217 days (p < 0.05) and was longer in the vonoprazan group than in the PPI group. However, for colorectal cancer, the median duration of bevacizumab treatment was 147 days longer in the PPI group than in the vonoprazan group. Selection of appropriate gastric acid secretion inhibitors may improve the therapeutic efficacy of anti-VEGF drugs, including bevacizumab. Oestrogen is a key regulator of this effect and may be responsible for the varying association between PPI or vonoprazan administration and the difference in bevacizumab treatment duration between colon cancer and other cancer types. Clinical and experimental medicine 23 6 2799 2804 20230204 10.1007/s10238-023-01008-1 36738305 read0138449/published_papers/41281514 Naoto Okada Shimizu Taro Hidenori Ando Shingen Nakamura Mitsuhiro Goda Masahiro Abe Takashi Kitahara Tatsuhiro Ishida Keisuke Ishizawa Clinical Impact of Antipolyethylene Glycol (PEG) Antibody in Hematological Patients Administered PEGylated-Granulocyte Colony-Stimulating Factor. Polyethylene glycol (PEG) is a polymer covalently attached to proteins to improve their half-life and efficacy. We previously reported that the PEGylated granulocyte colony-stimulating factor (PEG-G-CSF) is immunogenic, which could adversely impact drug efficacy and safety in animal models. Here, we analyzed the relationship between anti-PEG antibody titers and the clinical impact of PEG-G-CSF in 19 hematological patients. A gradual decrease of anti-PEG antibody titers from baseline was observed after PEG-G-CSF administration. Of the 19 participants, 10 were assessed for noninfectious fever after the first administration of PEG-G-CSF and three experienced this reaction. The receiver operating characteristic curve revealed that the cut-off values of pretreated anti-PEG IgM and IgG titers for noninfectious fever were set at 5.0 and 96.6 U/mL, respectively. All patients who experienced noninfectious fever had anti-PEG antibody titers above this cut-off value (P = .033). An enzyme-linked immunosorbent assay revealed that some anti-PEG antibodies in patients with anti-PEG antibody titers above the cut-off value reacted with the PEGylated liposome. These results indicate the reactivity of the anti-PEG antibodies to PEGylated therapeutics observed in hematologic patients and the possibility of the relationship between high titers of anti-PEG antibodies and the development of adverse events after PEG-G-CSF administration. Clinical pharmacology in drug development 12 8 826 831 20230128 10.1002/cpdd.1225 36708147 read0138449/published_papers/40881636 Rie Ando-Matsuoka Kenta Yagi Mayu Takaoka Yuko Sakajiri Tomokazu Shibata Ryusuke Sawada Akinori Maruo Koji Miyata Fuka Aizawa Hirofumi Hamano Takahiro Niimura Yuki Izawa-Ishizawa Mitsuhiro Goda Satoshi Sakaguchi Yoshito Zamami Yoshihiro Yamanishi Keisuke Ishizawa Differential effects of proton pump inhibitors and vonoprazan on vascular endothelial growth factor expression in cancer cells. Proton pump inhibitors (PPIs) are potent inhibitors of gastric acid secretion, used as first-line agents in treating peptic ulcers. However, we have previously reported that PPIs may diminish the therapeutic effect of anti-vascular endothelial growth factor (VEGF) drugs in patients with cancer. In this study, we explored the effects of vonoprazan, a novel gastric acid secretion inhibitor used for the treatment of peptic ulcers, on the secretion of VEGF in cancer cells and attempted to propose it as an alternative PPI for cancer chemotherapy. The effects of PPI and vonoprazan on VEGF expression in cancer cells were compared by real-time reverse transcription-polymerase chain reaction and ELISA. The interaction of vonoprazan and PPIs with transcriptional regulators by docking simulation analysis. In various cancer cell lines, including the human colorectal cancer cell line (LS174T), PPI increased VEGF messenger RNA expression and VEGF protein secretion, while this effect was not observed with vonoprazan. Molecular docking simulation analysis showed that vonoprazan had a lower binding affinity for estrogen receptor alpha (ER-α), one of the transcriptional regulators of VEGF, compared to PPI. Although the PPI-induced increase in VEGF expression was counteracted by pharmacological ER-α inhibition, the effect of vonoprazan on VEGF expression was unchanged. Vonoprazan does not affect VEGF expression in cancer cells, which suggests that vonoprazan might be an alternative to PPIs, with no interference with the therapeutic effects of anti-VEGF cancer chemotherapy. Drug development research 84 1 75 83 20221209 10.1002/ddr.22013 36484282 read0138449/published_papers/42709596 神田 将哉 合田 光寛 吉岡 俊彦 座間味 義人 石澤 啓介 小川 敦 石田 俊介 相澤 風花 新村 貴博 八木 健太 石澤 有紀 大規模医療情報解析を活用したシスプラチン誘発急性腎障害に対する予防薬の探索 徳島医学会 四国医学雑誌 2758-3279 78 5-6 249 250 20221200 read0138449/published_papers/42709590 合田 光寛 神田 将哉 吉岡 俊彦 相澤 風花 櫻田 巧 小川 敦 新村 貴博 八木 健太 石澤 有紀 石澤 啓介 がん薬物療法に伴う腎障害とその予防 (一社)日本臨床薬理学会 日本臨床薬理学会学術総会抄録集 2436-5580 43 1 3 20221200 read0138449/published_papers/42709585 合田 光寛 相澤 風花 八木 健太 新村 貴博 櫻田 巧 小川 敦 石澤 有紀 座間味 義人 石澤 啓介 医療ビッグデータ解析と基礎研究を融合した研究手法によるハイブリッド創薬 (一社)日本臨床薬理学会 日本臨床薬理学会学術総会抄録集 2436-5580 43 3 4 20221200 read0138449/published_papers/42709578 坂口 暁 佐藤 康敬 石田 光代 前田 和輝 二見 明香里 八木 健太 沖 良祐 藤田 浩司 楊河 宏章 和泉 唯信 梶 龍兒 石澤 啓介 高用量メチルコバラミンの筋萎縮性側索硬化症に対する第III相試験の被験者及び家族におけるアンケート調査 (一社)日本臨床薬理学会 日本臨床薬理学会学術総会抄録集 2436-5580 43 3 3 20221200 read0138449/published_papers/40864829 Takahiro Niimura Yoshito Zamami Koji Miyata Takahisa Mikami Mizuho Asada Keijo Fukushima Masaki Yoshino Satoru Mitsuboshi Naoto Okada Hirofumi Hamano Takumi Sakurada Rie Matsuoka-Ando Fuka Aizawa Kenta Yagi Mitsuhiro Goda Masayuki Chuma Toshihiro Koyama Yuki Izawa-Ishizawa Hiroaki Yanagawa Hiromichi Fujino Yoshihiro Yamanishi Keisuke Ishizawa Characterization of Immune Checkpoint Inhibitor-Induced Myasthenia Gravis Using the United States Food and Drug Administration Adverse Event Reporting System. Myasthenia gravis (MG) is a rare but fatal adverse event of immune checkpoint inhibitors (ICI). We assessed whether patient characteristics differed between those with immune checkpoint inhibitor-related MG and those with idiopathic MG. Reports from the United States Food and Drug Administration Adverse Event Reporting System were analyzed. Multivariate analyses were conducted to evaluate the associations between age, sex, and ICI treatment and the reporting rate of MG. Among 5,464,099 cases between 2011 to 2019, 53,447 were treated with ICIs. MG was reported more often in ICI user. Multiple logistic regression analyses showed that the reporting rate of ICI-related MG did not differ significantly between male and female; however, it was higher in older people than in younger people (adjusted odds ratio, 2.4 [95% confidence interval: 1.84-3.13]). We also investigated useful signs for the early detection of myositis and myocarditis, which are fatal when overlapping with ICI-related MG. Patients with elevated serum creatine kinase or troponin levels were more likely to have concurrent myositis and myocarditis. Unlike idiopathic MG, there was no sex difference in the development of ICI-related MG, which may be more common in older people. Considering the physiological muscle weakness that occurs in the elderly, it may be necessary to monitor ICI-related MG more closely in older people. This article is protected by copyright. All rights reserved. Journal of clinical pharmacology 63 4 473 479 20221201 10.1002/jcph.2187 36453166 read0138449/published_papers/39869716 Naoto Okada Mari Takahashi Yumiko Yano Masami Sato Akane Abe Keisuke Ishizawa Momoyo Azuma Hospital outbreak of extended-spectrum beta-lactamase-producing Escherichia coli potentially caused by toilet and bath chair use. Infection prevention in practice 4 4 100239 100239 20221200 10.1016/j.infpip.2022.100239 36052314 read0138449/published_papers/40144719 Masayuki Chuma Hirofumi Hamano Takashi Bando Masateru Kondo Naoto Okada Yuki Izumi Shunsuke Ishida Toshihiko Yoshioka Mizuho Asada Takahiro Niimura Yoshito Zamami Kenshi Takechi Mitsuhiro Goda Koji Miyata Kenta Yagi Sachiko Kasamo Yuki Izawa-Ishizawa Momoyo Azuma Hiroaki Yanagawa Yoshikazu Tasaki Keisuke Ishizawa Non-recovery of vancomycin-associated nephrotoxicity is related to worsening survival outcomes-combined retrospective analyses of two real-world databases. There has been growing concern in worsening survival and renal outcomes following vancomycin-associated nephrotoxicity (VAN) onset, but the factors associated with these phenomena remain unclear. To examine these factors, we performed a retrospective study combining the analysis of two real-world databases. Initially, the FDA Adverse Event Reporting System (FAERS) was used to evaluate the relationship between VAN and mortality using odds ratios (ORs) and 95% confidence intervals (CIs). Next, electronic medical records (EMRs) were examined in a more robust cohort for evaluation of the association between renal outcomes and worsening survival using Cox proportional hazards regression models. FAERS analysis revealed a significant correlation between VAN occurrence and increased mortality (OR: 1.30; 95% CI: 1.17-1.46). EMR analysis showed that non-recovery of VAN was associated with increased hospital mortality (hazard ratio [HR]: 4.05; 95% CI: 2.42-6.77) and one-year mortality (HR: 3.03, 95% CI: 1.98-4.64). The HR for VAN recovery was lower for patients with acute kidney injury (AKI) stage ≥ 2 (HR: 0.09; 95% CI: 0.02-0.40). Thus, worsening survival outcomes were associated with non-recovery of VAN, whereby AKI stage ≥ 2 was a significant risk factor. Progression to severe VAN should be prevented for better survival outcomes. Basic & clinical pharmacology & toxicology 131 6 525 535 20220928 10.1111/bcpt.13799 36169161 read0138449/published_papers/40144726 Hideki Nawa Hirofumi Hamano Takahiro Niimura Koji Miyata Kenta Yagi Mitsuhiro Goda Yoshito Zamami Keisuke Ishizawa Evaluation of the potential complication of interstitial lung disease associated with antifibrotic drugs using data from databases reporting spontaneous adverse effects. Interstitial lung disease (ILD), as an adverse effect of certain drugs, leads to inflammation and damage in the walls of the alveoli, making it difficult for the alveoli to take up oxygen. Interstitial pneumonia with no identifiable cause is called idiopathic interstitial pneumonia (IIP), and, among the major IIPs, idiopathic pulmonary fibrosis (IPF) is diagnosed in about half of patients. Current treatment options are limited, among which the antifibrotic drugs nintedanib (Ofev) and pirfenidone (Pirespa) are the first-line drugs. In this study, we investigated the incidence of ILD possibly caused by antifibrotic agents using data from the Japanese Adverse Drug Event Report (JADER) database, a database of spontaneous adverse event reports published by the Pharmaceuticals and Medical Devices Agency (PMDA), and the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), published by the FDA. We used the FAERS and JADER to detect the signals of adverse events on the basis of reporting odds ratios. The relationship between indications and adverse events was clarified by separating indications and adverse events using the spontaneous adverse event reporting database with novel drug involvement. Regarding the involvement of nintedanib and pirfenidone in the development of ILD, JADER and FAERS showed signals for both nintedanib and pirfenidone as suspect drugs, and no signals for nintedanib or pirfenidone as concomitant drug interactions were detected. We highlight this because there are only a few effective drugs for IPF, and effective and safe drug therapies should be implemented by taking into consideration drug-induced ILD. Clinical and translational science 15 12 2982 2988 20220920 10.1111/cts.13419 36128688 read0138449/published_papers/40163367 Naoto Okada Momoyo Azuma Kaito Tsujinaka Akane Abe Mari Takahashi Yumiko Yano Masami Sato Takahiro Shibata Mitsuhiro Goda Keisuke Ishizawa Clinical Impact of a Pharmacist-Driven Prospective Audit with Intervention and Feedback on the Treatment of Patients with Bloodstream Infection. Evidence for the utility of pharmacist-driven antimicrobial stewardship programs remains limited. This study aimed to evaluate the usefulness of our institutional pharmacist-driven prospective audit with intervention and feedback (PAF) on the treatment of patients with bloodstream infections (BSIs). The effect of pharmacist-driven PAF was estimated using an interrupted time series analysis with a quasi-experimental design. The proportion of de-escalation during BSI treatment increased by 44% after the implementation of pharmacist-driven PAF (95% CI: 30-58, p &lt; 0.01). The number of days of therapy decreased by 16 per 100 patient days for carbapenem (95% CI: -28 to -3.5, p = 0.012) and by 15 per 100 patient days for tazobactam/piperacillin (95% CI: -26 to -4.9, p &lt; 0.01). Moreover, the proportion of inappropriate treatment in empirical and definitive therapy was significantly reduced after the implementation of pharmacist-driven PAF. Although 30-day mortality did not change, compliance with evidenced-based bundles in the BSI of Staphylococcus aureus significantly increased (p &lt; 0.01). In conclusion, our pharmacist-driven PAF increased the proportion of de-escalation and decreased the use of broad-spectrum antibiotics, as well as the proportion of inappropriate treatment in patients with BSI. This indicates that pharmacist-driven PAF is useful in improving the quality of antimicrobial treatment and reducing broad-spectrum antimicrobial use in the management of patients with BSI. Antibiotics (Basel, Switzerland) 11 9 null null 20220824 10.3390/antibiotics11091144 36139925 read0138449/published_papers/38753844 Naoto Okada Akikazu Murakami Masami Sato Shingen Nakamura Shiro Fujii Kimiko Sogabe Mamiko Takahashi Asami Okada Akane Abe Hideki Fujii Masahiro Abe Momoyo Azuma Keisuke Ishizawa First reported case of Lachnoanaerobaculum gingivalis bacteremia in an acute myeloid leukemia patient with oral mucositis during high dose chemotherapy Elsevier BV Anaerobe 1075-9964 76 102610 102610 20220800 10.1016/j.anaerobe.2022.102610 read0138449/published_papers/40876875 合田 光寛 神田 将哉 吉岡 俊彦 吉田 愛美 糸林 小友理 新村 貴博 櫻田 巧 小川 敦 岡田 直人 相澤 風花 八木 健太 濱野 裕章 石澤 有紀 座間味 義人 石澤 啓介 遺伝子発現および大規模医療情報データベースを活用したシスプラチン関連腎障害に対する予防薬の探索 日本心脈管作動物質学会 血管 0911-4637 45 1 62 62 20220600 read0138449/published_papers/40172909 合田 光寛 神田 将哉 吉岡 俊彦 吉田 愛美 糸林 小友理 新村 貴博 櫻田 巧 小川 敦 岡田 直人 相澤 風花 八木 健太 濱野 裕章 石澤 有紀 座間味 義人 石澤 啓介 遺伝子発現および大規模医療情報データベースを活用したシスプラチン関連腎障害に対する予防薬の探索 日本心脈管作動物質学会 血管 0911-4637 45 1 62 62 20220600 read0138449/published_papers/37966120 Shiori Nishiuchi Kenta Yagi Hiroumi Saito Yoshito Zamami Takahiro Niimura Koji Miyata Yoshika Sakamoto Kimiko Fukunaga Shunsuke Ishida Hirofumi Hamano Fuka Aizawa Mitsuhiro Goda Masayuki Chuma Yuki Izawa-Ishizawa Hideki Nawa Hiroaki Yanagawa Yasunari Kanda Keisuke Ishizawa Investigation of drugs for the prevention of doxorubicin-induced cardiac events using big data analysis. AIM: Doxorubicin, an anthracycline anti-tumour agent, is an essential chemotherapeutic drug; however, the adverse events associated with doxorubicin usage, including cardiotoxicity, prevent patients from continuing treatment. Here, we used databases to explore existing approved drugs with potential preventative effects against doxorubicin-induced cardiac events and examined their efficacy and mechanisms. METHODS: The Gene Expression Omnibus (GEO), Library of Integrated Network-based Cellular Signatures (LINCS), and Food and Drug Administration Adverse Events Reporting System (FAERS) databases were used to extract candidate prophylactic drugs. Mouse models of doxorubicin-induced cardiac events were generated by intraperitoneal administration of 20 mg/kg of doxorubicin on Day 1 and oral administration of prophylactic candidate drugs for 6 consecutive days beginning the day before doxorubicin administration. On Day 6, mouse hearts were extracted and examined for mRNA expression of apoptosis-related genes. RESULTS: GEO analysis showed that doxorubicin administration upregulated 490 genes and downregulated 862 genes, and LINCS data identified sirolimus, verapamil, minoxidil, prednisolone, guanabenz, and mosapride as drugs capable of counteracting these genetic alterations. Examination of the effects of these drugs on cardiac toxicity using FAERS identified sirolimus and mosapride as new prophylactic drug candidates. In model mice, mosapride and sirolimus suppressed the Bax/Bcl-2 mRNA ratio, which is elevated in doxorubicin-induced cardiotoxicity. These drugs also suppressed the expression of inflammatory cytokines Il1b and Il6 and markers associated with myocardial fibrosis, including Lgal3 and Timp1. CONCLUSION: These findings suggest that doxorubicin-induced cardiac events are suppressed by the administration of mosapride and sirolimus. European journal of pharmacology 928 175083 175083 20220531 10.1016/j.ejphar.2022.175083 35659512 read0138449/published_papers/40876882 合田 光寛 神田 将哉 吉岡 俊彦 新村 貴博 櫻田 巧 小川 敦 岡田 直人 相澤 風花 八木 健太 濱野 裕章 石澤 有紀 座間味 義人 石澤 啓介 副作用対策は今後も進歩するのか?マンネリ化させない研究のデザイン力 医療ビッグデータ解析と基礎研究を融合した研究手法による抗がん剤誘発副作用に対する予防法の探索 (一社)日本臨床腫瘍薬学会 日本臨床腫瘍薬学会雑誌 2189-129X 25 241 241 20220500 read0138449/published_papers/39869725 合田 光寛 神田 将哉 吉岡 俊彦 新村 貴博 櫻田 巧 小川 敦 岡田 直人 相澤 風花 八木 健太 濱野 裕章 石澤 有紀 座間味 義人 石澤 啓介 副作用対策は今後も進歩するのか?マンネリ化させない研究のデザイン力 医療ビッグデータ解析と基礎研究を融合した研究手法による抗がん剤誘発副作用に対する予防法の探索 (一社)日本臨床腫瘍薬学会 日本臨床腫瘍薬学会雑誌 2189-129X 25 241 241 20220500 read0138449/published_papers/37928597 Masaya Kanda Mitsuhiro Goda Akiko Maegawa Toshihiko Yoshioka Ami Yoshida Koji Miyata Fuka Aizawa Takahiro Niimura Hirofumi Hamano Naoto Okada Takumi Sakurada Masayuki Chuma Kenta Yagi Yuki Izawa-Ishizawa Hiroaki Yanagawa Yoshito Zamami Keisuke Ishizawa Discovery of preventive drugs for cisplatin-induced acute kidney injury using big data analysis. Cisplatin is effective against many types of carcinoma. However, a high rate of renal damage is a clinical problem. Thus, there is a need to establish a method to prevent it. Although various compounds have been reported to be effective against cisplatin-induced renal injury, there are no examples of their clinical application. Therefore, we attempted to search for prophylactic agents with a high potential for clinical application. We used Cascade Eye to identify genes that are altered during cisplatin-induced renal injury, Library of Integrated Network-based Cellular Signatures (LINCS) to identify drugs that inhibit changes in gene expression, and a large database of spontaneous adverse drug reaction reports to identify drugs that could prevent cisplatin-induced kidney injury in clinical practice. In total, 10 candidate drugs were identified. Using the US Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS), we identified drugs that reduce cisplatin-induced kidney injury. Fenofibrate was selected as a candidate drug to prevent cisplatin-induced kidney injury based on the FAERS analysis. A model was used to evaluate the efficacy of fenofibrate against cisplatin-induced renal injury. Studies using HK2 cells and mouse models showed that fenofibrate significantly inhibited cisplatin-induced renal injury but did not inhibit the antitumor effect of cisplatin. Fenofibrate is a candidate prophylactic drug with high clinical applicability for cisplatin-induced renal injury. Analysis of data from multiple big databases will improve the search for novel prophylactic drugs with high clinical applicability. For the practical application of these findings, evaluation in prospective controlled trials is necessary. Clinical and translational science 15 7 1664 1675 20220420 10.1111/cts.13282 35445533 read0138449/published_papers/37928592 Kenta Yagi Yasutaka Sato Satoshi Sakaguchi Mitsuhiro Goda Hirofumi Hamano Fuka Aizawa Mayuko Shimizu Arisa Inoue-Hamano Toshihide Nishimori Masato Tagi Marina Kanno Rie Matsuoka-Ando Toshihiko Yoshioka Yoshiko Matstubara Yuki Izawa-Ishizawa Rieko Shimizu Akinori Maruo Yurika Kuniki Yoshika Sakamoto Sayuri Itobayashi Yoshito Zamami Hiroaki Yanagawa Keisuke Ishizawa A web-based survey of educational opportunities of medical professionals based on changes in conference design during the COVID-19 pandemic. Owing to the coronavirus disease 2019 (COVID-19) pandemic, understanding how to hold future online academic conferences effectively is imperative. We assessed the impact of COVID-19 on academic conferences, including facilities and settings for attendance, participation status, cost burden, and preferences for future styles of holding conferences, through a web-based questionnaire survey of 2,739 Japanese medical professionals, from December 2020 to February 2021. Of the participants, 28% preferred web conferences, 60% preferred a mix of web and on-site conferences, and 12% preferred on-site conferences. Additionally, 27% of the presenters stopped presenting new findings at web conferences. The proportion of participants who audio-recorded or filmed the sessions, despite prohibition, was six times higher at web than face-to-face conferences. Since the COVID-19 outbreak, the percentage of participants attending general presentations decreased from 91 to 51%. While web conferencing offers advantages, these are offset by a decrease in presentations pertaining to novel findings and data. Supplementary Information: The online version contains supplementary material available at 10.1007/s10639-022-11032-5. Education and information technologies 27 7 1 16 20220418 10.1007/s10639-022-11032-5 35464114 read0138449/published_papers/40943400 今倉 健 佐藤 正大 小山 壱也 新村 貴博 村上 行人 山下 雄也 土師 恵子 香川 耕造 河野 弘 座間味 義人 石澤 啓介 西岡 安彦 In silico解析により同定されたPLK阻害剤のブレオマイシン誘発肺線維症モデルマウスにおける効果の検討 (一社)日本呼吸器学会 日本呼吸器学会誌 2186-5884 11 243 243 20220400 read0138449/published_papers/37795062 Yoshito Zamami Takahiro Niimura Takehiro Kawashiri Mitsuhiro Goda Yutaro Naito Keijo Fukushima Soichiro Ushio Fuka Aizawa Hirofumi Hamano Naoto Okada Kenta Yagi Koji Miyata Kenshi Takechi Masayuki Chuma Toshihiro Koyama Daisuke Kobayashi Takao Shimazoe Hiromichi Fujino Yuki Izawa-Ishizawa Keisuke Ishizawa Identification of prophylactic drugs for oxaliplatin-induced peripheral neuropathy using big data. BACKGROUND: Drug repositioning is a cost-effective method to identify novel disease indications for approved drugs; it requires a shorter developmental period than conventional drug discovery methods. We aimed to identify prophylactic drugs for oxaliplatin-induced peripheral neuropathy by drug repositioning using data from large-scale medical information and life science information databases. METHODS: Herein, we analyzed the reported data between 2007 and 2017 retrieved from the FDA's database of spontaneous adverse event reports (FAERS) and the LINCS database provided by the National Institute of Health. The efficacy of the drug candidates for oxaliplatin-induced peripheral neuropathy obtained from the database analysis was examined using a rat model of peripheral neuropathy. Additionally, we compared the incidence of peripheral neuropathy in patients who received oxaliplatin at the Tokushima University Hospital, Japan. The effects of statins on the animal model were examined in six-week-old male Sprague-Dawley rats and seven or eight-week-old male BALB/C mice. Retrospective medical chart review included clinical data from Tokushima University Hospital from April 2009 to March 2018. RESULTS: Simvastatin, indicated for dyslipidemia, significantly reduced the severity of peripheral neuropathy and oxaliplatin-induced hyperalgesia. In the nerve tissue of model rats, the mRNA expression of Gstm1 increased with statin administration. A retrospective medical chart review using clinical data revealed that the incidence of peripheral neuropathy decreased with statin use. CONCLUSION AND RELEVANCE: Thus, drug repositioning using data from large-scale basic and clinical databases enables the discovery of new indications for approved drugs with a high probability of success. Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie 148 112744 112744 20220400 10.1016/j.biopha.2022.112744 35240525 read0138449/published_papers/37829859 Takumi Sakurada Hiroshi Nokihara Tadashi Koga Yoshito Zamami Mitsuhiro Goda Kenta Yagi Hirofumi Hamano Fuka Aizawa Hirokazu Ogino Seidai Sato Yasushi Kirino Hisatsugu Goto Yasuhiko Nishioka Keisuke Ishizawa Prevention of Pemetrexed-Induced Rash Using Low-Dose Corticosteroids: A Phase II Study. BACKGROUND: Rash eruptions are a common side-effect of pemetrexed, for which the administration of 8 mg/day of dexamethasone for 3 days from the day preceding pemetrexed administration is recommended. This study aimed to prospectively assess the effectiveness of prophylactic administration of low-dose dexamethasone for pemetrexed-induced rashes. METHODS: This single-arm, phase II study recruited patients with non-squamous non-small cell lung cancer and malignant pleural mesothelioma scheduled to receive chemotherapy including pemetrexed. Patients received 2 mg of dexamethasone daily from days 2 to 6 after chemotherapy with pemetrexed. The primary endpoint was the 3-week incidence of rash eruptions. RESULTS: Twenty-five patients were enrolled between September 2017 and May 2019. The incidence of rash after 3 weeks was 16.7%. Rashes erupted mainly on the upper half of the body, such as the chest and neck, and were of grades 1 and 2 in 2 patients each. No rashes of grade 3 or higher were observed, and there were no adverse events associated with additional corticosteroids. CONCLUSION: Prophylactic administration of low-dose dexamethasone for 5 days from the day after pemetrexed administration resulted in a milder incidence and severity of rash. These findings may provide a standard preventative strategy for pemetrexed-induced rashes. (Trial identifier: UMIN000025666). The oncologist 27 7 e554-e560 null 20220324 10.1093/oncolo/oyab077 35325241 read0138449/published_papers/37783367 Masayuki Chuma Aki Nakamoto Takashi Bando Takahiro Niimura Yutaka Kondo Hirofumi Hamano Naoto Okada Mizuho Asada Yoshito Zamami Kenshi Takechi Mitsuhiro Goda Koji Miyata Kenta Yagi Toshihiko Yoshioka Yuki Izawa-Ishizawa Hiroaki Yanagawa Yoshikazu Tasaki Keisuke Ishizawa Association between statin use and daptomycin-related musculoskeletal adverse events: A mixed approach combining a meta-analysis and a disproportionality analysis. BACKGROUND: There is a growing concern about the association between the combined use of daptomycin (DAP) and statins and the occurrence of musculoskeletal adverse events (MAEs), but this remains controversial. This study aimed to clarify the association between statin use and DAP-related MAEs. METHODS: We used a mixed approach that combines two methodologies. First, we conducted a meta-analysis to examine the effects of statin use on DAP-related MAEs. Second, we conducted a disproportionality analysis using the FDA Adverse Events Reporting System (FAERS) to further confirm the results of the meta-analysis and to examine the effect of each type of statin on DAP-related MAEs in a large population. RESULTS: In the meta-analysis, statin use significantly increased the incidence of DAP-related rhabdomyolysis (odds ratio [OR]: 3.83, 95% confidence interval [CI]: 1.43-10.26) but not DAP-related myopathy (OR: 1.72, 95% CI: 0.95-3.12). In the disproportionality analysis using the FAERS, the use of statin significantly increased the reporting OR (ROR) for DAP-related myopathy (ROR: 5.69, 95% CI: 4.31-7.51) and rhabdomyolysis (ROR: 5.77, 95% CI: 4.33-7.68). Atorvastatin, rosuvastatin, and simvastatin all increased the incidence of DAP-related myopathy and rhabdomyolysis. CONCLUSION: The mixed approach combining a meta-analysis and disproportionality analysis showed that statin use was associated with the occurrence of DAP-related rhabdomyolysis. The appropriate use of statins and DAP should be performed with careful consideration of its safety. Clinical infectious diseases : an official publication of the Infectious Diseases Society of America 75 8 1416 1422 20220309 10.1093/cid/ciac128 35262686 read0138449/published_papers/43905285 朝田 瑞穂 見神 尊修 新村 貴博 座間味 義人 中馬 真幸 合田 光寛 石澤 啓介 植沢 芳広 医療ビックデータを活用した免疫チェックポイント阻害剤関連肺炎のリスク因子に関する検討 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 142 26PO1 14 20220300 read0138449/published_papers/39822864 朝田 瑞穂 見神 尊修 新村 貴博 座間味 義人 中馬 真幸 合田 光寛 石澤 啓介 植沢 芳広 医療ビックデータを活用した免疫チェックポイント阻害剤関連肺炎のリスク因子に関する検討 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 142 26PO1 14 20220300 read0138449/published_papers/39100652 安藤 里英 八木 健太 岡本 尚大 高岡 麻佑 相澤 風花 濱野 裕章 石澤 有紀 合田 光寛 座間味 義人 石澤 啓介 各種プロトンポンプ阻害剤のがん細胞におけるVEGF発現に与える影響 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 142 28H pm04S 20220300 read0138449/published_papers/39100647 根石 茉実 濱野 裕章 新村 貴博 宮田 晃志 八木 健太 合田 光寛 座間味 義人 石澤 啓介 名和 秀起 有害事象自発報告データベースに基づく光学異性体が薬剤間相互作用に与える影響についての検討 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 142 28PO1 45S 20220300 read0138449/published_papers/39100643 大西 明日香 名和 秀起 濱野 裕章 新村 貴博 宮田 晃志 八木 健太 合田 光寛 座間味 義人 石澤 啓介 自発的副作用報告データベースを用いた，抗線維化薬と間質性肺疾患との関連性についての検討 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 142 28PO1 46 20220300 read0138449/published_papers/36448380 Satoru Mitsuboshi Takahiro Niimura Fuka Aizawa Mitsuhiro Goda Yoshito Zamami Keisuke Ishizawa Atenolol and mortality events in patients with chronic kidney disease: Analysis of data from the Japanese Adverse Drug Event Report database. Basic & clinical pharmacology & toxicology 130 4 553 556 20220216 10.1111/bcpt.13717 35174631 read0138449/published_papers/42007548 中馬 真幸 濱野 裕章 坂東 貴司 新村 貴博 岡田 直人 笠茂 紗千子 八木 健太 合田 光寛 座間味 義人 楊河 宏章 石澤 啓介 田崎 嘉一 バンコマイシン関連腎障害発症後の腎障害遷延は，生命予後を悪化させる― 2種類のリアルワールドデータを用いた融合解析 ― 【目的】バンコマイシン(VCM)関連腎障害(VAN; VCM-associated nephrotoxicity)は，投与症例の約10∼40%に発症する重篤な有害事象である．近年，発症後の腎障害遷延や生命予後の悪化が問題となっているが，転帰に関連する因子は明らかになっていない．今回，VAN発症後の腎障害遷延や生命予後に関連する因子について検討した． 【方法】2つのリアルワールドデータを用いて解析した．まず，世界最大規模の副作用自発報告が集積されているFAERS (FDA Adverse Event Reporting System)を用いてVAN発症と死亡の関係を検討した(1. FAERS解析)．次に，詳細な情報を得られる診療情報データ(EMR: Electronic Medical Records)を用いて，VAN発症後の腎機能遷延および生命予後の悪化に関連する因子を検討した(2. EMR解析)． (1.FAERS解析) 2004年第1期∼2020年第1期に，注射用VCMが投与された10,414例の報告を解析した．VAN発症と死亡の関係は，ロジスティック回帰分析により検討した． (2. EMR解析) 2006年1月∼2019年3月に徳島大学病院において，VCMが初回投与された482例を解析した．VAN発症後の腎障害遷延および生命予後に対する観察期間は，それぞれ7日，1年間とした．VAN発症後の転帰に関連する因子は，Cox比例ハザード分析により検討した． 【結果・考察】FAERS解析におけるVAN発症例の死亡率 (23.3%, 613/2634)は，非発症例 (17.2%, 1338/7780)よりも有意に高かった [調整オッズ比: 1.43, 95%信頼区間(CI): 1.28-1.59]．FAERS解析にてVAN発症後の死亡率上昇が示唆されたため，VAN発症後の予後悪化に関連する因子をEMR解析にて検討した．全482例中，VAN発症は72例(14.9%)，院内死亡は74例(15.4%)に認められた．1年の観察期間における生存は234例 (48.5%)，死亡は136例 (28.2%)，打ち切りは112例 (23.2%)であった．VAN発症後の腎障害遷延は，院内死亡[ハザード比 (HR):4.05, 95%CI: 2.42-6.77]および1年死亡(HR: 3.03, 95% CI: 1.98-4.64]に有意に関連していた．腎障害の改善率は，AKIステージ≧2に進展したVAN発症例で有意に低かった (HR: 0.09; 95% CI: 0.02-0.40)．VAN発症後の生命予後悪化には腎障害の遷延が関連しており，そのリスク因子はAKIステージ≧2への進展であることが示された． 【結論】VCM投与症例の生命予後改善には，VANの発症と重症化を予防することが重要である． 一般社団法人 日本臨床薬理学会 日本臨床薬理学会学術総会抄録集 2436-5580 43 3-C-O08-3 null 20220000 10.50993/jsptsuppl.43.0_3-c-o08-3 1390013087509529984 read0138449/published_papers/42007541 Niimura Takahiro 新村 貴博 Unten Hiroto 運天 拡人 Hamano Hirofumi 濱野 裕章 Uchida Kazushi 内田 和志 Tomochika Nanami 友近 七海 Miyata Koji 宮田 晃志 Goda Mitsuhiro 合田 光寛 Yagi Kenta 八木 健太 Aizawa Fuka 相澤 風花 Izawa-Ishizawa Yuki 石澤 有紀 Zamami Yoshito 座間味 義人 Ishizawa Keisuke 石澤 啓介 Development of a novel mouse model of immune checkpoint inhibitor-associated myocarditis 免疫チェックポイント阻害剤関連心筋炎の新規病態モデル開発 Immune Checkpoint Inhibitors (ICI) show anti-tumor activity against various types of cancer, but they also disrupt the balance of the immune system and cause autoimmune-like adverse events. ICI-related myocarditis, in particular, has a fatality rate of over 40%, making the development of preventive and therapeutic agents an urgent priority. In present study, we developed a simple and reproducible experimental model for ICI-associated myocarditis. Myocardial myosin peptide (50 µg) was administered subcutaneously to male, 8-week-old BALB/c wild-type and PD-1KO mice at day 0 and 7. Three weeks after the initial myosin administration, the development of myocarditis was evaluated. HE staining and Masson trichrome staining showed inflammatory cell infiltration and fibrosis in myocardial tissue in myosin peptide-treated PD-1 KO mice. Next, the involvement of CD4⁺ and CD8⁺ cells was examined by immunostaining, and the infiltration of CD4⁺ and CD8⁺ cells was confirmed in the hearts of myosin-treated PD-1KO mice. Finally, the results of real-time PCR showed that myosin administration tended to increase gene expression of inflammatory cytokines and fibrosis markers in the hearts of PD-1KO mice. It is expected that this model will be used to develop new prophylactic and therapeutic agents for ICI-associated myocarditis. Japanese Pharmacological Society 公益社団法人 日本薬理学会 Proceedings for Annual Meeting of The Japanese Pharmacological Society 日本薬理学会年会要旨集 2435-4953 96 YIA05-2 null 20220000 10.1254/jpssuppl.96.0_yia05-2 1390294562486025088 read0138449/published_papers/42007531 宮田 晃志 石澤 有紀 濱野 裕章 新村 貴博 相澤 風花 八木 健太 座間味 義人 合田 光寛 石澤 啓介 ホスホジエステラーゼ5阻害剤に関連した致死的な血管毒性 【目的】大動脈をはじめとした各種動脈における瘤・解離疾患は，死亡率の高い血管疾患の一つである．動脈瘤・解離の危険因子として高齢者，男性，喫煙，高血圧，動脈硬化，結合組織病などが知られているが，加えて，フルオロキノロン系抗菌薬や血管新生阻害剤などを用いた薬物治療の有害事象として，動脈瘤・解離のリスクが高まる可能性が示唆されている．近年，勃起障害などに使用されるcGMP特異的ホスホジエステラーゼ (PDE5) 阻害剤使用後に動脈瘤・解離を発症した患者の症例が複数報告されている．動脈瘤モデルマウスを用いた動物実験においても大動脈瘤を悪化させるという結果が得られており，PDE5阻害剤は動脈瘤・解離に関与する可能性が示唆される．本研究では，世界保健機関 (WHO) のグローバルファーマコビジランスデータベースであるVigiBaseを用いたファーマコビジランス手法により，PDE5阻害剤のヒトに対する動脈瘤・解離リスクを明らかにすることを目的として研究を行った．【方法】WHOの個別症例安全性報告データベースであるVigiBaseを使用し2021年12月までのデータを不均衡分析により解析した．PDE5阻害剤としてシルデナフィル，タダラフィル，バルデナフィル，ウデナフィル，アバナフィルに関して解析した．副作用発現の有無や薬剤使用の有無から報告オッズ比 (ROR) を算出し，RORの95%信頼区間の下限値が1を超えるものを，副作用シグナルが検出された，とみなした．【結果・考察】VigiBaseにある27,994,584件の報告のうち249件でPDE5阻害剤使用との関連が疑われる動脈瘤・解離が報告されていた．不均衡分析の結果ではPDE5阻害剤投与例において副作用シグナルが検出され，個別の薬剤としてはシルデナフィル，タダラフィルでシグナルを認めた．またPDE5阻害剤使用症例に関して，適応症ごと，または瘤・解離病変が形成された各動脈の部位ごとに実施した不均衡分析においても，それぞれシグナルが検出された．年齢・性別で層別化した解析でも同様にシグナルが検出された．これらの結果はPDE5阻害剤の使用と動脈瘤・解離の関連を示しており，PDE5阻害剤の使用が動脈瘤・解離発症のリスクを上昇させる可能性を示している．【結論】本研究によりPDE5阻害剤は動脈瘤・解離のリスクを高める可能性があり，PDE5阻害剤の使用と動脈瘤・解離発症の因果関係を証明するために，母集団解析を含むさらなる研究が必要であることが示された． 一般社団法人 日本臨床薬理学会 日本臨床薬理学会学術総会抄録集 2436-5580 43 1-C-P-011 null 20220000 10.50993/jsptsuppl.43.0_1-c-p-011 1390857512439610752 read0138449/published_papers/37934974 Miyata Koji 宮田 晃志 Izawa-Ishizawa Yuki 石澤 有紀 Kondo Masateru 近藤 正輝 Tsujinaka Kaito 辻中 海斗 Omine Kohei 大峯 航平 Nishi Honoka 西 穂香 Aizawa Fuka 相澤 風花 Hamano Hirofumi 濱野 裕章 Yagi Kenta 八木 健太 Zamami Yoshito 座間味 義人 Goda Mitsuhiro 合田 光寛 Ishizawa Keisuke 石澤 啓介 The effect of <i>Eucommia ulmoides</i> leaf extract on aortic dissection onset in mice 杜仲葉エキスによる大動脈解離発症抑制効果の検討 Aortic dissection is a severe aortic disease, in which the aortic wall is separated into two layers at the medial level, resulting in two lumens being created, a true and a false lumen. Most cases have a sudden onset resulting in death. Therefore, it is required to establish a preventive strategy. <i>Eucommia ulmoides</i> leaf (EUL) extract contains various flavonoids such as quercetin, chlorogenic acid, geniposidic acid, and so on, and it is suggested to have a protective effect against cardiovascular diseases. In this study, we investigated the preventive effect of EUL on the onset of aortic dissection. We generated pharmacologically-induced aortic dissection model mice (LAB model). In C57Bl / 6J mice, three agents are administered; (1) nitric oxide synthase inhibitor (L-NAME) that causes vascular endothelial damage, (2) angiotensin II (Ang II) that causes hypertention, and (3) lysyl oxidase inhibitor (BAPN) that causes medial fragility. EUL extract was orally administered daily throughout the experiment. Hypertension, caused by Ang II+BAPN loading was significantly suppressed by EUL. In the LAB model, macrophage infiltration into the aortic wall was increased, but it was suppressed by EUL administration. As a result, EUL showed the preventive effects against the onset of aortic aneurysm, dissection, and death from rupture. Japanese Pharmacological Society 公益社団法人 日本薬理学会 Proceedings for Annual Meeting of The Japanese Pharmacological Society 日本薬理学会年会要旨集 2435-4953 95 1-SS-37 null 20220000 10.1254/jpssuppl.95.0_1-ss-37 1390573242659092864 read0138449/published_papers/37934968 Yurika Kuniki 國木 悠理香 Yagi Kenta 八木 健太 Yoshida Rina 吉田 莉奈 Okamoto Naoki 岡本 尚大 Ando Rie 安藤 里英 Yamakawa Yusuke 山川 裕介 Hamano Hirofumi 濱野 裕章 Niimura Takahiro 新村 貴博 Aizawa Fuka 相澤 風花 Izawa-Ishizawa Yuki 石澤 有紀 Goda Mitsuhiro 合田 光寛 Zamami Yoshito 座間味 義人 Ishizawa Keisuke 石澤 啓介 The Effect of Combined Bcr-Abl Inhibitor and ALDH Inhibitor on Chronic Myelogenous Leukemia 慢性骨髄性白血病に対するBcr-Abl阻害剤とALDH阻害剤併用による抗腫瘍効果 【Introduction】Chronic myelogenous leukemia (CML) has become a disease with five-year-survival rate of more than 90% according to appearance of Bcr-Abl inhibitor. Stopping treatment with Bcr-Abl inhibitors leads to relapse in many patients. This is due to the fact that Bcr-Abl inhibitors are not effective against cancer stem cells, and suggests that a different drug is necessary to eradicate cancer stem cells. ALDH is overexpressed in cancer stem cells and promotes their survival. We have shown in past studies that Bcr-Abl inhibitors do not inhibit ALDH expression. In this study, we examine the effect of ALDH inhibitors on CML. 【Methods】We examined the effects of an ALDH inhibitor using K562 cells, which are CML cell line. We verified the effect of an ALDH inhibitor against CML using a WST-8 assay. We then measured ALDH protein expression using flow cytometry. 【Results】ALDH inhibitors reduced cell survival in a concentration-dependent manner, and when combined with a Bcr-Abl inhibitor, cell viability was synergistically decreased. ALDH protein expression was decreased in cells treated with ALDH inhibitor alone or Bcr-Abl inhibitor alone according to flow cytometry. In cells treated with ALDH inhibitor and Bcr-Abl inhibitor, ALDH protein expression was more strongly repressed. 【Conclusion】The results of this study suggest that ALDH inhibitor use might be effective in CML treatment. Japanese Pharmacological Society 公益社団法人 日本薬理学会 Proceedings for Annual Meeting of The Japanese Pharmacological Society 日本薬理学会年会要旨集 2435-4953 95 1-SS-66 null 20220000 10.1254/jpssuppl.95.0_1-ss-66 1390573242652851072 read0138449/published_papers/37934962 Aizawa Fuka 相澤 風花 Kajimoto Haruna 梶本 春奈 Moriyama Daishi 森山 大嗣 Okabayashi Ami 岡林 亜美 Goda Mitsuhiro 合田 光寛 Hamano Hirofumi 濱野 裕章 Yagi Kenta 八木 健太 Izawa- Ishizawa Yuki 石澤 有紀 Zamami Yoshito 座間味 義人 Ishizawa Keisuke 石澤 啓介 Development of Supportive Care for Anticancer Drugs Based on Real World Data; Evaluation of the Therapeutic and Preventive Effects of Statins on Peripheral Neuropathy リアルワールドデータに基づく抗がん剤支持療法の開発;スタチン系薬剤による末梢神経障害治療および予防効果の検証 Chemotherapy-induced peripheral neuropathy (CIPN) is one of the adverse events associated with the anticancer drugs, however, almost available analgesic drugs lack efficacy against CIPN. Previously our results using medical database, FAERS, suggested that HMG-CoA reductase inhibitors (statins) have the potential to ameliorate oxaliplatin-induced peripheral neuropathy (OIPN). In this study, we elucidated the effect and mechanism of statins to OIPN model mice and PC12 cell. Three statins (simvastatin, atorvastatin, and rosuvastatin) could not show the therapeutic and preventive effects against oxaliplatin-induced cold allodynia. On the other hand, repeated orally administration of each statins ameliorate development of oxaliplatin-induced mechanical allodynia and significantly suppressed already established allodynia induced by oxaliplatin. A gene-related database revealed that the expression of glutathione S-transferase (GST) family members is regulated by statins. Decreased survival rate of PC12 cells by treatment of oxaliplatin was canceled cotreatment of each statin for 24 hours. Furthermore, cell protective effect of statin was disappeared transfection of gstmu1 siRNA into PC12 cells. These our results suggest that statins might be one of the novel supportive care, which have neuroprotective effect to OIPN. Japanese Pharmacological Society 公益社団法人 日本薬理学会 Proceedings for Annual Meeting of The Japanese Pharmacological Society 日本薬理学会年会要旨集 2435-4953 95 1-O-024 null 20220000 10.1254/jpssuppl.95.0_1-o-024 1390573242652828288 read0138449/published_papers/37934956 Yoshioka Toshihiko 吉岡 俊彦 Goda Mitsuhiro 合田 光寛 Kanda Masaya 神田 将哉 Yoshida Ami 吉田 愛美 Itobayashi Sayuri 糸林 小友理 Sugimoto Yugo 杉本 祐悟 Izawa-Ishizawa Yuki 石澤 有紀 Yagi Kenta 八木 健太 Aizawa Fuka 相澤 風花 Hamano Hirofumi 濱野 裕章 Okada Naoto 岡田 直人 Zamami Yoshito 座間味 義人 Ishizawa Keisuke 石澤 啓介 Effects of sodium valproate on cisplatin-induced acute kidney injury シスプラチン誘発急性腎障害に対するバルプロ酸ナトリウムの影響 OBJECTIVE: Cisplatin-induced acute kidney injury (AKI) is well known, and the nephrotoxicity of cisplatin restricts its clinical application. Currently, there are no drugs are recommended for the prevention of cisplatin-induced AKI. Forced hydration and diuresis may partially prevent nephrotoxicity of cisplatin, but it is still difficult to entirely prevent kidney injury. Thus, establishment of a new preventive method against cisplatin-induced AKI is required. Therefore, in this study, the purpose of this study was to clarify the efficacy of sodium valproate in cisplatin-induced AKI. METHODS: In order to establish cisplatin‐induced AKI animal model, C57BL/6 mice were administered with either cisplatin (15 mg/kg, i.p.) or saline (control). The degree of renal damage was assessed by various renal function parameters and pathological evaluation. The effect of sodium valproate on cisplatin-induced cytotoxicity was evaluated using HK2 cells, MKN-1 cells and LLC cells. RESULTS: Cisplatin treatment worsened various renal function parameters and tubular damage scores, which were significantly improved by co-treatment with sodium valproate. The decrease in cell viability of HK2 cells by cisplatin was significantly improved by co-treatment with sodium valproate. On the other hand, sodium valproate had no adverse effect on the reduction of cell viability of various cancer cells by cisplatin. CONCLUSIONS: The results of this study indicated that sodium valproate could act as a potential preventive drug for cisplatin-induced AKI. Japanese Pharmacological Society 公益社団法人 日本薬理学会 Proceedings for Annual Meeting of The Japanese Pharmacological Society 日本薬理学会年会要旨集 2435-4953 95 1-SS-48 null 20220000 10.1254/jpssuppl.95.0_1-ss-48 1390291767676156800 read0138449/published_papers/37934949 Yoshika Sakamoto 阪本 淑華 Tomochika Nanami 友近 七海 Hamano Hirofumi 濱野 裕章 Goda Mitsuhiro 合田 光寛 Niimura Takahiro 新村 貴博 Aizawa Fuka 相澤 風花 Yagi Kenta 八木 健太 Nakamura Akihito 仲村 明人 Nishiuchi Shiori 西内 栞 Izawa-Ishizawa Yuki 石澤 有紀 Zamami Yoshito 座間味 義人 Ishizawa Keisuke 石澤 啓介 Exploration of preventive drugs for sunitinib-induced heart failure utilizing large-scale medical database 大規模医療情報データベースを用いたスニチニブ誘発心不全に対する予防薬の探索 <b>BACKGROUND</b>: Several studies have reported that patients treated with sunitinib, a tyrosine kinase inhibitor, have developed left ventricular dysfunction and heart failure, but there is currently no treatment for heart failure with sunitinib. The purpose of the present study is to identify candidate drugs for the treatment of sunitinib-induced heart failure using a large medical database. <b>METHOD</b>: We analyzed the FDA Adverse Event Reporting System (FAERS) and the WHO global adverse event reporting database (VigiBase) to find candidate drugs for prevention of sunitinib-induced heart failure. The effects of the candidate drugs on cell viability and cell morphology were evaluated using the WST-8 assay and immunostaining in H9c2 cells derived from rat cardiac rhabdomeres. <b>RESULTS</b>: FAERS and VigiBase searches revealed significantly higher reporting odds ratio (ROR) of heart failure in patients treated with sunitinib than in those not treated with sunitinib. The ROR was reduced by concomitant use of Vitamin D (FAERS: ROR 0.50, 95% CI 0.26-0.96; VigiBase: ROR 0.37, 95% CI 0.10-0.95). In vitro, Vitamin D significantly improved the viability and maintained the cell morphology in H9c2 cells exposed to sunitinib. <b>CONCLUSION</b>: The findings suggest the potential value of Vitamin D in preventing sunitinib-induced heart failure. Japanese Pharmacological Society 公益社団法人 日本薬理学会 Proceedings for Annual Meeting of The Japanese Pharmacological Society 日本薬理学会年会要旨集 2435-4953 95 1-SS-35 null 20220000 10.1254/jpssuppl.95.0_1-ss-35 1390010292711875584 read0138449/published_papers/36159912 Mami Uchida Soichiro Ushio Takahiro Niimura Kenshi Takechi Hitoshi Kawazoe Noriaki Hidaka Akihiro Tanaka Hiroaki Araki Yoshito Zamami Keisuke Ishizawa Yoshihisa Kitamura Toshiaki Sendou Hiromu Kawasaki Hiroyuki Namba Kazuhiko Shibata Mamoru Tanaka Shingo Takatori Renin-angiotensin-aldosterone system inhibitors prevent the onset of oxaliplatin-induced peripheral neuropathy: A retrospective multicenter study and in vitro evaluation. Oxaliplatin (OXA) is used in chemotherapy for various cancer types and is associated with acute and chronic neurotoxicity. However, a preventive strategy for OXA-induced peripheral neuropathy (OIPN) and its underlying mechanism remain unclear. We examined the effects of renin-angiotensin-aldosterone system inhibitors (RAASIs) on OIPN by performing a retrospective multicenter study and an in vitro assay. We retrospectively evaluated electronic medical records of 976 patients who underwent one or more courses of OXA-containing regimens at Ehime, Okayama, and Tokushima University Hospitals. The primary endpoint was the incidence of OIPN during or after OXA administration. The effects of RAASIs and OXA on the neurite length in PC12 cells were determined. The combined administration of an OXA-containing regimen and RAASI significantly inhibited the cumulative incidence grade-2 or higher OIPN (log-rank test; P=0.0001). RAASIs markedly suppressed the development of both acute and chronic OIPN (multivariate analysis; P=0.017 and P=0.011). In an in vitro assay, 10 µM OXA suppressed the neurite length; treatment with 1 μM aliskiren, spironolactone, 10 μM candesartan, and enalapril significantly restored neurite length to the control level. Moreover, 1 μM SCH772984 (a selective inhibitor of extracellular signal-regulated kinase, ERK1/2) and 500 μM SQ22536 (a cell-permeable adenylate cyclase [AC] inhibitor) markedly abolished neuroprotective effects of candesartan and enalapril. These results indicate that RAASIs possess preventive or therapeutic effects in acute and chronic OIPN, candesartan and enalapril may directly increase in the activity of ERK1/2 and AC in PC12 cells. Biological & pharmaceutical bulletin 45 2 226 234 20211120 10.1248/bpb.b21-00852 34803077 read0138449/published_papers/36159913 Satoru Mitsuboshi Takahiro Niimura Masaya Kanda Shunsuke Ishida Yoshito Zamami Keisuke Ishizawa Risk of Hematologic Events With Coadministration of Methotrexate and the Breast Cancer Resistance Protein Inhibitor Febuxostat. BACKGROUND: The breast cancer resistance protein (BCRP) is a key drug transporter found in the liver, kidney, central nervous system, and gastrointestinal tract. Due to the wide expression of BCRP, interactions of other drugs with methotrexate (MTX) may differ in oral and intravenous MTX users, and understanding of these interactions may be useful in preventing severe adverse events. Febuxostat, a urate-lowering drug, inhibits BCRP. OBJECTIVE: The objective of this study was to clarify the differences in the drug-drug interaction profiles of oral and intravenous methotrexate, associated with BCRP. METHODS: We analyzed the Japanese Adverse Drug Event Report database and compared the frequency of hematologic events in patients taking oral and intravenous MTX, with or without the concomitant use of febuxostat or allopurinol. Hematologic events were defined as pancytopenia and neutropenia. Multiple logistic regression analysis was then used to identify the risk factors for hematologic events in oral and intravenous MTX users. RESULTS: We identified 8 453 oral and 810 intravenous MTX users with 546 and 126 cases of hematologic events, respectively. Compared with those not using febuxostat, a disproportionate number of hematologic events was observed in intravenous MTX users concomitantly using febuxostat (P < 0.01). The multivariate logistic analysis of intravenous MTX users showed that hematologic events were significantly associated with febuxostat use (P < 0.01) and age ≥ 60 years (P < 0.01). CONCLUSION AND RELEVANCE: Our findings suggest that patients being treated with intravenous MTX who concomitantly use febuxostat may be at an increased risk of hematologic events, presumably due to BCRP-mediated drug-drug interaction. The Annals of pharmacotherapy 56 8 10600280211055794 10600280211055794 20211102 10.1177/10600280211055794 34726078 read0138449/published_papers/36159915 Naoto Okada Yuki Izumi Aki Nakamoto Masayuki Chuma Mitsuhiro Goda Kenta Yagi Fuka Aizawa Hirofumi Hamano Yoshito Zamami Momoyo Azuma Keisuke Ishizawa Impact of Area Under the Concentration-Time Curve on the Prevalence of Vancomycin-Induced Nephrotoxicity in Combination With Tazobactam/Piperacillin or Cefepime: A Single-Institution Retrospective Study. PURPOSE: Risk for vancomycin-induced nephrotoxicity (VIN) is reportedly reduced by AUC-guided vancomycin dosing. However, it remains unknown whether the increased VIN risk in combination treatment with vancomycin and tazobactam/piperacillin, which is a VIN risk factor, can be diminished by AUC-guided vancomycin dosing (vancomycin-AUC). The aim of this study was to assess whether the evaluation of vancomycin-AUC + tazobactam/piperacillin (VT) combination therapy could prevent VIN. METHODS: The data from patients who received VT or vancomycin + cefepime (VC; the control group) at Tokushima University Hospital (Kuramoto, Japan) between April 2010 and March 2020 were analyzed in this retrospective study. The between-group difference in the prevalence of VIN onset, stratified by AUC, was investigated. The AUC of vancomycin was calculated using the Bayesian method with the blood concentration of vancomycin. The risk factors and probability of VIN onset from the vancomycin exposure-toxicity curve were evaluated using the logistic model. FINDINGS: The prevalences of VIN were 29.5% (18/61) and 7.1% (3/42) in the VT and VC groups, respectively. Multivariate logistic regression analysis of data from all patients revealed concurrent use of tazobactam/piperacillin (odds ratio [OR] = 4.59; P = 0.039) and AUC increase (OR = 1.01; P < 0.01) as risk factors for VIN, but only concurrent use of tazobactam/piperacillin was identified as a risk factor in patients with an AUC of <600 μg · h/mL, the guideline-recommended value (OR = 9.52; P = 0.041). Moreover, the vancomycin exposure-toxicity curve showed that in the guideline-recommended AUC range, VIN probability was consistently higher and the slope of VIN probability was greater in the VT group than in the VC group. IMPLICATIONS: VIN risk was higher with VT than with VC, even when the AUC was controlled to the guideline-recommended range. These results strongly suggest that VIN prevention may be difficult with AUC-guided vancomycin dosing in patients receiving VT. Clinical therapeutics 43 11 1910 1920 20211100 10.1016/j.clinthera.2021.09.007 34642081 read0138449/published_papers/36159914 Minori Takei Naoto Okada Shingen Nakamura Kumiko Kagawa Shiro Fujii Hirokazu Miki Keisuke Ishizawa Masahiro Abe Youichi Sato A genome-wide association study predicts the onset of dysgeusia due to anti-cancer drug treatment. Dysgeusia is a major side effect of anti-cancer drug treatment. Since dysgeusia significantly lowers the patient's quality of life, predicting and avoiding its onset in advance is desirable. Accordingly, aims of the present study were to use a genome-wide association study (GWAS) to identify genes associated with the development of dysgeusia in patients taking anti-cancer drugs and to predict the development of dysgeusia using associated SNPs. GWAS was conducted on 76 patients admitted to the Department of Hematology, Tokushima University Hospital. Using Sanger sequencing for 23 separately collected validation samples, the top two single nucleotide polymorphisms (SNPs) associated with the development of dysgeusia were determined. GWAS identified rs73049478 and rs41396146 SNPs on the RARB gene associated with dysgeusia development due to the administration of anti-cancer drugs. Evaluation of the two SNPs using 23 validation samples indicated that the accuracy rate of rs73049478 was relatively high (87.0%). Thus, the findings of the present study suggest that the rs73049478 SNP of RARB can be used to predict the onset of dysgeusia caused by the administration of anti-cancer drugs. Biological & pharmaceutical bulletin 45 1 114 117 20211016 10.1248/bpb.b21-00745 34657909 read0138449/published_papers/39869731 岡田 直人 座間味 義人 石澤 啓介 腎臓病薬物療法研究を加速する，データベース研究ことはじめ リアルワールドデータを操り新たなエビデンスを創出する レセプトデータを中心に 日本腎臓病薬物療法学会 日本腎臓病薬物療法学会誌 2187-0411 10 S99 S99 20211000 read0138449/published_papers/37829871 林 明希 合田 光寛 座間味 義人 八木 健太 中馬 真幸 濱野 裕章 岡田 直人 桐野 靖 中村 敏己 石澤 啓介 薬学生を対象とした病院実務実習における栄養管理教育の効果 (一社)日本臨床栄養代謝学会 学会誌JSPEN 2434-4966 3 Suppl.1 844 844 20211000 read0138449/published_papers/37668034 林 明希 合田 光寛 座間味 義人 八木 健太 中馬 真幸 濱野 裕章 岡田 直人 桐野 靖 中村 敏己 石澤 啓介 薬学生を対象とした病院実務実習における栄養管理教育の効果 (一社)日本臨床栄養代謝学会 学会誌JSPEN 2434-4966 3 Suppl.1 844 844 20211000 read0138449/published_papers/36159916 Satoru Mitsuboshi Takahiro Niimura Masaki Yoshino Yoshika Sakamoto Yoshito Zamami Keisuke Ishizawa Fluoropyridmidine use and hypertriglyceridemia among Japanese patients: analysis of adverse event database. Background The association between fluoropyrimidines except for capecitabine and the risk of hypertriglyceridemia is unclear. Objective To investigate hypertriglyceridemia in patients receiving fluoropyrimidines. Method This observational study used anonymized patient data recorded in the open-access Japanese Adverse Drug Event Report database. All fluoropyrimidine and taxane users were investigated. Results We identified 29,451 fluoropyrimidine users and 21,266 taxane users. Disproportionality for both hypertriglyceridemia and an increase in serum triglyceride levels was observed in fluoropyrimidine users compared with in taxane users (reporting odds ratio, 6.74; 95% confidence interval [CI] 2.05-22.17; P < .001). Multivariate logistic analysis showed that both hypertriglyceridemia and an increase in serum triglyceride levels among fluoropyrimidines users were significantly associated with doxifluridine use (odds ratio [OR] 42.50; 95% CI 5.34-338.00; P < .001), tegafur use (OR 9.56; 95% CI 2.08-43.90; P < .001), capecitabine use (OR 12.30; 95% CI 2.67-56.80; P < .001), and breast cancer (OR 5.61; 95% CI 1.07-29.50; P = .042). Conclusion This study suggests that the use of tegafur and doxifluridine is associated with an increased risk of hypertriglyceridemia similar to that with the use of capecitabine; in particular, fluoropyrimidine users with breast cancer may have a high risk of hypertriglyceridemia. International journal of clinical pharmacy 44 1 260 263 20210905 10.1007/s11096-021-01324-0 34482500 read0138449/published_papers/37668037 辻中 海斗 石澤 有紀 新村 貴博 吉岡 俊彦 合田 光寛 近藤 正輝 大峯 航平 西 穂果 宮田 晃志 濱野 裕章 相澤 風花 八木 健太 座間味 義人 石澤 啓介 血管新生阻害剤における大動脈解離発症の関連要因解明 日本心脈管作動物質学会 血管 0911-4637 44 1 38 38 20210600 read0138449/published_papers/37563827 辻中 海斗 石澤 有紀 新村 貴博 吉岡 俊彦 合田 光寛 近藤 正輝 大峯 航平 西 穂果 宮田 晃志 濱野 裕章 相澤 風花 八木 健太 座間味 義人 石澤 啓介 血管新生阻害剤における大動脈解離発症の関連要因解明 日本心脈管作動物質学会 血管 0911-4637 44 1 38 38 20210600 read0138449/published_papers/35045094 座間味 義人 新村 貴博 川尻 雄大 合田 光寛 濱野 裕章 八木 健太 相澤 風花 小林 大介 島添 隆雄 石澤 有紀 楊河 宏章 石澤 啓介 医療ビッグデータを活用したドラッグリポジショニングによるオキサリプラチン誘発末梢神経障害の予防薬開発 (公財)臨床薬理研究振興財団 臨床薬理の進歩 0914-4366 42 72 84 20210600 read0138449/published_papers/35045109 相澤 風花 座間味 義人 濱野 裕章 石澤 啓介 梶本 春奈 森山 大嗣 新村 貴博 合田 光寛 八木 健太 石澤 有紀 オキサリプラチン誘発末梢神経障害に対するHMG-CoA還元酵素阻害剤の影響 徳島医学会 四国医学雑誌 0037-3699 77 1-2 109 109 20210400 read0138449/published_papers/35045101 石澤 有紀 合田 光寛 相澤 風花 座間味 義人 濱野 裕章 八木 健太 池田 康将 石澤 啓介 玉置 俊晃 薬剤誘発性大動脈解離易発症モデルマウスを用いた薬効評価 徳島医学会 四国医学雑誌 0037-3699 77 1-2 57 62 20210400 read0138449/published_papers/34680609 Hirofumi Hamano Yasumasa Ikeda Mitsuhiro Goda Keijo Fukushima Seiji Kishi Masayuki Chuma Michiko Yamashita Takahiro Niimura Kenshi Takechi Masaki Imanishi Yoshito Zamami Yuya Horinouchi Yuki Izawa-Ishizawa Licht Miyamoto Keisuke Ishizawa Hiromichi Fujino Toshiaki Tamaki Ken-Ichi Aihara Koichiro Tsuchiya Diphenhydramine may be a preventive medicine against cisplatin-induced kidney toxicity. Cisplatin is widely used as an anti-tumor drug for the treatment of solid tumors. Unfortunately, it causes kidney toxicity as a critical side effect, limiting its use, given that no preventive drug against cisplatin-induced kidney toxicity is currently available. Here, based on a repositioning analysis of the Food and Drug Administration Adverse Events Reporting System, we found that a previously developed drug, diphenhydramine, may provide a novel treatment for cisplatin-induced kidney toxicity. To confirm this, the actual efficacy of diphenhydramine was evaluated in in vitro and in vivo experiments. Diphenhydramine inhibited cisplatin-induced cell death in kidney proximal tubular cells. Mice administered cisplatin developed kidney injury with significant dysfunction (mean plasma creatinine: 0.43 vs 0.15 mg/dl) and showed augmented oxidative stress, increased apoptosis, elevated inflammatory cytokines, and MAPKs activation. However, most of these symptoms were suppressed by treatment with diphenhydramine. Furthermore, the concentration of cisplatin in the kidney was significantly attenuated in diphenhydramine-treated mice (mean platinum content: 70.0 vs 53.4 μg/g dry kidney weight). Importantly, diphenhydramine did not influence or interfere with the anti-tumor effect of cisplatin in any of the in vitro or in vivo experiments. In a selected cohort of 98 1:1 matched patients from a retrospective database of 1467 patients showed that patients with malignant cancer who had used diphenhydramine before cisplatin treatment exhibited significantly less acute kidney injury compared to ones who did not (6.1 % vs 22.4 %, respectively). Thus, diphenhydramine demonstrated efficacy as a novel preventive medicine against cisplatin-induced kidney toxicity. Kidney international 99 4 885 899 20210400 10.1016/j.kint.2020.10.041 33307103 read0138449/published_papers/35079343 内田 真美 牛尾 聡一郎 新村 貴博 飛鷹 範明 田中 亮裕 北村 佳久 千堂 年昭 座間味 義人 石澤 啓介 武智 研志 柴田 和彦 難波 弘行 川崎 博己 高取 真吾 次世代の若手研究者が切り開く薬学研究の発展と医療への貢献 レニン・アンジオテンシン・アルドステロン系阻害薬はオキサリプラチン誘発末梢神経障害の発症を抑制する (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 141 GS04 5 20210300 read0138449/published_papers/35045135 合田 光寛 座間味 義人 新村 貴博 萱野 純史 濱野 裕章 岡田 直人 相澤 風花 八木 健太 石澤 有紀 桐野 靖 中村 敏己 石澤 啓介 第5回病院薬剤師が実践するリバーストランスレーショナルリサーチの最前線∼臨床情報を突破口とした創薬・育薬研究∼ 大規模医療情報データベースを活用した抗がん剤副作用予防のためのリバーストランスレーショナルリサーチ (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 141 S21 3 20210300 read0138449/published_papers/35045130 阪本 淑華 座間味 義人 新村 貴博 相澤 風花 八木 健太 合田 光寛 石澤 有紀 石澤 啓介 次世代の若手研究者が切り開く薬学研究の発展と医療への貢献 大規模医療情報データベースを用いたドキソルビシン誘発心筋症に対する予防薬の探索 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 141 GS04 6 20210300 read0138449/published_papers/35045126 坂東 貴司 中馬 真幸 新村 貴博 座間味 義人 石澤 有紀 合田 光寛 八木 健太 濱野 裕章 岡田 直人 泉 侑希 桐野 靖 中村 敏己 石澤 啓介 大規模医療情報データベースを活用したバンコマイシン関連腎障害に対する薬剤性腎障害原因薬剤の多剤併用における影響 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 141 27V11 pm01 20210300 read0138449/published_papers/35045119 新村 貴博 座間味 義人 川尻 雄大 合田 光寛 相澤 風花 八木 健太 石澤 有紀 石澤 啓介 基礎研究と臨床研究の融合による薬剤性末梢神経障害に対する予防薬探索 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 141 27P02 198S 20210300 read0138449/published_papers/35045115 相澤 風花 座間味 義人 濱野 裕章 岡田 直人 林 明希 八木 健太 合田 光寛 桐野 靖 中村 敏己 石澤 啓介 COVID-19感染拡大に伴うオンライン型薬学実務実習の導入 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 141 28P01 257 20210300 read0138449/published_papers/34979528 岡田 直人 座間味 義人 石澤 啓介 【抗菌薬供給トラブル もし入手困難になったら，そのときどうする】主要な抗菌薬が供給不足になったときに考慮する代替薬 セファゾリン，セファレキシン (株)南山堂 薬局 0044-0035 72 3 422 426 20210300 read0138449/published_papers/34927039 合田 光寛 座間味 義人 新村 貴博 萱野 純史 濱野 裕章 岡田 直人 相澤 風花 八木 健太 石澤 有紀 桐野 靖 中村 敏己 石澤 啓介 第5回病院薬剤師が実践するリバーストランスレーショナルリサーチの最前線∼臨床情報を突破口とした創薬・育薬研究∼ 大規模医療情報データベースを活用した抗がん剤副作用予防のためのリバーストランスレーショナルリサーチ (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 141 S21 3 20210300 read0138449/published_papers/34927034 坂東 貴司 中馬 真幸 新村 貴博 座間味 義人 石澤 有紀 合田 光寛 八木 健太 濱野 裕章 岡田 直人 泉 侑希 桐野 靖 中村 敏己 石澤 啓介 大規模医療情報データベースを活用したバンコマイシン関連腎障害に対する薬剤性腎障害原因薬剤の多剤併用における影響 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 141 27V11 pm01 20210300 read0138449/published_papers/34927028 相澤 風花 座間味 義人 濱野 裕章 岡田 直人 林 明希 八木 健太 合田 光寛 桐野 靖 中村 敏己 石澤 啓介 COVID-19感染拡大に伴うオンライン型薬学実務実習の導入 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 141 28P01 257 20210300 read0138449/published_papers/37934998 宮田 晃志 坂東 寛 合田 光寛 中馬 真幸 新田 侑生 田崎 嘉一 吉岡 俊彦 小川 淳 座間味 義人 濱野 裕章 石澤 有紀 石澤 啓介 ラモトリギンの皮膚障害リスクに影響する因子の探索 【目的】てんかんおよび双極性障害の維持療法に適応を有するラモトリギンは，副作用として重篤な皮膚障害が現れることがあり，死亡に至った例も報告されたことから2015年に安全性速報で注意喚起がなされた．ラモトリギン誘発皮膚障害は，血中濃度の急激な上昇が関与しており，代謝経路に関与するUDP-グルクロン酸転移酵素(UGT)阻害作用を示すバルプロ酸との併用でリスクが高いことが知られている．しかし，UGT阻害作用を示す薬剤はバルプロ酸の他にも睡眠薬，鎮痛薬，免疫抑制薬など多数存在するにも関わらず，それらの薬剤併用によるラモトリギン誘発皮膚障害への影響は不明である．本研究では，医療ビッグデータ解析を用いてUGT阻害作用を示す薬剤がラモトリギン誘発皮膚障害の報告オッズ比に与える影響を検討した．さらに，徳島大学病院の病院診療情報を用いて，併用薬によるラモトリギンの皮膚障害リスクの変化を検討した．【方法】大規模副作用症例報告データベース(FAERS:FDA Adverse Event Reporting System)を用いて，ラモトリギンとの併用により皮膚障害報告数を上昇させる薬剤を探索した．さらに徳島大学病院診療録より，ラモトリギン服用を開始した患者を対象とし，ラモトリギンの投与量，併用薬，皮膚障害の有無などを調査した．【結果】FAERS解析から，UGT阻害作用を示す医薬品のうち，ラモトリギンとの併用により皮膚障害リスクの上昇が示唆される薬剤として，バルプロ酸(ROR: 2.98, 95%CI: 2.63-3.37)，フルニトラゼパム(ROR: 5.93, 95%CI: 4.33-8.14)およびニトラゼパム(ROR: 2.09, 95%CI: 1.24-3.51)が抽出された．徳島大学病院診療情報を用いた後方視的観察研究の結果，ラモトリギン服用が開始された患者の内，20%程度で皮膚障害が認められ，フルニトラゼパム併用患者では皮膚障害発生頻度が上昇する傾向が認められた．【考察】フルニトラゼパムおよびニトラゼパムは，UGT阻害作用を示す薬剤であることから，ラモトリギンの血中濃度に影響し，ラモトリギンの皮膚障害リスクを上昇させている可能性がある．また，睡眠薬であることから精神科領域で併用する可能性があり，睡眠薬の選択や併用時の副作用モニタリングに注意を要すると考えられる． 一般社団法人 日本臨床薬理学会 日本臨床薬理学会学術総会抄録集 2436-5580 42 3-P-R-2 null 20210000 10.50993/jsptsuppl.42.0_3-p-r-2 1390853365592301056 read0138449/published_papers/37934991 Ikeda Yasumasa 池田 康将 Hamano Hirofumi 濱野 裕章 Goda Mitsuhiro 合田 光寛 Fukushima Keijo 福島 圭穰 Kishi Seiji 岸 誠司 Chuma Masayuki 中馬 真幸 Zamami Yoshito 座間味 義人 Miyamoto Licht 宮本 理人 Ishizawa Keisuke 石澤 啓介 Fujino Hiromichi 藤野 裕道 Aihara Ken-ichi 粟飯原 賢一 Tsuchiya Koichiro 土屋 浩一郎 Tamaki Toshiaki 玉置 俊晃 Identification of a candidate drug for the prevention of cisplatin-induced nephrotoxicity by a database analysis-basic research-clinical study シスプラチン起因性腎障害の予防薬の同定 <b>Background</b>: Cisplatin is widely used as an anti-tumor drug for the treatment of solid tumors. Unfortunately, it causes nephrotoxicity as a critical side effect, limiting its use, given that no preventive drug against cisplatin-induced nephrotoxicity (CIN) is currently available. In the present study, we searched and identified candidate drugs for preventing CIN Methods: We used a database of medical big data for the screening of candidate drugs for the prevention of CIN. Based on the results of the analysis of medical big data, we evaluated the actual efficacy of DPH via <i>in vitro</i> and <i>in vivo</i> experiments<i> </i>in culture cells and a mouse model. Results: We identified that a previously developed drug, diphenhydramine (DPH), may provide a novel treatment for CIN by the analysis of medical big data. DPH inhibited cisplatin-induced cell death in renal proximal tubular cells. Mice administered cisplatin developed kidney injury with renal dysfunction, augmented oxidative stress, increased apoptosis, and elevated inflammatory cytokines; however, most of these symptoms were suppressed by treatment with DPH. Additionally, the renal concentration of cisplatin was attenuated in DPH-treated mice. Importantly, DPH did not i interfere with its anti-tumor effect in any of the <i>in vitro</i> or <i>in vivo</i> experiments. Moreover, a retrospective clinical study showed that patients with malignant cancer who had used DPH before cisplatin treatment exhibited less acute kidney injury. Conclusion: DPH may be a preventive medicine against CIN. Japanese Pharmacological Society 公益社団法人 日本薬理学会 Proceedings for Annual Meeting of The Japanese Pharmacological Society 日本薬理学会年会要旨集 2435-4953 94 2-O-D3-1 null 20210000 10.1254/jpssuppl.94.0_2-o-d3-1 1390850391141166208 read0138449/published_papers/37934980 西内 栞 斎藤 広海 新村 貴博 座間味 義人 合田 光寛 八木 健太 相澤 風花 濱野 裕章 石澤 有紀 石澤 啓介 ドキソルビシン誘発心筋症に対する予防薬探索を目的としたドラッグリポジショニング研究 【目的】 Doxorubicin (Dox)は累積投与量に依存して重篤な心筋症を発現することが知られている．Doxに関連した心筋症は，生命予後を著しく悪化させることが報告されているが，現在までに有効な対策は確立されておらず，予防薬の開発が喫緊の課題である．そこで，本研究では，大規模医療情報データベースを用いたドラッグリポジショニング研究によってDox誘発心筋症に対する予防薬を探索した． 【方法】 はじめに，遺伝子発現データベース(GEO) より得られたマイクロアレイデータの解析を行い，Dox投与後の心筋組織における発現変動遺伝子を抽出した．次に，創薬ツール(LINCS)を用いて，Doxによる遺伝子発現変動を打ち消す既存承認薬を探索した．さらに，有害事象自発報告データベース(FAERS)を解析し，LINCS解析によって抽出した薬剤がDox誘発心筋症の報告数に及ぼす影響を検討した．FAERS解析においても有効性が示唆された薬剤に関して，C57BL6マウスを用いてDox誘発心筋症モデルを作製し，心筋組織の炎症およびアポトーシス関連タンパク質のmRNA発現変化を評価した． 【結果】 マイクロアレイデータ解析より見出された発現変動遺伝子を用いて，LINCS解析を行った結果，既存承認薬6剤が候補薬として抽出された．FAERS解析によりこれらのうち3剤でDox誘発心筋症の報告オッズ比が減少する傾向が認められた．in vivoの検討において，Doxの投与によって上昇した心筋組織のIL-1b, IL-6およびBax/Bcl-2 mRNA発現比が予防薬候補の併用によって減少する傾向が認められた． 【考察】 異なる2種類のビッグデータ解析により抽出された3種類の既存承認薬は，臨床においてもDox誘発心筋症のリスクを軽減する薬剤となることが示唆される．Dox誘発心筋症モデルマウスを用いた検討結果から，抽出された予防薬候補は，Doxによる心筋組織の炎症反応を抑制することでアポトーシスを抑制する可能性が考えられる． 【結論】 本研究の結果から，創薬ツールおよび大規模医療情報データベース解析により見出された既存承認薬がDox誘発心筋症に対する新規予防薬となる可能性が示唆された． 一般社団法人 日本臨床薬理学会 日本臨床薬理学会学術総会抄録集 2436-5580 42 2-P-H-7 null 20210000 10.50993/jsptsuppl.42.0_2-p-h-7 1390008940662139904 read0138449/published_papers/35072048 Mitsuhiro Goda Momo Ikehara Mako Sakitani Kana Oda Keisuke Ishizawa Masato Otsuka Involvement of Human Multidrug and Toxic Compound Extrusion (MATE) Transporters in Testosterone Transport. Multidrug and toxic compound extrusion (MATE) transporters are primarily expressed in the kidneys and liver, where they contribute to the excretion of organic cations. Our previous study suggested that pig MATE2 (class III) participates in testosterone secretion from Leydig cells. In humans, it is unclear which MATE class is involved in testosterone transport. In this study, we aimed to clarify whether human MATE1 (hMATE1) or human MATE2K (hMATE2K) mediates testosterone transport. To confirm that testosterone inhibits transporter-mediated tetraethylammonium (TEA) uptake, a cis-inhibition assay was performed using cells that stably expressed hMATE1 or hMATE2K. Docking simulations were performed to characterize differences in the binding of hMATE1 and hMATE2K to testosterone. Transport experiments in LLC-PK1 cells that stably expressed hMATE1 were used to test whether hMATE1 mediates testosterone transport. We detected differences between the amino acid sequences of the substrate-binding sites of hMATE1 and hMATE2K that could potentially be involved in testosterone binding. Testosterone and estradiol inhibited TEA uptake mediated by hMATE1 but not that mediated by hMATE2K. Transport experiments in LLC-PK1 cells indicated that testosterone might be transported via hMATE1. This study suggested that hMATE1, but not hMATE2K, is involved in human testosterone transport. Biological & pharmaceutical bulletin 44 4 501 506 20210000 10.1248/bpb.b20-00753 33790101 read0138449/published_papers/34979531 中馬 真幸 岡田 直人 武智 研志 石澤 啓介 ビッグデータ解析を活用したバンコマイシン関連腎障害の新規予防薬探索と有用性の検討 (公社)日本化学療法学会 日本化学療法学会雑誌 1884-5886 69 1 82 82 20210100 read0138449/published_papers/34680592 Hirofumi Hamano Chisato Mitsuhashi Yoshiko Suzuki Yoshito Zamami Kaito Tsujinaka Naoto Okada Takahiro Niimura Tatsuya Hayama Toru Imai Shunsuke Ishida Kumiko Sakamoto Mitsuhiro Goda Kenshi Takechi Kenta Yagi Masayuki Chuma Yuya Horinouchi Kazuaki Shinomiya Yasumasa Ikeda Yasushi Kirino Toshimi Nakamura Hiroaki Yanagawa Yasuhiro Hamada Keisuke Ishizawa Effects of Palonosetron on Nausea and Vomiting Induced by Multiple-Day Chemotherapy: A Retrospective Study. Patients who undergo multiple-day chemotherapy sessions experience hard-to-treat nausea and vomiting. Currently, there is no effective standard treatment for this condition. This study compared the preventive effect of first-generation 5-hydroxytryptamine 3 receptor antagonists (5-HT3 RAs) and second-generation 5-HT3 RAs palonosetron in multiple-day chemotherapy-induced nausea and vomiting. The design of this study was a retrospective case-control study of patients who received a five-day cisplatin-based chemotherapy and were treated with aprepitant, dexamethasone, granisetron, and ramosetron or palonosetron. The patients were divided into two groups: patients given granisetron and ramosetron (the first-generation group), and those given palonosetron (palonosetron group). The percentage of patients with a complete response or total control was assessed. They were divided into three phases: 0-216 h (overall phase), 0-120 h (remedial phase), and 120-216 h (after phase). The remedial phase was further divided into 0-24 h (early phase) and 24-120 h (later phase). Moreover, the nutritional status of each patient was assessed by noting the patients' total calorie-intake per day and total parenteral nutrition. First-generation 5-HT3 RAs and palonosetron were used for treatment in 18 and 28 patients, respectively. The complete response rate and caloric oral intake of the later phase were higher in the palonosetron group than in the first-generation group. We conclude that palonosetron treatment was more effective than first-generation 5-HT3 RAs in controlling multiple-day chemotherapy-induced nausea and vomiting. Biological & pharmaceutical bulletin 44 4 478 484 20210000 10.1248/bpb.b20-00609 33790099 read0138449/published_papers/32798816 Naoto Okada Noriko Fujiwara Momoyo Azuma Kaito Tsujinaka Masayuki Chuma Kenta Yagi Hirofumi Hamano Fuka Aizawa Mitsuhiro Goda Yasushi Kirino Toshimi Nakamura Yoshito Zamami Ichiro Hashimoto Keisuke Ishizawa Assessment of Adherence to Post-exposure Prophylaxis with Oseltamivir in Healthcare Workers: A Retrospective Questionnaire-Based Study. Post-exposure prophylaxis (PEP) for healthcare workers is one of the effective strategies for preventing nosocomial outbreaks of influenza. However, PEP adherence in healthcare workers is rarely analysed, and no strategies have been established to improve adherence to PEP for healthcare workers. We aimed to retrospectively analyse adherence to PEP and the factors associated with non-adherence in healthcare workers. A survey of 221 healthcare workers who were eligible for PEP at Tokushima University Hospital in the 2016/2017 season was conducted. Once-daily oseltamivir (75 mg for 10 d) was used as the PEP regimen. Of the 221 healthcare workers, 175 received PEP and were surveyed for adherence using a questionnaire. Of the 130 healthcare workers who responded to the questionnaire, 121 (93.1%) had been vaccinated. In this survey, 82 healthcare workers (63.1%) did not fully complete PEP. Multiple logistic regression analysis revealed that physicians (odds ratio: 4.62, 95% confidence interval [CI]: 2.08-10.25) and non-vaccination (odds ratio: 9.60, 95% CI: 1.12-82.25) were the factors for non-adherence to PEP. Of the 47 healthcare workers who responded to the item regarding reasons for non-adherence, 36 (76.6%) reported forgetting to take oseltamivir or discontinuing it due to a misguided self-decision that continuation of PEP was unnecessary, and 5 (10.6%) reported discontinuing treatment due to adverse effects. In conclusion, healthcare workers, particularly physicians, had low PEP adherence owing to forgetting or stopping to take oseltamivir due to a misguided self-decision. To obtain the maximum preventive effect of PEP, medication education should be provided to endorse PEP compliance. Biological & pharmaceutical bulletin 44 6 869 874 20210000 10.1248/bpb.b21-00165 34078819 read0138449/published_papers/31053392 Kenta Yagi Marin Mitstui Yoshito Zamami Takahiro Niimura Yuki Izawa-Ishizawa Mitsuhiro Goda Masayuki Chuma Kimiko Fukunaga Takahiro Shibata Shunsuke Ishida Takumi Sakurada Naoto Okada Hirofumi Hamano Yuya Horinouchi Yasumasa Ikeda Hiroaki Yanagawa Keisuke Ishizawa Investigation of drugs affecting hypertension in bevacizumab-treated patients and examination of the impact on the therapeutic effect. BACKGROUND: In patients treated with bevacizumab, hypertension may be a biomarker of therapeutic efficacy. However, it is not clear whether drugs that control blood pressure influence bevacizumab's efficacy. In this study, we investigated drugs that may affect hypertension in bevacizumab-treated patients and examined the impact on the therapeutic effect. PATIENTS AND METHODS: We analyzed 3,724,555 reports from the third quarter of 2010 to the second quarter of 2015. All data were obtained from the Food and Drug Administration (FDA) Adverse Event Reporting System (FAERS) analysis. In this retrospective cohort study, we investigated a total of 58 patients diagnosed with colorectal cancer and treated for the first time with bevacizumab containing XELOX or mFOLFOX6 at The University of Tokushima Hospital between January 2010 and December 2015. The effect of the treatment was evaluated according to Response Evaluation Criteria in Solid Tumors version 1.0. Thereafter, the effect was confirmed using Gene Expression Omnibus (GEO) and cultured cells. RESULTS: There are few reports in FAERS of hypertension in patients treated with omeprazole on bevacizumab. Based on the chart review, patients who used proton pump inhibitors (PPI) had a lower response to treatment than those who did not (response rate: 25% vs 50%). Furthermore, experiments on GEO and cell lines suggested that induction of vascular endothelial growth factor (VEGF) gene expression by PPIs is the cause of the reduced therapeutic effect. CONCLUSION: PPIs prevent hypertension in bevacizumab-treated patients but may reduce bevacizumab's anti-tumoral effects by inducing VEGF expression. Cancer medicine 10 1 164 172 20201124 10.1002/cam4.3587 33231381 read0138449/published_papers/31053393 Kenta Yagi Kazuki Maeda Satoshi Sakaguchi Masayuki Chuma Yasutaka Sato Chikako Kane Akiyo Akaishi Keisuke Ishizawa Hiroaki Yanagawa Status of Institutional Review Board Meetings Conducted Through Web Conference Systems in Japanese National University Hospitals During the COVID-19 Pandemic: Questionnaire Study. BACKGROUND: With the global proliferation of the novel COVID-19 disease, conventionally conducting institutional review board (IRB) meetings has become a difficult task. Amid concerns about the suspension of drug development due to delays within IRBs, it has been suggested that IRB meetings should be temporarily conducted via the internet. OBJECTIVE: This study aimed to elucidate the current status of IRB meetings conducted through web conference systems. METHODS: A survey on conducting IRB meetings through web conference systems was administered to Japanese national university hospitals. Respondents were in charge of operating IRB offices at different universities. This study was not a randomized controlled trial. RESULTS: The survey was performed at 42 facilities between the end of May and early June, 2020, immediately after the state of emergency was lifted in Japan. The survey yielded a response rate of 74% (31/42). Additionally, while 68% (21/31) of facilities introduced web conference systems for IRB meetings, 13% (4/31) of the surveyed facilities postponed IRB meetings. Therefore, we conducted a further survey of 21 facilities that implemented web conference systems for IRB meetings. According to 71% (15/21) of the respondents, there was no financial burden for implementing these systems, as they were free of charge. In 90% (19/21) of the facilities, IRB meetings through web conference systems were already being conducted with personal electronic devices. Furthermore, in 48% (10/21) of facilities, a web conference system was used in conjunction with face-to-face meetings. CONCLUSIONS: Due to the COVID-19 pandemic, the number of reviews in clinical trial core hospitals has decreased. This suggests that the development of pharmaceuticals has stagnated because of COVID-19. According to 71% (15/21) of the respondents who conducted IRB meetings through web conference systems, the cost of introducing such meetings was US $0, showing a negligible financial burden. Moreover, it was shown that online deliberations could be carried out in the same manner as face-to-face meetings, as 86% (18/21) of facilities stated that the number of comments made by board members did not change. To improve the quality of IRB meetings conducted through web conference systems, it is necessary to further examine camera use and the content displayed on members' screens during meetings. Further examination of all members who use web conference systems is required. Our measures for addressing the requests and problems identified in our study could potentially be considered protocols for future IRB meetings, when the COVID-19 pandemic has passed and face-to-face meetings are possible again. This study also highlights the importance of developing web conference systems for IRB meetings to respond to future unforeseen pandemics. Journal of medical Internet research 22 11 e22302 null 20201119 10.2196/22302 33112758 read0138449/published_papers/34581244 岡田 直人 中馬 真幸 合田 光寛 八木 健太 座間味 義人 石澤 啓介 感染と腎機能 慢性期(寝たきりの人，筋力の落ちている人)への抗菌薬の使用方法 正確な腎機能評価に基づいた抗菌薬の投与設計 日本腎臓病薬物療法学会 日本腎臓病薬物療法学会誌 2187-0411 9 S63 S63 20201100 read0138449/published_papers/34581240 岡田 直人 中馬 真幸 合田 光寛 八木 健太 座間味 義人 石澤 啓介 腎とポリファーマシー対策 CKD・AKI患者におけるポリファーマシー 日本腎臓病薬物療法学会 日本腎臓病薬物療法学会誌 2187-0411 9 S80 S80 20201100 read0138449/published_papers/34581235 中馬 真幸 座間味 義人 合田 光寛 八木 健太 石澤 有紀 濱野 裕章 岡田 直人 近藤 正輝 楊河 宏章 石澤 啓介 臨床現場の疑問に応える(答える)腎臓病薬物療法研究 臨床現場で勤務する薬剤師の視点を生かしたトランスレーショナルリサーチ 日本腎臓病薬物療法学会 日本腎臓病薬物療法学会誌 2187-0411 9 S81 S81 20201100 read0138449/published_papers/35048450 濱野 裕章 三橋 知里 座間味 義人 岡田 直人 武智 研志 中馬 真幸 石田 俊介 坂本 久美子 合田 光寛 八木 健太 桐野 靖 中村 敏己 石澤 啓介 入院栄養管理において薬剤師に期待される業務の多職種アンケート調査 (一社)日本病院薬剤師会 日本病院薬剤師会雑誌 1341-8815 56 10 1181 1186 20201000 read0138449/published_papers/34874245 石澤 啓介 合田 光寛 中馬 真幸 八木 健太 石澤 有紀 座間味 義人 データ駆動型薬理学・臨床薬理学研究 有害事象自発報告データベースを活用した抗がん剤副作用に対する予防法の探索 (一社)日本臨床薬理学会 臨床薬理 1882-8272 51 Suppl. S140 S140 20201000 read0138449/published_papers/34874240 座間味 義人 川尻 雄大 牛尾 聡一郎 武智 研志 新村 貴博 合田 光寛 八木 健太 中馬 真幸 石澤 有紀 楊河 宏章 石澤 啓介 多施設・多職種連携による医薬品適正使用ならびに医療費削減の推進 大規模医療情報データベースを活用した有害事象軽減のための多施設共同研究 (一社)日本臨床薬理学会 臨床薬理 1882-8272 51 Suppl. S191 S191 20201000 read0138449/published_papers/34874234 八木 健太 中馬 真幸 武智 研志 坂口 暁 軒原 浩 加根 千賀子 佐藤 康敬 新村 貴博 合田 光寛 座間味 義人 石澤 啓介 楊河 宏章 研究者から見た特定臨床研究推進に寄与する因子 臨床研究法施行前後のアンケート調査 (一社)日本臨床薬理学会 臨床薬理 1882-8272 51 Suppl. S270 S270 20201000 read0138449/published_papers/34874225 前田 和輝 八木 健太 坂口 暁 中馬 真幸 加根 千賀子 佐藤 康敬 明石 晃代 鍛 美智子 石澤 啓介 楊河 宏章 国立大学附属病院臨床研究推進会議参加施設を対象とした，COVID-19流行下でのオンライン環境を利用したIRB(Web-IRB)の実態調査 (一社)日本臨床薬理学会 臨床薬理 1882-8272 51 Suppl. S331 S331 20201000 read0138449/published_papers/34721919 濱野 裕章 池田 康将 合田 光寛 福島 圭穣 岸 誠司 武智 研志 中馬 真幸 座間味 義人 堀之内 裕也 藤野 裕道 石澤 啓介 玉置 俊晃 シスプラチン誘発性腎障害を予防する既存薬物の同定と検証 (一社)日本臨床薬理学会 臨床薬理 1882-8272 51 Suppl. S261 S261 20201000 read0138449/published_papers/34581230 腫瘍循環器学(Cardio-Oncology)研究 ∼基礎-臨床間の双方向性研究を展開するために ビッグデータ解析と基礎研究を融合した新たな研究手法による腫瘍循環器学へのアプローチ 日本癌学会 日本癌学会総会記事 0546-0476 79 S8 2 20201000 read0138449/published_papers/34581224 石澤 啓介 合田 光寛 中馬 真幸 八木 健太 石澤 有紀 座間味 義人 データ駆動型薬理学・臨床薬理学研究 有害事象自発報告データベースを活用した抗がん剤副作用に対する予防法の探索 (一社)日本臨床薬理学会 臨床薬理 1882-8272 51 Suppl. S140 S140 20201000 read0138449/published_papers/34581219 座間味 義人 川尻 雄大 牛尾 聡一郎 武智 研志 新村 貴博 合田 光寛 八木 健太 中馬 真幸 石澤 有紀 楊河 宏章 石澤 啓介 多施設・多職種連携による医薬品適正使用ならびに医療費削減の推進 大規模医療情報データベースを活用した有害事象軽減のための多施設共同研究 (一社)日本臨床薬理学会 臨床薬理 1882-8272 51 Suppl. S191 S191 20201000 read0138449/published_papers/34581212 八木 健太 中馬 真幸 武智 研志 坂口 暁 軒原 浩 加根 千賀子 佐藤 康敬 新村 貴博 合田 光寛 座間味 義人 石澤 啓介 楊河 宏章 研究者から見た特定臨床研究推進に寄与する因子 臨床研究法施行前後のアンケート調査 (一社)日本臨床薬理学会 臨床薬理 1882-8272 51 Suppl. S270 S270 20201000 read0138449/published_papers/34581204 前田 和輝 八木 健太 坂口 暁 中馬 真幸 加根 千賀子 佐藤 康敬 明石 晃代 鍛 美智子 石澤 啓介 楊河 宏章 国立大学附属病院臨床研究推進会議参加施設を対象とした，COVID-19流行下でのオンライン環境を利用したIRB(Web-IRB)の実態調査 (一社)日本臨床薬理学会 臨床薬理 1882-8272 51 Suppl. S331 S331 20201000 read0138449/published_papers/34493230 濱野 裕章 三橋 知里 座間味 義人 岡田 直人 武智 研志 中馬 真幸 石田 俊介 坂本 久美子 合田 光寛 八木 健太 桐野 靖 中村 敏己 石澤 啓介 入院栄養管理において薬剤師に期待される業務の多職種アンケート調査 (一社)日本病院薬剤師会 日本病院薬剤師会雑誌 1341-8815 56 10 1181 1186 20201000 read0138449/published_papers/30485918 Masateru Kondo Yuki Izawa-Ishizawa Mitsuhiro Goda Mayuko Hosooka Yuu Kagimoto Naoko Saito Rie Matsuoka Yoshito Zamami Masayuki Chuma Kenta Yagi Kenshi Takechi Koichi Tsuneyama Keisuke Ishizawa Preventive Effects of Quercetin against the Onset of Atherosclerosis-Related Acute Aortic Syndromes in Mice. Atherosclerosis-related acute aortic syndromes, such as aortic aneurysms or aortic dissection are life-threatening diseases. Since they develop suddenly and progress rapidly, the establishment of preventive strategies is urgently needed. Quercetin, a flavonoid abundant in various vegetables and fruits, is suggested to reduce the risk of cardiovascular disease. Therefore, in this study, the preventive effect of quercetin was evaluated using a mouse model of aortic aneurysm and dissection. The model was established by administering angiotensin II (Ang II) and β-aminopropionitrile (BAPN), a lysyl oxidase inhibitor, to mice to induce hypertension and degeneration of the elastic lamina, which would eventually result in the onset of an aortic aneurysm. Ang II, BAPN, and a nitric oxide synthase inhibitor was administered to induce aortic dissection via endothelial dysfunction. Quercetin (60 mg/kg/day) was administered 2 weeks before inducing aortic diseases by the end of the experiments (8 weeks in the aneurysm model, 6 weeks in the dissection model). It was found to reduce the incidence of aneurysm (from 72 to 45%), dissection (from 17 to 10%), and rupture (from 33 to 15%) in mice. Elastin degradation was ameliorated in the quercetin-treated mice compared to that in the mice without quercetin treatment (degradation score 2.9 ± 0.3 vs 2.2 ± 0.2). Furthermore, quercetin suppressed the expression of vascular cell adhesion molecule-1, macrophage infiltration, and pro-matrix metalloproteinase-9 activity. Our results suggest that quercetin might prevent the onset of atherosclerosis-related acute aortic syndromes through its anti-inflammatory and endothelial cell-protective effects. International journal of molecular sciences 21 19 null null 20200930 10.3390/ijms21197226 33007902 read0138449/published_papers/34979536 岡田 直人 中馬 真幸 東 桃代 石澤 啓介 血液疾患患者における包括的腎障害リスク評価に基づいたバンコマイシン誘発急性腎障害の予防ストラテジーの構築 (公社)日本化学療法学会 日本化学療法学会雑誌 1884-5886 68 Suppl.A 328 328 20200900 read0138449/published_papers/34979534 中本 亜樹 中馬 真幸 岡田 直人 武智 研志 石澤 啓介 ダプトマイシンとHMG-CoA還元酵素阻害薬の併用における筋障害のリスクに関するメタアナリシス (公社)日本化学療法学会 日本化学療法学会雑誌 1884-5886 68 Suppl.A 357 357 20200900 read0138449/published_papers/30485920 Naoto Okada Rie Matsuoka Takumi Sakurada Mitsuhiro Goda Masayuki Chuma Kenta Yagi Yoshito Zamami Yasuhiko Nishioka Keisuke Ishizawa Risk factors of immune checkpoint inhibitor-related interstitial lung disease in patients with lung cancer: a single-institution retrospective study. Immune checkpoint inhibitors (ICIs) elicit antitumour effects by activating the host immunity and cause immune-related adverse events (irAEs). ICI-related interstitial lung disease (ICI-ILD) is a fatal irAE that is difficult to treat; moreover, its incidence is relatively higher in patients with lung cancer. Therefore, early ICI-ILD detection and intervention are important for patient safety. However, a risk assessment method for ICI-ILD has not been established and the prediction of ICI-ILD occurrence is difficult. The aim of our study was to identify the risk factors associated with ICI-ILD. To this end, we retrospectively analysed 102 patients with lung cancer who first received ICI and completed the treatment between April 2016 and December 2019 at Tokushima University Hospital. Nineteen patients had all grades of ICI-ILD and 10 had grade ≥ 3 ICI-ILD. The 30-day mortality rate of patients with grade ≥ 3 ICI-ILD was the highest among all patients (P < 0.01). The multivariate logistic analysis indicated that the performance status ≥ 2 alone and both performance status ≥ 2 and ≥ 50 pack-year were independent risk factors of ICI-ILD of grade ≥ 3 and all grades, respectively. Overall, our study provides insights to predict ICI-ILD occurrence. Scientific reports 10 1 13773 13773 20200813 10.1038/s41598-020-70743-2 32792640 read0138449/published_papers/35048456 中馬 真幸 武智 研志 座間味 義人 合田 光寛 石田 俊介 濱野 裕章 近藤 正輝 坂東 貴司 石澤 啓介 楊河 宏章 救急認定薬剤師に今後期待すること 救急認定薬剤師に対する研究のすすめ 共に歩もう! エビデンス創出へ!! (一社)日本臨床救急医学会 日本臨床救急医学会雑誌 2187-9001 23 3 351 351 20200800 read0138449/published_papers/30485922 Kenji Otsuka Atsushi Mitsuhashi Hisatsugu Goto Masaki Hanibuchi Kazuya Koyama Hirohisa Ogawa Hirokazu Ogino Atsuro Saijo Hiroyuki Kozai Hiroto Yoneda Makoto Tobiume Masatoshi Kishuku Keisuke Ishizawa Yasuhiko Nishioka Anti-PD-1 antibody combined with chemotherapy suppresses the growth of mesothelioma by reducing myeloid-derived suppressor cells. BACKGROUND: The combination of anti-PD-1/PD-L1 antibody with chemotherapy has been approved for the first-line therapy of lung cancer. However, the effects against malignant mesothelioma (MPM) and the immunological mechanisms by which chemotherapy enhances the effect of targeting PD-1/PD-L1 in MPM are poorly understood. MATERIALS AND METHODS: We utilized syngeneic mouse models of MPM and lung cancer and assessed the therapeutic effects of anti-PD-1 antibody and its combination with cisplatin (CDDP) and pemetrexed (PEM). An immunological analysis of tumor-infiltrating cells was performed with immunohistochemistry. RESULTS: We observed significant therapeutic effects of anti-PD-1 antibody against MPM. Although the effect was associated with CD8+ and CD4+ T cells in tumors, the number of Foxp3+ cells was not reduced but rather increased. Consequently, combination with CDDP/PEM significantly enhanced the antitumor effects of anti-PD-1 antibody by decreasing numbers of intratumoral myeloid-derived suppressor cells (MDSCs) and vessels probably through suppression of VEGF expression by CDDP + PEM. CONCLUSIONS: The combination of anti-PD-1 antibody with CDDP + PEM may be a promising therapy for MPM via inhibiting the accumulation of MDSCs and vessels in tumors. Lung cancer (Amsterdam, Netherlands) 146 86 96 20200800 10.1016/j.lungcan.2020.05.023 32526602 read0138449/published_papers/30485919 Masayuki Chuma Masateru Kondo Yoshito Zamami Kenshi Takechi Mitsuhiro Goda Naoto Okada Akitomo Shibata Mizuho Asada Jun Oto Hiroaki Yanagawa Keisuke Ishizawa Successful Vancomycin Dose Adjustment in a Sepsis patient with Bacterial Meningitis Using Cystatin C. Cystatin C-guided vancomycin (VCM) dosing is useful in critically ill patients. Its usefulness in septic patients with bacterial meningitis remains unknown, as there are no published reports. In this study, we sought to clarify its benefit. Cystatin C was used to guide VCM dosing in a septic bacterial meningitis patient with normal kidney function, according to therapeutic drug monitoring (TDM). Using cystatin C, the Bayesian method-based TDM made optimal VCM dosing possible, and decreased the predicted error (4.85 mg/L) compared to serum creatinine (16.83 mg/L). We concluded TDM of VCM using cystatin C can be considered in sepsis patients with bacterial meningitis with normal kidney function. Acta medica Okayama 74 4 365 370 20200800 10.18926/AMO/60376 32843769 read0138449/published_papers/27523444 Yasumasa Ikeda Hiroaki Watanabe Tetsuya Shiuchi Hirofumi Hamano Yuya Horinouchi Masaki Imanishi Mitsuhiro Goda Yoshito Zamami Kenshi Takechi Yuki Izawa-Ishizawa Licht Miyamoto Keisuke Ishizawa Ken-Ichi Aihara Koichiro Tsuchiya Toshiaki Tamaki Deletion of H-ferritin in macrophages alleviates obesity and diabetes induced by high-fat diet in mice. AIMS/HYPOTHESIS: Iron accumulation affects obesity and diabetes, both of which are ameliorated by iron reduction. Ferritin, an iron-storage protein, plays a crucial role in iron metabolism. H-ferritin exerts its cytoprotective action by reducing toxicity via its ferroxidase activity. We investigated the role of macrophage H-ferritin in obesity and diabetes. METHODS: Conditional macrophage-specific H-ferritin (Fth, also known as Fth1) knockout (LysM-Cre Fth KO) mice were used and divided into four groups: wild-type (WT) and LysM-Cre Fth KO mice with normal diet (ND), and WT and LysM-Cre Fth KO mice with high-fat diet (HFD). These mice were analysed for characteristics of obesity and diabetes, tissue iron content, inflammation, oxidative stress, insulin sensitivity and metabolic measurements. RAW264.7 macrophage cells were used for in vitro experiments. RESULTS: Iron concentration reduced, and mRNA expression of ferroportin increased, in macrophages from LysM-Cre Fth KO mice. HFD-induced obesity was lower in LysM-Cre Fth KO mice than in WT mice at 12 weeks (body weight: KO 34.6 ± 5.6 g vs WT 40.1 ± 5.2 g). mRNA expression of inflammatory cytokines and infiltrated macrophages and oxidative stress increased in the adipose tissue of HFD-fed WT mice, but was not elevated in HFD-fed LysM-Cre Fth KO mice. However, WT mice fed an HFD had elevated iron concentration in adipose tissue and spleen, which was not observed in LysM-Cre Fth KO mice fed an HFD (adipose tissue [μmol Fe/g protein]: KO 1496 ± 479 vs WT 2316 ± 866; spleen [μmol Fe/g protein]: KO 218 ± 54 vs WT 334 ± 83). Moreover, HFD administration impaired both glucose tolerance and insulin sensitivity in WT mice, which was ameliorated in LysM-Cre Fth KO mice. In addition, energy expenditure, mRNA expression of thermogenic genes, and body temperature were higher in KO mice with HFD than WT mice with HFD. In vitro experiments showed that iron content was reduced, and lipopolysaccharide-induced Tnf-α (also known as Tnf) mRNA upregulation was inhibited in a macrophage cell line transfected with Fth siRNA. CONCLUSIONS/INTERPRETATION: Deletion of macrophage H-ferritin suppresses the inflammatory response by reducing intracellular iron levels, resulting in the prevention of HFD-induced obesity and diabetes. The findings from this study highlight macrophage iron levels as a potential therapeutic target for obesity and diabetes. Diabetologia 63 8 1588 1602 20200800 10.1007/s00125-020-05153-0 32430665 read0138449/published_papers/30485921 Théo Brillatz Miwa Kubo Shimon Takahashi Natsumi Jozukuri Kenshi Takechi Emerson Ferreira Queiroz Laurence Marcourt Pierre-Marie Allard Richard Fish Kenichi Harada Keisuke Ishizawa Alexander D Crawford Yoshiyasu Fukuyama Jean-Luc Wolfender Metabolite Profiling of Javanese Ginger Zingiber purpureum and Identification of Antiseizure Metabolites via a Low-Cost Open-Source Zebrafish Bioassay-Guided Isolation. The rhizomes of Zingiber purpureum, "Bangle", were investigated for its antiseizure properties using a streamlined and cost-effective zebrafish screening strategy and a mouse epilepsy assay. Its hexane extract demonstrated strong antiseizure activity in zebrafish epilepsy assay and was, therefore, selected for bioactivity-guided fractionation. Twelve compounds (1-12) were isolated, and two bioactive phenylbutenoids, trans- (11) and cis-banglene (12), reduced up to 70% of pentylenetetrazole (PTZ)-induced seizures. These compounds showed moderate activity against PTZ-induced seizures in a mouse epilepsy assay. To understand the specificity of Z. purpureum active compounds, its chemical profile was compared to that of Z. officinale. Their composition was assessed by differential metabolite profiling visualized by a molecular network, which revealed only vanillin derivatives and terpenoids as common metabolites and gave a comprehensive view of Z. purpureum composition. This study demonstrates the efficacy of a streamlined zebrafish epilepsy assay, which is therefore suitable for routine screening in phytochemistry laboratories. Journal of agricultural and food chemistry 68 30 7904 7915 20200729 10.1021/acs.jafc.0c02641 32628839 read0138449/published_papers/41139235 泉 侑希 石田 俊介 長谷川 結美 武智 研志 合田 光寛 座間味 義人 桐野 靖 中村 敏己 寺岡 和彦 八木 秀介 佐田 政隆 石澤 啓介 循環器疾患治療薬の相互作用とポリファーマシー 高齢者の薬物療法管理ツールを活用した薬剤業務の効率化 (一社)日本循環器学会 日本循環器学会学術集会抄録集 84 3 5 20200700 read0138449/published_papers/34979548 岡田 直人 神農 麻里奈 中村 信元 三木 浩和 渡辺 浩良 合田 光寛 中馬 真幸 武智 研志 座間味 義人 桐野 靖 中村 敏己 寺岡 和彦 安倍 正博 石澤 啓介 血液凝固因子製剤の在庫適正化に向けた取り組みによる薬剤廃棄額の削減効果 (一社)日本病院薬剤師会 日本病院薬剤師会雑誌 1341-8815 56 7 803 808 20200700 read0138449/published_papers/34979541 中馬 真幸 岡田 直人 武智 研志 合田 光寛 近藤 正輝 座間味 義人 楊河 宏章 石澤 啓介 【薬物動態・薬物相互作用・薬物アレルギーから最適化 スペシャル・ポピュレーションの抗菌薬投与設計】(第3章)特殊病態の患者 敗血症患者 (株)じほう 薬事 0016-5980 62 10 2048 2055 20200700 read0138449/published_papers/34506096 泉 侑希 石田 俊介 長谷川 結美 武智 研志 合田 光寛 座間味 義人 桐野 靖 中村 敏己 寺岡 和彦 八木 秀介 佐田 政隆 石澤 啓介 循環器疾患治療薬の相互作用とポリファーマシー 高齢者の薬物療法管理ツールを活用した薬剤業務の効率化 (一社)日本循環器学会 日本循環器学会学術集会抄録集 84 3 5 20200700 read0138449/published_papers/34137623 岡田 直人 神農 麻里奈 中村 信元 三木 浩和 渡辺 浩良 合田 光寛 中馬 真幸 武智 研志 座間味 義人 桐野 靖 中村 敏己 寺岡 和彦 安倍 正博 石澤 啓介 血液凝固因子製剤の在庫適正化に向けた取り組みによる薬剤廃棄額の削減効果 (一社)日本病院薬剤師会 日本病院薬剤師会雑誌 1341-8815 56 7 803 808 20200700 read0138449/published_papers/34979560 中馬 真幸 武智 研志 座間味 義人 合田 光寛 岡田 直人 近藤 正輝 石澤 啓介 楊河 宏章 特殊病態・母集団における体内動態からみた抗菌薬投与設計の最適化 敗血症における抗菌薬投与設計の最適化に向けて (一社)日本感染症学会 感染症学雑誌 0387-5911 94 3 380 380 20200500 read0138449/published_papers/34137628 中馬 真幸 武智 研志 座間味 義人 合田 光寛 岡田 直人 近藤 正輝 石澤 啓介 楊河 宏章 特殊病態・母集団における体内動態からみた抗菌薬投与設計の最適化 敗血症における抗菌薬投与設計の最適化に向けて (公社)日本化学療法学会 日本化学療法学会雑誌 1884-5886 68 3 419 419 20200500 read0138449/published_papers/27523445 Masaki Imanishi Yusuke Yamakawa Keijo Fukushima Raiki Ikuto Akiko Maegawa Yuki Izawa-Ishizawa Yuya Horinouchi Masateru Kondo Masatoshi Kishuku Mitsuhiro Goda Yoshito Zamami Kenshi Takechi Masayuki Chuma Yasumasa Ikeda Koichiro Tsuchiya Hiromichi Fujino Koichi Tsuneyama Keisuke Ishizawa Fibroblast-specific ERK5 deficiency changes tumor vasculature and exacerbates tumor progression in a mouse model. The roles of cancer-associated fibroblasts (CAFs) have been studied in the tumor progression, and CAFs are expected to become the new targets for cancer pharmacotherapies. CAFs contribute to tumor cell survival and proliferation, tumor angiogenesis, immune suppression, tumor inflammation, tumor cell invasion and metastasis, and extracellular matrix remodeling. However, detailed mechanisms of how CAFs function in the living system remain unclear. CAFs include α-smooth muscle actin, expressing activated fibroblasts similar to myofibroblasts, and are highly capable of producing collagen. Several reports have demonstrated the contributions of extracellular-signal-regulated kinase 5 (ERK5) in fibroblasts to the fibrotic processes; however, the roles of CAF-derived ERK5 remain unclear. To investigate the roles of CAF-derived ERK5 in the tumor progression, we created mice lacking the ERK5 gene specifically in fibroblasts. Colon-26 mouse colon cancer cells were implanted into the mice subcutaneously, and the histological analyses of the tumor tissue were performed after 2 weeks. Immunofluorescence analyses showed that recipient-derived fibroblasts existed within the tumor tissue. The present study demonstrated that fibroblast-specific ERK5 deficiency exacerbated tumor progression and it was accompanied with thicker tumor vessel formation and the increase in the number of activated fibroblasts. We combined the results of The Cancer Genome Atlas (TCGA) database analysis with our animal studies, and indicated that regulating ERK5 activity in CAFs or CAF invasion into the tumor tissue can be important strategies for the development of new targets in cancer pharmacotherapies. Naunyn-Schmiedeberg's archives of pharmacology 393 7 1239 1250 20200419 10.1007/s00210-020-01859-5 32307577 read0138449/published_papers/37542592 津田 達也 橋本 一郎 堀ノ内 裕也 池田 康将 石澤 有紀 合田 光寛 座間味 義人 石澤 啓介 血管平滑筋細胞石灰化シグナルにおけるRhoキナーゼ-サイクロフィリンA経路の関与 徳島医学会 四国医学雑誌 0037-3699 76 1-2 119 119 20200400 read0138449/published_papers/34493283 前川 晃子 吉田 愛美 村井 陽一 新村 貴博 座間味 義人 石澤 啓介 合田 光寛 神田 将哉 濱野 裕章 岡田 直人 石澤 有紀 中馬 真幸 武智 研志 堀ノ内 裕也 池田 康将 シスプラチン誘発腎障害に対する新規予防薬の探索とその有効性の検証 徳島医学会 四国医学雑誌 0037-3699 76 1-2 116 116 20200400 read0138449/published_papers/34493274 濱野 裕章 合田 光寛 座間味 義人 石澤 啓介 池田 康将 堀ノ内 裕也 福島 圭穣 藤野 裕道 岸 誠司 武智 研志 中馬 真幸 宮本 理人 土屋 浩一郎 玉置 俊晃 シスプラチン誘発性腎障害を予防する既存薬物の同定 徳島医学会 四国医学雑誌 0037-3699 76 1-2 116 117 20200400 read0138449/published_papers/34137632 武智 研志 石田 俊介 坂東 寛 中馬 真幸 座間味 義人 合田 光寛 石澤 啓介 楊河 宏章 薬物療法にかかわる副作用マネジメントのエビデンス確立に向けて 薬剤師が実践する向精神薬の副作用対策に向けた臨床研究について エビデンスをもった効率的な副作用マネジメントを目指して (一社)日本病院薬剤師会 日本病院薬剤師会雑誌 1341-8815 56 4 373 376 20200400 read0138449/published_papers/34979555 遠藤 優香 田島 穂澄 岡田 直人 中村 信元 賀川 久美子 藤井 志朗 三木 浩和 石澤 啓介 安倍 正博 佐藤 陽一 機械学習を用いたゲノム情報によるシタラビン投与の副作用発現予測モデルの構築 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 140 26M am07S 20200300 read0138449/published_papers/34979551 武井 みのり 岡田 直人 中村 信元 賀川 久美子 藤井 志朗 三木 浩和 石澤 啓介 安倍 正博 佐藤 陽一 遺伝情報を用いた機械学習による抗がん剤投与の味覚障害発現予測モデルの構築 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 140 26M am08S 20200300 read0138449/published_papers/34493255 合田 光寛 座間味 義人 新村 貴博 川尻 雄大 武智 研志 中馬 真幸 萱野 純史 濱野 裕章 岡田 直人 小林 大介 島添 隆雄 石澤 有紀 石澤 啓介 第4回病院薬剤師が実践するリバーストランスレーショナルリサーチの最前線 ∼臨床薬剤師の視点から新たな薬物療法を提案する∼ 医療ビッグデータ解析と基礎研究を融合したオキサリプラチン誘発末梢神経障害に対する予防薬探索 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 140 S37 3 20200300 read0138449/published_papers/24600039 Tatsuya Tsuda Masaki Imanishi Mizuho Oogoshi Mitsuhiro Goda Yoshitaka Kihira Yuya Horinouchi Yoshito Zamami Keisuke Ishizawa Yasumasa Ikeda Ichiro Hashimoto Toshiaki Tamaki Yuki Izawa-Ishizawa Rho-associated protein kinase and cyclophilin a are involved in inorganic phosphate-induced calcification signaling in vascular smooth muscle cells. Arterial calcification, a risk factor of cardiovascular events, develops with differentiation of vascular smooth muscle cells (VSMCs) into osteoblast-like cells. Cyclophilin A (CypA) is a peptidyl-prolyl isomerase involved in cardiovascular diseases such as atherosclerosis and aortic aneurysms, and rho-associated protein kinase (ROCK) is involved in the pathogenesis of vascular calcification. CypA is secreted in a ROCK activity-dependent manner and works as a mitogen via autocrine or paracrine mechanisms in VSMCs. We examined the involvement of the ROCK-CypA axis in VSMC calcification induced by inorganic phosphate (Pi), a potent cell mineralization initiator. We found that Pi stimulated ROCK activity, CypA secretion, extracellular signal-regulated protein kinase (ERK) 1/2 phosphorylation, and runt-related transcription factor 2 expression, resulting in calcium accumulation in rat aortic smooth muscle cells (RASMCs). The ROCK inhibitor Y-27632 significantly suppressed Pi-induced CypA secretion, ERK1/2 phosphorylation, and calcium accumulation. Recombinant CypA was found to be associated with increased calcium accumulation in RASMCs. Based on these results, we suggest that autocrine CypA is mediated by ROCK activity and is involved in Pi-induced ERK1/2 phosphorylation following calcification signaling in RASMCs. Journal of pharmacological sciences 142 3 109 115 20200300 10.1016/j.jphs.2019.12.005 31882204 read0138449/published_papers/27523446 Hiromi Hagiwara Hidekatsu Fukuta Takahiro Niimura Yoshito Zamami Keisuke Ishizawa Kazunori Kimura Takeshi Kamiya Nobuyuki Ohte Comparison of Hemorrhagic Risk between Prasugrel and Clopidogrel: a Retrospective Study using Adverse Drug Event Reporting Databases. Background: Prasugrel inhibits platelet aggregation more potently and exerts therapeutic action faster than clopidogrel. In the global phase III trial conducted in Western and South American countries that excluded Asian countries, prasugrel reduced ischemic events but increased hemorrhagic risk compared with clopidogrel in patients with acute coronary syndrome scheduled for percutaneous coronary intervention. In the Japanese phase III trial for similar patients, the efficacy of prasugrel compared with clopidogrel was comparable to the global trial, but the safety could not be confirmed because of an insufficient number of patients. Furthermore, given the strict enrollment criteria, the results of these trials may not be applicable to routine clinical practice. Accordingly, we compared the hemorrhagic risk of prasugrel and clopidogrel in real-world settings by analyzing adverse drug event reports in post-marketing stages provided by the Japanese regulatory authorities and the U.S. Food and Drug Administration (FDA). Methods: We analyzed a total of 3,970 reports for prasugrel (n = 518) or clopidogrel (n = 3,452) between 2014 and 2017 in the Japanese Adverse Drug Event Report (JADER) and a total of 91,914 reports for either prasugrel (n = 5,992) or clopidogrel (n = 85,922) between 2009 and 2019 in the FDA Adverse Event Reporting System (FAERS). Results: In JADER and FAERS, prasugrel was more frequently and significantly associated with hemorrhagic event reports than clopidogrel. After adjustment for known confounders including age, sex, and concomitant medications (aspirin, anticoagulants, and proton pump inhibitors), the hemorrhagic risk of prasugrel compared with clopidogrel remained significant (adjusted reporting odds ratios [95% CI] for total, intracranial, and gastrointestinal hemorrhagic events = 2.42 [1.97-2.96], 2.45 [1.85-3.24], and 2.27 [1.73-2.97] in JADER, and 2.21 [2.09-2.34], 1.21 [1.09-1.33], and 1.41 [1.29-1.54] in FAERS). Conclusions: The hemorrhagic risk was found to be greater with prasugrel than clopidogrel in real-world patients, including Japanese patients. International journal of medical sciences 17 6 728 733 20200000 10.7150/ijms.43168 32218694 read0138449/published_papers/10861629 Hirofumi Hamano Takahiro Niimura Yuya Horinouchi Yoshito Zamami Kenshi Takechi Mitsuhiro Goda Masaki Imanishi Masayuki Chuma Yuki Izawa-Ishizawa Licht Miyamoto Keijo Fukushima Hiromichi Fujino Koichiro Tsuchiya Keisuke Ishizawa Toshiaki Tamaki Yasumasa Ikeda Proton pump inhibitors block iron absorption through direct regulation of hepcidin via the aryl hydrocarbon receptor-mediated pathway. Proton pump inhibitors (PPIs) have been used worldwide to treat gastrointestinal disorders. A recent study showed that long-term use of PPIs caused iron deficiency; however, it is unclear whether PPIs affect iron metabolism directly. We investigated the effect of PPIs on the peptide hepcidin, an important iron regulatory hormone. First, we used the FDA Adverse Event Reporting System database and analyzed the influence of PPIs. We found that PPIs, as well as H2 blockers, increased the odds ratio of iron-deficient anemia. Next, HepG2 cells were used to examine the action of PPIs and H2 blockers on hepcidin. PPIs augmented hepcidin expression, while H2 blockers did not. In fact, the PPI omeprazole increased hepcidin secretion, and omeprazole-induced hepcidin upregulation was inhibited by gene silencing or the pharmacological inhibition of the aryl hydrocarbon receptor. In mouse experiments, omeprazole also increased hepatic hepcidin mRNA expression and blood hepcidin levels. In mice treated with omeprazole, protein levels of duodenal and splenic ferroportin decreased. Taken together, PPIs directly affect iron metabolism by suppressing iron absorption through the inhibition of duodenal ferroportin via hepcidin upregulation. These findings provide a new insight into the molecular mechanism of PPI-induced iron deficiency. Toxicology letters 0378-4274 318 86 91 20200100 10.1016/j.toxlet.2019.10.016 31669099 read0138449/published_papers/29516402 吉田 愛美 前川 晃子 村井 陽一 新村 貴博 座間味 義人 石澤 啓介 合田 光寛 神田 将哉 濱野 裕章 岡田 直人 石澤 有紀 中馬 真幸 武智 研志 堀ノ内 裕也 池田 康将 シスプラチン誘発腎障害に対する新規予防薬の探索 徳島医学会 四国医学雑誌 0037-3699 75 5-6 245 246 20191200 read0138449/published_papers/10861630 Naoto Okada Masayuki Chuma Momoyo Azuma Shingen Nakamura Hirokazu Miki Hirofumi Hamano Mitsuhiro Goda Kenshi Takechi Yoshito Zamami Masahiro Abe Keisuke Ishizawa Effect of serum concentration and concomitant drugs on vancomycin-induced acute kidney injury in haematologic patients: a single-centre retrospective study. PURPOSE: Appropriate use of vancomycin (VCM) is important in preventing acute kidney injury (AKI). Because of the high frequency of VCM use for febrile neutropenia and concomitant use of other nephrotoxic drugs, haematologic patients have a different nephrotoxic background compared with patients with other diseases. Therefore, it is unclear whether the risk factors of VCM-induced AKI identified in other patient groups are also applicable to haematologic patients. Herein, we performed a single-centre retrospective analysis to identify the factors associated with VCM-induced AKI in haematologic patients. METHODS: We retrospectively analysed 150 haematologic patients to whom VCM was administered between April 2010 and March 2018 at Tokushima University Hospital. VCM-induced AKI was defined according to Kidney Disease Improving Global Outcomes (KDIGO) criteria. Multivariate logistic regression analyses were performed to identify risk factors for VCM-induced AKI. RESULTS: Seventeen patients had VCM-induced AKI. Multivariate analysis revealed that the risk factors of VCM-induced AKI were an initial VCM trough concentration of > 15 mg/L and concomitant use of tazobactam/piperacillin (TAZ/PIPC) and liposomal amphotericin B (L-AMB). Patients with an initial VCM trough concentration of < 10 mg/L showed significantly lower efficacy in febrile neutropenia. Interestingly, concomitant L-AMB use increased the incidence of VCM-induced AKI in a VCM concentration-dependent manner, whereas concomitant TAZ/PIPC increased the incidence in a VCM concentration-independent manner. CONCLUSIONS: The optimal initial VCM trough concentration was 10-15 mg/L in haematologic patients, considering safety and effectiveness. There were differences in the effect of VCM-induced AKI between nephrotoxic drugs. European journal of clinical pharmacology 0031-6970 75 12 1695 1704 20191200 10.1007/s00228-019-02756-4 31511938 read0138449/published_papers/29516384 堀ノ内 裕也 池田 康将 福島 圭穣 今西 正樹 濱野 裕章 石澤 有紀 座間味 義人 武智 研志 藤野 裕道 石澤 啓介 土屋 浩一郎 玉置 俊晃 認定薬剤師の科学力を考える 基礎研究と医療ビッグデータ解析を融合させたドラッグ・リボジショニングへの試み (一社)日本臨床薬理学会 臨床薬理 1882-8272 50 Suppl. S176 S176 20191100 read0138449/published_papers/29516373 合田 光寛 神田 将哉 前川 晃子 新村 貴博 石澤 有紀 座間味 義人 中馬 真幸 武智 研志 濱野 裕章 岡田 直人 福島 圭穰 藤野 裕道 土屋 浩一郎 堀ノ内 裕也 池田 康将 楊河 宏章 石澤 啓介 大規模医療情報データベースを活用したシスプラチン誘発腎障害に対する新規予防薬の探索とその有効性の検証 (一社)日本臨床薬理学会 臨床薬理 1882-8272 50 Suppl. S246 S246 20191100 read0138449/published_papers/10861631 Takumi Sakurada Sanako Bando Yoshito Zamami Kenshi Takechi Masayuki Chuma Mitsuhiro Goda Yasushi Kirino Toshimi Nakamura Kazuhiko Teraoka Masami Morimoto Akira Tangoku Keisuke Ishizawa Prophylactic administration of granulocyte colony-stimulating factor in epirubicin and cyclophosphamide chemotherapy for Japanese breast cancer patients: a retrospective study. PURPOSE: Epirubicin and cyclophosphamide (EC) therapy, a major chemotherapy for patients with early-stage breast cancer, has a low risk (< 10%) of febrile neutropenia (FN). However, data used in reports on the incidence rate of FN were derived primarily from non-Asian populations. In this study, we investigated the FN incidence rate using EC therapy among Japanese patients with breast cancer and evaluated the significance of prophylactic administration of granulocyte colony-stimulating factor (G-CSF). METHODS: We evaluated medical records of patients with early-stage breast cancer who had been treated with EC therapy as neoadjuvant or adjuvant therapy between November 2014 and July 2018. RESULTS: The incidence rate of FN was 23.9%. In patients who received G-CSF as primary prophylaxis, FN expression was completely suppressed. The incidence rate of severe leucopenia/neutropenia, emergency hospitalization, and the use of antimicrobial agents were low in patients receiving primary prophylaxis with G-CSF compared with those not receiving G-CSF (27.3% vs. 64.8%, 9.1% vs. 27.3%, and 27.3% vs. 71.6%, respectively). Furthermore, in all patients who received primary prophylaxis with G-CSF, a relative dose intensity > 85% using EC therapy was maintained. CONCLUSION: The incidence of FN in EC therapy among Japanese patients was higher than expected, EC therapy appears to be a high-risk chemotherapy for FN, and prophylactic administration of G-CSF is recommended. Maintaining high therapeutic intensity is associated with a positive prognosis for patients with early breast cancer, and prophylactic administration of G-CSF is likely to be beneficial in treatment involving EC therapy. Cancer chemotherapy and pharmacology 0344-5704 84 5 1107 1114 20191100 10.1007/s00280-019-03948-6 31502114 read0138449/published_papers/34979566 岡田 直人 座間味 義人 石澤 啓介 【医師・看護師のギモンに"的確"かつ"迅速"に答える!病棟・カンファレンスでそのまま使える想定問答集151】(第9章)感染症 (Q107)感染性心内膜炎に対する予防投与 感染性心内膜炎の予防では，どのような患者にどのような抗菌薬が使用されますか? (株)じほう 薬事 0016-5980 61 14 2685 2687 20191000 read0138449/published_papers/34979564 岡田 直人 座間味 義人 石澤 啓介 【医師・看護師のギモンに"的確"かつ"迅速"に答える!病棟・カンファレンスでそのまま使える想定問答集151】(第9章)感染症 (Q108)腸ろう患者へのボリコナゾール投与 経腸栄養剤を腸ろうから24時間持続投与している患者に対し，ボリコナゾールの経胃投与は可能ですか? (株)じほう 薬事 0016-5980 61 14 2688 2689 20191000 read0138449/published_papers/34979562 岡田 直人 座間味 義人 石澤 啓介 【医師・看護師のギモンに"的確"かつ"迅速"に答える!病棟・カンファレンスでそのまま使える想定問答集151】(第9章)感染症 (Q109)イトラコナゾール剤形変更時の注意点 イトラコナゾールをカプセルから内用液へと切り替える際の注意点を教えてください (株)じほう 薬事 0016-5980 61 14 2690 2691 20191000 read0138449/published_papers/29516413 中馬 真幸 合田 光寛 谷 友歩 座間味 義人 武智 研志 石澤 有紀 濱野 裕章 石田 俊介 新村 貴博 近藤 正輝 坂東 貴司 岡田 直人 福島 圭穣 藤野 裕道 土屋 浩一郎 堀ノ内 裕也 池田 康将 楊河 宏章 石澤 啓介 ドラッグリポジショニング手法を用いたバンコマイシン関連腎障害の予防薬探索とその有用性の検討 日本腎臓病薬物療法学会 日本腎臓病薬物療法学会誌 2187-0411 8 S138 S138 20191000 read0138449/published_papers/29516391 中馬 真幸 座間味 義人 合田 光寛 武智 研志 石澤 有紀 新村 貴博 濱野 裕章 近藤 正輝 楊河 宏章 石澤 啓介 医療ビッグデータを活用した救急薬学研究 (一社)日本救急医学会 日本救急医学会雑誌 1883-3772 30 9 506 507 20190900 read0138449/published_papers/10861632 Yoshito Zamami Takahiro Niimura Naoto Okada Toshihiro Koyama Keijo Fukushima Yuki Izawa-Ishizawa Keisuke Ishizawa Factors Associated With Immune Checkpoint Inhibitor-Related Myocarditis. JAMA oncology 2374-2437 5 11 1635 1637 20190822 10.1001/jamaoncol.2019.3113 31436802 read0138449/published_papers/21889908 Yasumasa Ikeda Akiho Satoh Yuya Horinouchi Hirofumi Hamano Hiroaki Watanabe Mizuki Imao Masaki Imanishi Yoshito Zamami Kenshi Takechi Yuki Izawa-Ishizawa Licht Miyamoto Tasuku Hirayama Hideko Nagasawa Keisuke Ishizawa Ken-Ichi Aihara Koichiro Tsuchiya Toshiaki Tamaki Iron accumulation causes impaired myogenesis correlated with MAPK signaling pathway inhibition by oxidative stress. Skeletal muscle atrophy is caused by disruption in the homeostatic balance of muscle degeneration and regeneration under various pathophysiological conditions. We have previously reported that iron accumulation induces skeletal muscle atrophy via a ubiquitin ligase-dependent pathway. However, the potential effect of iron accumulation on muscle regeneration remains unclear. To examine the effect of iron accumulation on myogenesis, we used a mouse model with cardiotoxin (CTX)-induced muscle regeneration in vivo and C2C12 mouse myoblast cells in vitro. In mice with iron overload, the skeletal muscles exhibited increased oxidative stress and decreased expression of satellite cell markers. Following CTX-induced muscle injury, these mice also displayed delayed muscle regeneration with a decrease in the size of regenerating myofibers, reduced expression of myoblast differentiation markers, and decreased phosphorylation of MAPK signaling pathways. In vitro, iron overload also suppressed the differentiation of C2C12 myoblast cells but the suppression could be reversed by superoxide scavenging using tempol. Excess iron inhibits myogenesis via oxidative stress, leading to an imbalance in skeletal muscle homeostasis.-Ikeda, Y., Satoh, A., Horinouchi, Y., Hamano, H., Watanabe, H., Imao, M., Imanishi, M., Zamami, Y., Takechi, K., Izawa-Ishizawa, Y., Miyamoto, L., Hirayama, T., Nagasawa, H., Ishizawa, K., Aihara, K.-I., Tsuchiya, K., Tamaki, T. Iron accumulation causes impaired myogenesis correlated with MAPK signaling pathway inhibition by oxidative stress. FASEB journal : official publication of the Federation of American Societies for Experimental Biology 0892-6638 33 8 9551 9564 20190800 10.1096/fj.201802724RR 31145863 read0138449/published_papers/29516421 石田 俊介 田中 里奈 武智 研志 濱野 裕章 合田 光寛 中馬 真幸 座間味 義人 桐野 靖 中村 敏己 寺岡 和彦 石澤 啓介 周術期医薬品管理ツールの開発と導入による効果 (一社)日本医薬品情報学会 日本医薬品情報学会総会・学術大会講演要旨集 22 71 71 20190600 read0138449/published_papers/34979575 中馬 真幸 武智 研志 座間味 義人 合田 光寛 岡田 直人 近藤 正輝 石澤 啓介 楊河 宏章 抗菌薬TDMガイドライン2019 再改訂のポイント 持続的腎代替療法 (公社)日本化学療法学会 日本化学療法学会雑誌 1884-5886 67 Suppl.A 137 137 20190300 read0138449/published_papers/34979569 谷垣 雄都 山口 裕大 岡田 直人 中村 信元 賀川 久美子 藤井 志朗 三木 浩和 石澤 啓介 安倍 正博 佐藤 陽一 ゲノムワイド関連解析を用いたテイコプラニン・バンコマイシン投与による皮疹発現および血中濃度関連遺伝子座の同定 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 139 3 57 57 20190300 read0138449/published_papers/34137636 中馬 真幸 座間味 義人 武智 研志 今西 正樹 岡田 直人 合田 光寛 近藤 正輝 石澤 啓介 楊河 宏章 抗菌薬の使い方 PK/PD理論やTDMに基づく用法・用量設定を中心に (公社)日本化学療法学会 日本化学療法学会雑誌 1884-5886 67 2 216 216 20190300 read0138449/published_papers/12877873 Hirofumi Hamano Marin Mitsui Yoshito Zamami Kenshi Takechi Takahiro Nimura Naoto Okada Keijo Fukushima Masaki Imanishi Masayuki Chuma Yuya Horinouchi Yuki Izawa-Ishizawa Yasushi Kirino Toshimi Nakamura Kazuhiko Teraoka Yasumasa Ikeda Hiromichi Fujino Hiroaki Yanagawa Toshiaki Tamaki Keisuke Ishizawa Irinotecan-induced neutropenia is reduced by oral alkalization drugs: analysis using retrospective chart reviews and the spontaneous reporting database. PURPOSE: SN-38, an active metabolite of irinotecan, is reabsorbed by the intestinal tract during excretion, causing diarrhoea and neutropenia. In addition, the association between blood levels of SN-38 and neutropenia has been reported previously, and the rapid excretion of SN-38 from the intestinal tract is considered to prevent neutropenia. Oral alkalization drugs are used as prophylactic agents for suppressing SN-38 reabsorption. The relationship between oral alkalization drugs and neutropenia, however, has not been well studied. The aim of this study was to investigate the relationship between oral alkalization drugs and neutropenia in irinotecan-treated patients. METHODS AND RESULTS: Patients with cervical or ovarian cancer were administered irinotecan and investigated by medical chart reviews to determine whether oral alkalization drugs were effective at ameliorating irinotecan-induced neutropenia. The drug combination in the oral alkalization drugs-ursodeoxycholic acid, magnesium oxide, and sodium hydrogen carbonate-significantly improved neutrophil counts and reduced dose intensity compared with those of non-users. In the large-scale Japanese Adverse Drug Event Report database, the reporting odds ratio of irinotecan-induced neutropenia was significantly lower when irinotecan had been given in combination with oral alkalization drugs. CONCLUSIONS: These data indicate that oral alkalization drugs may reduce the frequency of neutropenia caused by irinotecan administration, making it possible to increase the dose safely. Supportive care in cancer : official journal of the Multinational Association of Supportive Care in Cancer 0941-4355 27 3 849 856 20190300 10.1007/s00520-018-4367-y 30062585 read0138449/published_papers/34979587 中馬 真幸 近藤 正輝 武智 研志 座間味 義人 合田 光寛 岡田 直人 石澤 啓介 楊河 宏章 集中治療患者における臓器系統別評価方法の習得 臓器系統別評価3/5 感染・炎症・免疫管理 敗血症に対する抗菌薬治療を中心に (一社)日本病院薬剤師会 日本病院薬剤師会雑誌 1341-8815 55 2 163 166 20190200 read0138449/published_papers/34979582 中馬 真幸 武智 研志 座間味 義人 合田 光寛 岡田 直人 近藤 正輝 石澤 啓介 楊河 宏章 ASチームが知っておきたい薬物動態 侵襲時の薬物動態 (一社)日本環境感染学会 日本環境感染学会総会プログラム・抄録集 34 [ 2] 20190200 read0138449/published_papers/37935009 Horinouchi Yuya 堀ノ内 裕也 Ikeda Yasumasa 池田 康将 Hamano Hirofumi 濱野 裕章 Imanishi Masaki 今西 正樹 Fukushima Keijo 福島 圭穣 Goda Mitsuhiro 合田 光寛 Takechi Kenshi 武智 研志 Miyamoto Licht 宮本 理人 IZAWA-ISHIZAWA YUKI 石澤 有紀 Zamami Yoshito 座間味 義人 Fujino Hiromichi 藤野 裕道 Ishizawa Keisuke 石澤 啓介 Tsuchiya Koichiro 土屋 浩一郎 Tamaki Toshiaki 玉置 俊晃 Iron metabolism abnormality in skeletal muscle atrophy associated with chronic renal failure 慢性腎不全関連骨格筋萎縮における鉄代謝異常 Introduction and aims: Skeletal muscle atrophy is often observed in chronic renal failure (CRF) patients. However, the molecular mechanism of skeletal muscle atrophy in CRF has remained unclear. Iron is an essential trace metal for all living organisms. On the other hand, excessive iron catalyzes the formation of highly toxic hydroxyl radicals via the Fenton reaction. The purpose of this study was to determine whether iron is involved in CRF-related skeletal muscle atrophy. Methods: In this study, we divided 8-weeks-old C57BL/6J mice into two groups: vehicle-treated group (control mice) and adenine-injected group (CRF mice). Results: Iron content was elevated in the skeletal muscle in CRF mice. Although the expression of divalent metal transporter 1 did not change, the expression of transferrin receptor and ferroportin were downregulated in the skeletal muscle in CRF mice. The expression of ferritin heavy chain and ferritin light chain were upregulated in the skeletal muscle in CRF mice. CRF mice showed increased oxidative stress in the skeletal muscles. Conclusions: These results suggest that iron accumulation mediated oxidative stress has the potential to accelerate skeletal muscle atrophy in CRF. Japanese Pharmacological Society 公益社団法人 日本薬理学会 Proceedings for Annual Meeting of The Japanese Pharmacological Society 日本薬理学会年会要旨集 2435-4953 92 3-P-078 null 20190000 10.1254/jpssuppl.92.0_3-p-078 1390283659860719232 read0138449/published_papers/35048563 Zamami Yoshito 座間味 義人 Izawa-Ishizawa Yuki 石澤 有紀 Ikeda Yasumasa 池田 康将 Kobayashi Daisuke 小林 大介 Shimazoe Takao 島添 隆雄 Ishizawa Keisuke 石澤 啓介 Kawajiri Takehiro 川尻 雄大 Niimura Takahiro 新村 貴博 Goda Mitsuhiro 合田 光寛 Okada Naoto 岡田 直人 Hamano Hiroaki 濱野 裕章 Takechi Kenshi 武智 研志 Chuma Masayuki 中馬 真幸 Horinouchi Yuya 堀ノ内 裕也 Search for preventive drugs against anticancer drug-induced side effects using a large-scale medical information database 大規模医療情報データベースを活用した抗がん剤誘発副作用に対する予防薬の探索 <p>Treatment outcomes of cancer patients have improved with progress in oncology medication therapy, but side effects caused by anticancer agents are becoming widespread. Side effects caused by anticancer drugs not only significantly lower the patient's QOL but also often lead to dose reduction or discontinuation of the anticancer drugs. Addressing these side effects is important for improving patient prognosis. Therefore, improvement of the quality of cancer therapy through the development of preventive drugs against anticancer drug-induced side effects is an urgent goal. In recent years, clinical research has been carried out in Japan using large-scale medical information sources such as disease/side effect databases, in order to accurately evaluate the effects of drug used in clinical practice. Research utilizing such a large-scale medical information database can cover various patient parameters and a wide range of observation areas. Therefore, this approach is suitable for conducting clinical research on rare diseases and low-frequency side effects. In this symposium, we will introduce research conducted using drug discovery tools and cell/animal experiments based on a large-scale medical information database to search for preventive agents against anticancer drug-induced side effects, as well as consider future prospects for this approach.</p> Japanese Pharmacological Society 公益社団法人 日本薬理学会 Proceedings for Annual Meeting of The Japanese Pharmacological Society 日本薬理学会年会要旨集 92 2 AS1-3 20190000 10.1254/jpssuppl.92.0_2-AS1-3 read0138449/published_papers/34979588 岡田 直人 石澤 啓介 【薬の効果・副作用と検査値】抗炎症薬の薬理作用と検査値への影響 (株)医学書院 臨床検査 1882-1367 63 1 68 74 20190100 read0138449/published_papers/34721973 Goda Mitsuhiro 合田 光寛 Hamano Hirofumi 濱野 裕章 Ikuta Kenji 生田 賢治 Okada Naoto 岡田 直人 Takechi Kenshi 武智 研志 Horinouchi Yuya 堀ノ内 裕也 Ikeda Yasumasa 池田 康将 Ishizawa Keisuke 石澤 啓介 Saike Kazuhito 斉家 和仁 Kanda Masaya 神田 将哉 Murai Yoichi 村井 陽一 Yoshida Ami 吉田 愛美 Niimura Takahiro 新村 貴博 Izawa-Ishizawa Yuki 石澤 有紀 Zamami Yoshito 座間味 義人 Chuma Masayuki 中馬 真幸 Effect of the new preventive medicine on cisplatin-induced acute kidney injury シスプラチン誘発腎障害に対する新規予防薬の有効性の検証 <p>OBJECTIVE: Cisplatin (CDDP)-induced acute kidney injury (AKI) is highly expressed. Forced hydration and diuresis may partially prevent nephrotoxicity, but it is still difficult to completely prevent kidney injury, so establishment of a new preventive method is required. Therefore, in this study, we elected to candidates for preventive drugs of CDDP-induced AKI using big data analysis, and to verify the effectiveness of the drugs.</p><p>METHODS: Using FAERS (FDA Adverse Event Reporting System), existing drugs that may reduce CDDP-induced AKI were extracted. C57BL/6 mice were intraperitoneally administered with CDDP. Renal function was evaluated by serum creatinine and blood urea nitrogen. Histological damage in the cortex of kidney sections was scored. The effect of preventive drugs for CDDP-induced nephropathy was evaluated.</p><p>Results: The drug X was extracted a candidate drug suggesting the protective effect of CDDP-induced AKI by FAERS analysis. It was revealed that administration of the drug X significantly suppressed CDDP-induced AKI.</p><p>Conclusions: From the results of this study, it was suggested that existing pharmaceutical products elected by FAERS could be a preventive drug for CDDP-induced AKI.</p> Japanese Pharmacological Society 公益社団法人 日本薬理学会 Proceedings for Annual Meeting of The Japanese Pharmacological Society 日本薬理学会年会要旨集 92 0 3 P-076 20190000 10.1254/jpssuppl.92.0_3-P-076 read0138449/published_papers/29516436 堀ノ内 裕也 池田 康将 渡邉 大晃 濱野 裕章 石澤 有紀 今西 正樹 座間味 義人 武智 研志 宮本 理人 石澤 啓介 土屋 浩一郎 玉置 俊晃 マクロファージフェリチン欠損は肥満・糖尿病における脂肪炎症を抑制する 日本心脈管作動物質学会 血管 0911-4637 42 1 44 44 20190100 read0138449/published_papers/29516429 合田 光寛 斉家 和仁 神田 将哉 村井 陽一 吉田 愛美 新村 貴博 石澤 有紀 座間味 義人 中馬 真幸 武智 研志 濱野 裕章 岡田 直人 堀ノ内 裕也 池田 康将 石澤 啓介 シスプラチン誘発腎障害に対する各種5-HT3受容体拮抗薬の影響 日本心脈管作動物質学会 血管 0911-4637 42 1 49 49 20190100 read0138449/published_papers/18475679 Naoto Okada Hitoshi Kawazoe Kenshi Takechi Yoshihiro Matsudate Ryo Utsunomiya Yoshito Zamami Mitsuhiro Goda Masaki Imanishi Masayuki Chuma Noriaki Hidaka Koji Sayama Yoshiaki Kubo Akihiro Tanaka Keisuke Ishizawa Association Between Immune-Related Adverse Events and Clinical Efficacy in Patients with Melanoma Treated With Nivolumab: A Multicenter Retrospective Study. PURPOSE: Nivolumab, an anti-programmed death 1 antibody, produces antitumor effects by activating host immunity, which also causes immune-related adverse events (irAEs). The aim of this study was to analyze the association between antitumor effect and irAEs induced by nivolumab in patients with melanoma. METHODS: Fifteen patients with melanoma who had received nivolumab at Tokushima University Hospital or Ehime University Hospital between January 2015 and December 2016 were enrolled in this study. Patients who had and did not have irAEs during nivolumab treatment were classified into an irAEs-positive group (n = 8) and an irAEs-negative group (n = 7), respectively. We compared the disease control rate (DCR) and overall survival (OS) between the 2 groups. Data on blood cell counts were also analyzed. FINDINGS: After a median of 4 cycles of nivolumab treatment, irAEs occurred. The DCRs were 75% and 14% in the irAEs-positive and irAEs-negative groups, respectively (p < 0.05). OS in the irAEs-positive group was higher than that in the irAEs-negative group (p < 0.05). Multivariable Cox proportional hazards regression analysis revealed that irAE occurrence affected OS with nivolumab treatment. Moreover, the increase in baseline peripheral lymphocyte count at the time of onset of irAEs was significantly greater in the irAEs-positive group than in the irAEs-negative group after 4 cycles of nivolumab treatment (p < 0.05). IMPLICATIONS: Our study indicated that clinical response with nivolumab treatment improves with irAE occurrence in patients with melanoma. Moreover, the early increase in peripheral lymphocyte count may act as a biomarker for predicting the occurrence of irAEs induced by nivolumab. Clinical therapeutics 0149-2918 41 1 59 67 20190100 10.1016/j.clinthera.2018.11.004 30528047 read0138449/published_papers/18475678 Naoto Okada Takahiro Niimura Yoshito Zamami Hirofumi Hamano Shunsuke Ishida Mitsuhiro Goda Kenshi Takechi Masayuki Chuma Masaki Imanishi Keisuke Ishizawa Pharmacovigilance evaluation of the relationship between impaired glucose metabolism and BCR-ABL inhibitor use by using an adverse drug event reporting database. Breakpoint cluster region-Abelson murine leukemia (BCR-ABL) inhibitors markedly improve the prognosis of chronic myeloid leukemia. However, high treatment adherence is necessary for successful treatment with BCR-ABL inhibitors. Therefore, an adequate understanding of the adverse event profiles of BCR-ABL inhibitors is essential. Although many adverse events are observed in trials, an accurate identification of adverse events based only on clinical trial results is difficult because of strict entry criteria or limited follow-up durations. In particular, BCR-ABL inhibitor-induced impaired glucose metabolism remains controversial. Pharmacovigilance evaluations using spontaneous reporting systems are useful for analyzing drug-related adverse events in clinical settings. Therefore, we conducted signal detection analyses for BCR-ABL inhibitor-induced impaired glucose metabolism by using the FDA Adverse Event Reporting System (FAERS) and Japanese Adverse Drug Event Report (JADER) database. Signals for an increased reporting rate of impaired glucose metabolism were detected only for nilotinib use, whereas these signals were not detected for other BCR-ABL inhibitors. Subgroup analyses showed a clearly increased nilotinib-associated reporting rate of impaired glucose metabolism in male and younger patients. Although FAERS- and JADER-based signal detection analyses cannot determine causality perfectly, our study suggests the effects on glucose metabolism are different between BCR-ABL inhibitors and provides useful information for the selection of appropriate BCR-ABL inhibitors. Cancer medicine 8 1 174 181 20190100 10.1002/cam4.1920 30561126 read0138449/published_papers/16116720 Yoshito Zamami Takahiro Niimura Toshihiro Koyama Yuta Shigemi Yuki Izawa-Ishizawa Mizuki Morita Ayako Ohshima Keisaku Harada Toru Imai Hiromi Hagiwara Naoto Okada Mitsuhiro Goda Kenshi Takechi Masayuki Chuma Yutaka Kondo Koichiro Tsuchiya Shiro Hinotsu Mitsunobu R Kano Keisuke Ishizawa Search for Therapeutic Agents for Cardiac Arrest Using a Drug Discovery Tool and Large-Scale Medical Information Database. The survival rate of cardiac arrest patients is less than 10%; therefore, development of a therapeutic strategy that improves their prognosis is necessary. Herein, we searched data collected from medical facilities throughout Japan for drugs that improve the survival rate of cardiac arrest patients. Candidate drugs, which could improve the prognosis of cardiac arrest patients, were extracted using "TargetMine," a drug discovery tool. We investigated whether the candidate drugs were among the drugs administered within 1 month after cardiac arrest in data of cardiac arrest cases obtained from the Japan Medical Data Center. Logistic regression analysis was performed, with the explanatory variables being the presence or absence of the administration of those candidate drugs that were administered to ≥10 patients and the objective variable being the "survival discharge." Adjusted odds ratios for survival discharge were calculated using propensity scores for drugs that significantly improved the proportion of survival discharge; the influence of covariates, such as patient background, medical history, and treatment factors, was excluded by the inverse probability-of-treatment weighted method. Using the search strategy, we extracted 165 drugs with vasodilator activity as candidate drugs. Drugs not approved in Japan, oral medicines, and external medicines were excluded. Then, we investigated whether the candidate drugs were administered to the 2,227 cardiac arrest patients included in this study. The results of the logistic regression analysis showed that three (isosorbide dinitrate, nitroglycerin, and nicardipine) of seven drugs that were administered to ≥10 patients showed significant association with improvement in the proportion of survival discharge. Further analyses using propensity scores revealed that the adjusted odds ratios for survival discharge for patients administered isosorbide dinitrate, nitroglycerin, and nicardipine were 3.35, 5.44, and 4.58, respectively. Thus, it can be suggested that isosorbide dinitrate, nitroglycerin, and nicardipine could be novel therapeutic agents for improving the prognosis of cardiac arrest patients. Frontiers in pharmacology 10 1257 1257 20190000 10.3389/fphar.2019.01257 31780928 read0138449/published_papers/12877870 Yuki Izawa-Ishizawa Masaki Imanishi Yoshito Zamami Hiroki Toya Tomoko Nagao Marin Morishita Koichi Tsuneyama Yuya Horinouchi Yoshitaka Kihira Kenshi Takechi Yasumasa Ikeda Koichiro Tsuchiya Masanori Yoshizumi Toshiaki Tamaki Keisuke Ishizawa Development of a novel aortic dissection mouse model and evaluation of drug efficacy using in-vivo assays and database analyses. OBJECTIVE: Aortic dissection is a life-threatening disease. At present, the only therapeutic strategies available are surgery and antihypertensive drugs. Moreover, the molecular mechanisms underlying the onset of aortic dissection are still unclear. We established a novel aortic dissection model in mice using pharmacologically induced endothelial dysfunction. We then used the Japanese Adverse Drug Event Report database to investigate the role of pitavastatin in preventing the onset of aortic dissection. METHODS AND RESULTS: To induce endothelial dysfunction, Nω-nitro-L-arginine methyl ester, a nitric oxide synthase inhibitor, was administered to C57BL/6 mice. Three weeks later, angiotensin II (Ang II) and β-aminopropionitrile (BAPN), a lysyl oxidase inhibitor, were administered with osmotic mini-pumps. False lumen formation was used as the pathological determinant of aortic dissection. The incidences of aortic dissection and death from aneurysmal rupture were significantly higher in the Nω-nitro-L-arginine methyl ester, Ang II, and BAPN (LAB) group than they were in the Ang II and BAPN (AB) group.Pitavastatin was administered orally to LAB mice. It significantly lowered the incidences of dissection and rupture. It also decreased inflammation and medial degradation, both of which were exacerbated in the LAB group. The Japanese Adverse Drug Event Report database analysis indicated that there were 113 cases of aortic dissection out of 95 090 patients (0.12%) not receiving statins but only six cases out of 16 668 patients receiving statins (0.04%) (odds ratio: 0.30; P = 0.0043). CONCLUSION: Our results suggest that endothelial dysfunction is associated with the onset of aortic dissection and pitavastatin can help prevent this condition. Journal of hypertension 0263-6352 37 1 73 83 20190100 10.1097/HJH.0000000000001898 30303488 read0138449/published_papers/10861628 Ken Konaka Konaka K Takumi Sakurada Sakurada T Tatsuhiko Saito Saito T Sachiko Mori Mori S Masaki Imanishi Imanishi M Soji Kakiuchi Kakiuchi S Shuji Fushitani Fushitani S Keisuke Ishizawa Ishizawa K Study on the Optimal Dose of Irinotecan for Patients with Heterozygous Uridine Diphosphate-Glucuronosyltransferase 1A1 (UGT1A1). Uridine 5'-diphospho-glucuronosyltransferase (UGT), a metabolic enzyme of irinotecan active metabolite, has two genetic polymorphisms (UGT1A1*6 and UGT1A1*28). In UGT1A1 homozygous or heterozygous patients, metabolism is delayed and the risk of developing adverse effects is increased, and therefore, dose reduction of irinotecan is considered. However, the specific dose reduction rate of irinotecan for heterozygous patients is uncertain. We studied the necessity of irinotecan dose reduction and its optimal dose in UGT1A1 heterozygous patients with lung cancer. Patients with lung cancer treated with irinotecan in the Tokushima University Hospital or Tokushima Municipal Hospital were included in this study. The dose of irinotecan was evaluated based on the relative dose intensity (RDI). The time to treatment failure (TTF) was defined as the period until treatment change, death, or progressive disease based on response evaluation criteria of solid tumors. We targeted 31 patients treated with irinotecan: 12 wild types (WT), 14 heterozygotes, and 1 complex heterozygote and 4 homozygotes. There was no significant difference in the TTF, but the mean RDI during the entire treatment period was significantly different in the wild type (79%), heterozygous (62%), and complex heterozygous and homozygous groups (46%). In addition, the proportion of patients who completed treatment without dose reduction in the WT group tended to be higher than that in the other groups. For lung cancer patients with UGT1A1 heterozygote types who start irinotecan therapy, reducing the initial dose by approximately 20% might be a safer chemotherapy without decreasing the therapeutic effect. Biological & pharmaceutical bulletin 0918-6158 42 11 1839 1845 20190000 10.1248/bpb.b19-00357 31685767 read0138449/published_papers/24878599 Shunsuke Ishida Kenshi Takechi Hiroshi Bando Masaki Imanishi Yoshito Zamami Masayuki Chuma Hiroaki Yanagawa Yasushi Kirino Toshimi Nakamura Kazuhiko Teraoka Keisuke Ishizawa Development and pharmacist-mediated use of tools for monitoring atypical antipsychotic-induced side effects related to blood glucose levels. PURPOSE: Drug side effects often lead to serious outcomes. Administration of second-generation antipsychotics has resulted in diabetic ketoacidosis and diabetic coma leading to death. Therefore, pharmacists are required to collect information on clinical test values, determine the appropriate test timing, and coordinate with doctors for further clinical laboratory orders, all of which are labor-intensive and time-intensive tasks. In this study, we developed a side effect-monitoring tool and aimed to clarify the influence and efficiency of monitoring side effects by using the tool in patients taking atypical antipsychotics in whom it is necessary to check clinical test values such as blood sugar levels. METHODS: We extracted clinical test values for patients treated with second-generation antipsychotics from electronic medical records. The test values are automatically displayed in the side effect grade classification specified by CTCAE ver. 4.0. A database was constructed using scripts to provide alerts for the timing of clinical testing. The pharmacist used this tool to confirm clinical test values for patients taking medication and requested the physician to inspect orders based on the appropriate test timings. RESULTS: The management tool reduced the pharmacists' effort in collecting information on patients' prescription status and test values. It enabled patients to undergo tests at the appropriate time according to the progression of glucose metabolism and allowed for easy monitoring of side effects. CONCLUSIONS: The results suggested that regardless of pharmacists' experience or skill, the introduction of this tool enables centralization of side effect monitoring and can contribute to proper drug use. Pharmacoepidemiology and drug safety 1099-1557 27 12 1379 1384 20181200 10.1002/pds.4656 30221424 read0138449/published_papers/12877872 Ishida S Takechi K Bando H Imanishi M Zamami Y Chuma M Yanagawa H Kirino Y Nakamura T Teraoka K Ishizawa K Development and pharmacist-mediated use of tools for monitoring atypical antipsychotic-induced side effects related to blood glucose levels. Pharmacoepidemiology and drug safety 1053-8569 27 12 1379 1384 20180900 10.1002/pds.4656 30221424 read0138449/published_papers/12877874 Yuya Horinouchi Yasumasa Ikeda Keijo Fukushima Masaki Imanishi Hirofumi Hamano Yuki Izawa-Ishizawa Yoshito Zamami Kenshi Takechi Licht Miyamoto Hiromichi Fujino Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki Renoprotective effects of a factor Xa inhibitor: fusion of basic research and a database analysis. Renal tubulointerstitial injury, an inflammation-associated condition, is a major cause of chronic kidney disease (CKD). Levels of activated factor X (FXa), a blood coagulation factor, are increased in various inflammatory diseases. Therefore, we investigated the protective effects of an FXa inhibitor against renal tubulointerstitial injury using unilateral ureteral obstruction (UUO) mice (a renal tubulointerstitial fibrosis model) and the Food and Drug Administration Adverse Events Reporting System (FAERS) database. The renal expression levels of FX and the FXa receptors protease-activated receptor (PAR)-1 and PAR-2 were significantly higher in UUO mice than in sham-operated mice. UUO-induced tubulointerstitial fibrosis and extracellular matrix expression were suppressed in UUO mice treated with the FXa inhibitor edoxaban. Additionally, edoxaban attenuated UUO-induced macrophage infiltration and inflammatory molecule upregulation. In an analysis of the FAERS database, there were significantly fewer reports of tubulointerstitial nephritis for patients treated with FXa inhibitors than for patients not treated with inhibitors. These results suggest that FXa inhibitors exert protective effects against CKD by inhibiting tubulointerstitial fibrosis. Scientific reports 8 1 10858 10858 20180718 10.1038/s41598-018-29008-2 30022146 read0138449/published_papers/29516443 堀ノ内 裕也 池田 康将 石澤 有紀 玉置 俊晃 福島 圭穣 藤野 裕道 濱野 裕章 今西 正樹 座間味 義人 石澤 啓介 土屋 浩一郎 大規模医療情報データベース解析と基礎研究の融合による新規腎保護薬の探索 徳島医学会 四国医学雑誌 0037-3699 74 1-2 82 83 20180400 read0138449/published_papers/19038282 Hirofumi Hamano Yasumasa Ikeda Hiroaki Watanabe Yuya Horinouchi Yuki Izawa-Ishizawa Masaki Imanishi Yoshito Zamami Kenshi Takechi Licht Miyamoto Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki The uremic toxin indoxyl sulfate interferes with iron metabolism by regulating hepcidin in chronic kidney disease. Background: Hepcidin secreted by hepatocytes is a key regulator of iron metabolism throughout the body. Hepcidin concentrations are increased in chronic kidney disease (CKD), contributing to abnormalities in iron metabolism. Levels of indoxyl sulfate (IS), a uremic toxin, are also elevated in CKD. However, the effect of IS accumulation on iron metabolism remains unclear. Methods: We used HepG2 cells to determine the mechanism by which IS regulates hepcidin concentrations. We also used a mouse model of adenine-induced CKD. The CKD mice were divided into two groups: one was treated using AST-120 and the other received no treatment. We examined control mice, CKD mice, CKD mice treated using AST-120 and mice treated with IS via drinking water. Results: In the in vitro experiments using HepG2 cells, IS increased hepcidin expression in a dose-dependent manner. Silencing of the aryl hydrocarbon receptor (AhR) inhibited IS-induced hepcidin expression. Furthermore, IS induced oxidative stress and antioxidant drugs diminished IS-induced hepcidin expression. Adenine-induced CKD mice demonstrated an increase in hepcidin concentrations; this increase was reduced by AST-120, an oral adsorbent of the uremic toxin. CKD mice showed renal anemia, decreased plasma iron concentration, increased plasma ferritin and increased iron content in the spleen. Ferroportin was decreased in the duodenum and increased in the spleen. These changes were ameliorated by AST-120 treatment. Mice treated by direct IS administration showed hepatic hepcidin upregulation. Conclusions: IS affects iron metabolism in CKD by participating in hepcidin regulation via pathways that depend on AhR and oxidative stress. Nephrology, dialysis, transplantation : official publication of the European Dialysis and Transplant Association - European Renal Association 0931-0509 33 4 586 597 20180401 10.1093/ndt/gfx252 28992067 read0138449/published_papers/19480752 Naoto Okada Momoyo Azuma Masaki Imanishi Yoshito Zamami Yasushi Kirino Toshimi Nakamura Kazuhiko Teraoka Masahiro Abe Keisuke Ishizawa Potential Usefulness of Early Potassium Supplementation for Preventing Severe Hypokalemia Induced by Liposomal Amphotericin B in Hematologic Patients: A Retrospective Study. PURPOSE: Liposomal amphotericin B (L-AMB) is an essential antifungal agent for patients with hematologic diseases; however, the drug causes severe hypokalemia at a high frequency. Meanwhile, there is little evidence regarding the risk factors for L-AMB-induced severe hypokalemia, and the prevention protocol has not been established. The goal of this study was to identify the risk factors related to severe hypokalemia induced by L-AMB in hematologic patients. METHODS: Seventy-eight hematologic patients with a first administration of L-AMB were enrolled in the study. Eleven patients who had serum potassium levels <3.0 mmol/L before L-AMB administration and 12 patients who received L-AMB administration within 3 days were excluded. Patients who had a serum potassium level <3.0 mmol/L during L-AMB administration were classified into a hypokalemia group (n = 26), and those who had a serum potassium level ≥3.0 mmol/L were classified into a non-hypokalemia group (n = 29). The patient characteristics were analyzed retrospectively. In addition, the usefulness of potassium supplementation was analyzed for those patients who received potassium formulations (non-hypokalemia group, n = 15; hypokalemia group, n = 24). FINDINGS: Twenty-six patients had hypolalemia after L-AMB administration. Hypokalemia with serum potassium levels <3.0 mmol/L was observed ~7 days after starting L-AMB administration. The patient characteristics, L-AMB dose, and L-AMB administration period did not differ between the 2 groups. In the patients who received potassium formulations, the period between starting L-AMB administration and starting potassium supplementation was significantly shorter in the non-hypokalemia group than in the hypokalemia group (median, 0 vs 4 days, respectively; P < 0.01); the potassium dose was not different between the 2 groups. A receiver-operating characteristic curve revealed that the cutoff time for the start of potassium supplementation to reduce the incidence of L-AMB-induced hypokalemia was 3 days. Multivariate logistic regression analysis revealed that beginning potassium supplementation within 2 days from the start of L-AMB administration was an independent factor reducing the risk of L-AMB-induced hypokalemia (odds ratio, 0.094 [95% CI, 0.019-0.47]). IMPLICATIONS: This study showed that starting administration of a potassium formulation within 2 days from the start of L-AMB administration was a risk reduction factor for L-AMB-induced hypokalemia. This finding indicates that early potassium supplementation should be incorporated into the regimen of hypokalemia management when L-AMB is used. Clinical therapeutics 0149-2918 40 2 252 260 20180200 10.1016/j.clinthera.2017.12.006 29305017 read0138449/published_papers/25109885 Zamami Y Kouno Y Niimura T Chuma M Imai T Mitsui M Koyama T Kayano M Okada N Hamano H Goda M Imanishi M Takechi K Horinouchi Y Kondo Y Yanagawa H Kitamura Y Sendo T Ujike Y Ishizawa K Relationship between the administration of nicardipine hydrochloride and the development of delirium in patients on mechanical ventilation Pharmazie 0031-7144 73 12 740 743 20180000 10.1691/ph.2018.8711 30522561 2-s2.0-85058594813 read0138449/published_papers/22444259 Takahiro Niimura Yoshito Zamami Toru Imai Tsuyoshi Ito Hidenori Sagara Hichiya Hiroyuki Satoru Esumi Kenshi Takechi Masaki Imanishi Toshihiro Koyama Manabu Amano Naomi Kurata Yoshihisa Kitamura Hironori Nakura Toshiaki Sendo Keisuke Ishizawa Administration of Kampo medicine through a tube at an advanced critical care center. n emergency and critical care medical centers, tube administration is employed for patients who have difficulty swallowing oral drugs owing to decreased consciousness or mechanical ventilation. However, tube clogging due to drug injection is a concern. We compared the crushing method with the simple suspension method for the passage of amlodipine, an antihypertensive drug, in combination with rikkunshito, which has been used to treat upper gastrointestinal disorders such as functional dyspepsia and gastroesophageal reflux in emergency and critical care medical centers, to ascertain the effect of Kampo products on the passage of other drugs during tube administration. When the crushing method was employed, poorly water-soluble solid products were formed, while a uniformly dispersed suspension was obtained using the simple suspension method. In addition, the passage rate of amlodipine through the tube was 64% and 93% in the crushing and simple suspension methods, respectively, thereby indicating that the simple suspension method provided more favorable than the crushing method. The results of this study suggested that the passage rate of amlodipine for patients who received Kampo products concurrently was higher when the simple suspension method was used, and an appropriate drug amount might well be able to administered to patients using this method. J. Med. Invest. 65:32-36, February, 2018. The journal of medical investigation : JMI 1343-1420 65 1.2 32 36 20180000 10.2152/jmi.65.32 29593190 read0138449/published_papers/22444258 Takahiro Niimura Yoshito Zamami Toru Imai Kanako Nagao Masafumi Kayano Hidenori Sagara Mitsuhiro Goda Naoto Okada Masayuki Chuma Kenshi Takechi Masaki Imanishi Toshihiro Koyama Tadashi Koga Hironori Nakura Toshiaki Sendo Keisuke Ishizawa Evaluation of the Benefits of De-Escalation for Patients with Sepsis in the Emergency Intensive Care Unit. PURPOSE: Although the 2016 Japanese guidelines for the management of sepsis recommend de-escalation of treatment after identification of the causative pathogen, adherence to this practice remain unknown. The objective of this study was to evaluate the benefits of de-escalating treatment for sepsis patients at an advanced critical care and emergency medical centre. METHODS: Based on electronic patient information, 85 patients who were transported to the centre by ambulance, and diagnosed with sepsis between January 2008 and September 2013 were enrolled and evaluated. Patients were divided into two groups with and without de-escalation, and comparisons were conducted for several variables, including length of hospital stay, and length of antibiotic administration. Two types of subgroup analysis were conducted between patients with septic shock or positive blood cultures. Statistical analysis was conducted using chi-square and Mann-Whitney U tests. RESULTS: The length of hospital stay after diagnosis was significantly shorter for the de-escalation group than for the non-de-escalation group. In the subgroup analysis, de-escalation for blood culture-positive patients was beneficial in terms of the length of hospital stay and length of antibiotic administration. CONCLUSIONS: The findings of this study suggest that sepsis treatment de-escalation is beneficial for treatment efficacy and appropriate use of antibiotics. This article is open to POST-PUBLICATION REVIEW. Registered readers (see "For Readers") may comment by clicking on ABSTRACT on the issue's contents page. Journal of pharmacy & pharmaceutical sciences : a publication of the Canadian Society for Pharmaceutical Sciences, Societe canadienne des sciences pharmaceutiques 21 1 54 59 20180000 10.29173/jpps29737 29455711 read0138449/published_papers/12877871 Masaki Imanishi Yuki Izawa-Ishizawa Takumi Sakurada Yusuke Kohara Yuya Horinouchi Eriko Sairyo Yoshito Zamami Kenshi Takechi Masayuki Chuma Keijo Fukushima Yasumasa Ikeda Hiromichi Fujino Masanori Yoshizumi Koichiro Tsuchiya Toshiaki Tamaki Keisuke Ishizawa Nitrosonifedipine, a Photodegradation Product of Nifedipine, Suppresses Pharmacologically Induced Aortic Aneurysm Formation. BACKGROUND/AIMS: We have reported that nitrosonifedipine (NO-NIF), a photodegradation product of nifedipine, has strong antioxidant and endothelial protective effects, and can suppress several cardiovascular diseases in animal models. The objective of the present study was to investigate the effects of NO-NIF on aortic aneurysm formation. METHODS: The mice were infused with β-aminopropionitrile for 2 weeks and angiotensin II for 6 weeks to induce aortic aneurysm formation. The oxidative stress was measured by dihydroethidium staining and nitrotyrosine staining. The expressions of inflammation-related genes were assessed by quantitative real-time PCR and immunohistochemical staining. To clarify the mechanisms of how NO-NIF suppresses vascular cell adhesion molecule (VCAM)-1, endothelial cells were used in in vitro system. RESULTS: NO-NIF suppressed pharmacologically induced the aortic aneurysm formation and aortic expansion without blood pressure changes. NO-NIF suppressed elastin degradation and matrix metalloproteinase-2 mRNA expression. NO-NIF suppressed the reactive oxygen species-cyclophilin A positive feedback loop. Upregulated mRNA expressions of inflammation-related genes and endothelial VCAM-1 were suppressed by NO-NIF co-treatment in aortae. CONCLUSION: NO-NIF has the potential to be a new, nifedipine-derived therapeutic drug for suppressing aortic aneurysm formation by directly improving aortic structure with its strong ability to reduce oxidative stress and inflammation. Pharmacology 0031-7012 102 5-6 287 299 20180000 10.1159/000492577 30253416 read0138449/published_papers/19480753 Takahiro Niimura Yoshito Zamami Toshihiro Koyama Yuki Izawa-Ishizawa Masashi Miyake Tadashi Koga Keisaku Harada Ayako Ohshima Toru Imai Yutaka Kondo Masaki Imanishi Kenshi Takechi Keijo Fukushima Yuya Horinouchi Yasumasa Ikeda Hiromichi Fujino Koichiro Tsuchiya Toshiaki Tamaki Shiro Hinotsu Mitsunobu R Kano Keisuke Ishizawa Hydrocortisone administration was associated with improved survival in Japanese patients with cardiac arrest. There are few reports on hydrocortisone administration after cardiac arrest, and those that have been published included few subjects. This study aimed to evaluate the effect of hydrocortisone administration on the outcomes of patients who experienced cardiac arrest. We investigated the survival discharge rates and the length of hospital stay from cardiac arrest to discharge, stratified by use of hydrocortisone, using a Japanese health-insurance claims dataset that covers approximately 2% of the Japanese population. The study included the data of 2233 subjects who experienced either in-hospital or out-of-hospital cardiac arrest between January 2005 and May 2014. These patients were divided into two groups, based on the administration of hydrocortisone. We adjusted the baseline characteristics, medical treatment, and drug administration data of the two groups using propensity scores obtained via the inverse probability of treatment weighted method. The hydrocortisone group had a significantly higher survival discharge rate (13/61 [21.1%] vs. 240/2172 [11.0%], adjusted odds ratio: 4.2, 95% CI: 1.60-10.98, p = 0.004). In addition, the administration of hydrocortisone was independent predictor of survival to discharge (hazard ratio: 4.6, p < 0.001). The results demonstrate a correlation between hydrocortisone administration and the high rates of survival to discharge. Scientific reports 7 1 17919 17919 20171220 10.1038/s41598-017-17686-3 29263333 read0138449/published_papers/19480756 Keisuke Ishizawa Toshiyuki Irie Change Emergency Intensive Care!! Create and Disseminate Evidence That Contributes to Improving the Treatment of Critically Ill Patients Foreword YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN 0031-6903 137 12 1425 1425 20171200 10.1248/yakushi.17-00139-F 29199251 read0138449/published_papers/19480755 Yoshito Zamami Takahiro Niimura Kenshi Takechi Masaki Imanishi Toshihiro Koyama Keisuke Ishizawa Drug Repositioning Research Utilizing a Large-scale Medical Claims Database to Improve Survival Rates after Cardiopulmonary Arrest YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN 0031-6903 137 12 1439 1442 20171200 10.1248/yakushi.17-00139-3 29199254 read0138449/published_papers/19480754 Ise N Takechi K Miyamoto T Ishizawa K Yanagawa H Pharmacy Students' Knowledge and Attitude toward Registration Trials and Clinical Research: A Survey in a Japanese University Hospital. Clinical research plays a fundamental role in establishing new treatments. Clinical research coordinators are considered essential in clinical research, and medical professionals such as pharmacists often take on this role. Pharmacy students can be considered future candidates for this task. We used questionnaires to survey the knowledge of and attitudes toward registration trials and clinical research of pharmacy students at Tokushima University Hospital. All pharmacy students (103) to whom questionnaires were sent responded. Almost all respondents were aware of registration trials and clinical research. More than 90% were aware of the existence of clinical research coordinators, and about half (48.6%) understood their role. In clinical research terminology, most respondents were aware of informed consent and related issues, but fewer than 20% were aware of more practical things. In total, 29.1% and 40.8% of the respondents were willing to carry out and coordinate research. These findings suggest that pharmacy students have basic knowledge of clinical research and that many students are willing to carry out and coordinate clinical research. More practical exposure to clinical research may help to strengthen their future contribution. Further studies may help to determine how to provide education on registration trials and clinical research to pharmacy students. Pharmacy (Basel, Switzerland) 5 4 null null 20171200 10.3390/pharmacy5040067 29232893 read0138449/published_papers/19038284 Kenshi Takechi Yurika Yoshioka Hitoshi Kawazoe Mamoru Tanaka Shingo Takatori Miwako Kobayashi Ichiro Matsuoka Hiroaki Yanagawa Yoshito Zamami Masaki Imanishi Keisuke Ishizawa Akihiro Tanaka Hiroaki Araki Psychiatric Patients with Antipsychotic Drug-Induced Hyperprolactinemia and Menstruation Disorders BIOLOGICAL & PHARMACEUTICAL BULLETIN 0918-6158 40 10 1775 1778 20171000 10.1248/bpb.b17-00053 28966250 read0138449/published_papers/19038283 Shiho Sato Yoshito Zamami Toru Imai Satoshi Tanaka Toshihiro Koyama Takahiro Niimura Masayuki Chuma Tadashi Koga Kenshi Takechi Yasuko Kurata Yutaka Kondo Yuki Izawa-Ishizawa Toshiaki Sendo Hironori Nakura Keisuke Ishizawa Meta-analysis of the efficacies of amiodarone and nifekalant in shock-resistant ventricular fibrillation and pulseless ventricular tachycardia SCIENTIFIC REPORTS 2045-2322 7 1 12683 null 20171000 10.1038/s41598-017-13073-0 28978927 read0138449/published_papers/19038286 Yasumasa Ikeda Yuya Horinouchi Hirofumi Hamano Tasuku Hirayama Seiji Kishi Yuki Izawa-Ishizawa Masaki Imanishi Yoshito Zamami Kenshi Takechi Licht Miyamoto Keisuke Ishizawa Ken-Ichi Aihara Hideko Nagasawa Koichiro Tsuchiya Toshiaki Tamaki Dietary iron restriction alleviates renal tubulointerstitial injury induced by protein overload in mice. Increased proteinuria causes tubulointerstitial injury due to inflammation in chronic kidney disease (CKD). Iron restriction exhibits protective effects against renal dysfunction; however, its effects against protein overload-induced tubulointerstitial damage remain unclear. Here, we investigated dietary iron restriction effect on tubulointerstitial damage in mice with protein-overload tubulointerstitial injury. Renal tubulointerstitial injury in animal model was induced by intraperitoneal injection of an overdose of bovine serum albumin (BSA). We divided mice into three groups: normal saline + normal diet (ND), BSA + ND, and BSA + iron-restricted diet (IRD). BSA overload induced renal tubulointerstitial injury in the ND mice, which was ameliorated in the IRD mice. Inflammatory cytokines and extracellular matrix mRNA expression was upregulated in BSA + ND mice kidneys and was inhibited by IRD. BSA-induced increase in renal superoxide production, NADPH oxidase activity, and p22phox expression was diminished in the IRD mice. IRD suppression increased BSA-induced renal macrophage infiltration. Moreover, BSA mice exhibited nucleotide-binding oligomerisation domain-like receptor pyrin domain-containing protein (NLRP) inflammasome activation, which was inhibited by IRD. Ferrous iron increased in kidneys with BSA overload and was inhibited by IRD. Thus, iron restriction inhibited oxidative stress and inflammatory changes, contributing to the protective effect against BSA overload-induced tubulointerstitial injury. Scientific reports 7 1 10621 10621 20170906 10.1038/s41598-017-11089-0 28878231 read0138449/published_papers/19038288 Kenshi Takechi Hiroaki Yanagawa Yoshito Zamami Keisuke Ishizawa Akihiro Tanaka Hiroaki Araki Evaluation of factors associated with the achievement of an optimal teicoplanin trough concentration INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS 0946-1965 55 8 672 677 20170800 10.5414/CP203009 28655381 read0138449/published_papers/17622293 Keisuke Oshima Yasumasa Ikeda Yuya Horinouchi Hiroaki Watanabe Hirofumi Hamano Yoshitaka Kihira Seiji Kishi Yuki Izawa-Ishizawa Licht Miyamoto Tasuku Hirayama Hideko Nagasawa Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki Iron suppresses erythropoietin expression via oxidative stress-dependent hypoxia-inducible factor-2 alpha inactivation. Renal anemia is a major complication in chronic kidney disease (CKD). Iron supplementation, as well as erythropoiesis-stimulating agents, are widely used for treatment of renal anemia. However, excess iron causes oxidative stress via the Fenton reaction, and iron supplementation might damage remnant renal function including erythropoietin (EPO) production in CKD. EPO gene expression was suppressed in mice following direct iron treatment. Hypoxia-inducible factor-2 alpha (HIF-2α), a positive regulator of the EPO gene, was also diminished in the kidney of mice following iron treatment. Anemia-induced increase in renal EPO and HIF-2α expression was inhibited by iron treatment. In in vitro experiments using EPO-producing HepG2 cells, iron stimulation reduced the expression of the EPO gene, as well as HIF-2α. Moreover, iron treatment augmented oxidative stress, and iron-induced reduction of EPO and HIF-2α expression was restored by tempol, an antioxidant compound. HIF-2α interaction with the Epo promoter was inhibited by iron treatment, and was restored by tempol. These findings suggested that iron supplementation reduced EPO gene expression via an oxidative stress-HIF-2α-dependent signaling pathway. Laboratory investigation; a journal of technical methods and pathology 0023-6837 97 5 555 566 20170500 10.1038/labinvest.2017.11 28263291 read0138449/published_papers/29516453 濱野 裕章 池田 康将 渡邉 大晃 堀ノ内 裕也 石澤 有紀 石澤 啓介 土屋 浩一郎 玉置 俊晃 インドキシル硫酸はヘプシジンを介した鉄代謝異常に関与する (一社)日本腎臓学会 日本腎臓学会誌 1884-0728 59 3 321 321 20170400 read0138449/published_papers/17622294 Yutaka Fukunaga Yuki Izawa-Ishizawa Yuya Horinouchi Eriko Sairyo Yasumasa Ikeda Keisuke Ishizawa Koichiro Tsuchiya Yoshiro Abe Ichiro Hashimoto Toshiaki Tamaki Topical application of nitrosonifedipine, a novel radical scavenger, ameliorates ischemic skin flap necrosis in a mouse model. Ischemic skin flap necrosis can occur in random pattern flaps. An excess amount of reactive oxygen species is generated and causes necrosis in the ischemic tissue. Nitrosonifedipine (NO-NIF) has been demonstrated to possess potent radical scavenging ability. However, there has been no study on the effects of NO-NIF on ischemic skin flap necrosis. Therefore, they evaluated the potential of NO-NIF in ameliorating ischemic skin flap necrosis in a mouse model. A random pattern skin flap (1.0 × 3.0 cm) was elevated on the dorsum of C57BL/6 mice. NO-NIF was administered by topical injection immediately after surgery and every 24 hours thereafter. Flap survival was evaluated on postoperative day 7. Tissue samples from the skin flaps were harvested on postoperative days 1 and 3 to analyze oxidative stress, apoptosis and endothelial dysfunction. The viable area of the flap in the NO-NIF group was significantly increased (78.30 ± 7.041%) compared with that of the control group (47.77 ± 6.549%, p < 0.01). NO-NIF reduced oxidative stress, apoptosis and endothelial dysfunction, which were evidenced by the decrease of malondialdehyde, p22phox protein expression, number of apoptotic cells, phosphorylated p38 MAPK protein expression, and vascular cell adhesion molecule-1 protein expression while endothelial nitric oxide synthase protein expression was increased. In conclusion, they demonstrated that NO-NIF ameliorated ischemic skin flap necrosis by reducing oxidative stress, apoptosis, and endothelial dysfunction. NO-NIF is considered to be a candidate for the treatment of ischemic flap necrosis. Wound repair and regeneration : official publication of the Wound Healing Society [and] the European Tissue Repair Society 1067-1927 25 2 217 223 20170400 10.1111/wrr.12510 28090711 read0138449/published_papers/17622292 Naoto Okada Aki Murakami Shiori Urushizaki Misa Matsuda Kazuyoshi Kawazoe Keisuke Ishizawa Extracts of Immature Orange (Aurantii fructus immaturus) and Citrus Unshiu Peel (Citri unshiu pericarpium) Induce P-Glycoprotein and Cytochrome P450 3A4 Expression via Upregulation of Pregnane X Receptor FRONTIERS IN PHARMACOLOGY 1663-9812 8 1 9 20170200 10.3389/fphar.2017.00084 28270768 read0138449/published_papers/29516460 濱野 裕章 池田 康将 渡邉 大晃 堀ノ内 裕也 佐藤 明穂 大島 啓亮 石澤 有紀 石澤 啓介 土屋 浩一郎 玉置 俊晃 慢性腎不全における尿毒素蓄積が生体内鉄代謝に与える影響の検討 日本心脈管作動物質学会 血管 0911-4637 40 1 40 40 20170100 read0138449/published_papers/19038287 Ken Konaka Kota Moriyama Takumi Sakurada Naoto Okada Masaki Imanishi Yoshito Zamami Kazuyoshi Kawazoe Shuji Fushitani Keisuke Ishizawa Kamishoyosan and Shakuyakukanzoto promote recovery from paclitaxel-induced neurite retraction in PC12 cells. BACKGROUND: In chemotherapy, the full round of treatment must be completed as scheduled to achieve the strongest therapeutic effect. However, peripheral neuropathy, a severe side effect of the chemotherapeutic agent paclitaxel, can force the premature discontinuation of treatment. As some kampo practitioners have suggested that it may be possible to counteract such side effects, we analyzed the effects of Kamishoyosan, Shakuyakukanzoto, and Goshajinkigan in an in vitro model of paclitaxel-induced peripheral neuropathy. METHODS: Paclitaxel-treated PC12 cells were assessed for neurite length and performed Western blot analysis for growth-associated protein-43 (GAP-43) and light neurofilament protein (NF-L) levels in the presence of nerve growth factor (NGF); they were re-assessed, with additional testing for acetylcholinesterase levels, after application of one of the kampo. We also compared phosphorylation of extracellular signal-regulated kinase (Erk)1/2 and Akt via Western blot analysis. About effect of kampo to anticancer efficacy, we confirmed cell cytotoxicity in A549 cells using MTT assay. RESULTS: Addition of Kamishoyosan or Shakuyakukanzoto, but not Goshajinkigan, significantly improved neurite length and GAP-43 and NF-L levels from paclitaxel-treated PC12 cells, relative to those of only NGF-treated PC12 cells. The promoting effect of Kamishoyosan and Shakuyakukanzoto in neurite outgrowth is confirmed when NGF promoted neurite outgrowth, and it was inhibited partially when Erk1/2 and Akt were blocked by Erk1/2 inhibitor or Akt inhibitor alone. Furthermore, neurite outgrowth induced by TJ24 and TJ68 was inhibited more strongly when Erk1/2 inhibitor and Akt inhibitor were treated at the same time. NGF with Kamishoyosan or Shakuyakukanzoto promoted the proportion of phosphorylated Erk1/2 and phosphorylated Akt compare with NGF only. On the other hand, Kamishoyosan or Shakuyakukanzoto didn't influence cytotoxicity of paclitaxel in A549 cells. CONCLUSIONS: Kamishoyosan or Shakuyakukanzoto promotes neurite outgrowth with NGF via increasing the proportion of phosphorylated Erk1/2 and phosphorylated Akt in PC12 cells. The effect applies to recovery from paclitaxel-induced axonal involvement and might promote recovery from paclitaxel-induced neuropathy without influence of anticancer effect of paclitaxel. Journal of pharmaceutical health care and sciences 3 20 20 20170000 10.1186/s40780-017-0090-y 28748102 read0138449/published_papers/19038285 Yoshito Zamami Masaki Imanishi Kenshi Takechi Keisuke Ishizawa Pharmacological approach for drug repositioning against cardiorenal diseases. New applications of approved clinically used drugs are being discovered. Drug repositioning is a proposed strategy for developing these drugs as therapeutic agents for different diseases. Currently, approximately 2000 drugs are used in Japan. However, the compound targets and pathways involved in the pharmacological actions of 70-80% of these drugs have not been adequately clarified. Pharmacological examination of approved drugs is an important task in drug repositioning and vital for improving drug development efficiency. This review reports that angiotensin II type 1 receptor blockers show receptor-independent effects against reactive oxygen species generation in renal cells. Additionally, nitrosonifedipine has an antioxidative effect and protects endothelial cells against oxidative stress, and pioglitazone has multiple effects that improve dysfunctions in vascular control regulated by adrenergic and calcitonin gene-related peptide-containing nerves in animal models of diabetes. These data suggest that some approved drugs could be useful for treating cardiorenal diseases. Since cardiorenal diseases are likely to have chronic pathological conditions and require chronic drug administration, highly safe drugs are needed. Compared to newly developed drugs, drug repositioning of approved drugs with safety information is considered a particularly useful technique for searching new treatments for cardiorenal diseases. J. Med. Invest. 64: 197-201, August, 2017. The journal of medical investigation : JMI 1343-1420 64 3.4 197 201 20170000 10.2152/jmi.64.197 28954981 read0138449/published_papers/17622296 Naoto Okada Takeshi Hanafusa Shinji Abe Chiemi Sato Toshimi Nakamura Kazuhiko Teraoka Masahiro Abe Kazuyoshi Kawazoe Keisuke Ishizawa Evaluation of the risk factors associated with high-dose chemotherapy-induced dysgeusia in patients undergoing autologous hematopoietic stem cell transplantation: possible usefulness of cryotherapy in dysgeusia prevention SUPPORTIVE CARE IN CANCER 1433-7339 24 9 3979 3985 20160900 10.1007/s00520-016-3244-9 27129837 read0138449/published_papers/17622297 Yasumasa Ikeda Mizuki Imao Akiho Satoh Hiroaki Watanabe Hirofumi Hamano Yuya Horinouchi Yuki Izawa-Ishizawa Yoshitaka Kihira Licht Miyamoto Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki Iron-induced skeletal muscle atrophy involves an Akt-forkhead box O3-E3 ubiquitin ligase-dependent pathway. Skeletal muscle wasting or sarcopenia is a critical health problem. Skeletal muscle atrophy is induced by an excess of iron, which is an essential trace metal for all living organisms. Excessive amounts of iron catalyze the formation of highly toxic hydroxyl radicals via the Fenton reaction. However, the molecular mechanism of iron-induced skeletal muscle atrophy has remained unclear. In this study, 8-weeks-old C57BL6/J mice were divided into 2 groups: vehicle-treated group and the iron-injected group (10 mg iron day(-1)mouse(-1)) during 2 weeks. Mice in the iron-injected group showed an increase in the iron content of the skeletal muscle and serum and ferritin levels in the muscle, along with reduced skeletal muscle mass. The skeletal muscle showed elevated mRNA expression of the muscle atrophy-related E3 ubiquitin ligases, atrogin-1 and muscle ring finger-1(MuRF1), on days 7 and 14 of iron treatment. Moreover, iron-treated mice showed reduced phosphorylation of Akt and forkhead box O3 (FOXO3a) in skeletal muscles. Inhibition of FOXO3a using siRNA in vitro in C2C12 myotube cells inhibited iron-induced upregulation of atrogin-1 and MuRF1 and reversed the reduction in myotube diameters. Iron-load caused oxidative stress, and an oxidative stress inhibitor abrogated iron-induced muscle atrophy by reactivating the Akt-FOXO3a pathway. Iron-induced skeletal muscle atrophy is suggested to involve the E3 ubiquitin ligase mediated by the reduction of Akt-FOXO3a signaling by oxidative stress. Journal of trace elements in medicine and biology : organ of the Society for Minerals and Trace Elements (GMS) 0946-672X 35 66 76 20160500 10.1016/j.jtemb.2016.01.011 27049128 read0138449/published_papers/29516472 渡邉 大晃 池田 康将 濱野 裕章 佐藤 明穂 堀之内 裕也 石澤 有紀 木平 孝高 宮本 理人 土屋 浩一郎 玉置 俊晃 石澤 啓介 慢性腎臓病におけるヘプシジン制御メカニズムの検討 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 136 3 67 67 20160300 read0138449/published_papers/29516467 佐藤 明穂 池田 康将 堀ノ内 裕也 濱野 裕章 今尾 瑞季 渡邉 大晃 石澤 有紀 木平 孝高 石澤 啓介 玉置 俊晃 宮本 理人 土屋 浩一郎 鉄過剰による骨格筋分化抑制作用の解明 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 136 3 70 70 20160300 read0138449/published_papers/26416024 Kishibuchi Reina Kihira Yoshitaka Yamaguchi Kunihisa Izawa-Ishizawa Yuki Ikeda Yasumasa Ishizawa Keisuke Tomita Shuhei Tsuchiya Koichiro Tamaki Toshiaki HIF-1 alpha is involved in recovery from renal ischemia-reperfusion injury through regulations of apoptotic factors Bcl-2 and CHAC1 JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 130 3 S247 null 20160300 read0138449/published_papers/17622298 Naoto Okada Shuji Fushitani Momoyo Azuma Shingen Nakamura Toshimi Nakamura Kazuhiko Teraoka Hiroyoshi Watanabe Masahiro Abe Kazuyoshi Kawazoe Keisuke Ishizawa Clinical Evaluation of Pharmacist Interventions in Patients Treated with Anti-methicillin-Resistant Staphylococcus aureus Agents in a Hematological Ward BIOLOGICAL & PHARMACEUTICAL BULLETIN 0918-6158 39 2 295 300 20160200 10.1248/bpb.b15-00774 26830489 read0138449/published_papers/26977627 Naoto Okada Shuji Fushitani Momoyo Azuma Shingen Nakamura Toshimi Nakamura Kazuhiko Teraoka Hiroyoshi Watanabe Masahiro Abe Kazuyoshi Kawazoe Keisuke Ishizawa Clinical evaluation of pharmacist interventions in patients treated with anti-methicillin-resistant Staphylococcus aureus agents in a hematological ward Pharmaceutical Society of Japan Biological and Pharmaceutical Bulletin 1347-5215 39 2 295 300 20160000 10.1248/BPB.B15-00774 26830489 2-s2.0-85011854087 read0138449/published_papers/17622299 Naoto Okada Hiroyoshi Watanabe Shoji Kagami Keisuke Ishizawa Ifosfamide and etoposide chemotherapy may interact with warfarin, enhancing the warfarin-induced anticoagulant response INTERNATIONAL JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS 0946-1965 54 1 58 61 20160100 10.5414/CP202426 26587904 read0138449/published_papers/17622295 Zamami Y Imai T Imanishi M Takechi K Shiraishi N Koyama T Sagara H Shiino Y Sendo T Ishizawa K Evaluation of pharmaceutical lifesaving skills training oriented pharmaceutical intervention. BACKGROUND: Many pharmacists are participating in team-based medical care in emergency hospitals. Therefore, there is a desperate need to improve the education system. In the present study, we provided a "pharmaceutical lifesaving skills training" to the students in their fifth and sixth year of the pharmaceutical school and evaluated the program's impact on the students' learning and confidence in their ability to perform pharmaceutical interventions for emergency patients. METHODS: We conducted a pharmaceutical lifesaving skills training program with 12 participants who were in their fifth and six year of pharmaceutical school. We prepared a fictional scenario in which a patient with cardiac arrest has been rushed into a hospital. We measured the participants' level of knowledge of pharmaceutical lifesaving procedures and participants' confidence to perform pharmaceutical interventions before and after the training session. Using the data obtained from type II quantification method, we examined what elements in the content of the pharmaceutical lifesaving skill training attended by pharmacy students will affect the students' confidence to perform pharmaceutical interventions. In addition, using the correspondence structural analysis, we examined which sections of the content of the pharmaceutical lifesaving skill training should be improved in the future. RESULTS: When we evaluated the level of knowledge acquired in pharmaceutical lifesaving skills training, the post-training overall correct answer rate was significantly higher than the pre-training overall correct answer rate. And also, level of participants' confidence to perform pharmaceutical interventions similarly increased after pharmaceutical lifesaving skill training. The influence degree graph indicates that the items likely to have a major impact on the participants' confidence to perform pharmaceutical interventions was "Selecting medicine". According to the correspondence structural analysis graph based on the questionnaire survey, one item identified as an improvement required was "Selecting medicine". CONCLUSIONS: Our high-performance patient simulator-based lifesaving skills training program not only increased the participants' understanding of the training content but also increased their confidence in their ability to perform pharmaceutical interventions. Therefore, the pharmaceutical lifesaving skills training program we developed will contribute to the education of emergency care pharmacists who can perform pharmaceutical interventions for emergency patients. Journal of pharmaceutical health care and sciences 2 1 21 21 20160000 10.1186/s40780-016-0054-7 27606071 read0138449/published_papers/17622301 Maeda K Katashima R Ishizawa K Yanagawa H Japanese Physicians' Views on Drug Post-Marketing Surveillance. Journal of clinical medicine research 1918-3003 7 12 956 960 20151200 10.14740/jocmr2328w 26566409 read0138449/published_papers/24878769 Yasumasa Ikeda Hirofumi Hamano Akiho Satoh Yuya Horinouchi Yuki Izawa-Ishizawa Yoshitaka Kihira Keisuke Ishizawa Ken-Ichi Aihara Koichiro Tsuchiya Toshiaki Tamaki Bilirubin exerts pro-angiogenic property through Akt-eNOS-dependent pathway. Low serum bilirubin levels are associated with the risk of cardiovascular diseases including peripheral artery disease. Bilirubin is known to exert its property such as antioxidant effect or the enhancement of flow-mediated vasodilation, however, bilirubin action on angiogenesis remains unclear. To investigate the molecular mechanism of bilirubin on angiogenic effect, we first employed C57BL/6J mice with unilateral hindlimb ischemia surgery and divided the mice into two groups (vehicle-treated group and bilirubin-treated group). The analysis of laser speckle blood flow demonstrated the enhancement of blood flow recovery in response to ischemia of mice with bilirubin treatment. The density of capillaries was significantly higher in ischemic-adductor muscles of bilirubin-treated mice. The phosphorylated levels of endothelial nitric oxide synthase (eNOS) and Akt were increased in ischemic skeletal muscles of mice with bilirubin treatment compared with vehicle treatment. In in vitro experiments by using human aortic endothelial cells, bilirubin augmented eNOS and Akt phosphorylation, cell proliferation, cell migration and tube formation. These bilirubin actions on endothelial cell activation were inhibited by LY294002, a phosphatidylinositol 3-kinase inhibitor. In conclusion, bilirubin promotes angiogenesis through endothelial cells activation via Akt-eNOS-dependent manner. Hypertension research : official journal of the Japanese Society of Hypertension 1348-4214 38 11 733 40 20151100 10.1038/hr.2015.74 26134126 read0138449/published_papers/17622302 Takumi Sakurada Soji Kakiuchi Soichiro Tajima Yuya Horinouchi Ken Konaka Naoto Okada Hirotaka Nishisako Toshimi Nakamura Kazuhiko Teraoka Kazuyoshi Kawazoe Hiroaki Yanagawa Yasuhiko Nishioka Keisuke Ishizawa Pemetrexed-Induced Rash May Be Prevented by Supplementary Corticosteroids BIOLOGICAL & PHARMACEUTICAL BULLETIN 0918-6158 38 11 1752 1756 20151100 10.1248/bpb.b15-00435 26521826 read0138449/published_papers/13173025 Yasumasa Ikeda Hirofumi Hamano Akiho Satoh Yuya Horinouchi Yuki Izawa-Ishizawa Yoshitaka Kihira Keisuke Ishizawa Ken-ichi Aihara Koichiro Tsuchiya Toshiaki Tamaki Bilirubin exerts pro-angiogenic property through Akt-eNOS-dependent pathway HYPERTENSION RESEARCH 1348-4214 38 11 733 740 20151100 10.1038/hr.2015.74 26134126 read0138449/published_papers/24878775 Soichiro Tajima Yasumasa Ikeda Hideaki Enomoto Mizuki Imao Yuya Horinouchi Yuki Izawa-Ishizawa Yoshitaka Kihira Licht Miyamoto Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki Angiotensin II alters the expression of duodenal iron transporters, hepatic hepcidin, and body iron distribution in mice Dr. Dietrich Steinkopff Verlag GmbH and Co. KG European Journal of Nutrition 1436-6215 54 5 709 719 20150823 10.1007/s00394-014-0749-1 25096756 2-s2.0-84937513465 read0138449/published_papers/10131647 Soichiro Tajima Yasumasa Ikeda Hideaki Enomoto Mizuki Imao Yuya Horinouchi Yuki Izawa-Ishizawa Yoshitaka Kihira Licht Miyamoto Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki Angiotensin II alters the expression of duodenal iron transporters, hepatic hepcidin, and body iron distribution in mice EUROPEAN JOURNAL OF NUTRITION 1436-6215 54 5 709 719 20150800 10.1007/s00394-014-0749-1 25096756 read0138449/published_papers/26416019 Kishibuchi Reina Kihira Yoshitaka Yamaguchi Kunihisa Izawa-Ishizawa Yuki Ishizawa Keisuke Ikeda Yasumasa Tomita Shuuhei Tsuchiya Koichiro Tamaki Toshiaki Hypoxia-inducible factor-1 alpha. participates in induction of apoptosis in renal reperfusion injury JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 128 3 S204 null 20150700 read0138449/published_papers/28289389 Licht Miyamoto Yuko Yagi Aya Hatano Kazuyoshi Kawazoe Keisuke Ishizawa Kazuo Minakuchi Shuhei Tomita Koichiro Tsuchiya Spontaneously hyperactive MEK-Erk pathway mediates paradoxical facilitation of cell proliferation in mild hypoxia BIOCHIMICA ET BIOPHYSICA ACTA-GENERAL SUBJECTS 1872-8006 1850 4 640 646 20150400 10.1016/j.bbagen.2014.12.006 read0138449/published_papers/25106722 岡田 直人 伏谷 秀治 中村 敏己 寺岡 和彦 川添 和義 石澤 啓介 東 桃代 中村 信元 中曽 亜佐美 藤原 範子 渡辺 浩良 安倍 正博 病棟薬剤師による抗MRSA薬の適正使用に対する介入の効果 徳島医学会 四国医学雑誌 0037-3699 71 1-2 49 50 20150400 read0138449/published_papers/24878779 Yoshitaka Kihira Ariunzaya Burentogtokh Mari Itoh Yuki Izawa-Ishizawa Keisuke Ishizawa Yasumasa Ikeda Koichiro Tsuchiya Toshiaki Tamaki Hypoxia decreases glucagon-like peptide-1 secretion from the GLUTag cell line Pharmaceutical Society of Japan Biological and Pharmaceutical Bulletin 1347-5215 38 4 514 521 20150401 10.1248/bpb.b14-00612 25832631 2-s2.0-84928951796 read0138449/published_papers/12654751 Yoshitaka Kihira Ariunzaya Burentogtokh Mari Itoh Yuki Izawa-Ishizawa Keisuke Ishizawa Yasumasa Ikeda Koichiro Tsuchiya Toshiaki Tamaki Hypoxia decreases glucagon-like peptide-1 secretion from the GLUTag cell line Pharmaceutical Society of Japan Biological and Pharmaceutical Bulletin 1347-5215 38 4 514 521 20150401 10.1248/bpb.b14-00612 25832631 2-s2.0-84928951796 read0138449/published_papers/12210541 Miyamoto L Yagi Y Hatano A Kawazoe K Ishizawa K Minakuchi K Tomita S Tsuchiya K Spontaneously hyperactive MEK-Erk pathway mediates paradoxical facilitation of cell proliferation in mild hypoxia. BACKGROUND: Oxygen is important for common eukaryotic cells to generate ATP. Pathophysiological conditions such as ischemic diseases cause tissue hypoxia. In addition, oxygen availability in deep tissues is supposed to be far lower than surrounding atmosphere even in healthy animals, and the oxygen partial pressures in most normal tissues are estimated to be around 40-50mmHg, so-called mild hypoxia. Recent studies have demonstrated that mild hypoxia has distinct effects on living cells from severe hypoxia. For instance, mild hypoxia was reported to promote cell reprogramming. Although severe hypoxia is known to inhibit cell proliferation, mild hypoxia has been paradoxically demonstrated to increase cell proliferation. However, it has not been clarified by which molecular mechanisms mild hypoxia evokes the discontinuous increment of cell proliferation. METHODS: We established experimental conditions showing the opposite influences of mild and severe hypoxia on cell proliferation using undifferentiated Caco2 human colon carcinoma cells in order to clarify the underlying molecular mechanism. RESULTS: The basal activity of Erk, which is a typical mediator of mitogenic signals, is spontaneously increased specifically in cells exposed to mild hypoxia, and inhibition of MEK, an upstream kinase of the Erk, completely inhibited the mild hypoxia-induced enhancement of cell proliferation. CONCLUSIONS: Spontaneous hyperactivation of the MEK-Erk pathway by mild hypoxia should be the plausible molecular mechanism of the paradoxical promotion of cell proliferation. GENERAL SIGNIFICANCE: Our findings will provide clues to the molecular basis of mild hypoxia-evoked phenomena such as cell reprogramming. 4 Biochimica et biophysica acta 0006-3002 1850 4 640 646 20150400 10.1016/j.bbagen.2014.12.006 25497211 read0138449/published_papers/12210540 Takumi Sakurada Soji Kakiuchi Soichiro Tajima Yuya Horinouchi Naoto Okada Hirotaka Nishisako Toshimi Nakamura Kazuhiko Teraoka Kazuyoshi Kawazoe Hiroaki Yanagawa Yasuhiko Nishioka Kazuo Minakuchi Keisuke Ishizawa Characteristics of and Risk Factors for Interstitial Lung Disease Induced by Chemotherapy for Lung Cancer ANNALS OF PHARMACOTHERAPY 1542-6270 49 4 398 404 20150400 10.1177/1060028014566446 25565405 read0138449/published_papers/13173026 Noriko Yamano Yasumasa Ikeda Minoru Sakama Yuki Izawa-Ishizawa Yoshitaka Kihira Keisuke Ishizawa Licht Miyamoto Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki A Long-Term High-Fat Diet Changes Iron Distribution in the Body, Increasing Iron Accumulation Specifically in the Mouse Spleen JOURNAL OF NUTRITIONAL SCIENCE AND VITAMINOLOGY 1881-7742 61 1 20 27 20150200 10.3177/jnsv.61.20 25994136 read0138449/published_papers/8427727 Yuko Imamura Imamura Y Shuhei Tomita Tomita S Masaki Imanishi Imanishi M Yoshitaka Kihira Kihira Y Yasumasa Ikeda Ikeda Y Keisuke Ishizawa Ishizawa K Koichiro Tsuchiya Tsuchiya K Toshiaki Tamaki Tamaki T HIF-2 alpha/ARNT complex regulates hair development via induction of p21(Waf1/Cip1) and p27(Kip1) HIF-2α/ARNT complex regulates hair development via induction of p21Waf1/Cip1 and p27Kip1. FASEB JOURNAL FASEB journal : official publication of the Federation of American Societies for Experimental Biology 1530-6860 28 6 2517 2524 20140600 10.1096/fj.13-244079 24599965 read0138449/published_papers/8427522 Masaki Imanishi Keisuke Ishizawa Takumi Sakurada Yuki Ishizawa Noriko Yamano Yoshitaka Kihira Yasumasa Ikeda Koichiro Tsuchiya Toshiaki Tamaki Drug Development for Cardiorenal Disease Based on Oxidative Stress Control YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN 0031-6903 134 6 715 719 20140600 10.1248/yakushi.13-00255-4 24882646 read0138449/published_papers/8350920 Masaki Imanishi Imanishi M Shuhei Tomita Tomita S Keisuke Ishizawa Ishizawa K Yoshitaka Kihira Kihira Y Masaki Ueno Ueno M Yuki Izawa-Ishizawa Izawa-Ishizawa Y Yasumasa Ikeda Ikeda Y Noriko Yamano Yamano N Koichiro Tsuchiya Tsuchiya K Toshiaki Tamaki Tamaki T Smooth muscle cell-specific Hif-1 alpha deficiency suppresses angiotensin II-induced vascular remodelling in mice Smooth muscle cell-specific Hif-1α deficiency suppresses angiotensin II-induced vascular remodelling in mice. CARDIOVASCULAR RESEARCH Cardiovascular research 1755-3245 102 3 460 468 20140600 10.1093/cvr/cvu061 24623277 read0138449/published_papers/25362098 Miku Kita Jun Yamamoto Koji Ebisuno Chiaki Komiya Akira Shigenaga Licht Miyamoto Keisuke Ishizawa Koichiro Tsuchiya Akira Otaka Development of hydrogen peroxide-responsive amide bond cleavage device Peptide Science 2013 203 204 20140500 read0138449/published_papers/8350923 Yoshitaka Kihira Kihira Y Mariko Miyake Miyake M Manami Hirata Hirata M Yoji Hoshina Hoshina Y Kana Kato Kato K Hitoshi Shirakawa Shirakawa H Hiroshi Sakaue Sakaue H Noriko Yamano Yamano N Yuki Izawa-Ishizawa Izawa-Ishizawa Y Keisuke Ishizawa Ishizawa K Yasumasa Ikeda Ikeda Y Koichiro Tsuchiya Tsuchiya K Toshiaki Tamaki Tamaki T Shuhei Tomita Tomita S Deletion of Hypoxia-Inducible Factor-1 alpha in Adipocytes Enhances Glucagon-Like Peptide-1 Secretion and Reduces Adipose Tissue Inflammation Deletion of hypoxia-inducible factor-1α in adipocytes enhances glucagon-like Peptide-1 secretion and reduces adipose tissue inflammation. PLOS ONE PloS one 1932-6203 9 4 e93856 null 20140400 10.1371/journal.pone.0093856 24705496 read0138449/published_papers/25106724 秦野 彩 宮本 理人 八木 祐子 石澤 啓介 土屋 浩一郎 川添 和義 水口 和生 ヒト結腸腺癌由来Caco-2細胞の増殖に与える酸素分圧の影響 徳島医学会 四国医学雑誌 0037-3699 70 1-2 42 43 20140400 read0138449/published_papers/8350921 Yasumasa Ikeda Iori Ozono Soichiro Tajima Mizuki Imao Yuya Horinouchi Yuki Izawa-Ishizawa Yoshitaka Kihira Licht Miyamoto Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki Iron Chelation by Deferoxamine Prevents Renal Interstitial Fibrosis in Mice with Unilateral Ureteral Obstruction PLOS ONE 1932-6203 9 2 e89355 null 20140200 10.1371/journal.pone.0089355 24586712 read0138449/published_papers/8350922 Keisuke Ishizawa Yuki Izawa-Ishizawa Noriko Yamano Maki Urushihara Takumi Sakurada Masaki Imanishi Shoko Fujii Asami Nuno Licht Miyamoto Yoshitaka Kihira Yasumasa Ikeda Shoji Kagami Hiroyuki Kobori Koichiro Tsuchiya Toshiaki Tamaki Nitrosonifedipine Ameliorates the Progression of Type 2 Diabetic Nephropathy by Exerting Antioxidative Effects PLOS ONE 1932-6203 9 1 e86335 null 20140100 10.1371/journal.pone.0086335 24489716 read0138449/published_papers/7284832 Licht Miyamoto Masashi Watanabe Chiaki Taoka Mai Kono Yosuke Tomida Tsuyoshi Matsushita Masaki Kamiya Hatsuhiko Hattori Keisuke Ishizawa Shinji Abe Hisao Nemoto Koichiro Tsuchiya A Novel Prodrug Strategy for Extremely Hydrophobic Agents: Conjugation to Symmetrically Branched Glycerol Trimer Improves Pharmacological and Pharmacokinetic Properties of Fenofibrate MOLECULAR PHARMACEUTICS 1543-8384 10 7 2723 2729 20130700 10.1021/mp400133j 23672178 read0138449/published_papers/7193013 Yasumasa Ikeda Soichiro Tajima Yuki Izawa-Ishizawa Yoshitaka Kihira Keisuke Ishizawa Sumiko Yoshida Ken-Ichi Aihara Koichiro Tsuchiya Toshiaki Tamaki Bovine milk-derived lactoferrin exerts proangiogenic effects in an Src-Akt-eNOS-dependent manner in response to ischemia 5 Journal of Cardiovascular Pharmacology 0160-2446 61 5 423 429 20130500 10.1097/FJC.0b013e318287d526 23364610 2-s2.0-84877626280 read0138449/published_papers/24878798 Yasumasa Ikeda Soichiro Tajima Yuki Izawa-Ishizawa Yoshitaka Kihira Keisuke Ishizawa Sumiko Yoshida Ken-Ichi Aihara Koichiro Tsuchiya Toshiaki Tamaki Bovine milk-derived lactoferrin exerts proangiogenic effects in an Src-Akt-eNOS-dependent manner in response to ischemia Journal of Cardiovascular Pharmacology 0160-2446 61 5 423 429 20130500 10.1097/FJC.0b013e318287d526 23364610 2-s2.0-84877626280 read0138449/published_papers/7193012 Yasumasa Ikeda Hideaki Enomoto Soichiro Tajima Yuki Izawa-Ishizawa Yoshitaka Kihira Keisuke Ishizawa Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Dietary iron restriction inhibits progression of diabetic nephropathy in db/db mice AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY 1931-857X 304 7 F1028 F1036 20130400 10.1152/ajprenal.00473.2012 23389454 read0138449/published_papers/7193014 Yoshinori Iba Koushi Watanabe Kiyokazu Ozaki Osamu Aozasa Keisuke Ishizawa Tetsuro Matsuura Hiroshi Oyama Tohru Masukawa Altered gene expression profiles associated with enhanced skin inflammation induced by 12-O-tetradecanoylphorbol-13-acetate in streptozotocin-diabetic mice INTERNATIONAL IMMUNOPHARMACOLOGY 1567-5769 15 3 614 619 20130300 10.1016/j.intimp.2013.01.007 23339930 read0138449/published_papers/25362105 Akira Shigenaga Keiji Ogura Hiroko Hirakawa Jun Yamamoto Koji Ebisuno Licht Miyamoto Keisuke Ishizawa Koichiro Tsuchiya Akira Otaka Design and synthesis of hypoxia-responsive amino acid which causes peptide bond cleavage in hypoxic cells Peptide Science 2012 1344-7661 2012 135 136 20130301 read0138449/published_papers/24878794 Yasumasa Ikeda 池田 康将 Hideaki Enomoto 榎本 英明 Soichiro Tajima Yuki Izawa-Ishizawa 石澤 有紀 Yoshitaka Kihira 木平 孝高 Keisuke Ishizawa 石澤 啓介 Shuhei Tomita 冨田 修平 Koichiro Tsuchiya 土屋 浩一郎 Toshiaki Tamaki 玉置 俊晃 Dietary iron restriction inhibits progression of diabetic nephropathy in db/db mice. Excess iron causes oxidative stress through hydroxyl-radical production via Fenton/Haber-Weiss reactions. Recently, body iron reduction has been found to ameliorate diabetes. In the present study, we examined the protective effect of dietary iron restriction against diabetic nephropathy in the db/db mouse model of diabetic nephropathy using db/m mice as controls. The db/db mice were divided into 2 groups and fed a normal diet (ND) or a low iron diet (LID). Increasing urinary albumin excretion was observed in the ND db/db mice, but this was suppressed in db/db mice with LID. Histologically, the db/db mice in the ND group had increased glomerular volume and mesangial area compared to the LID group. Augmented deposition of extracellular matrices was decreased in db/db mice with LID. In terms of oxidative stress, increased superoxide production observed in the kidneys of the ND db/db mice was diminished in the LID group. NADPH oxidase activity and renal expression of NADPH oxidase components p22(phox) and NOX4 were augmented in the ND group, and this was abolished by LID. There were no differences in expression of renal iron importers, transferrin receptor, or divalent metal transporter-1 between db/m mice and db/db mice. The level of ferroportin, an iron exporter, increased in the kidneys of the db/db mice. Urinary iron excretion was significantly higher in ND db/db mice and was reduced in the LID group. These findings suggest that dietary iron restriction exerts a preventive effect on the progression of diabetic nephropathy partly due to the reduction of oxidative stress. American Journal of Physiology, Renal Physiology 1522-1466 304 7 F1028 F1036 20130206 10.1152/ajprenal.00473.2012 23389454 read0138449/published_papers/7193016 Takumi Sakurada Keisuke Ishizawa Masaki Imanishi Yuki Izawa-Ishizawa Shoko Fujii Erika Tominaga Teppei Tsuneishi Yuya Horinouchi Yoshitaka Kihira Yasumasa Ikeda Shuhei Tomita Ken-ichi Aihara Kazuo Minakuchi Koichiro Tsuchiya Toshiaki Tamaki Nitrosonifedipine ameliorates angiotensin II-induced vascular remodeling via antioxidative effects NAUNYN-SCHMIEDEBERGS ARCHIVES OF PHARMACOLOGY 0028-1298 386 1 29 39 20130100 10.1007/s00210-012-0810-7 23149861 read0138449/published_papers/24878807 Takumi Sakurada Keisuke Ishizawa Masaki Imanishi Yuki Izawa-Ishizawa Shoko Fujii Erika Tominaga Teppei Tsuneishi Yuya Horinouchi Yoshitaka Kihira Yasumasa Ikeda Shuhei Tomita Ken-Ichi Aihara Kazuo Minakuchi Koichiro Tsuchiya Toshiaki Tamaki Nitrosonifedipine ameliorates angiotensin II-induced vascular remodeling via antioxidative effects Naunyn-Schmiedeberg's Archives of Pharmacology 0028-1298 386 1 29 39 20130100 10.1007/s00210-012-0810-7 23149861 2-s2.0-84872316103 read0138449/published_papers/7193015 Licht Miyamoto Masashi Watanabe Yosuke Tomida Mai Kono Shoko Fujii Tsuyoshi Matsushita Hatsuhiko Hattori Keisuke Ishizawa Hisao Nemoto Koichiro Tsuchiya Acute oral toxicity evaluation of symmetrically branched glycerol trimer in ddY mice JOURNAL OF TOXICOLOGICAL SCIENCES 1880-3989 37 6 1253 1259 20121200 10.2131/jts.37.1253 23208440 read0138449/published_papers/25105649 Yusaku Maeda Shuhei Tomita Masaki Murakami Hisatsugu Kurobe Masaki Imanishi Yasushi Yoshida Yoichiro Hirata Yoshitaka Kihira Yuki Ishizawa Keisuke Ishizawa Yasumasa Ikeda Koichiro Tsuchiya Tetsuya Kitagawa Masataka Sata Toshiaki Tamaki Deficiency of Hypoxia Inducible Factor-1 alpha in SM-22 alpha-Expressing Bone Marrow-Derived Cells Alleviates Neointimal Formation Following Wire-induced Vascular Injury CIRCULATION 1524-4539 126 21 null null 20121100 read0138449/published_papers/24878817 Yuki Izawa-Ishizawa 石澤 有紀 Keisuke Ishizawa 石澤 啓介 Takumi Sakurada Masaki Imanishi Licht Miyamoto Shoko Fujii Hironori Taira Yoshitaka Kihira 木平 孝高 Yasumasa Ikeda 池田 康将 Shuichi Hamano 濱野 修一 Shuhei Tomita 冨田 修平 Koichiro Tsuchiya 土屋 浩一郎 Toshiaki Tamaki 玉置 俊晃 Angiotensin II receptor blocker improves tumor necrosis factor-α-induced cytotoxicity via antioxidative effect in human glomerular endothelial cells Pharmacology 0031-7012 90 5-6 324 331 20121100 10.1159/000343244 23052181 2-s2.0-84867214872 read0138449/published_papers/7193021 Ikeda Y Aihara K Yoshida S Iwase T Tajima S Izawa-Ishizawa Y Kihira Y Ishizawa K Tomita S Tsuchiya K Sata M Akaike M Kato S Matsumoto T Tamaki T Heparin cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the AMP-activated protein kinase-endothelial nitric-oxide synthase signaling pathway. We previously clarified that heparin cofactor II (HCII), a serine proteinase inhibitor, exerts various protective actions on cardiovascular diseases in both experimental and clinical studies. In the present study, we aimed to clarify whether HCII participates in the regulation of angiogenesis. Male heterozygous HCII-deficient (HCII(+/-)) mice and male littermate wild-type (HCII(+/+)) mice at the age of 12-16 weeks were subjected to unilateral hindlimb ligation surgery. Laser speckle blood flow analysis showed that blood flow recovery in response to hindlimb ischemia was delayed in HCII(+/-) mice compared with that in HCII(+/+) mice. Capillary number, arteriole number, and endothelial nitric-oxide synthase (eNOS), AMP-activated protein kinase (AMPK), and liver kinase B1 (LKB1) phosphorylation in ischemic muscles were decreased in HCII(+/-) mice. Human purified HCII (h-HCII) administration almost restored blood flow recovery, capillary density, and arteriole number as well as phosphorylation levels of eNOS, AMPK, and LKB1 in ischemic muscles of HCII(+/-) mice. Although treatment with h-HCII increased phosphorylation levels of eNOS, AMPK, and LKB1 in human aortic endothelial cells (HAECs), the h-HCII-induced eNOS phosphorylation was abolished by compound C, an AMPK inhibitor, and by AMPK siRNA. In a similar fashion, tube formation, proliferation, and migration of HAECs were also promoted by h-HCII treatment and were abrogated by pretreatment with compound C. HCII potentiates the activation of vascular endothelial cells and the promotion of angiogenesis in response to hindlimb ischemia via an AMPK-eNOS signaling pathway. These findings suggest that HCII is a novel therapeutic target for treatment of patients with peripheral circulation insufficiency. 41 The Journal of biological chemistry 0021-9258 287 41 34256 34263 20121000 10.1074/jbc.M112.353532 22904320 read0138449/published_papers/7193020 Hisao Nemoto Masaki Kamiya Aki Nakamoto Tsuyoshi Matsushita Kosuke Matsumura Hatsuhiko Hattori Tomoyuki Kawamura Chiaki Taoka Shinji Abe Keisuke Ishizawa Licht Miyamoto Koichiro Tsuchiya Synthesis of highly water-soluble fibrate derivatives via BGLation BIOORGANIC & MEDICINAL CHEMISTRY LETTERS 1464-3405 22 20 6425 6428 20121000 10.1016/j.bmcl.2012.08.057 22975299 read0138449/published_papers/7193019 Licht Miyamoto Masashi Watanabe Mai Kono Tsuyoshi Matsushita Hatsuhiko Hattori Keisuke Ishizawa Hisao Nemoto Koichiro Tsuchiya Cytotoxicity evaluation of symmetrically branched glycerol trimer in human hepatocellular carcinoma HepG2 cells JOURNAL OF TOXICOLOGICAL SCIENCES 1880-3989 37 5 1059 1063 20121000 10.2131/jts.37.1059 23038013 read0138449/published_papers/24878825 Yasumasa Ikeda 池田 康将 Ken-ichi Aihara 粟飯原 賢一 Sumiko Yoshida 吉田 守美子 Takashi Iwase 岩瀬 俊 Soichiro Tajima Yuki Izawa-Ishizawa 石澤 有紀 Yoshitaka Kihira 木平 孝高 Keisuke Ishizawa 石澤 啓介 Shuhei Tomita 冨田 修平 Koichiro Tsuchiya 土屋 浩一郎 Masataka Sata 佐田 政隆 Masashi Akaike 赤池 雅史 Shigeaki Kato Toshio Matsumoto 松本 俊夫 Toshiaki Tamaki 玉置 俊晃 Heparin cofactor II, a serine protease inhibitor, promotes angiogenesis via activation of the AMP-activated protein kinase-endothelial nitric-oxide synthase signaling pathway We previously clarified that heparin cofactor II (HCII), a serine proteinase inhibitor, exerts various protective actions on cardiovascular diseases in both experimental and clinical studies. In the present study, we aimed to clarify whether HCII participates in the regulation of angiogenesis. Male heterozygous HCII-deficient (HCII(+/-)) mice and male littermate wild-type (HCII(+/+)) mice at the age of 12-16 weeks were subjected to unilateral hindlimb ligation surgery. Laser speckle blood flow analysis showed that blood flow recovery in response to hindlimb ischemia was delayed in HCII(+/-) mice compared with that in HCII(+/+) mice. Capillary number, arteriole number, and endothelial nitric-oxide synthase (eNOS), AMP-activated protein kinase (AMPK), and liver kinase B1 (LKB1) phosphorylation in ischemic muscles were decreased in HCII(+/-) mice. Human purified HCII (h-HCII) administration almost restored blood flow recovery, capillary density, and arteriole number as well as phosphorylation levels of eNOS, AMPK, and LKB1 in ischemic muscles of HCII(+/-) mice. Although treatment with h-HCII increased phosphorylation levels of eNOS, AMPK, and LKB1 in human aortic endothelial cells (HAECs), the h-HCII-induced eNOS phosphorylation was abolished by compound C, an AMPK inhibitor, and by AMPK siRNA. In a similar fashion, tube formation, proliferation, and migration of HAECs were also promoted by h-HCII treatment and were abrogated by pretreatment with compound C. HCII potentiates the activation of vascular endothelial cells and the promotion of angiogenesis in response to hindlimb ischemia via an AMPK-eNOS signaling pathway. These findings suggest that HCII is a novel therapeutic target for treatment of patients with peripheral circulation insufficiency. The Journal of Biological Chemistry 1083-351X 287 41 34256 34263 20121000 10.1074/jbc.M112.353532 22904320 read0138449/published_papers/7193022 Hisao Nemoto Ayato Katagiri Masaki Kamiya Tomoyuki Kawamura Tsuyoshi Matsushita Kosuke Matsumura Tomohiro Itou Hatsuhiko Hattori Miho Tamaki Keisuke Ishizawa Licht Miyamoto Shinji Abe Koichiro Tsuchiya Synthesis of Paclitaxel-BGL Conjugates BIOORGANIC & MEDICINAL CHEMISTRY 0968-0896 20 18 5559 5567 20120900 10.1016/j.bmc.2012.07.031 22892212 read0138449/published_papers/7193023 Yasumasa Ikeda Soichiro Tajima Yuki Izawa-Ishizawa Yoshitaka Kihira Keisuke Ishizawa Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Estrogen Regulates Hepcidin Expression via GPR30-BMP6-Dependent Signaling in Hepatocytes PLOS ONE 1932-6203 7 7 e40465 null 20120700 10.1371/journal.pone.0040465 22792339 read0138449/published_papers/7193024 Akira Shigenaga Keiji Ogura Hiroko Hirakawa Jun Yamamoto Koji Ebisuno Licht Miyamoto Keisuke Ishizawa Koichiro Tsuchiya Akira Otaka Development of a Reduction-Responsive Amino Acid that Induces Peptide Bond Cleavage in Hypoxic Cells CHEMBIOCHEM 1439-4227 13 7 968 971 20120500 10.1002/cbic.201200141 22505188 read0138449/published_papers/7193025 Soichiro Tajima Yasumasa Ikeda Kaori Sawada Noriko Yamano Yuya Horinouchi Yoshitaka Kihira Keisuke Ishizawa Yuki Izawa-Ishizawa Kazuyoshi Kawazoe Shuhei Tomita Kazuo Minakuchi Koichiro Tsuchiya Toshiaki Tamaki Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM 0193-1849 302 1 E77 E86 20120100 10.1152/ajpendo.00033.2011 21917632 read0138449/published_papers/7193018 Yuki Izawa-Ishizawa Izawa-Ishizawa Y Keisuke Ishizawa Ishizawa K Takumi Sakurada Sakurada T Masaki Imanishi Imanishi M Licht Miyamoto Miyamoto L Shoko Fujii Fujii S Hironori Taira Taira H Yoshitaka Kihira Kihira Y Yasumasa Ikeda Ikeda Y Shuichi Hamano Hamano S Shuhei Tomita Tomita S Koichiro Tsuchiya Tsuchiya K Toshiaki Tamaki Tamaki T Angiotensin II Receptor Blocker Improves Tumor Necrosis Factor-alpha-Induced Cytotoxicity via Antioxidative Effect in Human Glomerular Endothelial Cells Angiotensin II receptor blocker improves tumor necrosis factor-α-induced cytotoxicity via antioxidative effect in human glomerular endothelial cells. PHARMACOLOGY Pharmacology 0031-7012 90 5-6 324 331 20120000 10.1159/000343244 23052181 read0138449/published_papers/7193017 Ishizawa K Ninomiya M Nakazato Y Yamamoto T Araki N "Heart appearance" infarction of the pons: a case report. Case reports in radiology 2090-6862 2012 690903 null 20120000 10.1155/2012/690903 23094180 read0138449/published_papers/24878837 Soichiro Tajima Yasumasa Ikeda Kaori Sawada Noriko Yamano Yuya Horinouchi Yoshitaka Kihira Keisuke Ishizawa Yuki Izawa-Ishizawa Kazuyoshi Kawazoe Shuhei Tomita Kazuo Minakuchi Koichiro Tsuchiya Toshiaki Tamaki Iron reduction by deferoxamine leads to amelioration of adiposity via the regulation of oxidative stress and inflammation in obese and type 2 diabetes KKAy mice American Journal of Physiology - Endocrinology and Metabolism 0193-1849 302 1 E77 E86 20120100 10.1152/ajpendo.00033.2011 21917632 2-s2.0-83455242995 read0138449/published_papers/7193027 Yoshitaka Kihira Kihira Y Noriko Yamano Yamano N Yuki Izawa-Ishizawa Izawa-Ishizawa Y Keisuke Ishizawa Ishizawa K Yasumasa Ikeda Ikeda Y Koichiro Tsuchiya Tsuchiya K Toshiaki Tamaki Tamaki T Shuhei Tomita Tomita S Basic fibroblast growth factor regulates glucose metabolism through glucose transporter 1 induced by hypoxia-inducible factor-1 alpha in adipocytes Basic fibroblast growth factor regulates glucose metabolism through glucose transporter 1 induced by hypoxia-inducible factor-1α in adipocytes. INTERNATIONAL JOURNAL OF BIOCHEMISTRY & CELL BIOLOGY The international journal of biochemistry & cell biology 1878-5875 43 11 1602 1611 20111100 10.1016/j.biocel.2011.07.009 21810481 read0138449/published_papers/25105744 Yasumasa Ikeda Ken-ichi Aihara Sumiko Yoshida Yoshitaka Kihira Keisuke Ishizawa Yuki Izawa-Ishizawa Shuhei Tomita Masataka Sata Masashi Akaike Shigeaki Kato Toshio Matsumoto Toshiaki Tamaki Heparin Cofactor II Promotes Angiogenesis via an AMPK-eNOS Signaling Pathway HYPERTENSION 0194-911X 58 5 E97 E97 20111100 read0138449/published_papers/24878844 Yoshitaka Kihira 木平 孝高 Noriko Yamano 山野 範子 Yuki Izawa-Ishizawa 石澤 有紀 Keisuke Ishizawa 石澤 啓介 Yasumasa Ikeda 池田 康将 Koichiro Tsuchiya 土屋 浩一郎 Toshiaki Tamaki 玉置 俊晃 Shuhei Tomita 冨田 修平 Basic fibroblast growth factor regulates glucose metabolism through glucose transporter 1 induced by hypoxia-inducible factor-1α in adipocytes International Journal of Biochemistry and Cell Biology The International Journal of Biochemistry & Cell Biology 1357-2725 43 11 1602 1611 20111100 10.1016/j.biocel.2011.07.009 21810481 2-s2.0-80053380538 read0138449/published_papers/7193026 Keisuke Ishizawa Drug Discovery for Improvement of Chronic Kidney Disease and Cardiovascular Disease YAKUGAKU ZASSHI-JOURNAL OF THE PHARMACEUTICAL SOCIETY OF JAPAN 0031-6903 131 9 1347 1352 20110900 10.1248/yakushi.131.1347 21881310 read0138449/published_papers/25106734 田島 壮一郎 池田 康将 土屋 浩一郎 堀ノ内 裕也 山野 範子 木平 孝高 石澤 啓介 川添 和義 冨田 修平 水口 和生 玉置 俊晃 ヒト腎糸球体血管内皮細胞において細胞内遊離鉄はangiotensin IIによるICAM-1の発現を増強する (一社)日本腎臓学会 日本腎臓学会誌 0385-2385 53 3 395 395 20110500 read0138449/published_papers/7193031 Yasumasa Ikeda Soichiro Tajima Sumiko Yoshida Noriko Yamano Yoshitaka Kihira Keisuke Ishizawa Ken-ichi Aihara Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Deferoxamine promotes angiogenesis via the activation of vascular endothelial cell function ATHEROSCLEROSIS 0021-9150 215 2 339 347 20110400 10.1016/j.atherosclerosis.2011.01.009 21315355 read0138449/published_papers/7193029 Shuhei Tomita Tomita S Yoshitaka Kihira Kihira Y Masaki Imanishi Imanishi M Yayoi Fukuhara Fukuhara Y Yuko Imamura Imamura Y Keisuke Ishizawa Ishizawa K Yasumasa Ikeda Ikeda Y Koichiro Tsuchiya Tsuchiya K Toshiaki Tamaki Tamaki T Inflammatory Responses of Hypoxia-Inducible Factor 1 alpha (HIF-1 alpha) in T Cells Observed in Development of Vascular Remodeling Pathophysiological response to hypoxia - from the molecular mechanisms of malady to drug discovery:inflammatory responses of hypoxia-inducible factor 1α (HIF-1α) in T cells observed in development of vascular remodeling. JOURNAL OF PHARMACOLOGICAL SCIENCES Journal of pharmacological sciences 1347-8613 115 4 433 439 20110400 10.1254/jphs.10R22FM 21422726 read0138449/published_papers/7193028 Keisuke Ishizawa Masanori Yoshizumi Yoshichika Kawai Junji Terao Yoshitaka Kihira Yasumasa Ikeda Shuhei Tomita Kazuo Minakuchi Koichiro Tsuchiya Toshiaki Tamaki Metabolism of Quercetin In Vivo and Its Protective Effect Against Arteriosclerosis JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 115 4 466 470 20110400 10.1254/jphs.10R38FM 21436601 read0138449/published_papers/7193032 Yuya Horinouchi Koichiro Tsuchiya Chiaki Taoka Soichiro Tajima Yoshitaka Kihira Yuko Matsuda Kozo Shishido Masahiro Yoshida Shuichi Hamano Kazuyoshi Kawazoe Yasumasa Ikeda Keisuke Ishizawa Shuhei Tomita Toshiaki Tamaki Antioxidant Effects of Photodegradation Product of Nifedipine CHEMICAL & PHARMACEUTICAL BULLETIN 0009-2363 59 2 208 214 20110200 10.1248/cpb.59.208 21297301 read0138449/published_papers/7193030 Yayoi Fukuhara Koichiro Tsuchiya Yuya Horinouchi Soichiro Tajima Yoshitaka Kihira Shuichi Hamano Kazuyoshi Kawazoe Yasumasa Ikeda Keisuke Ishizawa Shuhei Tomita Toshiaki Tamaki Protective effect of photodegradation product of nifedipine against tumor necrosis factor alpha-induced oxidative stress in human glomerular endothelial cells 1-2 Journal of Medical Investigation 1343-1420 58 1-2 118 126 20110200 10.2152/jmi.58.118 21372496 2-s2.0-79951919933 read0138449/published_papers/25105255 Yasumasa Ikeda Soichiro Tajima Sumiko Yoshida Noriko Yamano Yoshitaka Kihira Keisuke Ishizawa Ken-ichi Aihara Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Deferoxamine promotes angiogenesis via the activation of vascular endothelial cell function. BACKGROUND: Deferoxamine (DFO), an iron chelator for disorders of excess iron, upregulates the expression of angiogenic factors, such as vascular endothelial growth factor (VEGF) and cyclooxygenase-2 (COX-2), indicating that it affects angiogenesis. Herein, we clarify the effect and mechanism of action of DFO on angiogenesis. METHODS AND RESULTS: In an in vitro study, DFO increased endothelial nitric oxide synthesis (eNOS) phosphorylation in human aortic endothelial cells (HAECs), which were inhibited by the phosphatidylinositol 3-kinase inhibitor LY294002. Tube formation, cell proliferation, and cell migration in HAECs were promoted by DFO, which were significantly reduced by LY294002. In an in vivo study, DFO promoted blood flow recovery in response to the hindlimb ischemia in mice with unilateral hindlimb surgery. The density of capillaries and arterioles in ischemic muscle was higher in DFO-treated mice compared to vehicle-treated mice. Endothelial cell proliferation increased and oxidative stress and apoptosis decreased in ischemic muscles of DFO-treated mice. The phosphorylation of Akt and eNOS on the ischemic side was elevated and urinary nitric oxide/nitric dioxide (NOx) excretion was higher in DFO-treated mice compared to vehicle-treated mice. The effect of DFO on angiogenesis was abolished in eNOS-deficient mice with hindlimb ischemia. CONCLUSION: These findings indicate that DFO promotes revascularization via the activation of vascular endothelial cell function by an Akt-eNOS-dependent mechanism. Atherosclerosis 1879-1484 215 2 339 347 20110121 10.1016/j.atherosclerosis.2011.01.009 21315355 read0138449/published_papers/7193033 Soichiro Tajima Koichiro Tsuchiya Yuya Horinouchi Keisuke Ishizawa Yasumasa Ikeda Yoshitaka Kihira Masayuki Shono Kazuyoshi Kawazoe Shuhei Tomita Toshiaki Tamaki Effect of angiotensin II on iron-transporting protein expression and subsequent intracellular labile iron concentration in human glomerular endothelial cells HYPERTENSION RESEARCH 0916-9636 33 7 713 721 20100700 10.1038/hr.2010.63 20431588 read0138449/published_papers/7193036 Keisuke Ishizawa Yuki Izawa-Ishizawa Narantungalag Dorjsuren Erika Miki Yoshitaka Kihira Yasumasa Ikeda Shuichi Hamano Kazuyoshi Kawazoe Kazuo Minakuchi Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Angiotensin II receptor blocker attenuates PDGF-induced mesangial cell migration in a receptor-independent manner NEPHROLOGY DIALYSIS TRANSPLANTATION 0931-0509 25 2 364 372 20100200 10.1093/ndt/gfp520 19812233 read0138449/published_papers/7193035 Koichiro Tsuchiya Shuhei Tomita Keisuke Ishizawa Shinji Abe Yasumasa Ikeda Yoshitaka Kihira Toshiaki Tamaki Dietary nitrite ameliorates renal injury in L-NAME-induced hypertensive rats NITRIC OXIDE-BIOLOGY AND CHEMISTRY 1089-8603 22 2 98 103 20100200 10.1016/j.niox.2009.12.002 20005970 read0138449/published_papers/7193034 Hirotsugu Kurobe Masahisa Urata Masaki Ueno Masaaki Ueki Shiro Ono Yuki Izawa-Ishizawa Yayoi Fukuhara Yu Lei Adiratna Mat Ripen Tamotsu Kanbara Ken-ichi Aihara Keisuke Ishizawa Masashi Akaike Frank J. Gonzalez Toshiaki Tamaki Yousuke Takahama Masanori Yoshizumi Tetsuya Kitagawa Shuhei Tomita Role of Hypoxia-Inducible Factor 1 alpha in T Cells as a Negative Regulator in Development of Vascular Remodeling ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY 1524-4636 30 2 210 217 20100200 10.1161/ATVBAHA.109.192666 20007912 read0138449/published_papers/24878856 Hirotsugu Kurobe 黒部 裕嗣 Masahisa Urata Masaki Ueno Masaaki Ueki Shiro Ono Yuki Izawa-Ishizawa 石澤 有紀 Yayoi Fukuhara Yu Lei Adiratna Mat Ripen Tamotsu Kanbara 神原 保 Ken-ichi Aihara 粟飯原 賢一 Keisuke Ishizawa 石澤 啓介 Masashi Akaike 赤池 雅史 Frank J Gonzalez Frank J. Gonzalez Toshiaki Tamaki 玉置 俊晃 Yousuke Takahama 高浜 洋介 Masanori Yoshizumi 吉栖 正典 Tetsuya Kitagawa 北川 哲也 Shuhei Tomita 冨田 修平 Role of hypoxia-inducible factor 1alpha in T cells as a negative regulator in development of vascular remodeling. 血管リモデリングの進行においてT細胞に発現するHif-1αは負の制御を担っている BACKGROUND AND PURPOSE: Recent studies have shown that the cellular immune response in the development of vascular remodeling modulates the resulting pathological alterations. We show that hypoxia-inducible factor 1 (Hif-1) (specifically expressed in T cells) is involved in the immune response to vascular remodeling that accompanies arteriosclerosis. METHODS AND RESULTS: To study the role of T cells in the development of vascular remodeling, femoral arterial injury induced by an external vascular polyethylene cuff was examined in mice lacking Hif-1 (specifically in T cells). We found that cuff placement caused prominent neointimal hyperplasia of the femoral artery in Hif-1- (T-cell)-deficient mice compared with that in control mice and that infiltration of inflammatory cells at the adventitia was markedly increased in the mutant mice. Studies to clarify the mechanism of augmented vascular remodeling in the mutant mice showed enhanced production of cytokines by activated T cells and augmented antibody production in response to a T-dependent antigen in the mutant mice. CONCLUSIONS: The results of this study revealed that Hif-1alpha in T cells plays a crucial role in vascular inflammation and remodeling in response to cuff injury as a negative regulator of T cell-mediated immune response. Potential new therapeutic strategies that target Hif-1alpha are described. Recent studies have shown that the cellular immune response in the development of vascular remodeling modulates the resulting pathological alterations. We show that hypoxia-inducible factor 1 (Hif-1) (specifically expressed in T cells) is involved in the immune response to vascular remodeling that accompanies arteriosclerosis. To study the role of T cells in the development of vascular remodeling, femoral arterial injury induced by an external vascular polyethylene cuff was examined in mice lacking Hif-1 (specifically in T cells). We found that cuff placement caused prominent neointimal hyperplasia of the femoral artery in Hif-1- (T-cell)-deficient mice compared with that in control mice and that infiltration of inflammatory cells at the adventitia was markedly increased in the mutant mice. Studies to clarify the mechanism of augmented vascular remodeling in the mutant mice showed enhanced production of cytokines by activated T cells and augmented antibody production in response to a T-dependent antigen in the mutant mice. The results of this study revealed that Hif-1alpha in T cells plays a crucial role in vascular inflammation and remodeling in response to cuff injury as a negative regulator of T cell-mediated immune response. Potential new therapeutic strategies that target Hif-1alpha are described. Arteriosclerosis, thrombosis, and vascular biology Arteriosclerosis, Thrombosis, and Vascular Biology 1524-4636 30 2 210 7 20100200 10.1161/ATVBAHA.109.192666 20007912 read0138449/published_papers/24878851 Keisuke Ishizawa Yuki Izawa-Ishizawa Narantungalag Dorjsuren Erika Miki Yoshitaka Kihira Yasumasa Ikeda Shuichi Hamano Kazuyoshi Kawazoe Kazuo Minakuchi Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Angiotensin II receptor blocker attenuates PDGF-induced mesangial cell migration in a receptor-independent manner Nephrology Dialysis Transplantation 0931-0509 25 2 364 372 20100200 10.1093/ndt/gfp520 19812233 2-s2.0-75649123444 read0138449/published_papers/7193037 Keisuke Ishizawa Narantungalag Dorjsuren Yuki Izawa-Ishizawa Rika Sugimoto Yasumasa Ikeda Yoshitaka Kihira Kazuyoshi Kawazoe Shuhei Tomita Koichiro Tsuchiya Kazuo Minakuchi Toshiaki Tamaki Inhibitory effects of adiponectin on platelet-derived growth factor-induced mesangial cell migration JOURNAL OF ENDOCRINOLOGY 0022-0795 202 2 309 316 20090800 10.1677/JOE-08-0469 19460854 read0138449/published_papers/24878864 Keisuke Ishizawa 石澤 啓介 Narantungalag Dorjsuren Yuki Izawa-Ishizawa 石澤 有紀 Rika Sugimoto Yasumasa Ikeda 池田 康将 Yoshitaka Kihira 木平 孝高 Kazuyoshi Kawazoe 川添 和義 Shuhei Tomita 冨田 修平 Koichiro Tsuchiya 土屋 浩一郎 Kazuo Minakuchi 水口 和生 Toshiaki Tamaki 玉置 俊晃 Inhibitory effects of adiponectin on platelet-derived growth factor-induced mesangial cell migration Adiponectin, an adipocyte-derived hormone, has been involved in metabolic syndrome, a known risk factor for the development of chronic kidney disease (CKD). Recent studies have demonstrated that plasma adiponectin levels are elevated when kidney function declines in patients with CKD. Excessive mesangial cell (MC) turnover is one of the important features of CKD. The aim of the present study is to elucidate the effects of adiponectin on platelet-derived growth factor (PDGF)-induced cell migration and intracellular signaling pathways, in cultured rat MCs (RMCs). PDGF-induced RMC migration was significantly inhibited by the pretreatment of adiponectin. Adiponectin alone had no effect on RMC migration. Big mitogen-activated protein (MAP) kinase 1 (BMK1), p38 MAP kinase, and Akt were activated by PDGF stimulation in a time- and concentration-dependent manner in RMC. Adiponectin alone did not affect BMK1, p38 MAP kinase, and Akt phosphorylations in RMC. PDGF-induced BMK1 and p38 MAP kinase phosphorylations were significantly attenuated by the pretreatment of adiponectin in RMCs. On the other hand, the phosphorylation of Akt by PDGF was not diminished by the pretreatment of adiponectin. Adiponectin had no effects on PDGF-receptor autophosphorylation by PDGF. We also confirmed that PDGF-induced RMC migration was significantly suppressed by siBMK1 transfection or SB203580, a p38 MAP kinase inhibitor. From these findings, it is implied that the elevated plasma adiponectin levels in patients with CKD might play a compensatory role aimed at counteracting renal dysfunction related to MC disorders. The Journal of Endocrinology 1479-6805 202 2 309 316 20090800 10.1677/JOE-08-0469 19460854 read0138449/published_papers/7193038 Yuki Motobayashi Yuki Izawa-Ishizawa Keisuke Ishizawa Sakiko Orino Kunihisa Yamaguchi Kazuyoshi Kawazoe Shuichi Hamano Koichiro Tsuchiya Shuhei Tomita Toshiaki Tamaki Adiponectin inhibits insulin-like growth factor-1-induced cell migration by the suppression of extracellular signal-regulated kinase 1/2 activation, but not Akt in vascular smooth muscle cells HYPERTENSION RESEARCH 0916-9636 32 3 188 193 20090300 10.1038/hr.2008.19 19262481 read0138449/published_papers/29911990 冨田 修平 黒部 裕嗣 浦田 将久 福原 弥生 石澤 有紀 神原 保 石澤 啓介 土屋 浩一郎 北川 哲也 吉栖 正典 玉置 俊晃 動脈硬化の病態進展におけるT細胞のHIF-1αの役割 (公社)日本薬理学会 日本薬理学雑誌 1347-8397 133 3 25P 25P 20090300 read0138449/published_papers/7193039 Keisuke Ishizawa Yuki Izawa-Ishizawa Sachiyo Ohnishi Yuki Motobayashi Kazuyoshi Kawazoe Shuichi Hamano Koichiro Tsuchiya Shuhei Tomita Kazuo Minakuchi Toshiaki Tamaki Quercetin Glucuronide Inhibits Cell Migration and Proliferation by Platelet-Derived Growth Factor in Vascular Smooth Muscle Cells JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 109 2 257 264 20090200 10.1254/jphs.08236FP 19202317 read0138449/published_papers/7193040 Keisuke Ishizawa Kunihisa Yamaguchi Yuya Horinouchi Yayoi Fukuhara Soichiro Tajima Shuichi Hamano Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Drug Discovery for Overcoming Chronic Kidney Disease (CKD): Development of Drugs on Endothelial Cell Protection for Overcoming CKD JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8648 109 1 14 19 20090100 10.1254/jphs.08R08FM 19151535 read0138449/published_papers/29911994 浦田 将久 冨田 修平 福原 弥生 宮本 直輝 黒部 裕嗣 吉田 誉 石澤 啓介 土屋 浩一郎 北川 哲也 玉置 俊晃 肺高血圧症モデルマウスにおける血管内皮細胞の低酸素応答転写因子(HIF1-β)の役割 日本心脈管作動物質学会 血管 0911-4637 32 1 23 23 20090100 read0138449/published_papers/29056365 S. Tajima K. Tsuchiya Y. Horinouchi Y. Kihira Y. Ikeda K. Ishizawa K. Teraoka S. Tomita K. Kawazoe H. Houchi K. Minakuchi T. Tamaki Effect of angiotensin receptor blocker on induction of iron metabolism of HGECs by transferrin 9TH CONGRESS OF THE EUROPEAN ASSOCIATION FOR CLINICAL PHARMACOLOGY AND THERAPEUTICS - EACPT 197 + 20090000 read0138449/published_papers/26416037 Shuhei Tomita Kunihisa Yamaguchi Keisuke Ishizawa Yuko Imamura Yayoi Fukuhara Koichiro Tsutiya Toshiaki Tamaki Loss of function in Hypoxia inducible factor-1 alpha impaired the ability to ameliorate acute tubular necrosis in ischemic acute renal failure JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 109 135P 135P 20090000 read0138449/published_papers/26416032 Shuhei Tomita Kunihisa Yamaguchi Keisuke Ishizawa Yuko Imamura Yayoi Fukuhara Koichiro Tsuchiya Toshiaki Tamaki AMELIORATION OF ACUTE TUBULAR NECROSIS IN ISCHEMIC ACUTE RENAL FAILURE WAS IMPAIRED IN MICE LUCKING HYPOXIA INDUCIBLE FACTOR-1 alpha GENE JOURNAL OF PHYSIOLOGICAL SCIENCES 1880-6546 59 162 162 20090000 read0138449/published_papers/24878870 Yuki Motobayashi Yuki Izawa-Ishizawa Keisuke Ishizawa Sakiko Orino Kunihisa Yamaguchi Kazuyoshi Kawazoe Shuichi Hamano Koichiro Tsuchiya Shuhei Tomita Toshiaki Tamaki Adiponectin inhibits insulin-like growth factor-1-induced cell migration by the suppression of extracellular signal-regulated kinase 1/2 activation, but not Akt in vascular smooth muscle cells Hypertension Research 0916-9636 32 3 188 193 20090000 10.1038/hr.2008.19 19262481 2-s2.0-68249150893 read0138449/published_papers/7193042 Yasuhisa Kanematsu Kunihisa Yamaguchi Hideki Ohnishi Yuki Motobayashi Keisuke Ishizawa Yuki Izawa Kazuyoshi Kawazoe Shuji Kondo Shoji Kagami Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Dietary doses of nitrite restore circulating nitric oxide level and improve renal injury in L-NAME-induced hypertensive rats AMERICAN JOURNAL OF PHYSIOLOGY-RENAL PHYSIOLOGY 1931-857X 295 5 F1457 F1462 20081100 10.1152/ajprenal.00621.2007 18753302 read0138449/published_papers/7193041 Hideki Ohnishi Satoshi Iwanaga Kazuyoshi Kawazoe Keisuke Ishizawa Sakiko Orino Shuhei Tomita Koichiro Tsuchiya Yasuhisa Kanematsu Nagakatsu Harada Kazuhiro Mori Tomoko Tsuchihashi Yasuko Ishikawa Toshiaki Tamaki Effect of Iron-Quercetin Complex on Reduction of Nitrite in in Vitro and in Vivo Systems JOURNAL OF AGRICULTURAL AND FOOD CHEMISTRY 0021-8561 56 21 10092 10098 20081100 10.1021/jf801010j 18831560 read0138449/published_papers/29795153 Yasuhisa Kanematsu Kunihisa Yamaguchi Hideki Ohnishi Yuki Motobayashi Keisuke Ishizawa Yuki Izawa Kazuyoshi Kawazoe Shuji Kondo Shoji Kagami Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Dietary doses of nitrite restore circulating nitric oxide level and improve renal injury in L-NAME-induced hypertensive rats American Journal of Physiology - Renal Physiology 0363-6127 295 5 F1457 F1462 20081100 10.1152/ajprenal.00621.2007 18753302 2-s2.0-57349179059 read0138449/published_papers/29911998 浦田 将久 冨田 修平 黒部 裕嗣 吉田 誉 石澤 啓介 Gonzalez Frank 北川 哲也 玉置 俊晃 肺高血圧症モデルマウスにおける血管内皮細胞の低酸素応答転写因子(HIF1-β)の役割 (一社)日本炎症・再生医学会 Inflammation and Regeneration 1880-8190 28 4 371 371 20080700 read0138449/published_papers/26416008 Soichiro Tajimai Koichiro Tsuchiya Mai Hamamoto Hideki Ohnishi Yuki Motobayashi Yuya Horinouchi Kunihisa Yamaguchi Keisuke Ishizawa Kazuyoshi Kawazoe Kazuo Minakuchi Toshiaki Tamaki Angiotensin II increases the intracellular labile iron in endothelial cells JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 106 70P 70P 20080000 read0138449/published_papers/7193043 Yuki Izawa Masanori Yoshizumi Keisuke Ishizawa Yoshiko Fujita Shuji Kondo Shoji Kagami Kazuyoshi Kawazoe Koichiro Tsuchiya Shuhei Tomita Toshiaki Tamaki Big mitogen-activated protein kinase 1 (BMKI)/extracellular signal regulated kinase 5 (ERK5) is involved in platelet-derived growth factor (PDGF)-induced vascular smooth muscle cell migration HYPERTENSION RESEARCH 0916-9636 30 11 1107 1117 20071100 10.1291/hypres.30.1107 18250560 read0138449/published_papers/7193046 Yoshizumi M Ishizawa K Izawa Y Tamaki T [Intracellular signal transduction of vascular injury in insulin resistance]. 近年，メタボリック症候群の疾患概念が確立され，本邦でもその診断基準が発表された．メタボリック症候群の根底にはインスリン抵抗性が存在するといわれるが，高血圧，動脈硬化などの血管病にインスリン抵抗性がどのように関っているかは未だ明らかではない．我々はこの数年，血管病の発症，進展に関わるインスリン抵抗性の細胞内情報伝達機構について研究を行なってきた．糖尿病モデル動物のOLETFラットを用いた検討では，アンジオテンシンII受容体拮抗薬の投与が末梢での糖利用臓器のインスリン抵抗性を改善させ，レニン-アンジオテンシン系のメタボリック症候群への関与が示唆された．培養血管平滑筋細胞を用いた細胞内情報伝達機構の検討では，アンジオテンシンII刺激によって活性化されるMAPキナーゼの一つ，ERK1/2がインスリン抵抗性の発現に関与していることが明らかになった．また，血管リモデリング進展過程のひとつである血管平滑筋細胞の遊走において，SrcチロシンキナーゼやCasアダプタータンパクが細胞内分子として重要な役割を果たしていることを見いだした．血管病におけるインスリン抵抗性に関わる標的分子の探求は，今後も増加することが予想されるメタボリックシンドローム治療のための創薬に有用な情報をもたらすことが期待される．<br> 3 Nihon yakurigaku zasshi. Folia pharmacologica Japonica 0015-5691 128 3 147 152 20060900 10.1254/fpj.128.147 16971777 read0138449/published_papers/7193045 Nermin Ali Masanori Yoshizumi Seiji Yano Saburo Sone Hideki Ohnishi Keisuke Ishizawa Yasuhisa Kanematsu Koichiro Tsuchiya Toshiaki Tamaki The novel Src kinase inhibitor M475271 inhibits VEGF-induced vascular endothelial-cadherin and beta-catenin phosphorylation but increases their association. M475271, 4-quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl) methoxy]-(9Cl), is a new anilinoquinazoline derivative that displays selective inhibition of Src kinase activity and tumor growth in vivo. Vascular endothelial growth factor (VEGF)-induced angiogenesis plays a pivotal role in tumor growth and metastasis. Vascular endothelial (VE)-cadherin is an endothelial cell-specific adhesion molecule that can interact with the cytoskeleton via several anchoring molecules such as beta-catenin. Here, we examined the effect of M475271 on VE-cadherin and beta-catenin phosphorylation and association. We also examined its effect on VEGF-induced human umbilical vein endothelial cell (HUVEC) proliferation, migration, and tube formation. The findings reveal pretreatment with M475271 significantly inhibits VEGF-induced VE-cadherin and beta-catenin phosphorylation. However, M475271 significantly increases VE-cadherin and beta-catenin association compared to the VEGF-treated group. Confocal laser microscopic examination confirmed the augmentation effect of M475271 on VE-cadherin and beta-catenin association. Finally, M475271 was shown to have inhibitory effects comparable to those of PP2 and Herbimycin A on VEGF-induced HUVEC proliferation, migration, and tube formation. These findings suggest that M475271 attenuates VEGF-induced angiogenesis by maintaining cell-cell junction stability. Although the involvement of other signaling molecules cannot be ruled out, M475271 has potential as a drug for the inhibition of the angiogenesis needed for tumor growth and metastasis. 1 Journal of pharmacological sciences 1347-8613 102 1 112 20 20060900 10.1254/jphs.FP0060357 16974068 read0138449/published_papers/7193044 Shinji Abe Hideki Ohnishi Koichiro Tsuchiya Keisuke Ishizawa Mayumi Torii Yasuhisa Kanematsu Kazuyoshi Kawazoe Kazuo Minakuchi Masanori Yoshizumi Toshiaki Tamaki Calcium and reactive oxygen species mediated Zn2+-induced apoptosis in PC12 cells JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8648 102 1 103 111 20060900 10.1254/jphs.FP0060342 16990703 read0138449/published_papers/7193047 Yasuhisa Kanematsu Koichiro Tsuchiya Hideki Ohnishi Yuki Motobayashi Yuki Izawa Manabu Ishihara Keisuke Ishizawa Shinji Abe Kazuyoshi Kawazoe Toshiaki Tamaki Effects of angiotensin II type 1 receptor blockade on the systemic blood nitric oxide dynamics in N-omega-nitro-L-arginine methyl ester-treated rats HYPERTENSION RESEARCH 0916-9636 29 5 369 374 20060500 10.1291/hypres.29.369 16832158 read0138449/published_papers/7193048 Y Fujita M Yoshizumi Y Izawa N Ali H Ohnishi Y Kanematsu K Ishizawa K Tsuchiya T Tamaki Transactivation of fetal liver kinase-1/kinase-insert domain-econtaining receptor by lysophosphatidylcholine induces vascular endothelial cell proliferation ENDOCRINOLOGY 0013-7227 147 3 1377 1385 20060300 10.1210/en.2005-0644 16322069 read0138449/published_papers/38889253 K. Tsuchiya Y. Kanematsu K. Ishizawa S. Abe H. Ohnishi S. Tajima K. Kawazoe Y. Takiguchi T. Tamaki Dietary nitrite is an alternative source of NO in vivo PROCEEDINGS OF THE XIII CONGRESS OF THE SOCIETY FOR FREE RADICAL RESEARCH INTERNATIONAL 325 + 20060000 read0138449/published_papers/7193049 K Ishizawa Y Izawa H Ito C Miki K Miyata Y Fujita Y Kanematsu K Tsuchlya T Tamaki A Nishiyama M Yoshizumi Aldosterone stimulates vascular smooth muscle cell proliferation via big mitogen-activated protein kinase 1 activation HYPERTENSION 0194-911X 46 4 1046 1052 20051000 10.1161/01.HYP.0000172622.51973.f5 16087789 read0138449/published_papers/24878881 Keisuke Ishizawa 石澤 啓介 Yuki Izawa 井澤 有紀 Hiroyuki Ito 伊藤 浩敬 Chieko Miki Kayoko Miyama Yoshiko Fujita 藤田 佳子 Yasuhisa Kanematsu 兼松 康久 Koichiro Tsuchiya 土屋 浩一郎 Toshiaki Tamaki 玉置 俊晃 Akira Nishiyama 西山 成 Masanori Yoshizumi 吉栖 正典 Aldosterone stimulates vascular smooth muscle cell proliferation via big mitoten-activated protein kinase 1 activation The nongenomic effects of aldosterone have been implicated in the pathogenesis of various cardiovascular diseases. Aldosterone-induced nongenomic effects are attributable in part to the activation of extracellular signal-regulated kinase 1/2 (ERK1/2), a classical mitogen-activated protein (MAP) kinase. Big MAP kinase 1 (BMK1), a newly identified MAP kinase, has been shown to be involved in cell proliferation, differentiation, and survival. We examined whether aldosterone stimulates BMK1-mediated proliferation of cultured rat aortic smooth muscle cells (RASMCs). Mineralocorticoid receptor (MR) expression and localization were evaluated by Western blotting analysis and fluorolabeling methods. ERK1/2 and BMK1 activities were measured by Western blotting analysis with the respective phosphospecific antibodies. Cell proliferation was determined by Alamar Blue colorimetric assay. Aldosterone (0.1 to 100 nmol/L) dose-dependently activated BMK1 in RASMCs, with a peak at 30 minutes. To clarify whether aldosterone-induced BMK1 activation is an MR-mediated phenomenon, we examined the effect of eplerenone, a selective MR antagonist, on aldosterone-induced BMK1 activation. Eplerenone (0.1 to 10 micromol/L) dose-dependently inhibited aldosterone-induced BMK1 activation in RASMCs. Aldosterone also stimulated RASMC proliferation, which was inhibited by eplerenone. Aldosterone-mediated phenomena were concluded to be attributable to a nongenomic effect because cycloheximide failed to inhibit aldosterone-induced BMK1 activation. Transfection of dominant-negative MAP kinase/ERK kinase 5 (MEK5), which is an upstream regulator of BMK1, partially inhibited aldosterone-induced RASMC proliferation, which was almost completely inhibited by MEK inhibitor PD98059. In addition to the classical steroid activity, rapid nongenomic effects induced by aldosterone may represent an alternative etiology for vascular diseases such as hypertension. Hypertension 1524-4563 46 4 1046 1052 20050808 10.1161/01.HYP.0000172622.51973.f5 16087789 read0138449/published_papers/7193051 Y Izawa M Yoshizumi Y Fujita N Ali Y Kanematsu K Ishizawa K Tsuchiya T Obata Y Ebina S Tomita T Tamaki ERK1/2 activation by angiotensin II inhibits insulin-induced glucose uptake in vascular smooth muscle cells EXPERIMENTAL CELL RESEARCH 0014-4827 308 2 291 299 20050800 10.1016/j.yexcr.2005.04.028 15921682 read0138449/published_papers/7193050 Nermin Ali Masanori Yoshizumi Yoshiko Fujita Yuki Izawa Yasuhisa Kanematsu Keisuke Ishizawa Koichiro Tsuchiya Seiji Yano Saburo Sone Toshiaki Tamaki A novel Src kinase inhibitor, M475271, inhibits VEGF-induced human umbilical vein endothelial cell proliferation and migration. Vascular endothelial growth factor (VEGF) was reported to be a potent proangiogenic factor that plays a pivotal role in both physiological and pathological angiogenesis. M475271, 4-quinazolinamine, N-(2-chloro-5-methoxyphenyl)-6-methoxy-7-[(1-methyl-4-piperidinyl) methoxy]-(9Cl), is a new anilinoquinazoline derivative that showed selective inhibition of Src kinase activity and tumor growth in vivo. Here, we examined the effect of M475271 on VEGF-induced human umbilical vein endothelial cell (HUVEC) proliferation and migration and their intracellular mechanisms. Our findings showed that M475271 pretreatment resulted in a significant inhibition of VEGF-induced HUVEC proliferation, [(3)H]thymidine incorporation, and migration. M475271 inhibited VEGF-induced Flk-1 and Src phosphorylation and their association. Confocal laser microscopic examination confirmed the inhibitory effect of M475271 on VEGF-induced Flk-1/Src association. M475271 inhibited VEGF-induced extracellular signal-regulated kinase1/2 (ERK1/2) and p38 but not Akt activation in a concentration-dependent manner. M475271, PI3-K inhibitor, and p38 inhibitor inhibited VEGF-induced HUVEC proliferation and migration. However, a MEK1/2 inhibitor inhibited VEGF-induced proliferation but not migration. These findings suggest that M475271 attenuates VEGF-induced HUVEC proliferation and migration through the inhibition of signaling pathways involving Src, ERK1/2, and/or p38. Taken together, these data indicate that M475271 may be a useful candidate for inhibition of endothelial cell proliferation and migration relevant to angiogenesis. 2 Journal of pharmacological sciences 1347-8613 98 2 130 41 20050600 10.1254/jphs.FP0040850 15937404 read0138449/published_papers/7193052 M Kyaw M Yoshizumi K Tsuchiya Y Izawa Y Kanematsu Y Fujita N Ali K Ishizawa A Yamauchi T Tamaki Antioxidant effects of stereoisomers of N-acetylcysteine (NAC), L-NAC and D-NAC, on angiotensin II-stimulated MAP kinase activation and vascular smooth muscle cell proliferation JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 95 4 483 486 20040800 10.1254/jphs.SC0040061 15297771 read0138449/published_papers/7193053 K Ishizawa M Yoshizumi K Tsuchiya H Houchi K Minakuchi Y Izawa Y Kanematsu S Kagami M Hirose T Tamaki Dual effects of endothelin-1 (1-31): Induction of mesangial cell migration and facilitation of monocyte recruitment through monocyte chemoattractant protein-1 production by mesangial cells HYPERTENSION RESEARCH 0916-9636 27 6 433 440 20040600 10.1291/hypres.27.433 15253109 read0138449/published_papers/38744522 泉 美也子 中川 達夫 須崎 友紀 西岡 安彦 曽根 三郎 石澤 啓介 伏谷 秀治 久次米 敏秀 芳地 一 水口 和生 楊河 宏章 苛原 稔 徳島大学病院における医師主導の臨床試験の支援体制 : 薬剤師の立場から 一般社団法人 日本臨床薬理学会 臨床薬理 = JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS 0388-1601 35 1 65S null 20040131 10.3999/jscpt.35.65S read0138449/published_papers/38744519 楊河 宏章 吉栖 正典 古本 博孝 西良 浩一 宮本 登志子 乾 加代子 井村 光子 中西 りか 西矢 昌子 山上 真樹子 浦川 典子 泉 美也子 中川 達夫 石澤 啓介 伏谷 秀治 久次米 敏秀 高松 典通 寺尾 純二 曽根 三郎 苛原 稔 医学部学生に対する臨床試験教育の試み 一般社団法人 日本臨床薬理学会 臨床薬理 = JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS 0388-1601 35 1 59S null 20040131 10.3999/jscpt.35.59S read0138449/published_papers/7193054 M Azuma H Houchi H Nishisako K Ishizawa K Tsuchiya K Teraoka T Ikehara T Kusumi K Minakuchi Inhibitory action of novel arginine derivative on catecholamine secretion evoked by acetylcholine from cultured bovine adrenal chromaffin cells JOURNAL OF CARDIOVASCULAR PHARMACOLOGY 0160-2446 42 S15 S18 20031200 14871022 read0138449/published_papers/7193055 M Yoshizumi T Kogame Y Suzaki Y Fujita M Kyaw K Kirima K Ishizawa K Tsuchiya S Kagami T Tamaki Ebselen attenuates oxidative stress-induced apoptosis via the inhibition of the c-Jun N-terminal kinase and activator protein-1 signalling pathway in PC12 cells BRITISH JOURNAL OF PHARMACOLOGY 0007-1188 136 7 1023 1032 20020800 10.1038/sj.bjp.0704808 12145102 read0138449/published_papers/25107008 吉栖正典 小亀敏明 土屋浩一郎 須崎友紀 KYAW M 桐間一嘉 石沢啓介 玉置俊晃 酸化ストレスによる神経細胞死に対するEbselenの抑制効果 JNK/c‐Jun情報伝達系の阻害作用 一般社団法人 日本臨床薬理学会 臨床薬理 0388-1601 33 2 293S-294S 294S 20020331 10.3999/jscpt.33.2_293S read0138449/published_papers/25106964 吉栖正典 石沢啓介 土屋浩一郎 玉置俊晃 インスリン抵抗性に対するロサルタンおよびロサルタンと運動の併用による効果 モデルラットを用いたin vivoでの検討 健康医科学研究助成論文集 17 124 134 20020312 read0138449/published_papers/25107024 K Ishizawa M Yoshizumi K Tsuchiya E Takishita Y Nakaya K Kishi Y Ebina H Houchi K Minakuchi T Tamaki Effects of losartan in combination with or without exercise on insulin resistance in Otsuka Long-Evans Tokushima Fatty rats EUROPEAN JOURNAL OF PHARMACOLOGY 0014-2999 430 2-3 359 367 20011100 10.1016/S0014-2999(01)01405-4 11711055 2-s2.0-0035798388 read0138449/published_papers/7193062 Y Sugimoto K Ishizawa K Saitou G Suzuki T Tarumi H Nakahara Y Kirino C Kamei Effect of mometasone furoate by topical application on allergic rhinitis model in rats PHARMACOLOGY 0031-7012 61 2 91 95 20000000 10.1159/000028386 10940782 read0138449/published_papers/7193061 K Ishizawa Z Chen C Okuma Y Sugimoto Y Fujii C Kamei Participation of GABAergic and histaminergic systems in inhibiting amygdaloid kindled seizures JAPANESE JOURNAL OF PHARMACOLOGY 0021-5198 82 1 48 53 20000100 10.1254/jjp.82.48 10874588 read0138449/published_papers/7193060 Y Sugimoto Y Iba K Ishizawa G Suzuki C Kawei Effects of levocabastine on lipid mediator release from guinea pig lung fragments ACTA MEDICA OKAYAMA 0386-300X 53 6 271 274 19991200 10.18926/AMO/31623 10631382 read0138449/published_papers/7193059 M Fukinaga K Ishizawa C Kamei Anticonvulsant properties of 1,4-benzodiazepine derivatives in amygdaloid-kindled seizures and their chemical structure-related anticonvulsant action PHARMACOLOGY 0031-7012 57 5 233 241 19981100 10.1159/000028247 9742288 read0138449/published_papers/7193058 H Kakinoki K Ishizawa M Fukunaga Y Fujii C Kamei The effects of histamine H-3-receptor antagonists on amygdaloid kindled seizures in rats BRAIN RESEARCH BULLETIN 0361-9230 46 5 461 465 19980700 10.1016/S0361-9230(98)00048-3 9739010 read0138449/published_papers/7193057 C Kamei K Ishizawa H Kakinoki M Fukunaga Histaminergic mechanisms in amygdaloid-kindled seizures in rats EPILEPSY RESEARCH 0920-1211 30 3 187 194 19980500 10.1016/S0920-1211(98)00005-9 9657646 read0138449/misc/52863933 Mitsuhiro Goda Masaya Kanda Kei Kawada Atsushi Ogawa Mizusa Hyodo Kenta Yagi Fuka Aizawa Takahiro Niimura Yuki Izawa-Ishizawa Keisuke Ishizawa MATE ARE BOUND TO A MULTIPROTEIN COMPLEX CONTAINING NHE3, AND IT'S CAUSING FUNCTIONAL INTERACTIONS DRUG METABOLISM AND PHARMACOKINETICS 1880-0920 61 null null 20250600 read0138449/misc/54165399 吉岡俊彦 吉岡俊彦 八木健太 八木健太 竹内大平 新村貴博 新村貴博 相澤風花 相澤風花 合田光寛 合田光寛 川田敬 川田敬 石澤有紀 石澤有紀 滝沢宏光 石澤啓介 石澤啓介 石澤啓介 Impact of surgical procedure on prognosis in lung cancer: a real-world data analysis 肺がん術式選択が予後に与える影響:リアルワールドデータ解析 日本薬学会年会要旨集(Web) 0918-9823 145th null null 20250000 read0138449/misc/54165393 新田綾香 合田光寛 新村貴博 佐藤真希 川田敬 辻中海斗 宮田晃志 河野祐輝 相澤風花 石澤啓介 石澤有紀 新田綾香 合田光寛 辻中海斗 相澤風花 石澤啓介 新村貴博 八木健太 石澤啓介 中馬真幸 川田敬 石澤有紀 股関節形成術の術後感染症における抗MRSA薬とリファンピシン併用の実臨床成績:診療報酬データベースを用いたレトロスペクティブ解析 四国医学雑誌(Web) 2758-3279 80 5-6 null null 20250000 read0138449/misc/54165386 新村貴博 八木健太 石澤啓介 Development of drugs for sarcopenia using large-scale medical data 医療ビッグデータを用いたサルコペニア治療薬の開発 臨床薬理の進歩 0914-4366 46 null null 20250000 read0138449/misc/54165375 薗田悠平 相澤風花 西橋彩香 八木健太 新村貴博 合田光寛 川田敬 石澤有紀 石澤啓介 薗田悠平 相澤風花 合田光寛 石澤啓介 八木健太 新村貴博 石澤啓介 川田敬 石澤有紀 胆汁酸製剤による多発性硬化症抑制効果の検討 四国医学雑誌(Web) 2758-3279 81 1-2 null null 20250000 read0138449/misc/54165370 佐川真琳 八木健太 八木健太 高岡麻佑 相澤風花 相澤風花 合田光寛 合田光寛 新村貴博 新村貴博 川田敬 川田敬 石澤有紀 石澤有紀 櫻田巧 櫻田巧 石澤啓介 石澤啓介 石澤啓介 Investigation of drugs that enhance the efficacy of hematopoietic stem cell pretransplantation drugs 造血幹細胞移植前処置薬の薬効を増強する薬剤の探索 日本臨床腫瘍学会学術集会(CD-ROM) 22nd null null 20250000 read0138449/misc/54165363 兵藤瑞紗 石澤有紀 石澤有紀 糸数柊人 宮田辰巳 福岡媛乃 山尾珠美 相澤風花 相澤風花 新村貴博 新村貴博 堀川伊和 堀川伊和 八木健太 八木健太 川田敬 川田敬 合田光寛 合田光寛 石澤啓介 石澤啓介 石澤啓介 大動脈疾患発症における血管内皮ERK5シグナルの役割検討 日本薬理学雑誌 0015-5691 160 Supplement null null 20250000 read0138449/misc/54165357 川田敬 合田光寛 合田光寛 相澤風花 新村貴博 石澤有紀 八木健太 石澤啓介 石澤啓介 石澤啓介 若手薬剤師とともに取り組む臨床研究~実臨床の問題解決と薬物療法の最適化~ 医療薬学フォーラム講演要旨集 1348-0863 33rd null null 20250000 read0138449/misc/54165351 八木健太 八木健太 新村貴博 新村貴博 相澤風花 相澤風花 川田敬 川田敬 合田光寛 合田光寛 石澤有紀 石澤有紀 矢野貴久 石澤啓介 石澤啓介 石澤啓介 臨床・基礎研究を加速するデータベース解析の活用 医療薬学フォーラム講演要旨集 1348-0863 33rd null null 20250000 read0138449/misc/54165345 相澤風花 相澤風花 西橋彩香 薗田悠平 薗田悠平 谷田奨太 八木健太 八木健太 新村貴博 新村貴博 山崎博輝 山崎博輝 合田光寛 合田光寛 川田敬 川田敬 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 胆汁酸-胆汁酸受容体TGR5シグナルによる多発性硬化症改善機構の解明 医療薬学フォーラム講演要旨集 1348-0863 33rd null null 20250000 read0138449/misc/54165336 新村貴博 新村貴博 植田詩穂 村川和奏奈 阿部菜摘 八木健太 八木健太 相澤風花 相澤風花 川田敬 川田敬 合田光寛 合田光寛 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 Development of a novel drug for sarcopenia utilizing medical data 医療データを用いたサルコペニア新薬の開発 日本解剖学会総会・全国学術集会抄録集(CD-ROM) 130th null null 20250000 read0138449/misc/54165330 相澤風花 相澤風花 岡林亜美 新村貴博 新村貴博 武内香凛 八木健太 八木健太 座間味義人 合田光寛 合田光寛 川田敬 川田敬 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 HMG-CoA reductase inhibitors alleviate different types of chemotherapy induced-peripheral neuropathy via activation of GST HMG-CoA還元酵素阻害剤は,GSTの活性化を介して様々なタイプの化学療法誘発性末梢神経障害を軽減する 日本解剖学会総会・全国学術集会抄録集(CD-ROM) 130th null null 20250000 read0138449/misc/54165313 薗田悠平 薗田悠平 相澤風花 相澤風花 西橋彩香 八木健太 八木健太 新村貴博 新村貴博 合田光寛 合田光寛 川田敬 川田敬 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 多発性硬化症に対するウルソデオキシコール酸投与の影響 日本薬理学雑誌 0015-5691 160 Supplement null null 20250000 read0138449/misc/49948865 坂口暁 沖良祐 佐藤康敬 八木健太 藤田浩司 楊河宏章 和泉唯信 石澤啓介 ALSを対象とした医師主導治験の被験者及びその家族を対象としたアンケート調査 日本内科学会雑誌 0021-5384 114 null null 20250000 read0138449/misc/54165384 前田和輝 二見明香理 森本恭代 三谷友紀子 穐山隼也 明石晃代 新村貴博 新村貴博 八木健太 八木健太 坂口暁 石澤啓介 石澤啓介 石澤啓介 ALCOAの原則に則り原資料を電子カルテに記載する運用方法の検討 CRCと臨床試験のあり方を考える会議プログラム・抄録集 24th (CD-ROM) null null 20240000 read0138449/misc/54165380 二見明香理 前田和輝 明石晃代 佐藤康敬 八木健太 八木健太 坂口暁 沖良祐 梶龍兒 和泉唯信 石澤啓介 石澤啓介 石澤啓介 ALS医師主導治験における施設委嘱,訪問看護の利用~CRC実務を通してみえた課題~ CRCと臨床試験のあり方を考える会議プログラム・抄録集 24th (CD-ROM) null null 20240000 read0138449/misc/54165340 相澤風花 相澤風花 八木健太 八木健太 石澤啓介 石澤啓介 石澤啓介 既存医薬品を活用した抗がん剤誘発性末梢神経障害の発現機構解明 鎮痛薬・オピオイドペプチドシンポジウムプログラム・抄録集 43rd null null 20240000 read0138449/misc/54165323 相澤風花 相澤風花 薗田悠平 薗田悠平 西橋彩香 高橋志門 八木健太 八木健太 新村貴博 新村貴博 合田光寛 合田光寛 川田敬 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 胆汁酸製剤がもたらす多発性硬化症抑制作用とメカニズムの検討 日本臨床薬理学会学術総会抄録集(Web) 2436-5580 45th null null 20240000 read0138449/misc/54165318 新村貴博 新村貴博 植田詩穂 村川和奏奈 阿部菜摘 八木健太 八木健太 相澤風花 相澤風花 合田光寛 合田光寛 石澤有紀 石澤啓介 石澤啓介 石澤啓介 糖尿病治療薬に関連した筋萎縮に関する検討 日本臨床薬理学会学術総会抄録集(Web) 2436-5580 45th null null 20240000 read0138449/misc/54165307 八木健太 八木健太 高岡麻佑 佐川真琳 相澤風花 相澤風花 新村貴博 新村貴博 合田光寛 合田光寛 川田敬 川田敬 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 造血幹細胞移植前処置薬とシナジー効果を示す薬剤の探索とそのメカニズムの解明 日本臨床薬理学会学術総会抄録集(Web) 2436-5580 45th null null 20240000 read0138449/misc/52653373 石田智滉 常風興平 常風興平 川田敬 川田敬 森沢惇平 白石久 田村尚久 西村さとみ 合田光寛 石澤啓介 浜田幸宏 田村尚久 西村さとみ 合田光寛 石澤啓介 浜田幸宏 オミックス解析を用いた蒼朮由来Exosome like nanoparticlesの神経炎症抑制作用に関する作用機序の解明 日本生薬学会年会講演要旨集 0919-1992 70th null null 20240000 read0138449/misc/49948968 吉岡俊彦 合田光寛 神田将哉 杉本祐悟 石澤有紀 八木健太 相澤風花 宮田晃志 新村貴博 櫻田巧 桐野靖 石澤啓介 吉岡俊彦 合田光寛 神田将哉 相澤風花 櫻田巧 桐野靖 石澤啓介 石澤有紀 新村貴博 八木健太 石澤啓介 バルプロ酸ナトリウムのシスプラチン誘発腎障害予防薬としての可能性 四国医学雑誌(Web) 2758-3279 79 5-6 null null 20240000 read0138449/misc/49948960 糸数柊人 宮田辰巳 糸数柊人 宮田晃志 宮田辰巳 近藤正輝 相澤風花 新村貴博 八木健太 合田光寛 石澤啓介 石澤有紀 近藤正輝 相澤風花 合田光寛 石澤啓介 新村貴博 八木健太 石澤啓介 川田敬 杜仲葉エキスによる大動脈疾患発症抑制効果の検討 四国医学雑誌(Web) 2758-3279 80 1-2 null null 20240000 read0138449/misc/49948955 宮田辰巳 糸数柊人 福岡媛乃 宮田辰巳 宮田晃志 糸数柊人 辻中海斗 福岡媛乃 相澤風花 新村貴博 八木健太 合田光寛 石澤啓介 石澤有紀 辻中海斗 相澤風花 合田光寛 石澤啓介 新村貴博 八木健太 石澤啓介 川田敬 レボフロキサシンの血管炎症への影響 四国医学雑誌(Web) 2758-3279 80 1-2 null null 20240000 read0138449/misc/49948950 内田和志 運天拡人 運天拡人 濱野裕章 新村貴博 新村貴博 合田光寛 合田光寛 八木健太 八木健太 相澤風花 相澤風花 石澤有紀 石澤有紀 座間味義人 石澤啓介 石澤啓介 石澤啓介 Development of mouse model for immune checkpoint inhibitor-related myocarditis and preventive effects of Calcitriol on model mice 免疫チェックポイント阻害剤関連心筋炎モデルマウスの作製とモデルマウスに対するカルシトリオール投与による心筋炎予防効果 日本薬学会年会要旨集(Web) 0918-9823 144th null null 20240000 read0138449/misc/49948924 新村貴博 新村貴博 合田光寛 合田光寛 八木健太 八木健太 相澤風花 相澤風花 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 マクロライド系抗菌薬における心血管毒性プロファイルの網羅的解析 医療薬学フォーラム講演要旨集 1348-0863 32nd null null 20240000 read0138449/misc/49948919 八木健太 八木健太 鍛治園誠 鍛治園誠 丸尾陽成 吉岡俊彦 相澤風花 相澤風花 新村貴博 新村貴博 合田光寛 合田光寛 石澤有紀 石澤有紀 座間味義人 石澤啓介 石澤啓介 石澤啓介 医療費の削減に薬剤投与量の調整は有効性を示す 医療薬学フォーラム講演要旨集 1348-0863 32nd null null 20240000 read0138449/misc/49948913 石田朋奈 合田光寛 合田光寛 神田将哉 神田将哉 加納菜々 吉岡俊彦 吉岡俊彦 川田敬 川田敬 相澤風花 相澤風花 新村貴博 新村貴博 八木健太 八木健太 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 シスプラチン誘発腎障害に対するSGLT2阻害薬の有効性の検証 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2024 null null 20240000 read0138449/misc/49948908 高岡麻佑 八木健太 八木健太 合田光寛 合田光寛 相澤風花 相澤風花 新村貴博 新村貴博 川田敬 川田敬 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 造血幹細胞移植治療成績向上を目指した移植前処置薬の作用増強薬の探索 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2024 null null 20240000 read0138449/misc/49948903 新村貴博 新村貴博 植田詩穂 村川和奏奈 阿部菜摘 八木健太 八木健太 相澤風花 相澤風花 合田光寛 合田光寛 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 クリニカルフェノミクスによる筋萎縮抑制薬の創出 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2024 null null 20240000 read0138449/misc/49948898 神田将哉 神田将哉 合田光寛 合田光寛 石田朋奈 石田俊介 石田俊介 櫻田巧 櫻田巧 坂東貴司 坂東貴司 川田敬 川田敬 相澤風花 相澤風花 新村貴博 新村貴博 八木健太 八木健太 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 シスプラチン誘発腎障害の原因にアプローチする新たな予防戦略の開発 日本薬理学雑誌 0015-5691 159 Supplement null null 20240000 read0138449/misc/49948892 石澤有紀 石澤有紀 宮田晃志 辻中海斗 辻中海斗 糸数柊人 宮田辰巳 近藤正輝 近藤正輝 新村貴博 新村貴博 吉岡俊彦 吉岡俊彦 相澤風花 相澤風花 八木健太 八木健太 川田敬 合田光寛 合田光寛 石澤啓介 石澤啓介 石澤啓介 フルオロキノロン系抗菌薬による大動脈疾患リスクに関する2つの矛盾 日本薬理学雑誌 0015-5691 159 Supplement null null 20240000 read0138449/misc/49948887 相澤風花 相澤風花 岡林亜美 森山大嗣 八木健太 八木健太 新村貴博 新村貴博 合田光寛 合田光寛 石澤有紀 石澤有紀 川田敬 川田敬 石澤啓介 石澤啓介 石澤啓介 HMG-CoA還元酵素阻害剤はGSTを介して抗がん剤誘発性機械的刺激応答閾値低下を改善する 日本薬理学雑誌 0015-5691 159 Supplement null null 20240000 read0138449/misc/49948882 八木健太 今若清香 高岡麻佑 岡本尚大 岡本尚大 相澤風花 相澤風花 新村貴博 新村貴博 合田光寛 合田光寛 川田敬 川田敬 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 Bcr-Abl阻害剤に対する慢性骨髄性白血病細胞の耐性獲得メカニズムの探索 日本薬理学雑誌 0015-5691 159 Supplement null null 20240000 read0138449/misc/49948877 新田綾香 新田綾香 合田光寛 合田光寛 新村貴博 新村貴博 佐藤真希 中馬真幸 宮田晃志 河野祐輝 川田敬 石澤有紀 石澤有紀 八木健太 八木健太 相澤風花 相澤風花 櫻田巧 櫻田巧 桐野靖 桐野靖 石澤啓介 石澤啓介 石澤啓介 A comprehensive search for factors influencing the treatment of surgical site infections in orthopedic surgery 整形外科領域の手術部位感染症治療に影響を及ぼす因子の網羅的探索 日本薬学会年会要旨集(Web) 0918-9823 144th null null 20240000 read0138449/misc/49948870 新村貴博 新村貴博 植田詩穂 阿部菜摘 村川和奏奈 八木健太 八木健太 相澤風花 相澤風花 合田光寛 合田光寛 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 フェノミクス解析を用いたサルコペニア治療法の開発 生体機能と創薬シンポジウム要旨集 2024 null null 20240000 read0138449/misc/52526635 座間味義人 濱野裕章 牛尾聡一郎 新村貴博 合田光寛 合田光寛 石澤有紀 石澤啓介 石澤啓介 石澤啓介 Development of preventive methods for drug-induced cardiotoxicity using a large-scale medical information database 大規模医療情報データベースを用いた薬剤性心毒性の予防法の開発 日本薬学会年会要旨集(Web) 0918-9823 143rd null null 20230000 read0138449/misc/49949118 相澤風花 相澤風花 岡林亜美 森山大嗣 八木健太 八木健太 高橋志門 新村貴博 新村貴博 合田光寛 合田光寛 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 スタチンはOxaliplatinおよびPaclitaxcel誘発性末梢神経障害を改善する 医療薬学フォーラム講演要旨集 1348-0863 31st null null 20230000 read0138449/misc/49949112 川田敬 石田智滉 相澤風花 八木健太 石澤有紀 新村貴博 阿部真治 合田光寛 石澤啓介 川田敬 相澤風花 八木健太 石澤有紀 新村貴博 合田光寛 石澤啓介 石澤啓介 植物由来細胞外膜小胞を用いた抗神経炎症治療薬の開発 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2023 null null 20230000 read0138449/misc/49949105 吉岡俊彦 合田光寛 杉本祐悟 石田朋奈 神田将哉 櫻田巧 相澤風花 新村貴博 八木健太 石澤有紀 石澤啓介 吉岡俊彦 合田光寛 神田将哉 櫻田巧 相澤風花 新村貴博 八木健太 石澤有紀 石澤啓介 石澤啓介 シスプラチン誘発腎障害に対するバルプロ酸ナトリウムの予防効果 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2023 null null 20230000 read0138449/misc/49949099 坂東寛 合田光寛 新村貴博 新田侑生 中馬真幸 北川航平 相澤風花 八木健太 石澤有紀 櫻田巧 石澤啓介 坂東寛 合田光寛 新村貴博 相澤風花 八木健太 石澤有紀 櫻田巧 石澤啓介 石澤啓介 大規模医療情報データベース解析を基盤としたラモトリギンの皮膚障害発現リスクに影響する薬剤の探索 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2023 null null 20230000 read0138449/misc/49949092 今若清香 八木健太 岡本尚大 高岡麻佑 合田光寛 相澤風花 新村貴博 石澤有紀 石澤啓介 八木健太 岡本尚大 合田光寛 相澤風花 新村貴博 石澤啓介 石澤啓介 慢性骨髄性白血病の薬剤耐性に有用な薬剤の探索 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2023 null null 20230000 read0138449/misc/49949086 西穂香 石澤有紀 辻中海斗 宮田晃志 吉岡俊彦 近藤正輝 糸数柊人 宮田辰巳 新村貴博 相澤風花 八木健太 座間味義人 合田光寛 石澤啓介 石澤有紀 辻中海斗 吉岡俊彦 近藤正輝 新村貴博 相澤風花 八木健太 合田光寛 石澤啓介 石澤啓介 血管新生阻害剤による大動脈解離発症のリスク因子解明 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2023 null null 20230000 read0138449/misc/49949080 内田和志 運天拡人 濱野裕章 新村貴博 合田光寛 八木健太 相澤風花 石澤有紀 座間味義人 石澤啓介 運天拡人 新村貴博 合田光寛 八木健太 相澤風花 石澤有紀 石澤啓介 石澤啓介 免疫チェックポイント阻害剤関連心筋炎モデルマウスの作製とモデルマウスを用いた予防薬探索 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2023 null null 20230000 read0138449/misc/49949073 森山大嗣 相澤風花 岡林亜美 合田光寛 八木健太 新村貴博 石澤有紀 石澤啓介 相澤風花 合田光寛 八木健太 新村貴博 石澤有紀 石澤啓介 石澤啓介 抗がん剤誘発性末梢神経障害に対するスタチン系薬剤の有効性ならびに作用標的の検討 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2023 null null 20230000 read0138449/misc/49949067 杉本祐悟 合田光寛 石田朋奈 加納菜々 神田将哉 吉岡俊彦 相澤風花 新村貴博 八木健太 石澤有紀 石澤啓介 合田光寛 神田将哉 吉岡俊彦 相澤風花 新村貴博 八木健太 石澤有紀 石澤啓介 石澤啓介 シスプラチン誘発腎障害に対するSGLT2阻害薬の影響 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2023 null null 20230000 read0138449/misc/49949062 坂東寛 坂東寛 合田光寛 合田光寛 新村貴博 新村貴博 新田侑生 中馬真幸 北川航平 相澤風花 相澤風花 八木健太 八木健太 石澤有紀 石澤有紀 櫻田巧 櫻田巧 石澤啓介 石澤啓介 石澤啓介 大規模医療情報データベース解析を基盤としたラモトリギンの皮膚障害発現リスクに影響する薬剤の探索 生体機能と創薬シンポジウム要旨集 2023 null null 20230000 read0138449/misc/49949054 吉岡俊彦 吉岡俊彦 合田光寛 合田光寛 杉本祐悟 石田朋奈 神田将哉 神田将哉 櫻田巧 櫻田巧 相澤風花 相澤風花 新村貴博 新村貴博 八木健太 八木健太 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 シスプラチン誘発腎障害に対するバルプロ酸ナトリウムの予防効果 生体機能と創薬シンポジウム要旨集 2023 null null 20230000 read0138449/misc/49949048 新村貴博 新村貴博 宮田晃志 八木健太 八木健太 相澤風花 相澤風花 濱野裕章 濱野裕章 石澤有紀 石澤有紀 合田光寛 合田光寛 座間味義人 座間味義人 石澤啓介 石澤啓介 石澤啓介 有害事象報告データベースを活用したALK阻害薬の心血管毒性プロファイル解明 生体機能と創薬シンポジウム要旨集 2023 null null 20230000 read0138449/misc/49949041 宮田晃志 石澤有紀 濱野裕章 濱野裕章 新村貴博 新村貴博 相澤風花 相澤風花 八木健太 八木健太 座間味義人 座間味義人 合田光寛 合田光寛 石澤啓介 石澤啓介 石澤啓介 Arterial Diseases Associated with Phosphodiesterase 5 Inhibitors ホスホジエステラーゼ5阻害剤に関連した動脈疾患 日本薬学会年会要旨集(Web) 0918-9823 143rd null null 20230000 read0138449/misc/49949034 相澤風花 相澤風花 岡林亜美 森山大嗣 八木健太 八木健太 合田光寛 合田光寛 新田綾香 新田綾香 新村貴博 新村貴博 石澤有紀 石澤啓介 石澤啓介 石澤啓介 Investigation of the novel effect of statins for the development of supportive care to chemotherapy-induced peripheral neuropathy 抗がん剤誘発性末梢神経障害克服に向けたスタチン系薬剤による有効性検討 日本薬学会年会要旨集(Web) 0918-9823 143rd null null 20230000 read0138449/misc/49949027 合田光寛 合田光寛 糸林小友理 神田将哉 神田将哉 吉岡俊彦 吉岡俊彦 杉本祐悟 石田朋奈 相澤風花 相澤風花 新村貴博 新村貴博 八木健太 八木健太 石澤有紀 櫻田巧 櫻田巧 桐野靖 桐野靖 石澤啓介 石澤啓介 石澤啓介 Mechanism of the prophylactic effect of sodium valproate on cisplatin-induced renal injury. バルプロ酸ナトリウムのシスプラチン誘発腎障害に対する予防効果の作用機序解明 日本薬学会年会要旨集(Web) 0918-9823 143rd null null 20230000 read0138449/misc/49949021 八木健太 八木健太 高岡麻佑 吉武愛哉 丸尾陽成 安藤里英 安藤里英 相澤風花 相澤風花 新村貴博 新村貴博 石澤有紀 濱野裕章 濱野裕章 合田光寛 座間味義人 座間味義人 石澤啓介 石澤啓介 石澤啓介 Effect of proton pump inhibitors and Vonoprazan on VEGF expression プロトンポンプ阻害剤およびボノプラザンがVEGF発現に与える影響 日本薬学会年会要旨集(Web) 0918-9823 143rd null null 20230000 read0138449/misc/49949014 新村貴博 新村貴博 運天拡人 濱野裕章 濱野裕章 内田和志 友近七海 宮田晃志 合田光寛 合田光寛 八木健太 八木健太 相澤風花 相澤風花 石澤有紀 座間味義人 座間味義人 石澤啓介 石澤啓介 石澤啓介 Development of a immune checkpoint inhibitor-related myocarditis model mouse using genome-edited mice 遺伝子改変マウスを用いた免疫チェックポイント阻害剤関連心筋炎の病態モデル開発 日本薬学会年会要旨集(Web) 0918-9823 143rd null null 20230000 read0138449/misc/49949007 西内栞 合田光寛 新村貴博 生田賢治 八木健太 相澤風花 濱野裕章 座間味義人 石澤啓介 西内栞 合田光寛 生田賢治 相澤風花 石澤啓介 新村貴博 八木健太 石澤啓介 濱野裕章 座間味義人 石澤有紀 ドキソルビシン誘発心筋障害の予防薬探索 四国医学雑誌(Web) 2758-3279 79 1-2 null null 20230000 read0138449/misc/49949000 吉岡俊彦 吉岡俊彦 合田光寛 合田光寛 糸林小友理 杉本祐悟 石田朋奈 神田将哉 神田将哉 小川敦 小川敦 櫻田巧 櫻田巧 相澤風花 相澤風花 新村貴博 新村貴博 八木健太 八木健太 石澤有紀 石澤啓介 石澤啓介 石澤啓介 抗がん剤誘発急性腎障害に対するバルプロ酸ナトリウムの効果 日本薬理学雑誌 0015-5691 158 Supplement null null 20230000 read0138449/misc/49948994 西穂香 石澤有紀 辻中海斗 辻中海斗 大峯航平 糸数柊人 宮田晃志 近藤正輝 近藤正輝 合田光寛 合田光寛 新村貴博 新村貴博 濱野裕章 濱野裕章 相澤風花 相澤風花 八木健太 八木健太 座間味義人 座間味義人 石澤啓介 石澤啓介 石澤啓介 抗悪性腫瘍薬スニチニブが大動脈解離発症に及ぼす影響 日本薬理学雑誌 0015-5691 158 Supplement null null 20230000 read0138449/misc/49948987 西内栞 西内栞 合田光寛 合田光寛 新村貴博 新村貴博 座間味義人 座間味義人 八木健太 八木健太 相澤風花 相澤風花 濱野裕章 濱野裕章 石澤有紀 石澤啓介 石澤啓介 石澤啓介 ビッグデータ解析を基盤としたドキソルビシン誘発心筋炎の予防薬探索 日本薬理学雑誌 0015-5691 158 Supplement null null 20230000 read0138449/misc/49948978 川田敬 川田敬 石田智滉 常風興平 森沢惇平 相澤風花 相澤風花 八木健太 八木健太 石澤有紀 石澤有紀 新村貴博 新村貴博 阿部真治 合田光寛 合田光寛 石澤啓介 石澤啓介 石澤啓介 植物由来Exosome like nanoparticles(ELNs)の医療への応用-蒼朮由来ELNsによる抗神経炎症作用の検討- 日本薬理学雑誌 0015-5691 158 Supplement null null 20230000 read0138449/misc/49948973 岡本尚大 岡本尚大 八木健太 八木健太 今若清香 高岡麻佑 國木悠理香 石澤有紀 石澤有紀 相澤風花 相澤風花 新村貴博 新村貴博 合田光寛 合田光寛 石澤啓介 石澤啓介 石澤啓介 慢性骨髄性白血病に対する新規分子標的治療薬の耐性メカニズムの探索 日本薬理学雑誌 0015-5691 158 Supplement null null 20230000 read0138449/misc/49948942 濱野裕章 牛尾聡一郎 松本准 新村貴博 相澤風花 八木健太 合田光寛 合田光寛 石澤啓介 石澤啓介 石澤啓介 座間味義人 医療ビッグデータ活用を基盤としたデータサイエンスによる臨床エビデンスの創出 日本医療薬学会年会講演要旨集(Web) 2424-2470 33rd null null 20230000 read0138449/misc/49948934 八木健太 八木健太 新村貴博 新村貴博 坂口暁 石澤啓介 石澤啓介 石澤啓介 社会実装を目指した臨床研究とは 日本医療薬学会年会講演要旨集(Web) 2424-2470 33rd null null 20230000 read0138449/misc/49948929 相澤風花 岡林亜美 森山大嗣 八木健太 八木健太 合田光寛 合田光寛 新村貴博 新村貴博 石澤有紀 石澤有紀 石澤啓介 石澤啓介 石澤啓介 HMG-CoA還元酵素阻害剤-GSTシグナルはオキサリプラチンおよびパクリタキセルによる神経障害を抑制する 日本医療薬学会年会講演要旨集(Web) 2424-2470 33rd null null 20230000 read0138449/misc/47284126 友近七海 相澤風花 薗田悠平 西橋彩香 宮内奏穂 合田光寛 八木健太 新村貴博 石澤有紀 朝田瑞穂 植沢芳広 石澤啓介 相澤風花 薗田悠平 合田光寛 八木健太 新村貴博 石澤有紀 石澤啓介 石澤啓介 実験的多発性硬化症モデルマウスに対するウルソデオキシコール酸の治療効果の検討 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2023 null null 20230000 read0138449/misc/47284114 埜本隼助 朝田瑞穂 朝田瑞穂 見神尊修 合田光寛 合田光寛 薗田悠平 薗田悠平 高橋志門 高橋志門 相澤風花 相澤風花 新村貴博 新村貴博 座間味義人 中馬真幸 石澤啓介 石澤啓介 石澤啓介 植沢芳広 Search for steroid-related drugs that inhibit multiple sclerosis using the FDA Adverse Event Reporting System database 大規模有害事象データベースFAERSを用いた多発性硬化症を抑制するステロイド関連医薬品の探索 日本薬学会年会要旨集(Web) 0918-9823 143rd null null 20230000 read0138449/misc/46245816 佐藤康敬 坂口暁 坂口暁 沖良祐 八木健太 八木健太 二見明香理 前田和輝 明石晃代 石田光代 藤田浩司 梶龍兒 楊河宏章 楊河宏章 和泉唯信 石澤啓介 石澤啓介 石澤啓介 筋萎縮性側索硬化症における訪問看護を活用した医師主導治験の実際について 薬理と治療 0386-3603 51 9 null null 20230000 read0138449/misc/46011180 川田敬 川田敬 石田智滉 福田仁 兵頭勇己 浜田知幸 久保亨 相澤風花 相澤風花 八木健太 八木健太 石澤有紀 石澤有紀 新村貴博 新村貴博 合田光寛 合田光寛 石澤啓介 石澤啓介 石澤啓介 機械学習解析を用いた心不全治療薬の年齢別有効性の検討-高知急性非代償性心不全レジストリ研究より- 日本臨床薬理学会学術総会抄録集(Web) 2436-5580 44th null null 20230000 read0138449/misc/44024835 八木健太 相澤風花 新村貴博 石澤有紀 濱野裕章 合田光寛 座間味義人 石澤啓介 八木健太 相澤風花 新村貴博 合田光寛 座間味義人 石澤啓介 石澤啓介 VEGF発現にプロトンポンプ阻害剤が与える影響 日本循環薬理学会口演要旨集 32nd null null 20230000 read0138449/misc/44024823 新村貴博 運天拡人 濱野裕章 内田和志 宮田晃志 合田光寛 八木健太 相澤風花 石澤有紀 座間味義人 石澤啓介 新村貴博 濱野裕章 合田光寛 八木健太 相澤風花 座間味義人 石澤啓介 石澤啓介 PD-1ノックアウトマウスを用いた免疫チェックポイント阻害剤関連心筋炎の新規病態モデル開発 日本循環薬理学会口演要旨集 32nd null null 20230000 read0138449/misc/52526656 濱野裕章 濱野裕章 新村貴博 内田和志 運天拡人 牛尾聡一郎 合田光寛 合田光寛 座間味義人 石澤啓介 石澤啓介 石澤啓介 がん免疫療法関連心筋炎を再現する実験的発症モデルの開発 医療薬学フォーラム講演要旨集 1348-0863 30th null null 20220000 read0138449/misc/52526601 合田光寛 神田将哉 神田将哉 吉岡俊彦 吉岡俊彦 吉田愛美 糸林小友理 新村貴博 櫻田巧 小川敦 岡田直人 相澤風花 八木健太 濱野裕章 石澤有紀 座間味義人 座間味義人 石澤啓介 石澤啓介 遺伝子発現および大規模医療情報データベースを活用したシスプラチン関連腎障害に対する予防薬の探索 血管(Web) 2759-2286 45 1 null null 20220000 read0138449/misc/49949319 合田光寛 合田光寛 吉岡俊彦 吉岡俊彦 神田将哉 神田将哉 吉田愛美 糸林小友理 杉本祐悟 相澤風花 八木健太 新村貴博 石澤有紀 座間味義人 座間味義人 石澤啓介 石澤啓介 石澤啓介 Effect of Eucommia leaf extract on cisplatin-induced renal injury シスプラチン誘発腎障害に対する杜仲葉エキスの有用性 日本杜仲研究会定期大会講演要旨集 16th null null 20220000 read0138449/misc/49949313 相澤風花 森山大嗣 岡林亜美 高橋志門 薗田悠平 新村貴博 合田光寛 合田光寛 八木健太 石澤有紀 座間味義人 石澤啓介 石澤啓介 Pharmacist-Scientistが目指すDry&Wet研究によるエビデンスの創出 日本緩和医療薬学会年会プログラム・要旨集 15th null null 20220000 read0138449/misc/49949307 坂東貴司 坂東貴司 中馬真幸 合田光寛 合田光寛 谷友歩 國木悠理香 小川敦 櫻田巧 相澤風花 新村貴博 八木健太 石澤有紀 座間味義人 座間味義人 石澤啓介 石澤啓介 石澤啓介 医療ビッグデータ解析および基礎研究を融合したバンコマイシン関連腎障害に対する予防薬探索 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2022 null null 20220000 read0138449/misc/49949300 相澤風花 岡林亜美 森山大嗣 薗田悠平 薗田悠平 高橋志門 高橋志門 新田綾香 新田綾香 合田光寛 合田光寛 八木健太 新村貴博 座間味義人 座間味義人 石澤有紀 石澤啓介 石澤啓介 石澤啓介 スタチンのpleiotropic effects:抗がん剤誘発性末梢神経障害抑制作用の検討 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2022 null null 20220000 read0138449/misc/49949294 糸林小友理 合田光寛 合田光寛 杉本祐悟 石田朋奈 神田将哉 神田将哉 吉岡俊彦 吉岡俊彦 小川敦 櫻田巧 相澤風花 新村貴博 八木健太 石澤有紀 座間味義人 座間味義人 石澤啓介 石澤啓介 石澤啓介 シスプラチン誘発急性腎障害に対するバルプロ酸ナトリウムの予防効果 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2022 null null 20220000 read0138449/misc/49949286 神田将哉 合田光寛 吉岡俊彦 神田将哉 合田光寛 吉岡俊彦 小川敦 石田俊介 新村貴博 相澤風花 八木健太 石澤有紀 座間味義人 座間味義人 石澤啓介 石澤啓介 石澤啓介 医療ビッグデータ解析を基盤としたシスプラチン誘発腎障害予防薬の探索 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2022 null null 20220000 read0138449/misc/49949240 國木悠理香 八木健太 高岡麻佑 岡本尚大 岡本尚大 濱野裕章 合田光寛 合田光寛 新村貴博 相澤風花 石澤有紀 座間味義人 石澤啓介 石澤啓介 石澤啓介 慢性骨髄性白血病に対するBCR-ABL阻害剤とALDH阻害剤併用による抗腫瘍効果増強の検討 医療薬学フォーラム講演要旨集 1348-0863 30th null null 20220000 read0138449/misc/49949216 大峯航平 近藤正輝 近藤正輝 合田光寛 西穂香 宮田晃志 辻中海斗 辻中海斗 濱野裕章 相澤風花 八木健太 座間味義人 石澤啓介 石澤啓介 石澤啓介 石澤有紀 大動脈瘤,解離に対する杜仲葉エキスの抑制効果の検討 医療薬学フォーラム講演要旨集 1348-0863 30th null null 20220000 read0138449/misc/49949210 阪本淑華 友近七海 新村貴博 合田光寛 合田光寛 相澤風花 八木健太 西内栞 西内栞 生田賢治 濱野裕章 石澤有紀 座間味義人 石澤啓介 石澤啓介 石澤啓介 医療ビッグデータを活用したスニチニブ誘発心毒性に対する予防薬の探索 医療薬学フォーラム講演要旨集 1348-0863 30th null null 20220000 read0138449/misc/49949203 運天拡人 濱野裕章 新村貴博 友近七海 西内栞 西内栞 合田光寛 合田光寛 八木健太 相澤風花 座間味義人 石澤啓介 石澤啓介 石澤啓介 大規模医療情報データベースを用いたドキソルビシン誘発心筋症に対する予防薬の探索 医療薬学フォーラム講演要旨集 1348-0863 30th null null 20220000 read0138449/misc/49949195 糸林小友理 合田光寛 合田光寛 杉本祐悟 神田将哉 神田将哉 吉岡俊彦 吉岡俊彦 小川敦 櫻田巧 相澤風花 八木健太 石澤有紀 座間味義人 座間味義人 石澤啓介 石澤啓介 石澤啓介 抗がん剤誘発急性腎障害に対するバルプロ酸ナトリウムの影響 医療薬学フォーラム講演要旨集 1348-0863 30th null null 20220000 read0138449/misc/49949189 八木健太 高岡麻佑 丸尾陽成 相澤風花 新村貴博 石澤有紀 濱野裕章 合田光寛 合田光寛 座間味義人 座間味義人 石澤啓介 石澤啓介 石澤啓介 プロトンポンプ阻害剤,ボノプラザンが抗VEGF療法に与える影響 医療薬学フォーラム講演要旨集 1348-0863 30th null null 20220000 read0138449/misc/49949153 相澤風花 岡林亜美 森山大嗣 薗田悠平 高橋志門 新村貴博 合田光寛 合田光寛 座間味義人 吉岡俊彦 八木健太 石澤有紀 石澤啓介 石澤啓介 石澤啓介 臨床薬理の視点で実践する創薬研究:抗がん剤有害事象とターゲットとしたトランスレーショナルリサーチ 日本医療薬学会年会講演要旨集(Web) 2424-2470 32 null null 20220000 read0138449/misc/49949147 山川裕介 八木健太 吉岡俊彦 吉岡俊彦 佐藤真希 丸尾陽成 宮田晃志 相澤風花 國木悠理香 新村貴博 坂口暁 石澤有紀 合田光寛 合田光寛 座間味義人 石澤啓介 石澤啓介 石澤啓介 慢性骨髄性白血病患者におけるBcr-Abl阻害剤治療期間とアルコール摂取の関連 日本医療薬学会年会講演要旨集(Web) 2424-2470 32 null null 20220000 read0138449/misc/49949140 八木健太 丸尾陽成 石田俊介 鍛治園誠 相澤風花 新村貴博 石澤有紀 濱野裕章 合田光寛 合田光寛 座間味義人 座間味義人 石澤啓介 石澤啓介 石澤啓介 ベバシズマブ治療継続にプロトンポンプ阻害剤,ボノプラザンが与える影響 日本医療薬学会年会講演要旨集(Web) 2424-2470 32 null null 20220000 read0138449/misc/49949133 岡田直人 中村信元 清水太郎 安藤英紀 相澤風花 新村貴博 八木健太 合田光寛 合田光寛 石田竜弘 石澤啓介 石澤啓介 石澤啓介 免疫不全リスクを有する患者における新型コロナワクチンによる抗体獲得能に影響を与える因子の検討 日本医療薬学会年会講演要旨集(Web) 2424-2470 32 null null 20220000 read0138449/misc/49949126 合田光寛 合田光寛 神田将哉 神田将哉 吉岡俊彦 吉岡俊彦 新村貴博 櫻田巧 小川敦 相澤風花 八木健太 石澤有紀 座間味義人 座間味義人 石澤啓介 石澤啓介 石澤啓介 薬物療法の最適化を目指すリアルワールドデータ駆動型臨床薬理学研究 日本医療薬学会年会講演要旨集(Web) 2424-2470 32 null null 20220000 read0138449/misc/44024884 大峯航平 近藤正輝 近藤正輝 合田光寛 合田光寛 西穂香 宮田晃志 辻中海斗 辻中海斗 濱野裕章 相澤風花 相澤風花 八木健太 座間味義人 石澤啓介 石澤啓介 石澤有紀 杜仲葉エキスによる大動脈疾患発症抑制効果の検討 日本薬理学雑誌 0015-5691 157 Supplement null null 20220000 read0138449/misc/44024878 安藤里英 安藤里英 八木健太 岡本尚大 岡本尚大 相澤風花 濱野裕章 石澤有紀 合田光寛 合田光寛 座間味義人 座間味義人 石澤啓介 石澤啓介 ボノプラザンががん細胞のVEGF発現に与える影響に関する検討 日本薬理学雑誌 0015-5691 157 Supplement null null 20220000 read0138449/misc/44024867 宮田晃志 石澤有紀 近藤正輝 近藤正輝 辻中海斗 辻中海斗 大峯航平 西穂香 糸数柊人 新村貴博 相澤風花 相澤風花 濱野裕章 濱野裕章 八木健太 座間味義人 座間味義人 合田光寛 合田光寛 石澤啓介 石澤啓介 石澤啓介 フルオロキノロン系抗菌薬による血管毒性の病態解明 日本薬理学雑誌 0015-5691 157 Supplement null null 20220000 read0138449/misc/44024859 運天拡人 濱野裕章 濱野裕章 新村貴博 内田和志 友近七海 宮田晃志 石田俊介 合田光寛 合田光寛 八木健太 相澤風花 石澤有紀 座間味義人 座間味義人 石澤啓介 石澤啓介 石澤啓介 免疫チェックポイント阻害剤関連心筋炎の解析に適した実験的病態モデルの開発 日本薬理学雑誌 0015-5691 157 Supplement null null 20220000 read0138449/misc/44024852 吉田愛美 合田光寛 合田光寛 杉本祐悟 八木田ひかり 神田将哉 神田将哉 吉岡俊彦 吉岡俊彦 櫻田巧 相澤風花 濱野裕章 岡田直人 八木健太 石澤有紀 座間味義人 座間味義人 石澤啓介 石澤啓介 シスプラチン誘発腎障害に対する新規予防薬候補の効果 日本薬理学雑誌 0015-5691 157 Supplement null null 20220000 read0138449/misc/40881651 宮田晃志 石澤有紀 近藤正輝 近藤正輝 辻中海斗 辻中海斗 大峯航平 西穂香 糸数柊人 新村貴博 相澤風花 相澤風花 濱野裕章 濱野裕章 八木健太 座間味義人 座間味義人 合田光寛 合田光寛 石澤啓介 石澤啓介 石澤啓介 フルオロキノロン系抗菌薬に関連した動脈瘤・解離の病態解明 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2022 null null 20220000 read0138449/misc/40881645 國木悠理香 八木健太 高岡麻佑 岡本尚大 岡本尚大 濱野裕章 濱野裕章 相澤風花 新村貴博 石澤有紀 合田光寛 合田光寛 座間味義人 座間味義人 石澤啓介 石澤啓介 石澤啓介 慢性骨髄性白血病に対する既存治療薬とALDH阻害剤併用の有効性 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2022 null null 20220000 read0138449/misc/39100661 宮田晃志 合田光寛 吉岡俊彦 座間味義人 石澤啓介 坂東寛 合田光寛 吉岡俊彦 小川淳 石澤啓介 濱野裕章 中馬真幸 新田侑生 田崎嘉一 座間味義人 石澤有紀 有害事象自発報告データベースを活用したラモトリギンによる皮膚障害発生リスクに影響を与える因子の探索 四国医学雑誌 0037-3699 78 1-2 null null 20220000 read0138449/misc/54076750 岡田直人 座間味義人 座間味義人 座間味義人 石澤啓介 石澤啓介 透析・腎移植患者におけるがん免疫療法の最新知見 日本医療薬学会年会講演要旨集(Web) 2424-2470 31 null null 20210000 read0138449/misc/52526592 辻中海斗 辻中海斗 石澤有紀 新村貴博 新村貴博 吉岡俊彦 吉岡俊彦 合田光寛 近藤正輝 近藤正輝 大峯航平 西穂果 宮田晃志 濱野裕章 相澤風花 八木健太 座間味義人 座間味義人 石澤啓介 石澤啓介 血管新生阻害剤における大動脈解離発症の関連要因解明 血管(Web) 2759-2286 44 1 null null 20210000 read0138449/misc/49949326 石澤有紀 合田光寛 近藤正輝 近藤正輝 大峯航平 西穂香 辻中海斗 辻中海斗 武智研志 相澤風花 相澤風花 八木健太 座間味義人 座間味義人 石澤啓介 石澤啓介 Preventive effect of Eucommia leaf extract or quercetin on the onset of aortic dissection in mice 杜仲葉エキス及び含有フラボノイドによる大動脈解離発症抑制効果の検討 日本杜仲研究会定期大会講演要旨集 15th null null 20210000 read0138449/misc/49949252 八木健太 合田光寛 合田光寛 濱野裕章 坂口暁 楊河宏章 石澤啓介 石澤啓介 臨床研究における倫理指針と個人情報の基礎知識 日本医療薬学会年会講演要旨集(Web) 2424-2470 31 null null 20210000 read0138449/misc/49949249 中馬真幸 中本亜樹 坂東貴司 新村貴博 岡田直人 相澤風花 濱野裕章 八木健太 合田光寛 座間味義人 座間味義人 石澤啓介 石澤啓介 田崎嘉一 メタアナリシスとデータベース解析の融合によるハイインパクトエビデンスの創出 日本医療薬学会年会講演要旨集(Web) 2424-2470 31 null null 20210000 read0138449/misc/49949231 濱野裕章 座間味義人 座間味義人 座間味義人 合田光寛 相澤風花 八木健太 石澤啓介 石澤啓介 データサイエンスと基礎研究手法の融合 日本医療薬学会年会講演要旨集(Web) 2424-2470 31 null null 20210000 read0138449/misc/49949223 座間味義人 座間味義人 座間味義人 新村貴博 濱野裕章 合田光寛 合田光寛 相澤風花 八木健太 石澤有紀 石澤啓介 石澤啓介 リアルワールドデータを活用したドラッグリポジショニング研究 日本医療薬学会年会講演要旨集(Web) 2424-2470 31 null null 20210000 read0138449/misc/49949182 相澤風花 梶本春奈 森山大嗣 新村貴博 合田光寛 合田光寛 新田綾香 高橋志門 濱野裕章 八木健太 石澤有紀 座間味義人 座間味義人 座間味義人 石澤啓介 石澤啓介 医療ビッグデータを基盤とした迅速かつ安全ながん支持療法の開発 日本医療薬学会年会講演要旨集(Web) 2424-2470 31 null null 20210000 read0138449/misc/49949175 神田将哉 神田将哉 合田光寛 合田光寛 吉岡俊彦 吉岡俊彦 吉田愛美 新村貴博 櫻田巧 小川敦 岡田直人 相澤風花 座間味義人 座間味義人 座間味義人 八木健太 濱野裕章 石澤有紀 石澤啓介 石澤啓介 抗がん剤副作用予防のための大規模医療情報データベース解析を活用したリバーストランスレーショナルリサーチ 日本医療薬学会年会講演要旨集(Web) 2424-2470 31 null null 20210000 read0138449/misc/49949167 辻中海斗 岡田直人 岡田直人 藤原範子 合田光寛 八木健太 相澤風花 濱野裕章 櫻田巧 桐野靖 座間味義人 座間味義人 東桃代 石澤啓介 石澤啓介 医療従事者におけるインフルエンザ暴露後予防目的におけるオセルタミビルのアドヒアランス解析 日本医療薬学会年会講演要旨集(Web) 2424-2470 31 null null 20210000 read0138449/misc/49949161 岡田直人 岡田直人 中本亜樹 泉侑希 中馬真幸 合田光寛 八木健太 相澤風花 濱野裕章 座間味義人 座間味義人 東桃代 石澤啓介 石澤啓介 タゾバクタム・ピペラシリン併用時のバンコマイシン誘発腎障害は血中濃度時間曲線下面積を指標としたTDMによって回避可能か? 日本医療薬学会年会講演要旨集(Web) 2424-2470 31 null null 20210000 read0138449/misc/37966137 神田将哉 神田将哉 合田光寛 合田光寛 吉岡俊彦 吉岡俊彦 前川晃子 吉田愛美 中馬真幸 新村貴博 相澤風花 八木健太 濱野裕章 岡田直人 石澤有紀 座間味義人 座間味義人 石澤啓介 石澤啓介 大規模医療情報を用いたシスプラチン誘発腎障害に対する予防薬探索 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2021 null null 20210000 read0138449/misc/37966130 坂東貴司 坂東貴司 中馬真幸 合田光寛 合田光寛 新村貴博 石澤有紀 八木健太 濱野裕章 岡田直人 泉侑希 座間味義人 座間味義人 石澤啓介 石澤啓介 バンコマイシン関連腎障害に対する薬剤性腎障害原因薬剤の多剤併用による影響 次世代を担う若手のための創薬・医療薬理シンポジウムプログラム・要旨集 2021 null null 20210000 read0138449/misc/37935035 西内栞 西内栞 斎藤広海 新村貴博 座間味義人 座間味義人 座間味義人 合田光寛 合田光寛 八木健太 相澤風花 濱野裕章 石澤有紀 石澤啓介 石澤啓介 ドキソルビシン誘発心筋症に対する予防薬探索を目的としたドラッグリポジショニング研究 日本臨床薬理学会学術総会抄録集(Web) 2436-5580 42nd null null 20210000 read0138449/misc/37935029 宮田晃志 坂東寛 合田光寛 合田光寛 中馬真幸 新田侑生 田崎嘉一 吉岡俊彦 吉岡俊彦 小川淳 座間味義人 座間味義人 座間味義人 濱野裕章 石澤有紀 石澤啓介 石澤啓介 ラモトリギンの皮膚障害リスクに影響する因子の探索 日本臨床薬理学会学術総会抄録集(Web) 2436-5580 42nd null null 20210000 read0138449/misc/37935023 宮田晃志 辻中海斗 辻中海斗 新村貴博 新村貴博 吉岡俊彦 吉岡俊彦 近藤正輝 近藤正輝 大峯航平 西穂果 濱野裕章 濱野裕章 相澤風花 相澤風花 座間味義人 座間味義人 石澤啓介 石澤啓介 石澤有紀 合田光寛 八木健太 血管新生阻害剤による有害事象発症の関連要因探索 四国医学雑誌 0037-3699 77 5-6 null null 20210000 read0138449/misc/37836806 高橋志門 高橋志門 武智研志 定作奈津美 濱野裕章 相澤風花 八木健太 合田光寛 座間味義人 座間味義人 石澤有紀 石澤啓介 石澤啓介 大規模医療情報データベースを用いたドラッグリポジショニングによる新規抗てんかん薬の探索 日本薬理学雑誌 0015-5691 156 Supplement null null 20210000 read0138449/misc/37836799 谷友歩 中馬真幸 合田光寛 坂東貴司 近藤正輝 國木悠理香 濱野裕章 新村貴博 岡田直人 相澤風花 八木健太 石澤有紀 座間味義人 座間味義人 石澤啓介 石澤啓介 大規模医療情報および遺伝子発現データベースを活用したバンコマイシン関連腎障害に対する予防薬の探索とその有用性の検討 日本薬理学雑誌 0015-5691 156 Supplement null null 20210000 read0138449/misc/37829876 梶本春奈 森山大嗣 相澤風花 新村貴博 座間味義人 座間味義人 合田光寛 八木健太 濱野裕章 石澤有紀 石澤啓介 石澤啓介 オキサリプラチン誘発末梢神経障害に対するスタチン系薬剤の予防効果 日本薬理学雑誌 0015-5691 156 Supplement null null 20210000 read0138449/misc/37644231 相澤風花 梶本春奈 森山大嗣 新村貴博 新田綾香 合田光寛 八木健太 濱野裕章 石澤有紀 座間味義人 座間味義人 座間味義人 石澤啓介 石澤啓介 オキサリプラチン誘発性末梢神経障害克服を目指したデータサイエンスによるアプローチ 鎮痛薬・オピオイドペプチドシンポジウムプログラム・抄録集 40th null null 20210000 read0138449/misc/37563833 岡田直人 岡田直人 中本亜樹 泉侑希 中馬真幸 合田光寛 八木健太 相澤風花 濱野裕章 座間味義人 座間味義人 座間味義人 東桃代 石澤啓介 石澤啓介 タゾバクタム・ピペラシリン併用時における血中濃度時間曲線下面積に基づくバンコマイシン誘発腎障害の評価 日本腎臓病薬物療法学会誌 2187-0411 10 null null 20210000 read0138449/misc/35048489 三橋知里 濱野裕章 山田苑子 山田苑子 座間味義人 座間味義人 合田光寛 桐野靖 中村敏己 桐野靖 濱田康弘 濱田康弘 石澤啓介 石澤啓介 大規模医療情報データベース研究と後方視的研究の手法を用いた抗がん剤治療に伴う口内炎の予防薬探索 日本緩和医療薬学会年会プログラム・要旨集 14th null null 20210000 read0138449/misc/35048485 濱野裕章 三橋知里 座間味義人 座間味義人 合田光寛 桐野靖 中村敏己 石澤啓介 石澤啓介 FAERSを用いたオピオイド鎮痛薬の有害事象を増強させる薬剤の探索 日本緩和医療薬学会年会プログラム・要旨集 14th null null 20210000 read0138449/misc/49949333 座間味義人 座間味義人 新村貴博 合田光寛 八木健太 相澤風花 石澤有紀 石澤啓介 石澤啓介 大規模医療情報データベースを活用した抗がん剤誘発副作用に対する予防法の開発 次世代を担う若手のための医療薬科学シンポジウム講演要旨集 14th null null 20200000 read0138449/misc/49949280 中馬真幸 座間味義人 座間味義人 合田光寛 八木健太 濱野裕章 岡田直人 近藤正輝 楊河宏章 石澤啓介 石澤啓介 臨床研究から発想を得た薬剤耐性菌治療薬による副作用予防のためのドラッグリポジショニング研究 日本医療薬学会年会講演要旨集(Web) 2424-2470 30 null null 20200000 read0138449/misc/49949273 座間味義人 座間味義人 新村貴博 石澤有紀 合田光寛 濱野裕章 岡田直人 八木健太 中馬真幸 桐野靖 中村敏己 石澤啓介 石澤啓介 医療ビッグデータを活用したドラッグリポジショニング研究 日本医療薬学会年会講演要旨集(Web) 2424-2470 30 null null 20200000 read0138449/misc/49949266 中馬真幸 座間味義人 座間味義人 合田光寛 八木健太 岡田直人 濱野裕章 近藤正輝 楊河宏章 石澤啓介 石澤啓介 集中治療領域の臨床研究を進めるノウハウと工夫 日本医療薬学会年会講演要旨集(Web) 2424-2470 30 null null 20200000 read0138449/misc/49949257 新村貴博 座間味義人 座間味義人 合田光寛 中馬真幸 八木健太 福島圭穣 石澤有紀 藤野裕道 石澤啓介 石澤啓介 免疫チェックポイント阻害剤関連致死的有害事象のリスク因子評価 日本医療薬学会年会講演要旨集(Web) 2424-2470 30 null null 20200000 read0138449/misc/37829883 新村貴博 座間味義人 座間味義人 川尻雄大 合田光寛 岡田直人 萱野純史 八木健太 中馬真幸 福島圭穣 石澤有紀 池田康将 小林大介 藤野裕道 島添隆雄 石澤啓介 石澤啓介 大規模医療情報および遺伝子発現データベースを活用した薬剤性末梢神経障害に対する予防薬の探索 日本薬理学雑誌 0015-5691 155 Supplement null null 20200000 read0138449/misc/37526283 神田将哉 神田将哉 合田光寛 合田光寛 吉岡俊彦 吉岡俊彦 吉田愛美 新村貴博 石澤有紀 座間味義人 座間味義人 中馬真幸 濱野裕章 岡田直人 池田康将 桐野靖 中村敏己 石澤啓介 石澤啓介 5-HT₃受容体拮抗薬併用によるシスプラチン誘発腎機能障害に与える影響 日本薬理学雑誌 0015-5691 155 Supplement null null 20200000 read0138449/misc/34722059 前川晃子 合田光寛 吉田愛美 神田将哉 神田将哉 生田賢治 新村貴博 石澤有紀 座間味義人 座間味義人 中馬真幸 武智研志 濱野裕章 岡田直人 堀ノ内裕也 池田康将 石澤啓介 石澤啓介 大規模医療情報データベースを活用したシスプラチン誘発腎障害に対する新規予防薬の探索とその有効性の検証 日本薬理学雑誌 0015-5691 155 Supplement null null 20200000 read0138449/misc/34722044 濱野裕章 池田康将 合田光寛 福島圭穣 岸誠司 武智研志 中馬真幸 座間味義人 座間味義人 堀之内裕也 藤野裕道 石澤啓介 石澤啓介 玉置俊晃 シスプラチン誘発性腎障害を予防する既存薬物の同定と検証 臨床薬理 0388-1601 51 Supplement null null 20200000 read0138449/misc/34722026 中馬真幸 座間味義人 座間味義人 合田光寛 八木健太 石澤有紀 濱野裕章 岡田直人 近藤正輝 楊河宏章 石澤啓介 石澤啓介 ビッグデータ解析を基盤としたバンコマイシン関連腎障害予防のためのドラッグリポジショニング研究 日本感染症学会西日本地方会学術集会・日本感染症学会中日本地方会学術集会・日本化学療法学会西日本支部総会合同開催プログラム・抄録集 90th-63rd-68th null null 20200000 read0138449/misc/34721979 相澤風花 相澤風花 相澤風花 相澤風花 合田光寛 合田光寛 神田将哉 神田将哉 吉岡俊彦 吉岡俊彦 吉田愛美 新村貴博 八木健太 濱野裕章 岡田直人 座間味義人 座間味義人 石澤有紀 石澤啓介 石澤啓介 シスプラチンと5-HT₃受容体拮抗薬併用が腎機能障害に与える影響 日本循環薬理学会口演要旨集 30th null null 20200000 read0138449/misc/25105138 堀ノ内 裕也 池田 康将 福島 圭穣 今西 正樹 濱野 裕章 石澤 有紀 座間味 義人 武智 研志 藤野 裕道 石澤 啓介 土屋 浩一郎 玉置 俊晃 認定薬剤師の科学力を考える 基礎研究と医療ビッグデータ解析を融合させたドラッグ・リボジショニングへの試み (一社)日本臨床薬理学会 臨床薬理 1882-8272 50 Suppl. S176 S176 20191100 read0138449/misc/25105130 合田 光寛 神田 将哉 前川 晃子 新村 貴博 石澤 有紀 座間味 義人 中馬 真幸 武智 研志 濱野 裕章 岡田 直人 福島 圭穰 藤野 裕道 土屋 浩一郎 堀ノ内 裕也 池田 康将 楊河 宏章 石澤 啓介 大規模医療情報データベースを活用したシスプラチン誘発腎障害に対する新規予防薬の探索とその有効性の検証 (一社)日本臨床薬理学会 臨床薬理 1882-8272 50 Suppl. S246 S246 20191100 read0138449/misc/25105122 新村 貴博 座間味 義人 内藤 優太朗 川尻 雄大 合田 光寛 武智 研志 中馬 真幸 堀ノ内 裕也 石澤 有紀 池田 康将 石澤 啓介 抗がん剤誘発末梢神経障害の予防薬開発を目的とした医療ビッグデータ解析および基礎研究 (一社)日本臨床薬理学会 臨床薬理 1882-8272 50 Suppl. S265 S265 20191100 read0138449/misc/24878679 中馬 真幸 合田 光寛 谷 友歩 座間味 義人 武智 研志 石澤 有紀 濱野 裕章 石田 俊介 新村 貴博 近藤 正輝 坂東 貴司 岡田 直人 福島 圭穣 藤野 裕道 土屋 浩一郎 堀ノ内 裕也 池田 康将 楊河 宏章 石澤 啓介 ドラッグリポジショニング手法を用いたバンコマイシン関連腎障害の予防薬探索とその有用性の検討 日本腎臓病薬物療法学会 日本腎臓病薬物療法学会誌 2187-0411 8 S138 S138 20191000 read0138449/misc/24878673 岡田 直人 座間味 義人 石澤 啓介 【医師・看護師のギモンに"的確"かつ"迅速"に答える!病棟・カンファレンスでそのまま使える想定問答集151】(第9章)感染症 (Q107)感染性心内膜炎に対する予防投与 感染性心内膜炎の予防では，どのような患者にどのような抗菌薬が使用されますか? (株)じほう 薬事 0016-5980 61 14 2685 2687 20191000 read0138449/misc/24878671 岡田 直人 座間味 義人 石澤 啓介 【医師・看護師のギモンに"的確"かつ"迅速"に答える!病棟・カンファレンスでそのまま使える想定問答集151】(第9章)感染症 (Q108)腸ろう患者へのボリコナゾール投与 経腸栄養剤を腸ろうから24時間持続投与している患者に対し，ボリコナゾールの経胃投与は可能ですか? (株)じほう 薬事 0016-5980 61 14 2688 2689 20191000 read0138449/misc/24878669 岡田 直人 座間味 義人 石澤 啓介 【医師・看護師のギモンに"的確"かつ"迅速"に答える!病棟・カンファレンスでそのまま使える想定問答集151】(第9章)感染症 (Q109)イトラコナゾール剤形変更時の注意点 イトラコナゾールをカプセルから内用液へと切り替える際の注意点を教えてください (株)じほう 薬事 0016-5980 61 14 2690 2691 20191000 read0138449/misc/24878692 座間味 義人 合田 光寛 石澤 啓介 【薬剤疫学】薬剤疫学の応用 ドラッグリポジショニング (一社)日本病院薬剤師会 日本病院薬剤師会雑誌 1341-8815 55 8 919 921 20190800 read0138449/misc/24878695 櫻田 巧 中馬 真幸 座間味 義人 石澤 啓介 考え方がわかれば解き方がみえてくる クリニカル・クエスチョンの解決への筋道(第8回) ペメトレキセドによる皮疹の予防方法を教えてください (株)じほう 薬事 0016-5980 61 8 1461 1467 20190600 read0138449/misc/25901548 岡田 直人 座間味 義人 合田 光寛 石澤 啓介 河添 仁 飛鷹 範明 田中 亮裕 松立 吉弘 久保 宜明 武智 研志 中馬 真幸 宇都宮 亮 佐山 浩二 悪性黒色腫患者においてニボルマブによる免疫関連有害事象の発現は治療効果を予測するバイオマーカーである 多施設共同後ろ向き研究による検討 徳島医学会 四国医学雑誌 0037-3699 75 1-2 84 84 20190400 read0138449/misc/25105169 合田 光寛 斉家 和仁 神田 将哉 村井 陽一 吉田 愛美 新村 貴博 石澤 有紀 座間味 義人 中馬 真幸 武智 研志 生田 賢治 濱野 裕章 岡田 直人 堀ノ内 裕也 池田 康将 桐野 靖 中村 敏己 寺岡 和彦 石澤 啓介 ビッグデータを用いたシスプラチン誘発腎障害に対する新規予防薬の探索とその有効性の検証 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 139 4 132 132 20190300 read0138449/misc/25105153 武智 研志 中馬 真幸 石田 俊介 坂東 寛 座間味 義人 石澤 有紀 堀ノ内 裕也 池田 康将 石澤 啓介 楊河 宏章 第2回領域別専門薬剤師によるclinical questionの解決手段と，薬物療法のエビデンス創出に向けて 向精神薬の副作用対策を基盤とした臨床研究とその活用 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 139 1 261 261 20190300 read0138449/misc/25105146 近藤 正輝 今西 正樹 生藤 来希 村井 陽一 福島 圭穣 堀ノ内 裕也 石澤 有紀 合田 光寛 座間味 義人 武智 研志 中馬 正幸 池田 康将 藤野 裕道 土屋 浩一郎 石澤 啓介 大学院生が期待するウェットからドライな薬学研究の未来 キサンチンオキシダーゼ阻害剤による新規血管線維化抑制機構の検討 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 139 1 328 328 20190300 read0138449/misc/24878688 中馬 真幸 座間味 義人 武智 研志 今西 正樹 岡田 直人 合田 光寛 近藤 正輝 石澤 啓介 楊河 宏章 抗菌薬の使い方 PK/PD理論やTDMに基づく用法・用量設定を中心に (一社)日本感染症学会 感染症学雑誌 0387-5911 93 2 168 168 20190300 read0138449/misc/40881677 座間味義人 座間味義人 石澤有紀 新村貴博 小山敏広 濱野裕章 岡田直人 合田光寛 武智研志 中馬真幸 堀ノ内裕也 桐野靖 中村敏己 寺岡和彦 石澤啓介 石澤啓介 大規模医療情報データベースを活用した周術期領域における薬剤疫学研究 日本医療薬学会年会講演要旨集(Web) 2424-2470 29 null null 20190000 read0138449/misc/40881668 神田将哉 神田将哉 合田光寛 合田光寛 村井陽一 吉田愛美 新村貴博 石澤有紀 座間味義人 座間味義人 中馬真幸 濱野裕章 岡田直人 武智研志 堀ノ内裕也 池田康将 桐野靖 中村敏己 寺岡和彦 石澤啓介 石澤啓介 シスプラチン誘発腎障害に対する各種5-HT3受容体拮抗薬の影響 日本医療薬学会年会講演要旨集(Web) 2424-2470 29 null null 20190000 read0138449/misc/40881663 合田光寛 合田光寛 座間味義人 座間味義人 新村貴博 川尻雄大 武智研志 中馬真幸 萱野純史 濱野裕章 岡田直人 小林大介 島添隆雄 石澤有紀 桐野靖 中村敏己 寺岡和彦 石澤啓介 石澤啓介 大規模医療情報データベースを活用したオキサリプラチン誘発末梢神経障害に対する予防薬探索 日本医療薬学会年会講演要旨集(Web) 2424-2470 29 null null 20190000 read0138449/misc/40881657 濱野裕章 池田康将 堀ノ内裕也 合田光寛 座間味義人 座間味義人 桐野靖 中村敏己 寺岡和彦 石澤啓介 石澤啓介 プロトンポンプ阻害剤はヘプシジンを介して鉄代謝異常に関与する 日本医療薬学会年会講演要旨集(Web) 2424-2470 29 null null 20190000 read0138449/misc/37644258 合田光寛 斉家和仁 神田将哉 神田将哉 新村貴博 石澤有紀 座間味義人 座間味義人 中馬真幸 濱野裕章 生田賢治 岡田直人 武智研志 堀ノ内裕也 池田康将 桐野靖 中村敏己 寺岡和彦 石澤啓介 石澤啓介 シスプラチン誘発腎障害に対する新規予防薬の有効性の基礎的検証 日本臨床腫瘍薬学会学術大会講演要旨集 2019 null null 20190000 read0138449/misc/37644241 堀ノ内裕也 池田康将 濱野裕章 今西正樹 福島圭穣 石澤有紀 合田光寛 座間味義人 座間味義人 武智研志 宮本理人 藤野裕道 石澤啓介 石澤啓介 土屋浩一郎 玉置俊晃 慢性腎不全関連サルコペニアにおける鉄代謝異常 日本サルコペニア・フレイル学会誌 2433-1805 3 2 null null 20190000 read0138449/misc/34721990 岡田直人 座間味義人 座間味義人 新村貴博 濱野裕章 合田光寛 中馬真幸 武智研志 桐野靖 中村敏己 寺岡和彦 石澤啓介 石澤啓介 in silicoアプローチによるトランスレーショナルリサーチの実践:大規模医療データベースを活用したBCR-ABL阻害薬の有害事象解析 医療薬学フォーラム講演要旨集 1348-0863 27th null null 20190000 read0138449/misc/34721984 池田康将 堀ノ内祐也 濱野裕章 石澤啓介 土屋浩一郎 玉置俊晃 玉置俊晃 シスプラチン腎障害における鉄依存性細胞死の検討 日本循環薬理学会口演要旨集 29th null null 20190000 read0138449/misc/35048541 大島 啓亮 池田 康将 堀ノ内 裕也 渡邉 大晃 濱野 裕章 木平 孝高 岸 誠司 石澤 有紀 宮本 理人 平山 祐 永澤 秀子 石澤 啓介 土屋 浩一郎 玉置 玉置 Iron suppresses erythropoietin expression via oxidative stress-dependent hypoxia-inducible factor-2 alpha inactivation. 鉄は酸化ストレス依存的低酸素誘導因子2 α不活性化を介してエリスロポエチンの発現を抑制する 0288724X 福山大学薬学部研究年報 = Annual report of the Faculty of Pharmacy & Pharmaceutical Sciences, Fukuyama University 0288-724X 36 52 53 20181225 read0138449/misc/25105176 合田 光寛 濱野 裕章 岡田 直人 今西 正樹 座間味 義人 桐野 靖 中村 敏己 寺岡 和彦 石澤 啓介 斉家 和仁 新村 貴博 池田 康将 伊勢 諒 石澤 有紀 堀ノ内 裕也 中馬 真幸 武智 研志 シスプラチン誘発腎障害に対する新規予防薬の探索とその有効性の検証 徳島医学会 四国医学雑誌 0037-3699 74 5-6 219 220 20181200 read0138449/misc/24878698 岡田 直人 中馬 真幸 座間味 義人 石澤 啓介 考え方がわかれば解き方がみえてくる クリニカル・クエスチョンの解決への筋道(第2回) デノスマブによる低カルシウム血症は，どのような患者で起こりやすいのかを教えてください (株)じほう 薬事 0016-5980 60 16 3119 3125 20181200 read0138449/misc/24878683 新村 貴博 座間味 義人 石澤 有紀 石澤 啓介 大規模医療情報・生命科学データベースを活用したドラッグリポジショニング研究 日本亜鉛栄養治療研究会 亜鉛栄養治療 2187-9133 9 1 15 21 20181000 read0138449/misc/34721947 Yuya Horinouchi Yasumasa Ikeda Keijo Fukushima Masaki Imanishi Hirofumi Hamano Yuki Izawa-Ishizawa Yoshito Zamami Hiromichi Fujino Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki Utilizing Real-World Big Data in the Search for New Renoprotective Drugs HYPERTENSION 1524-4563 72 null null 20180900 read0138449/misc/26266536 岡田直人 河添仁 武智研志 座間味義人 座間味義人 今西正樹 中馬真幸 飛鷹範明 桐野靖 中村敏己 寺岡和彦 田中亮裕 石澤啓介 石澤啓介 ニボルマブによる免疫関連有害事象の発現予測バイオマーカーの探索:多施設共同後ろ向き研究による検討 医療薬学フォーラム講演要旨集 1348-0863 26th 247 null 20180600 read0138449/misc/24878541 新村 貴博 座間味 義人 石澤 啓介 今西 正樹 石澤 有紀 堀ノ内 裕也 池田 康将 玉置 俊晃 武智 研志 福島 圭穣 藤野 裕道 土屋 浩一郎 大規模医療情報を活用した心肺停止患者に対するニコランジルの有効性に関する検討 徳島医学会 四国医学雑誌 0037-3699 74 1-2 79 80 20180400 read0138449/misc/24878535 武智 研志 楊河 宏章 座間味 義人 今西 正樹 石澤 啓介 堀ノ内 裕也 石澤 有紀 池田 康将 玉置 俊晃 てんかん誘発性精神症状の行動学的解析および治療薬の探索と作用機序の解明 徳島医学会 四国医学雑誌 0037-3699 74 1-2 80 80 20180400 read0138449/misc/24878529 今西 正樹 近藤 正輝 座間味 義人 石澤 啓介 田中 恭平 生藤 来希 村井 陽一 武智 研志 堀ノ内 裕也 石澤 有紀 池田 康将 玉置 俊晃 藤野 裕道 土屋 浩一郎 Febuxostatの尿酸合成抑制作用とは独立した血管線維化抑制機構の解明 徳島医学会 四国医学雑誌 0037-3699 74 1-2 80 80 20180400 read0138449/misc/24878524 高橋 志門 座間味 義人 石澤 啓介 城ヶ瀧 里奈 高橋 撤多 相良 英憲 武智 研志 PTSDモデルラットにおける文脈的恐怖記憶の消去に対する治療薬の探索 徳島医学会 四国医学雑誌 0037-3699 74 1-2 80 81 20180400 read0138449/misc/24878522 石澤 有紀 岩田 悠佑 堀ノ内 裕也 池田 康将 玉置 俊晃 鍵本 優有 座間味 義人 石澤 啓介 今西 正樹 武智 研志 マウス大動脈瘤形成に対するケルセチンの効果 徳島医学会 四国医学雑誌 0037-3699 74 1-2 81 82 20180400 read0138449/misc/24878515 堀ノ内 裕也 池田 康将 石澤 有紀 玉置 俊晃 福島 圭穣 藤野 裕道 濱野 裕章 今西 正樹 座間味 義人 石澤 啓介 土屋 浩一郎 大規模医療情報データベース解析と基礎研究の融合による新規腎保護薬の探索 徳島医学会 四国医学雑誌 0037-3699 74 1-2 82 83 20180400 read0138449/misc/25901595 内田 真美 高取 真吾 河添 仁 森下 茉鈴 魚住 龍史 座間味 義人 石澤 啓介 川崎 博己 難波 弘行 田中 亮裕 荒木 博陽 医療のさらなる安心・安全を志向する若手研究者のイノベーティブチャレンジ 抗がん剤誘発末梢神経障害に及ぼすレニン・アンジオテンシン系阻害薬の影響 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 138 1 334 334 20180300 read0138449/misc/24878546 座間味 義人 阿部 奈都美 中馬 真幸 武智 研志 今井 徹 今西 正樹 桐野 靖 中村 敏己 寺岡 和彦 石澤 啓介 集中治療における薬剤師教育 (一社)日本集中治療医学会 日本集中治療医学会雑誌 1340-7988 25 Suppl. [CP4 4] 20180200 read0138449/misc/37644277 堀ノ内裕也 池田康将 福島圭穣 今西正樹 濱野裕章 石澤有紀 座間味義人 座間味義人 藤野裕道 石澤啓介 石澤啓介 土屋浩一郎 玉置俊晃 大規模医療情報データベースを活用した新規腎保護薬の探索 医療薬学フォーラム講演要旨集 1348-0863 26th null null 20180000 read0138449/misc/35048528 斉家和仁 合田光寛 伊勢諒 新村貴博 石澤有紀 座間味義人 座間味義人 中馬真幸 濱野裕章 岡田直人 武智研志 今西正樹 今西正樹 堀ノ内裕也 池田康将 土屋浩一郎 石澤啓介 石澤啓介 シスプラチン誘発腎障害に対するフェノフィブラートの有効性の検証 日本医療薬学会年会講演要旨集(Web) 2424-2470 28 null null 20180000 read0138449/misc/35048515 堀ノ内裕也 池田康将 福島圭穣 濱野裕章 今西正樹 石澤有紀 座間味義人 座間味義人 武智研志 藤野裕道 石澤啓介 石澤啓介 土屋浩一郎 玉置俊晃 リアルワールドビッグデータを活用した新規腎保護薬の探索 日本医療薬学会年会講演要旨集(Web) 2424-2470 28 null null 20180000 read0138449/misc/35048507 合田光寛 斉家和仁 伊勢諒 新村貴博 石澤有紀 座間味義人 座間味義人 中馬真幸 濱野裕章 岡田直人 武智研志 今西正樹 今西正樹 堀ノ内裕也 池田康将 桐野靖 中村敏己 寺岡和彦 石澤啓介 石澤啓介 シスプラチン誘発腎障害に対する新規予防薬の探索とその有効性の検証 日本医療薬学会年会講演要旨集(Web) 2424-2470 28 null null 20180000 read0138449/misc/34722005 堀ノ内裕也 池田康将 渡邉大晃 濱野裕章 石澤有紀 今西正樹 座間味義人 座間味義人 武智研志 宮本理人 石澤啓介 石澤啓介 土屋浩一郎 玉置俊晃 マクロファージ鉄の肥満・糖尿病における役割 日本鉄バイオサイエンス学会学術集会プログラム・抄録集 42nd null null 20180000 read0138449/misc/25106935 三橋知里 濱野裕章 中本亜樹 田中里奈 櫻田巧 今西正樹 座間味義人 桐野靖 中村敏己 寺岡和彦 石澤啓介 第二世代5‐HT₃受容体拮抗薬は第一世代と比較して抗癌剤連日投与中の嘔吐を抑制する 日本緩和医療薬学会年会プログラム・要旨集 12th 214 null 20180000 read0138449/misc/25106933 座間味義人 三井茉綸 新村貴博 櫻田巧 今西正樹 武智研志 桐野靖 中村敏己 寺岡和彦 石澤啓介 有害事象自発報告データベースを活用したベバシズマブの抗腫瘍効果を減弱させる薬剤の探索研究 日本臨床腫瘍薬学会学術大会講演要旨集 2018 206 null 20180000 read0138449/misc/25106931 櫻田巧 今西正樹 座間味義人 桐野靖 中村敏己 寺岡和彦 石澤啓介 腎機能がペメトレキセド治療における安全性に影響を与えるか 日本臨床腫瘍薬学会学術大会講演要旨集 2018 172 null 20180000 read0138449/misc/25106799 小中健 櫻田巧 斉藤辰彦 盛佐知子 柿内聡司 石澤啓介 伏谷秀治 UGT1A1ヘテロ接合体を有する患者におけるイリノテカンの減量に関する検討 日本臨床腫瘍薬学会学術大会講演要旨集 2018 204 null 20180000 read0138449/misc/24878700 座間味 義人 新村 貴博 武智 研志 今西 正樹 小山 敏広 石澤 啓介 心肺停止患者における生存率の向上を志向したドラッグリポジショニング研究 大規模医療情報を活用した検討 近年，既存薬の新しい薬効を発見し，それを別の疾患の治療薬として開発するドラッグリポジショニングという創薬戦略が提案されている．ドラッグリポジショニングでは，安全性を確保しながら開発期間を短縮することが可能であり，新規化合物に比べ開発成功率も高くなる．心肺停止患者の生存率を向上させることを目的として，ドラッグリポジショニングの創薬戦略により実施した大規模データベースを紹介し，今後の展望についても考察した． (公社)日本薬学会 薬学雑誌 1347-5231 137 12 1439 1442 20171200 read0138449/misc/24878551 新村 貴博 座間味 義人 今西 正樹 石澤 啓介 武智 研志 堀ノ内 裕也 石澤 有紀 池田 康将 玉置 俊晃 藤野 裕道 土屋 浩一郎 新規心肺蘇生薬の開発を目的としたドラッグリポジショニング研究 大規模医療情報を活用した検討 徳島医学会 四国医学雑誌 0037-3699 73 5-6 323 323 20171200 read0138449/misc/28028825 Yuya Horinouchi Yasumasa Ikeda Hirofumi Hamano Masaki Imanishi Yuki Izawa-Ishizawa Yoshito Zamami Kenshi Takechi Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki The Effect of Iron on Skeletal Muscle Atrophy in Chronic Kidney Disease FREE RADICAL BIOLOGY AND MEDICINE 1873-4596 112 204 205 20171100 10.1016/j.freeradbiomed.2017.10.323 read0138449/misc/24878558 新村 貴博 座間味 義人 石澤 有紀 今西 正樹 武智 研志 福島 圭穣 堀ノ内 裕也 池田 康将 藤野 裕道 土屋 浩一郎 玉置 俊晃 石澤 啓介 大規模医療情報を用いて新規心肺蘇生後症候群治療薬の開発を志向したドラッグリポジショニング研究 (一社)日本臨床薬理学会 臨床薬理 0388-1601 48 Suppl. S344 S344 20171100 read0138449/misc/25106603 吾妻 雅彦 長宗 雅美 岩田 貴 石澤 啓介 川添 和義 西岡 安彦 赤池 雅史 徳島大学における担当患者を用いた多職種連携教育の取り組み (一社)日本医学教育学会 医学教育 0386-9644 48 Suppl. 223 223 20170800 read0138449/misc/25035439 池田康将 堀ノ内裕也 濱野裕章 濱野裕章 平山祐 岸誠司 石澤有紀 今西正樹 座間味義人 座間味義人 武智研志 宮本理人 石澤啓介 石澤啓介 粟飯原賢一 永澤秀子 土屋浩一郎 玉置俊晃 鉄摂取制限による尿細管間質障害の抑制効果の検討 日本鉄バイオサイエンス学会学術集会プログラム・抄録集 41st 40 null 20170800 read0138449/misc/35594957 荒木 博陽 石澤 啓介 「あ，検査値が変わった」そのとき，薬のリスクは? じほう 調剤と情報 = Rx info 1341-5212 23 9 1031 1185 20170600 read0138449/misc/26266541 大森理央 佐藤陽一 木口美沙妃 岡田直人 中村信元 賀川久美子 藤井志郎 三木浩和 石澤啓介 石澤啓介 安部正博 山内あい子 ビンクリスチンによる副作用発現とMDR1遺伝子多型との関連性 (一社)日本医薬品情報学会 日本医薬品情報学会総会・学術大会講演要旨集 20th 181 181 20170600 read0138449/misc/26266538 山口裕大 佐藤陽一 谷垣雄都 岡田直人 中村信元 賀川久美子 藤井志朗 三木浩和 石澤啓介 石澤啓介 安部正博 山内あい子 バンコマイシン投与による副作用発現及び血中濃度とCYP遺伝子多型との関連解析 (一社)日本医薬品情報学会 日本医薬品情報学会総会・学術大会講演要旨集 20th 181 181 20170600 read0138449/misc/25106953 坂東左奈子 櫻田巧 岡田直人 今西正樹 座間味義人 寺岡和彦 中村敏己 石澤啓介 エピルビシン,シクロフォスファミド投与による持続型G‐CSF製剤の有効性の検討 日本外科系連合学会誌 0385-7883 42 3 593 null 20170500 read0138449/misc/25106951 井上貴久 櫻田巧 柴田高洋 岡田直人 座間味義人 今西正樹 中村敏己 寺岡和彦 石澤啓介 抗EGFR抗体薬の投与による低Mg血症発現率の比較検討 日本外科系連合学会誌 0385-7883 42 3 594 null 20170500 read0138449/misc/28031088 Hirofumi Hamano Yasumasa Ikeda Hiroaki Watanabe Yuya Horinouchi Yuki Izawa-Ishizawa Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki Indoxyl Sulfate Involves Abnormality of Iron Metabolism Through Hepcidin Regulation FASEB JOURNAL 1530-6860 31 null null 20170400 read0138449/misc/24878510 井上 貴久 櫻田 巧 柴田 高洋 今西 正樹 座間味 義人 中村 敏己 寺岡 和彦 石澤 啓介 岡田 直人 抗EGFR抗体薬による低Mg血症発現率の比較検討 徳島医学会 四国医学雑誌 0037-3699 73 1-2 137 138 20170400 read0138449/misc/37644270 濱野裕章 濱野裕章 池田康将 渡邉大晃 堀ノ内裕也 石澤有紀 今西正樹 座間味義人 座間味義人 武智研志 石澤啓介 石澤啓介 土屋浩一郎 玉置俊晃 慢性腎臓病における尿毒素蓄積によるヘプシジン制御と鉄代謝破綻のメカニズムの解明 日本鉄バイオサイエンス学会学術集会プログラム・抄録集 41st null null 20170000 read0138449/misc/37644248 濱野裕章 三井茉綸 座間味義人 座間味義人 新村貴博 武智研志 岡田直人 今西正樹 桐野靖 中村敏己 寺岡和彦 石澤啓介 石澤啓介 アルカリ化剤はイリノテカン誘発性好中球減少症を予防する 日本医療薬学会年会講演要旨集(Web) 2424-2470 27 null null 20170000 read0138449/misc/34722015 濱野裕章 濱野裕章 池田康将 渡邉大晃 堀ノ内裕也 石澤有紀 今西正樹 座間味義人 座間味義人 武智研志 石澤啓介 石澤啓介 土屋浩一郎 玉置俊晃 インドキシル硫酸蓄積はヘプシジン制御を介して鉄代謝恒常性破綻に関与する 日本薬理学会近畿部会プログラム・要旨集 131st null null 20170000 read0138449/misc/34721997 渡邉大晃 池田康将 濱野裕章 濱野裕章 堀ノ内裕也 石澤有紀 今西正樹 座間味義人 座間味義人 武智研志 宮本理人 土屋浩一郎 玉置俊晃 石澤啓介 石澤啓介 肥満・糖尿病におけるマクロファージ鉄制御機構の検討 日本薬理学会近畿部会プログラム・要旨集 132nd null null 20170000 read0138449/misc/26266543 中本亜樹 岡田直人 濱野裕章 安井苑子 安井苑子 西麻希 今西正樹 座間味義人 座間味義人 中村敏己 寺岡和彦 浜田康弘 浜田康弘 石澤啓介 石澤啓介 頭頸部癌に対する化学放射線療法におけるCDDP単独療法及び5‐FU+CDDP療法による副作用発現の比較 日本緩和医療薬学会年会プログラム・要旨集 11th 257 null 20170000 read0138449/misc/25106937 井上貴久 櫻田巧 柴田高洋 岡田直人 座間味義人 今西正樹 中村敏己 寺岡和彦 石澤啓介 抗EGFR抗体薬における副作用としての低Mg血症発現率の比較検討 日本薬学会年会要旨集(CD-ROM) 137th ROMBUNNO.26PB-pm248 null 20170000 read0138449/misc/25152670 座間味 義人 今西 正樹 武智 研志 小山 敏広 大島 礼子 樋之津 史郎 狩野 光伸 石澤 啓介 新規心肺蘇生薬の開発を目指したドラッグリポジショニング研究 (NPO)日本高血圧学会 日本高血圧学会総会プログラム・抄録集 39 437 437 20160900 read0138449/misc/25152674 座間味義人 今西正樹 武智研志 小山敏広 大島礼子 今井徹 樋之津史郎 狩野光伸 石澤啓介 石澤啓介 ドラッグリポジショニングを切り口とした新規心肺蘇生薬の探索研究―大規模医療情報を活用した検討― 医療薬学フォーラム講演要旨集 1348-0863 24th 193 null 20160600 read0138449/misc/22435672 柴田 高洋 柴田 洋文 岡田 直人 伏谷 秀治 長尾 多美子 高開 登茂子 川添 和義 石澤 啓介 PCR法を用いた病院内の実態調査からみる来院者がMRSA分布に及ぼす影響 PCR法を用いた病院内の実態調査からみる来院者がMRSA分布に及ぼす影響について検討した．外来診療棟の玄関ホールに設置された長椅子19脚，小児科外来の廊下に設置された長椅子18脚，内科外来の廊下に設置された長椅子14脚を対象として，それぞれ2回行った．調査した全ての長椅子から好気性細菌を検出した．そのうち，S.aureusは，玄関ホールの長椅子29脚，小児科外来の長椅子25脚，内科外来の長椅子22脚から検出し，MRSAは，玄関ホールの長椅子14脚，内科外来の長椅子16脚から検出した．玄関ホールと内科の間には有意差は見られなかったが，小児科と内科を比較すると，内科が高い分布域にあることが示された．小児科病棟プレイルームの壁面，壁の開口部下縁および遊具を調査した．好気性細菌は，壁面を除き，ほぼ全ての調査部位から検出した．S.aureus検出数の分布は，壁面が壁開口部下縁と比較して低い分布域を示した．玄関ホール待合用長椅子から得られたMRSAは24株，小児科外来待合用長椅子から得られたMRSAは1株であった． (一社)日本医療薬学会 医療薬学 1882-1499 42 6 400 407 20160600 10.5649/jjphcs.42.400 read0138449/misc/28139644 Yasumasa Ikeda Keisuke Oshima Yuya Horinouchi Yuki Izawa-Ishizawa Yoshitaka Kihira Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki The Involvement of Iron on Erythropoietin Expression FASEB JOURNAL 1530-6860 30 null null 20160400 read0138449/misc/26266544 濱野 裕章 中本 亜樹 村上 明希 田中 里奈 岡田 直人 寺岡 和彦 中村 敏己 石澤 啓介 アルカリ化剤はイリノテカンによる好中球減少症を予防する 徳島医学会 四国医学雑誌 0037-3699 72 1-2 66 67 20160400 read0138449/misc/25106941 今西正樹 石澤啓介 櫻田巧 小原祐介 戸谷紘基 長尾朋子 細岡真由子 土屋浩一郎 壱岐豊 石澤有紀 木平孝高 池田康将 玉置俊晃 ニフェジピン光分解産物による血管リモデリング抑制効果 四国医学雑誌 0037-3699 72 1/2 67 null 20160400 read0138449/misc/22435673 石澤 啓介 サイエンスを基盤とする臨床薬剤業務の実践 合理的な薬剤業務を実践するには，科学的方法に基づいてエビデンスを整理・応用して，論理的に薬物療法を組み立てる能力が必要である．サイエンスを基盤とする臨床薬剤業務の実践に向けた徳島大学病院の取り組みについて，以下の項目に分けて紹介した．1)薬剤業務の変遷，2)エビデンスを創出する薬剤業務の実践(抗MRSA薬を用いた薬物療法における薬剤師介入の有用性，ペメトレキセドによる発疹に対するステロイドの有効性と至適投与量の解析)，3)心腎血管疾患を標的とする薬理学的研究，として述べた． 徳島医学会 四国医学雑誌 0037-3699 72 1-2 25 30 20160400 read0138449/misc/34721957 Hirofumi Hamano Yasumasa Ikeda Hiroaki Watanabe Akiho Satoh Keisuke Oshima Yuya Horinouchi Yuki Izawa-Ishizawa Yoshitaka Kihira Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki The impact of uremic toxin on hepcidin regulation JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8648 130 3 S141 S141 20160300 read0138449/misc/34721936 Akiho Satoh Yasumasa Ikeda Yuya Horinouchi Hirofumi Hamano Mizuki Imao Hiroaki Watanabe Yuki Izawa-Ishizawa Yoshitaka Kihira Licht Miyamoto Keisuke Ishizawa Koichiro Tsuchiya Yoshiaki Tamaki The impact of iron deficiency on skeleta muscle atrophy JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8648 130 3 S105 S105 20160300 read0138449/misc/25152677 座間味 義人 今西 正樹 小山 敏広 大島 礼子 樋之津 史郎 狩野 光伸 石澤 啓介 救急集中治療を変える!!薬学から重症患者の治療向上に寄与するエビデンスを創り，発信する 心肺停止患者における社会復帰率の向上を志向したドラッグリポジショニング研究 (公社)日本薬学会 (CD-ROM) 日本薬学会年会要旨集 0918-9823 136 1 159 159 20160300 read0138449/misc/25106619 小中 健 花房 剛志 田中 恭平 岡田 直人 今西 正樹 座間味 義人 川添 和義 石澤 啓介 パクリタキセル誘発性神経障害に対する漢方製剤抽出物の影響 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 136 3 188 188 20160300 read0138449/misc/25106614 岡田 直人 花房 剛志 阿部 真治 佐藤 智恵美 中村 敏己 寺岡 和彦 石澤 啓介 川添 和義 自家造血幹細胞移植併用大量化学療法における味覚障害の発現に関与する危険因子の探索 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 136 4 89 89 20160300 read0138449/misc/35048532 中本亜樹 濱野裕章 岡田直人 今西正樹 座間味義人 座間味義人 中村敏己 寺岡和彦 石澤啓介 石澤啓介 DPP-4阻害薬服用患者における他のDPP-4阻害薬への切り替えによるLDL-C低下作用の検討 日本医療薬学会年会講演要旨集(Web) 2424-2470 26 null null 20160000 read0138449/misc/34722033 濱野裕章 中本亜樹 岡田直人 今西正樹 座間味義人 座間味義人 中村敏己 寺岡和彦 石澤啓介 石澤啓介 GEM+nabPTX療法における高ビリルビン血症が副作用発現に与える影響 日本医療薬学会年会講演要旨集(Web) 2424-2470 26 null null 20160000 read0138449/misc/25106949 堀ノ内裕也 櫻田巧 中村敏己 寺岡和彦 石澤啓介 ベバシズマブ投与患者における高血圧のリスクファクター 日本薬学会年会要旨集(CD-ROM) 136th ROMBUNNO.27AB-AM343 null 20160000 read0138449/misc/25106946 今西正樹 石澤啓介 小原佑介 櫻田巧 戸谷紘基 長尾朋子 壱岐豊 細岡真由子 石澤有紀 木平孝高 池田康将 土屋浩一郎 玉置俊晃 ニトロソニフェジピンによる抗大動脈瘤機序の検討 血管 0911-4637 39 1 41 null 20160100 read0138449/misc/25106800 櫻田巧 石澤啓介 柿内聡司 西岡安彦 石澤啓介 ペメトレキセド投与後の皮疹発現状況調査とデキサメタゾン追加の有効性の検討 四国医学雑誌 0037-3699 71 5/6 171 172 20151225 read0138449/misc/26266549 岡田直人 石澤啓介 岡田直人 石澤啓介 今求められているNSTと薬剤師の役割(75)臨床・研究・教育を柱とするNST活動の実践 週刊薬事新報 0289-3290 2921 1306 1310 20151224 read0138449/misc/22435674 岡田 直人 石澤 啓介 今求められているNSTと薬剤師の役割 臨床・研究・教育を柱とするNST活動の実践 (株)薬事新報社 薬事新報 0289-3290 2921 9 13 20151200 read0138449/misc/37496183 石田 俊介 伏谷 秀治 坂本 久美子 中村 敏己 寺岡 和彦 川添 和義 石澤 啓介 P0775-22-PM 臨床検査値を指標とする副作用モニタリング管理ツールの構築(医薬品情報・データベース,ポスター,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-) 日本医療薬学会 日本医療薬学会年会講演要旨集 25 395 395 20151023 read0138449/misc/26266548 柴田高洋 岡田直人 伏谷秀治 柴田洋文 川添和義 川添和義 石澤啓介 石澤啓介 院内MRSA分布へ来院者が及ぼす影響 日本医療薬学会年会講演要旨集 25th 240 null 20151023 read0138449/misc/26266532 柴田 高洋 岡田 直人 伏谷 秀治 柴田 洋文 川添 和義 石澤 啓介 22-7-O44-28 院内MRSA分布へ来院者が及ぽす影響(感染制御,口頭発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-) 日本医療薬学会 日本医療薬学会年会講演要旨集 25 240 240 20151023 read0138449/misc/26266530 岡田 直人 伏谷 秀治 東 桃代 中村 敏己 寺岡 和彦 川添 和義 石澤 啓介 21-5-O5-02 抗MRSA薬を用いた治療に対する薬剤師介入の有用性 : プロトコルに基づく薬物治療管理と多職種介入による臨床効果及び医療経済効果(病棟薬剤業務,口頭発表,一般演題,医療薬学の進歩と未来-次の四半世紀に向けて-) 日本医療薬学会 日本医療薬学会年会講演要旨集 25 200 200 20151023 read0138449/misc/25106627 石田 俊介 伏谷 秀治 前田 和輝 渡邉 美穂 中村 敏己 寺岡 和彦 川添 和義 石澤 啓介 当院薬剤部における管理ツール作成による副作用情報収集の効率化 (一社)日本医薬品情報学会 日本医薬品情報学会総会・学術大会講演要旨集 18 130 130 20150600 read0138449/misc/25106626 桐野 靖 中村 敏巳 寺岡 和彦 川添 和義 石澤 啓介 精神科病棟における炭酸リチウムの適正使用状況の推移 (一社)日本医薬品情報学会 日本医薬品情報学会総会・学術大会講演要旨集 18 140 140 20150600 read0138449/misc/26266545 岡田直人 下岡幸恵 東桃代 石澤啓介 石澤啓介 プロトコルに基づく薬物治療管理が医師の診療行動へ与える影響 日本化学療法学会雑誌 1340-7007 63 Supplement-A 179 null 20150509 read0138449/misc/28357156 Yasumasa Ikeda Yusuke Kanai Yuya Horinouchi Yuki Izawa-Ishizawa Yoshitaka Kihira Licht Miyamoto Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki The Effects of Bilirubin on Angiogenesis in Mice with Hindlimb Ischemia FASEB JOURNAL 1530-6860 29 null null 20150400 read0138449/misc/25106625 小林 真也 森山 耕太 松田 実紗 岡田 直人 福壽 由法 富加見 正樹 森本 俊司 川添 和義 石澤 啓介 キクイモ(Helianthus tuberosus)の肝臓における脂肪蓄積抑制効果の検討 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 135 2 93 93 20150300 read0138449/misc/25106624 岡田 直人 伏谷 秀治 東 桃代 中村 敏己 寺岡 和彦 川添 和義 渡辺 浩良 安倍 正博 石澤 啓介 病棟薬剤師によるプロトコルに基づく薬物治療管理の実践 抗MRSA薬の適正使用に対する効果 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 135 4 87 87 20150300 read0138449/misc/25106623 西迫 寛隆 中川 博之 東 桃代 下岡 幸恵 伏谷 秀治 中村 敏己 寺岡 和彦 川添 和義 石澤 啓介 徳島大学病院における真菌感染BUNDLEの活用について (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 135 4 89 89 20150300 read0138449/misc/37644286 濱野裕章 濱野裕章 池田康将 堀ノ内裕也 堀ノ内裕也 佐藤明穂 渡邉大晃 大島啓亮 石澤有紀 木平孝高 石澤啓介 石澤啓介 土屋浩一郎 玉置俊晃 慢性腎不全における尿毒素によるヘプシジン制御機構 日本薬理学会近畿部会プログラム・要旨集 128th null null 20150000 read0138449/misc/34994946 小倉圭司 平川寛子 森崎巧也 山本純 戎野紘司 宮本理人 石澤啓介 石澤啓介 土屋浩一郎 重永章 大高章 低酸素環境応答型アミノ酸の開発研究 日本薬学会年会要旨集(CD-ROM) 135th null null 20150000 read0138449/misc/26416072 木平孝高 岸渕麗奈 山口邦久 石澤有紀 池田康将 石澤啓介 冨田修平 土屋浩一郎 玉置俊晃 腎虚血再灌流障害において低酸素誘導因子が制御する因子の探索 日本薬学会年会要旨集(CD-ROM) 135th ROMBUNNO.28PB-AM190 null 20150000 read0138449/misc/37726076 K. Ishizawa Y. Kohara T. Sakurada H. Toya Y. Iki Y. Izawa-Ishizawa Y. Kihira Y. Ikeda K. Tsuchiya T. Tamaki Nitrosonifedipine ameliorates the progression of aortic aneurysms by exerting antioxidative effects EUROPEAN HEART JOURNAL 1522-9645 35 786 786 20140900 read0138449/misc/25106806 小原佑介 石澤啓介 櫻田巧 戸谷紘基 長尾朋子 壱岐豊 石澤有紀 木平孝高 池田康将 土屋浩一郎 玉置俊晃 薬剤誘導性大動脈瘤モデルに対するニトロソニフェジピンの効果 日本薬理学会近畿部会プログラム・要旨集 125th 96 null 20140500 read0138449/misc/28037755 Yasumasa Ikeda Soichiro Tajima Mizuki Imao Yuya Horinouchi Yuki Izawa-Ishizawa Yoshitaka Kihira Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki Ferritin induces IL-1 beta production through inflammasome activation via NF-kappa B-dependent manner in macrophages FASEB JOURNAL 1530-6860 28 1 null null 20140400 read0138449/misc/28109848 Licht Miyamoto Megumi Yamane Yosuke Tomida Kazuya Takenokuma Keisuke Ishizawa Toshiaki Tamaki Koichiro Tsuchiya Significance of AMPK in renal protective and metabolic actions of nitrite JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8648 124 93P 93P 20140000 read0138449/misc/28069600 Keisuke Ishizawa Yuki Ishizawa Noriko Yamano Asami Nuno Masaki Imanishi Takumi Sakurada Yoshitaka Kihira Yasumasa Ikeda Koichiro Tsuchiya Toshiaki Tamaki Nitrosonifedipine ameliorates the progression of renal disease associated with endothelial dysfunction independently of eNOS JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8648 124 223P 223P 20140000 read0138449/misc/25106811 小原佑介 石澤啓介 櫻田巧 戸谷紘基 長尾朋子 壱岐豊 細岡真由子 石澤有紀 木平孝高 池田康将 土屋浩一郎 玉置俊晃 ニトロソニフェジピンは大動脈瘤の形成を抑制する 次世代を担う創薬・医療薬理シンポジウムプログラム・要旨集 2014 81 null 20140000 read0138449/misc/22435675 Masaki Imanishi 今西 正樹 Keisuke Ishizawa 石澤 啓介 Takumi Sakurada 櫻田 巧 Yuki Ishizawa 石澤 有紀 Noriko Yamano 山野 範子 Yoshitaka Kihira 木平 孝高 Yasumasa Ikeda 池田 康将 Koichiro Tsuchiya 土屋 浩一郎 Toshiaki Tamaki 玉置 俊晃 Drug development for cardiorenal disease based on oxidative stress control 酸化ストレス制御を基盤とする新規心腎血管障害治療薬の開発 (公社)日本薬学会 Yakugaku Zasshi 薬学雑誌 1347-5231 134 6 715 719 20140000 10.1248/yakushi.13-00255-4 24882646 2-s2.0-84922245064 read0138449/misc/28210928 Licht Miyamoto Yosuke Tomida Aya Kawasaki Tomomi Yamaoka Megumi Yamane Mai Kono Keisuke Ishizawa Koichiro Tsuchiya Significance of Hepatic AMPK Activation in Metabolic Regulation by Autonomic Nervous System DIABETES 1939-327X 62 A486 A486 20130700 read0138449/misc/25106816 石澤啓介 山野範子 石澤有紀 櫻田巧 今西正樹 布あさ美 木平孝高 池田康将 土屋浩一郎 玉置俊晃 ニトロソニフェジピンは血管内皮保護作用を示して糖尿病性腎症進展を抑制する 日本腎臓学会誌 0385-2385 55 3 378 null 20130425 read0138449/misc/28240622 Koichiro Tsuchiya Licht Miyamoto Megumi Yamane Mai KonoA Yosuke Tomida Keisuke Ishizawa Yoshitaka Kihira Yasumasa Ikeda Toshiaki Tamaki Significance of AMPK-eNOS pathway in renal protective effects of nitrite NITRIC OXIDE-BIOLOGY AND CHEMISTRY 1089-8603 31 S24 S24 20130400 10.1016/j.niox.2013.02.029 read0138449/misc/28203749 Yasumasa Ikeda Hideaki Enomoto Soichiro Tajima Yuki Izawa-Ishizawa Yoshitaka Kihira Keisuke Ishizawa Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki The effect of dietary iron restriction against diabetic nephropathy in db/db mice FASEB JOURNAL 0892-6638 27 null null 20130400 read0138449/misc/25106826 石澤有紀 石澤啓介 山野範子 櫻田巧 今西正樹 藤井聖子 布あさ美 木平孝高 池田康将 土屋浩一郎 玉置俊晃 ニトロソニフェジピンは血管内皮細胞障害を伴う糖尿病性腎症の進展を抑制する 血管 0911-4637 36 1 44 null 20130131 read0138449/misc/25106821 土肥紗希子 石澤有紀 石澤啓介 櫻田巧 今西正樹 小原佑介 長尾朋子 木平孝高 池田康将 土屋浩一郎 玉置俊晃 無機リン刺激による血管平滑筋細胞石灰化におけるRho‐kinaseの関与 血管 0911-4637 36 1 27 null 20130131 read0138449/misc/28262760 Yuki Izawa-Ishizawa Keisuke Ishizawa Sakiko Doi Masaki Imanishi Takumi Sakurada Noriko Yamano Yusuke Kohara Tomoko Nagao Yoshitaka Kihira Yasumasa Ikeda Koichiro Tsuchiya Toshiaki Tamaki Y-27632, a rho-kinase inhibitor, inhibits inorganic phosphate-induced ERK1/2 phosphorylation and ALP activity in vascular smooth muscle cells JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 121 205P 205P 20130000 read0138449/misc/28251933 Noriko Yamano Keisuke Ishizawa Shoko Fujii Asami Nuno Masaki Imanishi Takumi Sakurada Yuta Suzuki Furi Endo Yuki Ishizawa Yoshitaka Kihira Yasumasa Ikeda Koichiro Tsuchiya Toshiaki Tamaki Effects of nitrosonifedipine on the diabetic nephropathy with the endothelial dysfunction JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 121 76P 76P 20130000 read0138449/misc/28245477 Yasumasa Ikeda Soichiro Tajima Yuki Ishizawa-Izawa Yoshitaka Kihira Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki Bovine lactoferrin stimulated angiogenesis in response to ischemic hindlimb via Src-Akt-eNOS-dependent manner JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 121 103P 103P 20130000 read0138449/misc/28237088 Mari Itoh Yoshitaka Kihira Noriko Yamano Yuki Ishizawa Keisuke Ishizawa Yasumasa Ikeda Koichiro Tsuchiya Shuhei Tomita Toshiaki Tamaki Secretion of glucagon-like peptide-1 from intestinal L cell in hypoxia JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 121 229P 229P 20130000 read0138449/misc/28216695 Iori Ozono Yasumasa Ikeda Soichiro Tajima Yuki Ishizawa-Izawa Yoshitaka Kihira Keisuke Ishizawa Koichiro Tsuchiya Toshiaki Tamaki The Effects of Iron chelation against Renal Fibrosis in Unilateral Ureteral Obstruction Mice Model JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 121 92P 92P 20130000 read0138449/misc/28211472 Yoji Hoshina Yoshitaka Kihira Shuhei Tomita Mariko Miyake Noriko Yamano Yuki Ishizawa Keisuke Ishizawa Yasumasa Ikeda Koichiro Tsuchiya Toshiaki Tamaki Adipocyte-specific hypoxia-inducible factor-1alpha knockout stimulated GLP-1 and insulin secretions in mice JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 121 151P 151P 20130000 read0138449/misc/25106831 今西正樹 石澤啓介 櫻田巧 石澤有紀 山野範子 木平孝高 池田康将 土屋浩一郎 玉置俊晃 酸化ストレスに起因する心腎血管障害の克服を目指す新規治療薬開発 日本薬学会年会要旨集(CD-ROM) 133rd ROMBUNNO.GS-1-4 null 20130000 read0138449/misc/28662403 Masaki Imanishi Shuhei Tomita Keisuke Ishizawa Yoshitaka Kihira Yasumasa Ikeda Noriko Yamano Yuki Ishizawa Koichiro Tsuchiya Toshiaki Tamaki Hypoxia-inducible Factor-1 alpha in Vascular Smooth Muscle Cells Regulates Angiotensin II-induced Vascular Remodeling and AT1 Receptor Expression in Mouse Aortic Media CIRCULATION 1524-4539 126 21 null null 20121100 read0138449/misc/28634979 Yasumasa Ikeda Hideaki Enomoto Soichiro Tajima Yuki Izawa-Ishizawa Yoshitaka Kihira Keisuke Ishizawa Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Iron Restriction Prevents the Progression of Diabetic Nephropathy in db/db Mice CIRCULATION 1524-4539 126 21 null null 20121100 read0138449/misc/25106843 田島壮一郎 池田康将 土屋浩一郎 堀ノ内裕也 櫻田巧 木平孝高 石澤有紀 石澤啓介 川添和義 冨田修平 水口和生 玉置俊晃 十二指腸からの鉄吸収に対するAngiotensin IIの影響 日本鉄バイオサイエンス学会学術集会プログラム・抄録集 36th 35 null 20120800 read0138449/misc/25106849 藤井聖子 石澤啓介 櫻田巧 山野範子 石澤有紀 今西正樹 布あさ美 鈴木雄太 木平孝高 池田康将 冨田修平 土屋浩一郎 玉置俊晃 ニフェジピン光分解産物による糖尿病性腎症進展抑制作用 医療薬学フォーラム講演要旨集 1348-0863 20th 215 null 20120700 read0138449/misc/25106855 石澤啓介 櫻田巧 今西正樹 藤井聖子 石澤有紀 宮本理人 山野範子 木平孝高 池田康将 冨田修平 土屋浩一郎 玉置俊晃 Nitrosonifedipineはangiotensin II誘発のマウス血管リモデリングを改善する 日本酸化ストレス学会学術集会プログラム・抄録集 65th 49 null 20120605 read0138449/misc/25106861 藤井聖子 石澤啓介 櫻田巧 今西正樹 石澤有紀 木平孝高 池田康将 冨田修平 土屋浩一郎 玉置俊晃 糖尿病モデルマウスにおいてニトロソニフェジピンは腎症の進展を抑制する 日本腎臓学会誌 0385-2385 54 3 346 null 20120425 read0138449/misc/28635512 Takumi Sakurada Keisuke Ishizawa Shoko Fujii Yuki Izawa-Ishizawa Masaki Imanishi Asami Nuno Yoshitaka Kihira Yasumasa Ikeda Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Effects of nitrosonifedipine, a photodegradation product of nifedipine, on diabetic nephropathy in type II diabetic mice FASEB JOURNAL 0892-6638 26 null null 20120400 read0138449/misc/25106867 布あさ美 石澤啓介 藤井聖子 石澤有紀 今西正樹 櫻田巧 木平孝高 池田康将 冨田修平 土屋浩一郎 玉置俊晃 2型糖尿病性腎症に対するニトロソニフェジピンの効果 日本薬学会年会要旨集 0918-9823 132nd 3 116 null 20120305 read0138449/misc/25106673 田島 壮一郎 池田 康将 土屋 浩一郎 堀ノ内 裕也 櫻田 巧 石澤 有紀 木平 孝高 石澤 啓介 川添 和義 冨田 修平 水口 和生 玉置 俊晃 鉄キレート剤は肥満の脂肪肥大進展を抑制する (公社)日本薬理学会 日本薬理学雑誌 0015-5691 139 3 30P 30P 20120300 read0138449/misc/25106873 石澤啓介 藤井聖子 布あさ美 石澤有紀 今西正樹 櫻田巧 木平孝高 池田康将 冨田修平 土屋浩一郎 玉置俊晃 Nitrosonifedipineは2型糖尿病モデルマウスにおける腎症進展を抑制する 血管 0911-4637 35 1 56 null 20120131 read0138449/misc/28667079 Noriko Yamano Yasumasa Ikeda Minoru Sakama Yuki Ishizawa Yoshitaka Kihira Keisuke Ishizawa Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Accumulated iron storage in high fat diet-induced obese and diabetic mice JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 118 215P 215P 20120000 read0138449/misc/28663066 Hideaki Enomoto Yasumasa Ikeda Soichiro Tajima Yuki Ishizawa Yoshitaka Kihira Keisuke Ishizawa Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Protective effect of dietary iron restriction on diabetic nephropathy JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 118 247P 247P 20120000 read0138449/misc/28626838 Shuhei Tomita Mitsuru Takaku Noriko Yamano Yuki Ishizawa Yoshitaka Kihira Keisuke Ishizawa Yasumasa Ikeda Koichiro Tsuchiya Toshiaki Tamaki Preoperative stabilization of HIF-1 by systemic introduction of dimethyloxalylglycine (DMOG), improves skin flap survival JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 118 86P 86P 20120000 read0138449/misc/28620588 Manami Hirata Yoshitaka Kihira Mariko Miyake Yuki Izawa-Ishizawa Keisuke Ishizawa Yasumasa Ikeda Koichiro Tsuchiya Toshiaki Tamaki Shuhei Tomita High fat diet-induced inflammation in adipose tissues is reduced in adipocyte-specific hypoxia-inducible factor-1 alpha knockout mice. JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 118 71P 71P 20120000 read0138449/misc/28619304 Masaki Imanishi Keisuke Ishizawa Yoshitaka Kihira Yasumasa Ikeda Noriko Yamano Yuki Ishizawa Koichiro Tsuchiya Toshiaki Tamaki Shuhei Tomita The inhibitory effects of smooth muscle cell-specific hypoxia-inducible factor-1 alpha deficiency on angiotensin II-induced vascular remodeling in mice JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 118 77P 77P 20120000 read0138449/misc/28612242 Shoko Fujii Keisuke Ishizawa Takumi Sakurada Yuki Izawa-Ishizawa Masaki Imanishi Asami Nuno Yuta Suzuki Yoshitaka Kihira Yasumasa Ikeda Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Nitrosonifedipine prevents the progression of diabetic nephropathy in type II diabetic mice JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 118 92P 92P 20120000 read0138449/misc/25106878 布あさ美 石澤啓介 藤井聖子 櫻田巧 山野範子 石澤有紀 今西正樹 鈴木雄太 木平孝高 池田康将 土屋浩一郎 玉置俊晃 糖尿病性腎症進展に対するニトロソニフェジピンの抑制作用 次世代を担う創薬・医療薬理シンポジウムプログラム・要旨集 2012 67 null 20120000 read0138449/misc/28341849 Yuki Ishizawa Keisuke Ishizawa Takumi Sakurada Masaki Imanishi Shoko Fujii Yoshitaka Kihira Yasumasa Ikeda Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Angiotensin II-Induced Vascular Remodeling Is Improved by Nitorosonifedipine, a Possible New Class Drug Against Oxidative Stress HYPERTENSION 0194-911X 58 5 E43 E44 20111100 read0138449/misc/28322365 Kazuyuki Yamaguchi Yoshitaka Kihira Noriko Yamano Yuki Izawa-Ishizawa Keisuke Ishizawa Yasumasa Ikeda Koichiro Tsuchiya Shuhei Tomita Toshiaki Tamaki Glucose Metabolism of Adipocytes is Regulated by Basic Fibroblast Growth Factor Via Hypoxia-Inducible Factor-1 alpha HYPERTENSION 0194-911X 58 5 E166 E166 20111100 read0138449/misc/28316786 Masaki Imanishi Keisuke Ishizawa Yoshitaka Kihira Yasumasa Ikeda Noriko Yamano Yuki Ishizawa Koichiro Tsuchiya Toshiaki Tamaki Shuhei Tomita Smooth Muscle Cell-Specific Hypoxia-Inducible Factor-1 alpha Deficiency Attenuates Angiotensin II-Induced Vascular Remodeling in Mice CIRCULATION 0009-7322 124 21 null null 20111100 read0138449/misc/28309628 Masaki Imanishi Keisuke Ishizawa Yoshitaka Kihira Yasumasa Ikeda Noriko Yamano Yuki Ishizawa Koichiro Tsuchiya Toshiaki Tamaki Shuhei Tomita Hypoxia-Inducible Factor-1 alpha Deficiency in Smooth Muscle Cells Suppresses Angiotensin II-Induced Vascular Remodeling in Mice HYPERTENSION 0194-911X 58 5 E145 E145 20111100 read0138449/misc/28248066 Soichiro Tajima Yasumasa Ikeda Noriko Yamano Koichiro Tsuchiya Yuki Ishizawa Yoshitaka Kihira Keisuke Ishizawa Kazuyoshi Kawazoe Shuhei Tomita Kazuo Minakuchi Toshiaki Tamaki Inhibition of Adipocyte Hypertrophy by Deferoxamine in Diabetic KKAy Mice HYPERTENSION 0194-911X 58 5 E166 E166 20111100 read0138449/misc/38015517 阿部 真治 土屋 浩一郎 Williams Dennis 山下 美妃 町田 麻衣子 石澤 啓介 川添 和義 東 満美 水口 和生 際田 弘志 P-1267 日米の薬学部学生間におけるビデオ会議システムを用いた症例検討カンファレンス実施の試み(一般演題 ポスター発表,薬学教育(その他),Enjoy Pharmacists' Lifestyles) 日本医療薬学会 日本医療薬学会年会講演要旨集 21 393 393 20110909 read0138449/misc/37726089 K. Ishizawa T. Sakurada M. Imanishi F. Fujii Y. Ishizawa Y. Kihira Y. Ikeda S. Tomita K. Tsuchiya T. Tamaki Nitorosonifedipine is a new class drug to improves angiotensin II-induced vascular remodeling EUROPEAN HEART JOURNAL 0195-668X 32 33 33 20110800 read0138449/misc/28288803 Hatsuhiko Hattori Kohsuke Yoshitomi Ayato Katagiri Tsuyoshi Matsushita Masaki Kamiya Keisuke Ishizawa Koichiro Tsuchiya Hisao Nemoto Efficient and practical method for the preparation of branched oligoglycerols (BGL) from 1,3-methyleneglycerol for water-solubilization of medicinal compounds ABSTRACTS OF PAPERS OF THE AMERICAN CHEMICAL SOCIETY 0065-7727 242 null null 20110800 read0138449/misc/25106888 田島壮一郎 池田康将 土屋浩一郎 山野範子 堀ノ内裕也 櫻田巧 木平孝高 井澤(石澤)有紀 石澤啓介 川添和義 冨田修平 水口和生 玉置俊晃 肥満の脂肪組織における鉄の役割 日本鉄バイオサイエンス学会学術集会プログラム・抄録集 35th 55 null 20110800 read0138449/misc/25106894 今西正樹 石澤啓介 櫻田巧 富永えりか 堀ノ内裕也 谷口順平 藤井聖子 木平孝高 池田康将 冨田修平 水口和生 土屋浩一郎 玉置俊晃 Nitrosonifedipineによる血管リモデリング抑制効果の検討 日本薬学会年会要旨集 0918-9823 131st 3 73 null 20110305 read0138449/misc/25106667 堀ノ内 裕也 土屋 浩一郎 田島 壮一郎 木平 孝高 池田 康将 石澤 啓介 冨田 修平 川添 和義 玉置 俊晃 水口 和生 Nitrosonifedipineの細胞保護効果に関する検討 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 131 3 193 193 20110300 read0138449/misc/25106899 櫻田巧 石澤啓介 今西正樹 堀ノ内裕也 富永えりか 谷口順平 藤井聖子 木平孝高 池田康将 冨田修平 土屋浩一郎 玉置俊晃 Angiotensin II誘発血管リモデリングに対するニトロソニフェジピンの抑制作用 血管 0911-4637 34 1 36 null 20110131 read0138449/misc/28337144 Yasumasa Ikeda Soichiro Tajima Sumiko Yoshida Noriko Yamano Yoshitaka Kihira Keisuke Ishizawa Ken-ichi Aihara Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Deferoxamine, an iron chelator, promotes revascularization via endothelial cells activation JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 115 106P 106P 20110000 read0138449/misc/28317842 Masaki Imanishi Keisuke Ishizawa Yoshitaka Kihira Yasumasa Ikeda Koichiro Tsuchiya Toshiaki Tamaki Shuhei Tomita Angiotensin II-induced vascular remodeling is suppressed in smooth muscle cell-specific hypoxia-inducible factor-1 alpha deficient mice JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 115 86P 86P 20110000 read0138449/misc/28309669 Yayoi Fukuhara Shuhei Tomita Masahisa Urata Yoshitaka Kihira Mitsuru Takaku Keisuke Ishizawa Yasumasa Ikeda Koichiro Tsuchiya Toshiaki Tamaki Role of HIF-1 beta in endothelial cells in monocrotaline-induced pulmonary hypertension JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 115 208P 208P 20110000 read0138449/misc/28308430 Yoshitaka Kihira Keisuke Ishizawa Yasumasa Ikeda Koichiro Tsuchiya Shuhei Tomita Toshiaki Tamaki bFGF and insulin differentially regulate hypoxia-inducible factor-1alpha in adipocytes JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 115 224P 224P 20110000 read0138449/misc/28282598 Noriko Yamano Yasumasa Ikeda Minoru Sakama Soichiro Tajima Yoshitaka Kihira Keisuke Ishizawa Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki The alternation of iron transport-related genes in high fat diet-induced obese and diabetic mice JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 115 225P 225P 20110000 read0138449/misc/28272939 Takumi Sakurada Keisuke Ishizawa Masaki Imanishi Erika Tominaga Junpei Taniguchi Shoko Fujii Yoshitaka Kihira Yasumasa Ikeda Shuhei Tomita Koichiro Tsuchiya Toshiaki Tamaki Nitorosonifedipine, a photodegradative metabolite of nifedipine, improves angiotensin II-induced vascular remodeling JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 115 105P 105P 20110000 read0138449/misc/25106902 櫻田巧 石澤啓介 今西正樹 谷口順平 藤井聖子 布あさ美 鈴木雄太 石澤有紀 土屋浩一郎 玉置俊晃 Nitrosonifedipineによるマウス血管リモデリング抑制機構の解明 次世代を担う創薬・医療薬理シンポジウムプログラム・要旨集 2011 49 null 20110000 read0138449/misc/25106687 田島 壮一郎 池田 康将 土屋 浩一郎 山野 範子 堀ノ内 裕也 木平 孝高 石澤 啓介 川添 和義 冨田 修平 水口 和生 玉置 俊晃 鉄除去は脂肪肥大を抑制して糖尿病を改善する 日本心脈管作動物質学会 血管 0911-4637 34 1 40 41 20110100 read0138449/misc/15347984 石澤啓介 腎・心血管障害における細胞内分子機構の解明とその治療法の開発 薬学雑誌 131 1347 1352 20110000 10.1248/yakushi.131.1347 read0138449/misc/28943426 Shuhei Tomita Masahisa Urata Yayoi Fukuhara Yoshitaka Kihira Yasumasa Ikeda Keisuke Ishizawa Koichiro Tsuchiya Tetsuya Kitagawa Toshiaki Tamaki Endothelial-Targeted Hypoxia-Inducible Factor-1 beta (Hif-1 beta) Loss-of Function Alleviates the Monocrotaline-Induced Pulmonary Hypertension in Mice. CIRCULATION 0009-7322 122 21 null null 20101100 read0138449/misc/37991658 石澤 啓介 中西 智子 柴田 洋文 阿部 真治 杉村 真由美 奥村 千恵子 吉村 好之 佐藤 陽一 新垣 尚捷 川添 和義 東 満美 土屋 浩一郎 山内 あい子 山崎 哲男 水口 和生 P1-571 徳島大学における薬学部・薬剤部連携による病院実務実習の実践(一般演題 ポスター発表,薬学教育(実務実習),臨床から学び臨床へと還元する医療薬学) 日本医療薬学会 日本医療薬学会年会講演要旨集 20 382 382 20101025 read0138449/misc/25106910 今西正樹 石澤啓介 富永えりか 櫻田巧 堀ノ内裕也 谷口順平 藤井聖子 木平孝高 池田康将 冨田修平 土屋浩一郎 玉置俊晃 Angiotensin IIによる血管リモデリングに対するNifedipine代謝物の効果 日本高血圧学会総会プログラム・抄録集 33rd 260 null 20101015 read0138449/misc/25106917 田島壮一郎 池田康将 土屋浩一郎 山野範子 堀ノ内裕也 櫻田巧 木平孝高 石澤啓介 川添和義 冨田修平 水口和生 玉置俊晃 2型糖尿病モデルマウスに対する鉄キレート剤による糖尿病改善効果の検討 日本鉄バイオサイエンス学会学術集会プログラム・抄録集 34th 42 null 20100800 read0138449/misc/25106922 石澤啓介 今西正樹 富永えりか 堀ノ内裕也 櫻田巧 谷口順平 藤井聖子 木平孝高 池田康将 冨田修平 玉置俊晃 土屋浩一郎 Nifedipine代謝物はangiotensin IIによる血管平滑筋細胞遊走および増殖を抑制する 日本酸化ストレス学会学術集会プログラム・抄録集 63rd 111 null 20100624 read0138449/misc/28982883 Soichiro Tajima Yasumasa Ikeda Yoshitaka Kihira Keisuke Ishizawa Kazuyoshi Kawazoe Shuhei Tomita Kazuo Minakuchi Toshiaki Tamaki Koichiro Tsuchiya Deferoxamine, an iron chelator, promotes angiogenesis after ischemic hind limb through Akt-eNOS-dependent pathway NITRIC OXIDE-BIOLOGY AND CHEMISTRY 1089-8603 22 S65 S66 20100600 10.1016/j.niox.2010.05.190 read0138449/misc/42729847 福原 弥生 冨田 修平 浦田 将久 木平 孝高 池田 康将 石澤 啓介 土屋 浩一郎 玉置 俊晃 モノクロタリン誘導肺高血圧症モデルマウスにおける血管内皮細胞の低酸素応答因子(HIF-1β)の役割 (公社)日本薬理学会 日本薬理学雑誌 0015-5691 135 3 25P 25P 20100300 read0138449/misc/42729837 福原弥生 冨田修平 木平孝高 池田康将 石澤啓介 土屋浩一郎 吉栖正典 玉置俊晃 T細胞のHIF‐1αは,動脈硬化に伴う血管リモデリングを抑制的に制御する 日本心脈管作動物質学会 血管 0911-4637 33 1 33 33 20100131 read0138449/misc/28972178 Yasumasa Ikeda Koichiro Tsuchiya Soichiro Tajima Yuya Horinouchi Yoshitaka Kihira Keisuke Ishizawa Shuhei Tomita Yoshihisa Takaishi Toshiaki Tamaki The effect of SUDACHI peel, a specialty of Tokushima, as anti-metabolic syndrome JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 112 21P 21P 20100000 read0138449/misc/28971034 Soichiro Tajima Yasumasa Ikeda Koichiro Tsuchiya Yuya Horinouchi Takumi Sakurada Yoshitaka Kihira Keisuke Ishizawa Kazuyoshi Kawazoe Shuhei Tomita Kazuo Minakuchi Toshiaki Tamaki Amelioration of diabetes-associated pathophysiological changes by iron deprivation with deferoxamine in KK-Ay mice JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 112 65P 65P 20100000 read0138449/misc/28949258 Keisuke Ishizawa Masanori Yoshizumi Dorjsuren Narantungalag Yuko Imamura Yasumasa Ikeda Junji Terao Koichiro Tsuchiya Toshiaki Tamaki Metabolism of quercetin in vivo and its protective effect against arteriosclerosis JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 112 35P 35P 20100000 read0138449/misc/28944197 Koichiro Tsuchiya Yuya Horinouchi Soichiro Tajima Yoshitaka Kihira Yasumasa Ikeda Keisuke Ishizawa Yoshiyuki Yoshimura Shuhei Tomita Shuichi Hamano Toshiaki Tamaki Antioxidant Effects of the Photodegradation Product of Nifedipine FREE RADICAL BIOLOGY AND MEDICINE 0891-5849 49 S202 S202 20100000 10.1016/j.freeradbiomed.2010.10.586 read0138449/misc/25106927 今西正樹 石澤啓介 富永えりか 櫻田巧 堀ノ内裕也 谷口順平 藤井聖子 木平孝高 池田康将 冨田修平 土屋浩一郎 玉置俊晃 Nifedipine代謝物によるangiotensin II誘発血管平滑筋細胞遊走及び増殖に対する抑制作用 日本薬理学会近畿部会プログラム・要旨集 117th 41 null 20100000 read0138449/misc/29048341 Yasumasa Ikeda Kaori Sato David R. Pimentel Yoshitaka Kihira Keisuke Ishizawa Shuhei Tomita Flora Sam Toshiaki Tamaki Kenneth Walsh LKB1 Gene in Myocytes Plays a Critical Role to Regulate the Coordinated Cardiac Growth and Capillary Development CIRCULATION 0009-7322 120 18 S791 S791 20091100 read0138449/misc/25106694 富永 えりか 石澤 啓介 櫻田 巧 今西 正樹 谷口 順平 川添 和義 木平 孝高 池田 康将 冨田 修平 土屋 浩一郎 水口 和生 玉置 俊晃 Angiotensin IIによる血管平滑筋細胞遊走に対するnifedipine代謝物の影響 (一社)日本臨床薬理学会 臨床薬理 0388-1601 40 Suppl. S193 S193 20091100 read0138449/misc/42729842 浦田将久 冨田修平 福原弥生 木平孝高 池田康将 石澤啓介 土屋浩一郎 北川哲也 玉置俊晃 肺高血圧症モデルマウスにおける血管内皮細胞の低酸素応答転写因子(HIF1‐β)の役割 (NPO)日本高血圧学会 日本高血圧学会総会プログラム・抄録集 32nd 280 280 20091001 read0138449/misc/25106680 田島 壮一郎 土屋 浩一郎 堀ノ内 裕也 木平 孝高 池田 康将 石澤 啓介 川添 和義 冨田 修平 水口 和生 玉置 俊晃 AngiotensinII刺激による細胞内酸化ストレスと遊離鉄 (NPO)日本高血圧学会 日本高血圧学会総会プログラム・抄録集 32 257 257 20091000 read0138449/misc/29047294 S. Tajima K. Tsuchiya Y. Horinouchi K. Ishizawa K. Teraoka S. Tomita K. Kawazoe H. Houchi T. Tamaki K. Minakuchi ANGIOTENSIN II INCREASED INTRACELLULAR LABILE IRON IN THE PRESENCE OF TRANSFERRIN IN HGEC BASIC & CLINICAL PHARMACOLOGY & TOXICOLOGY 1742-7835 105 127 127 20090800 read0138449/misc/29055229 Koichiro Tsuchiya Shuhei Tomita Keisuke Ishizawa Toshiaki Tamaki Dietary doses of nitrite improve renal injury in L-NAME-induced hypertensive rats NITRIC OXIDE-BIOLOGY AND CHEMISTRY 1089-8603 20 S46 S46 20090600 read0138449/misc/26416129 山口邦久 冨田修平 今村優子 福原弥生 石澤啓介 土屋浩一郎 玉置俊晃 Hypoxia inducible factor‐1αは,腎虚血再灌流障害による急性尿細管壊死の軽減と回復に関与する 日本腎臓学会誌 0385-2385 51 3 359 null 20090425 read0138449/misc/25106699 田島 壮一郎 土屋 浩一郎 濱本 磨以 堀ノ内 裕也 富田 修平 石澤 啓介 川添 和義 玉置 俊晃 水口 和生 Angiotensin IIによるヒト腎糸球体血管内皮細胞(HGEC)内における鉄動態の検討 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 129 4 252 252 20090300 read0138449/misc/29057950 Koichiro Tsuchiya Soichiro Tajima Keisuke Ishizawa Shuhei Tomita Toshitaka Kihira Yasumasa Ikeda Yoshiyuki Yoshimura Shuichi Hamano Toshiaki Tamaki Effect of Angiotensin II on the Intracellular Labile Iron Concentration in HGECs FREE RADICAL BIOLOGY AND MEDICINE 0891-5849 47 S67 S67 20090000 read0138449/misc/26415987 山口 邦久 石澤 啓介 冨田 修平 玉置 俊晃 土屋 浩一郎 井崎 博文 高橋 正幸 福森 知治 金山 博臣 PP-147 腎虚血 : 再灌流障害に対するHif-1α(hypoxia inducible factor-1α)が与える影響に関する検討(上部尿路/機能,一般演題ポスター,第97回日本泌尿器科学会総会) 一般社団法人 日本泌尿器科学会 日本泌尿器科学会雑誌 100 2 353 353 20090000 10.5980/jpnjurol.100.353_3 read0138449/misc/25109039 Yuki Motobayashi Yuki Izawa-Ishizawa Keisuke Ishizawa Sakiko Orino Kunihisa Yamaguchi Kazuyoshi Kawazoe Shuichi Hamano Koichiro Tsuchiya Shuhei Tomita Toshiaki Tamaki Adiponectin inhibits vascular smooth muscle cell migration via the suppression of extracellular signal-regulated kinase 1/2 activation, but not Akt Hypertens Res 32 188 193 20090000 10.1038/hr.2008.19 read0138449/misc/26416139 土屋浩一郎 大西秀樹 岩永智史 堀ノ内裕也 田島壮一郎 三口弘介 石澤啓介 山口邦久 濱野修一 冨田修平 玉置俊晃 食餌性亜硝酸による生体内NO生成における鉄イオンの役割 日本薬理学雑誌 0015-5691 132 3 26P null 20080901 read0138449/misc/26416134 恒石鉄兵 石澤啓介 福原弥生 DORJSUREN Narantungalag 大野呂知之 山口邦久 冨田修平 土屋浩一郎 玉置俊晃 高血圧モデルラットにおけるnifedipine代謝物による臓器保護作用の検討 日本薬理学雑誌 0015-5691 132 3 18P null 20080901 read0138449/misc/26416143 福原弥生 石澤啓介 堀ノ内裕也 山口邦久 DORJSUREN Narantungalag 冨田修平 土屋浩一郎 玉置俊晃 ヒト血管内皮細胞における細胞接着分子発現に対するnifedipine代謝物の影響 日本腎臓学会誌 0385-2385 50 3 285 null 20080425 read0138449/misc/26416156 田島壮一郎 土屋浩一郎 濱本磨以 大西秀樹 元林有紀 堀ノ内裕也 山口邦久 石澤啓介 川添和義 水口和生 玉置俊晃 Angiotensin IIによる細胞内遊離2価鉄動態の検討 日本鉄バイオサイエンス学会学術集会プログラム・抄録集 32nd 26 null 20080000 read0138449/misc/26416150 石澤啓介 福原弥生 DORJSUREN Narantungalag 堀ノ内裕也 恒石鉄兵 山口邦久 冨田修平 土屋浩一郎 玉置俊晃 L‐NAME慢性投与ラットにおける臓器障害に及ぼすnifedipine代謝物の影響 日本循環薬理学会口演要旨集 18th 42 null 20080000 read0138449/misc/25109048 土屋浩一郎 大西秀樹 石澤啓介 山口邦久 田島壮一郎 堀ノ内裕也 玉置俊晃 ROS検出試薬・ジヒドロエチジウムの光化学反応 Pharma Merdica 26 132- null 20080000 read0138449/misc/15347983 石澤啓介 三木恵里加 石澤(井澤)有紀 大西秀樹 Narantungalag Dorjsuren 元林有紀 山口邦久 土屋浩一郎 冨田修平 玉置俊晃 PDGFによるメサンギウム細胞遊走に対するオルメサルタンの抑制効果とその分子機構 血管 31 59 64 20080000 read0138449/misc/26416162 田岡千明 土屋浩一郎 神谷昌樹 根本尚夫 石澤啓介 山口邦久 滝口祥令 玉置俊晃 水溶性フェノフィブラート製剤の作成と中性脂肪低下作用の検討 日本薬理学雑誌 0015-5691 130 3 12P null 20070901 read0138449/misc/8978905 石澤啓介 水口和生 玉置俊晃 医療人としての薬剤師養成教育の実践∼米国の薬学教育ならびに日本の医学教育から学ぶ∼ 医薬ジャーナル 43 871 null 20070000 read0138449/misc/28808461 Yayoi Fukuhara Koichiro Tsuchiya Yuya Horinouchi Chiaki Taoka Sakiko Orino Ken-ichi Chikutei Yuki Motobayashi Yasuhisa Kanematsu Keisuke Ishizawa Toshiaki Tamaki Cell-protective effects of nifedipine metabolite in HGEC JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 103 97P 97P 20070000 read0138449/misc/28772110 Hironori Taira Keisuke Ishizawa Narantungalag Dorjsuren Yuki Izawa Erika Miki Arisa Hironaga Yuki Motobayashi Kazuyoshi Kawazoe Kazuo Minakuchi Toshiaki Tamaki RNH-6270, angiotensin II receptor blocker inhibits TNF-alpha-induced cytotoxicity in endothelial cells JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 103 78P 78P 20070000 read0138449/misc/26416177 福原弥生 石澤啓介 堀ノ内裕也 田岡千明 山口邦久 DORJSUREN Narantungalag 折野早紀子 土屋浩一郎 玉置俊晃 ヒト血管内皮細胞におけるnifedipine代謝物による細胞障害抑制効果 日本循環薬理学会口演要旨集 17th 50 null 20070000 read0138449/misc/26416173 石澤啓介 DORJSUREN Narantungalag 石澤(井澤)有紀 恒石鉄兵 山口邦久 土屋浩一郎 玉置俊晃 TNF‐αによる血管内皮細胞障害に対するオルメサルタンの抑制効果とその分子機構の検討 日本高血圧学会総会プログラム・抄録集 30th 229 null 20070000 read0138449/misc/26416169 玉置俊晃 堀之内裕也 福原弥生 田島壮一郎 田岡千明 石澤啓介 山口邦久 土屋浩一郎 Nifedipineの血管内皮保護作用におけるnitroso‐nifedipine radicalの役割 日本高血圧学会総会プログラム・抄録集 30th 206 null 20070000 read0138449/misc/25109045 玉置俊晃 山口邦久 石澤啓介 薬理作用から見た健康食品 四国医学雑誌 null null 20070000 read0138449/misc/25109044 石澤啓介 水口和生 玉置俊晃 <薬学教育6年制とこれからの展望> 医療人としての薬剤師育成教育の実践∼米国の薬学教育ならび日本の医学教育から学ぶ∼ 医薬ジャーナル 43 371 374 20070000 read0138449/misc/28885103 Hideki Ohnishi Koichiro Tsuchiya Yasuhisa Kanematsu Keisuke Ishizawa Shinji Abe Soichiro Tajima Toshiaki Tamaki Effects of quercetin on no production from nitrite JOURNAL OF HYPERTENSION 0263-6352 24 395 395 20061200 read0138449/misc/25106719 川添 和義 松村 敏彦 黒川 ふみ 榊原 啓之 石澤 啓介 土屋 浩一郎 清水 寛 寺尾 純二 玉置 俊晃 水口 和生 ラット強制水泳試験による漢方薬の抗うつ作用評価 (公社)日本薬理学会 日本薬理学雑誌 0015-5691 128 2 11P 11P 20060800 read0138449/misc/25106715 榊原 啓之 吉野 早紀 松村 敏彦 石澤 啓介 川添 和義 土屋 浩一郎 玉置 俊晃 河合 慶親 寺尾 純二 イチョウ葉抽出物による脳内神経伝達物質含量の調節効果 (一社)和漢医薬学会 Journal of Traditional Medicines 1880-1447 23 Suppl. 113 113 20060800 read0138449/misc/25106712 田島 壮一郎 石澤 啓介 桐野 靖 元林 有紀 西迫 寛隆 土屋 浩一郎 川添 和義 滝口 祥令 玉置 俊晃 水口 和生 徳島大学病院における降圧薬の使用動向調査 高血圧治療ガイドライン2004発行をふまえて (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 126 2 208 208 20060300 read0138449/misc/25106707 黒川 ふみ 富永 樹 石澤 啓介 鳥井 真由美 濱野 修一 川添 和義 芳地 一 水口 和生 ヒト血小板凝集能に対するアスピリンと非ステロイド性消炎鎮痛薬の影響 (公社)日本薬学会 日本薬学会年会要旨集 0918-9823 126 3 147 147 20060300 read0138449/misc/8978906 YOSHIZUMI Masanori 吉栖正典 ISHIZAWA Keisuke 石澤啓介 IZAWA Yuki 井澤有紀 TAMAKI Toshiaki 玉置俊晃 Intracellular signal transduction of vascular injury in insulin resistance インスリン抵抗性による血管障害の細胞内情報伝達機構 近年，メタボリック症候群の疾患概念が確立され，本邦でもその診断基準が発表された．メタボリック症候群の根底にはインスリン抵抗性が存在するといわれるが，高血圧，動脈硬化などの血管病にインスリン抵抗性がどのように関っているかは未だ明らかではない．我々はこの数年，血管病の発症，進展に関わるインスリン抵抗性の細胞内情報伝達機構について研究を行なってきた．糖尿病モデル動物のOLETFラットを用いた検討では，アンジオテンシンII受容体拮抗薬の投与が末梢での糖利用臓器のインスリン抵抗性を改善させ，レニン-アンジオテンシン系のメタボリック症候群への関与が示唆された．培養血管平滑筋細胞を用いた細胞内情報伝達機構の検討では，アンジオテンシンII刺激によって活性化されるMAPキナーゼの一つ，ERK1/2がインスリン抵抗性の発現に関与していることが明らかになった．また，血管リモデリング進展過程のひとつである血管平滑筋細胞の遊走において，SrcチロシンキナーゼやCasアダプタータンパクが細胞内分子として重要な役割を果たしていることを見いだした．血管病におけるインスリン抵抗性に関わる標的分子の探求は，今後も増加することが予想されるメタボリックシンドローム治療のための創薬に有用な情報をもたらすことが期待される．<br> The Japanese Pharmacological Society 公益社団法人 日本薬理学会 Folia Pharmacologica Japonica 日薬理誌 0015-5691 128 3 147 151 20060000 10.1254/fpj.128.147 read0138449/misc/28880605 Koichiro Tsuchiya Yuhya Horinouchi Yasuhisa Kanematsu Shinji Abe Hideki Ohnishi Soichiro Tojima Keisuke Ishizawa Toshiaki Tamaki Yoshiharu Takiguchi Production of nitrosonifedipine radical from nifedipine and its antioxidative activity in cultured cells FREE RADICAL BIOLOGY AND MEDICINE 0891-5849 41 S22 S22 20060000 read0138449/misc/28872440 Y Izawa K Ishizawa Y Fujita Y Fukuhara H Ohnishi Y Motobayashi Y Kanematsu K Tsuchiya T Tamaki Adiponectin inhibits cell migration induced by insulin-like growth factor-1 in vascular smooth muscle cells JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 100 176P 176P 20060000 read0138449/misc/39085105 桐野 靖 石澤 啓介 鳥井 真由美 阿部 真治 岡崎 真由美 山内 あい子 木原 勝 芳地 一 水口 和生 P-712 静脈経腸栄養計算支援ソフトの作成およびその活用(14.輸液，経腸栄養管理1,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-) 日本医療薬学会 日本医療薬学会年会講演要旨集 15 406 406 20050901 read0138449/misc/39085086 阿部 真治 蔭山 千恵子 伏谷 秀治 石澤 啓介 久次米 敏秀 寺岡 和彦 芳地 一 楊河 宏章 水口 和生 苛原 稔 P-741 薬剤師による医師主導臨床試験の支援業務(16.臨床試験(治験)2,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-) 日本医療薬学会 日本医療薬学会年会講演要旨集 15 414 414 20050901 read0138449/misc/39084806 下岡 幸恵 鳥井 真由美 藤原 崇 桐野 靖 石澤 啓介 阿部 真治 芳地 一 水口 和生 P-539 注射剤調製に関する情報提供の効率化 : リスク軽減へ向けて(5.医薬品情報・データベース4,医療薬学の未来へ翔(はばた)く-薬剤師の薬剤業務・教育・研究への能動的関わり-) 日本医療薬学会 日本医療薬学会年会講演要旨集 15 363 363 20050901 read0138449/misc/8978904 Ikuta Masako 生田雅子 Aida Maki 合田真規 Ishizawa Keisuke 石澤啓介 Minakuchi Kazuo 水口和生 Tsuchiya Koichiro 土屋浩一郎 Kihara Masaru 木原勝 Yamauchi Aiko 山内あい子 Evaluation of a Computer-Assisted TPN Prescription System in Tokushima University Hospital, and its Improvement 徳島大学病院におけるTPN処方設計支援ソフトの使用評価と改良 Fluid therapy is a fundamental treatment for almost all inpatients, and nutritional therapy is the most important type of such therapy. Currently, total parenteral nutrition (TPN) is widely used to provide complete nutritional support but 30-40% of TPN recipients are considered to in a malnourished state due to inappropriate TPN prescriptions. Computer-assisted TPN prescription systems are thought to be useful to clinical professionals in solving this problem because they can perform complicated calculations that make it easy to draw up correct TPN prescriptions. So, we made a prototype system for aiding the preparation of TPN prescriptions based on Microsoft^[○!R] EXCEL and it was tested by physicians, pharmacists, dietitians and nurses engaged in TPN therapy at Tokushima University Hospital. We also had them fill out a questionnaire on the system in which they rated it for ease of operation and usefulness according to a scoring system in which 5 indicated full marks. Our Computer-Assisted TPN Prescription System was improved on the basis of the questionnaire results and is now being effectively used by the nutrition support team (NST) in Tokushima University Hospital. Japanese Society of Pharmaceutical Health Care and Sciences 日本医療薬学会 Iryo Yakugaku (Japanese Journal of Pharmaceutical Health Care and Sciences) 医療薬学 1346-342X 31 4 279 286 20050000 10.5649/jjphcs.31.279 read0138449/misc/39724704 中西 りか 宮本 登志子 乾 加代子 井村 光子 西矢 昌子 泉 美也子 中川 達夫 須崎 友紀 石澤 啓介 伏谷 秀治 久次米 敏秀 高松 典通 山上 真樹子 浦川 典子 松崎 健司 新井 英一 楊河 宏章 寺屋 純二 苛原 稔 被験者ケア向上のために : 被験者の診察環境の検討 一般社団法人 日本臨床薬理学会 臨床薬理 = JAPANESE JOURNAL OF CLINICAL PHARMACOLOGY AND THERAPEUTICS 0388-1601 35 1 27S null 20040131 10.3999/jscpt.35.27S read0138449/misc/8978907 石澤啓介 芳地一 水口和生 大学病院における栄養支援チーム(NST)と薬剤師 日本病院薬剤師会雑誌 40 1245 null 20040000 read0138449/misc/48470243 Y Fujita M Yoshizumi N Ali K Ishizawa T Hasegawa M Okamoto Y Kanematsu K Tsuchiya T Tamaki Lysophosphatidylcholine (LPC) transactivates VEGF receptor fetal liver kinase-1/kinase-insert domain-containing receptor (Flk-1/KDR) in HUVEC JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 94 159P 159P 20040000 read0138449/misc/47984681 大西祥代 石沢啓介 吉栖正典 土屋浩一郎 玉置俊晃 芳地一 水口和生 Quercetin glucuronideによる培養ラット大動脈平滑筋細胞の遊走および増殖に対する影響 日本薬学会年会要旨集 0918-9823 124th 4 null null 20040000 read0138449/misc/47984631 石沢啓介 吉栖正典 藤田佳子 大西祥代 土屋浩一郎 芳地一 水口和生 玉置俊晃 培養ラット大動脈平滑筋細胞の遊走および増殖に対するQuercetin glucuronideの影響 日本薬理学雑誌 0015-5691 124 2 null null 20040000 read0138449/misc/28539290 H Houchi H Nishisako K Ishizawa Y Ozawa T Ikehara K Minakuchi Effects of sodium/calcium exchanger inhibitors on catecholamine secretion from cultured bovine adrenal chromaffin cells JOURNAL OF NEUROCHEMISTRY 0022-3042 87 46 46 20031200 read0138449/misc/38855922 石澤 啓介 西迫 寛隆 大西 祥代 石橋 広樹 武田 英二 杉原 治美 山田 静恵 久次米 敏秀 芳地 一 水口 和生 P-143 在宅中心静脈栄養法 (HPN) 導入における薬剤師の関与 日本医療薬学会 日本医療薬学会年会講演要旨集 13 194 194 20030901 read0138449/misc/47740467 Kyaw Moe 吉栖 正典 土屋 浩一郎 Ali Nermin 須崎 友紀 石澤 啓介 井澤 有紀 玉置 俊晃 Angiotensin IIによる培養ラット大動脈平滑筋細胞のmigrationにおけるSrc tyrosine kinaseとCasアダプター蛋白の役割 (公社)日本薬理学会 日本薬理学雑誌 1347-8397 122 2 6P 6P 20030800 read0138449/misc/47740475 石澤 啓介 吉栖 正典 土屋 浩一郎 Kyaw Moe 須崎 友紀 Ali Nermin 東 満美 芳地 一 水口 和生 玉置 俊晃 メサンギウム細胞及びモノサイトの遊走におけるエンドセリン(ET)の役割 (公社)日本薬理学会 日本薬理学雑誌 1347-8397 121 3 46P 46P 20030300 read0138449/misc/46469931 Y Suzaki M Yoshizumi Y Ozawa K Ishizawa N Ali K Tsuchiya T Tamaki High glucose activates BMK1 in cultured rat mesangial cells. JOURNAL OF PHARMACOLOGICAL SCIENCES 1347-8613 91 80P 80P 20030000 read0138449/misc/47740490 石澤 啓介 吉栖 正典 土屋 浩一郎 Kyaw Moe 東 満美 芳地 一 水口 和生 玉置 俊晃 インスリン抵抗性モデルラットにおけるロサルタン及びロサルタンと運動の併用による影響 (公社)日本薬理学会 日本薬理学雑誌 1347-8397 118 4 29P 29P 20011000 read0138449/misc/38651225 石澤 啓介 須崎 友紀 小澤 祐一 土屋 浩一郎 吉栖 正典 寺岡 和彦 芳地 一 玉置 俊晃 水口 和生 P-20 ロサルタンと運動療法のインスリン抵抗性に対する効果 : インスリン抵抗性モデルラットを用いての検討 日本医療薬学会 日本医療薬学会年会講演要旨集 11 115 115 20010901 read0138449/misc/47984690 吉栖正典 小亀敏明 土屋浩一郎 須崎友紀 MOE K 桐間一嘉 石沢啓介 玉置俊晃 酸化ストレスによる神経細胞死に対するEbselenの抑制効果 JNK/c-Jun情報伝達系の阻害作用 日本臨床薬理学会年会プログラム・要旨集 22nd null null 20010000 read0138449/misc/40800111 柿本雅範 杉本幸雄 原田路子 小林陽子 多賀千与美 大熊千尋 石沢啓介 亀井千晃 生薬配合鼻疾患治療剤(フジビトール)のラットアレルギー性鼻炎モデルに対する影響 日本薬学会年会要旨集 0918-9823 120th 2 null null 20000000 read0138449/books_etc/9509011 土屋浩一郎 石澤啓介 臨床思考プロセス―薬物治療学 最適治療への論理スパイラル 京都廣川書店 20130300 read0138449/books_etc/9509016 石澤啓介 玉置俊晃 疾患モデルの作製と利用 循環器疾患 LIFE-SCIENCE INFORMATION CENTER 20100800 read0138449/books_etc/9509017 石澤啓介 水口和生 南山堂医学大辞典 改訂19版 南山堂 20060000 read0138449/books_etc/8502252 石澤啓介 栄養管理のチーム医療 急性および慢性疾患に対するNST 文光堂 20060000 石澤 啓介 博慈会 老人病研究所 先端奨励論文賞 20140200 石澤 啓介 徳島大学若手研究者学長賞 20131100 石澤 啓介 日本薬学会中国四国支部奨励賞 20101100 石澤 啓介 岡奨学賞 20090300 日本心脈管作動物質学会研究奨励賞 20070200